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RÉSUMÉ 
 
Les mutations du gène SCN1A, codant pour le canal sodique de type 1 potentiel-
dépendant (Nav1.1), sont impliquées dans plusieurs formes d'épilepsie du nourrisson, 
comme le Syndrome de Dravet (SD), une épilepsie rare et pharmaco-résistante ou 
l’Epilepsie généralisée avec crises fébriles plus (GEFS+), une épilepsie plus légère. GEFS+ 
et SD sont associés à des crises épileptiques fébriles dès l’âge de 6 mois. Le SD constitue la 
forme la plus grave où l’on voit apparaitre des retards mentaux mais également des déficits 
moteurs, visuels, langagiers et mnésiques au cours de l’évolution de la maladie. L’impact 
des crises épileptiques au cours de la petite enfance sur ces déficits cognitifs n’est pas 
connu. Jusqu'à présent, le SD était considéré comme étant une encéphalopathie épileptique 
où les crises étaient les principales responsables du phénotype à l’âge adulte.  Cependant, 
récemment, un rôle potentiel de la mutation dans les troubles cognitifs a été mis en évidence 
changeant a priori la définition de SD d’encéphalopathie épileptique à une canalopathie 
(Bender et al., 2013, 2016; Han et al., 2012a). Notre projet adresse la question suivante: 
Quel est le rôle des crises épileptiques répétées présentées par les enfants SD sur les 
fonctions cognitives à l’âge adulte?  Pour cela nous avons utilisé un modèle murin de la 
maladie portant une mutation faux-sens du gène Scn1a (R1648H), et qui présente une 
pathologie très légère. Nous avons induit des crises épileptiques par hyperthermie à l’âge de 
21 jours pendant 10 jours et testé les effets à long-terme sur ces animaux à l’âge adulte. Nos 
résultats révèlent que l’induction de crises épileptiques par hyperthermie induit une 
hyperactivité, des altérations dans les interactions sociales et des déficits en mémoire 
hippocampo-dépendante et cortex préfronto-dépendante. Ces modifications 
comportementales sont associées à des modifications de l’électrocorticogramme avec 
apparition de crises spontanées et à d’importantes modifications de l’excitabilité neuronale  
intrinsèque dans l’hippocampe. Même si le rôle possible  du canal NaV1.1 dans le 
dysfonctionnement neuronal et l’effet des crises répétées ne sont probablement pas 
mutuellement distinctes, l’induction de crises répétées à un jeune âge semble donc 
suffisante pour convertir un modèle léger portant la mutation du gène Scn1a en un modèle 
sévère. Ainsi nous avons mis en évidence que les crises épileptiques répétées pendant le 
développement ont un fort impact sur la fonction cérébrale et qu’il est donc capital de  les 
prévenir afin de diminuer, voir de prévenir, ces déficits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
 
Sodium voltage-gated channel alpha subunit 1 (SCN1A) gene code for type-I 
voltage-gated sodium channels (NaV1.1) in human and rodent central nervous systems.  
SCN1A mutations cause genetic epilepsies, as Generalized Epilepsy with Febrile Seizures 
plus (GEFS+), a mild epileptic syndrome, or Dravet Syndrome (DS), a rare, severe and 
drug-resistant epileptic encephalopathy (EE). DS children present multiform and intractable 
seizures starting in the first year of life and severe cognitive, social and neurological deficits 
that, according to the definition of EE, should be caused by the recurrent epileptic activity. 
Yet, there are currently two main hypotheses that could explain behavioral and cognitive 
outcome in DS children. The first hypothesis states that the Nav 1.1 mutation per se causes 
neuron network functional alterations responsible for behavioral outcome. Recent work in 
mice models of the disease supports this first hypothesis (Bender et al., 2013, 2016; Han et 
al., 2012a). The other hypothesis, supported by the classical definition of EE, is that the 
repeated seizures in early childhood cause the behavioral outcome.  However, this second 
hypothesis currently lacks experimental and clinical support. Identification of the 
pathomechanisms responsible for disease progression is crucial for the development of 
efficient treatments. We therefore tested this second hypothesis. We studied the implication 
of repeated seizures during childhood to the later long-term modifications on 
cognitive/behavioral and epileptic phenotypes by submitting the Scn1a mouse model 
carrying the R1648H missense mutation and presenting mild phenotype to a protocol of 
repeated seizures induction by hyperthermia (10 days/one seizure per day). We observed 
that early life seizures can worsen the epileptic phenotype and induce cognitive/behavioral 
defects notably by inducing hyperactivity, sociability deficits and hippocampus- and 
prefrontal cortex-dependent memory deficits. These deficits are correlated with changes in 
the intrinsic neuronal excitability in the hippocampus without major cytoarchitecture 
changes or neuronal death. 
Although the effect of NaV1.1 dysfuntion in altering brain synchrony and the effect 
of repeated seizure activity in the young brain are not mutually exclusive, we thus conclude 
that epileptic seizures are sufficient to convert a Scn1a mouse model carrying a mild 
phenotype into a severe phenotype. This work points the necessity of treating the epileptic 
seizures for a better long-term outcome in DS patients.  
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LIST OF DEFINITIONS 
 
Some concepts are defined in this list and marked in the text with a *. 
 
ELECTROENCEPHALOGRAPHY AND SEIZURES: 
ICTAL ACTIVITY: Electroencephalogram record ing during a seizure.  
INTERICTAL ACTIVITY: EEG activity between 2 seizure events. 
DELTA WAVES: Usually slow waves, but the highest in amplitude. Frequency <4Hz 
THETA WAVES: Seen normally in young children, or h igh relaxation states in humans  (Frequency 4-7 Hz). The 
theta frequency is the most prominent oscillation in the rat hippocampus  when engaged in active motor 
behavior such as walking or exp loratory sniffing, and also during REM (rapid eye movement) sleep.  
GAMMA WAVES: Gamma rhythms are thought to represent binding of different populations of neurons  
together into a network for the purpose of carrying out a certain cognitive or motor function. Frequency 30–
100Hz. 
STATUS EPILEPTICUS: Seizures that last longer than 30 minutes. 
GENERALIZED TO NIC CLONIC SEIZURES: Seizures involving both hemispheres of the brain and presenting a 
clonic phase followed by a tonic phase. Also called “grand mal seizures”. 
 
GENETICS: 
MO SAICISM: Two or more cell types that carry different genotypes.Mutatios that are not present in all cells of 
the same indiv idual.  
HAPLO INSUFFICIENCY: Caused by a loss-of-function mutation, in which only  one functional copy of the wild 
type allele is not sufficient enough to express the wild type phenotype. 
SPLICE MUTATIO NS: Mutations that inserts, deletes or changes nucleotides at the boundary of an exon and an 
intron (splice site). This change can disrupt RNA splicing resulting in the loss of exons or the inclusion of 
introns and an altered protein-coding sequence. 
NO NSENSE/ TRUNCATION MUTATIO N: Mutations that prematurely stops the translation of messenger RNA 
resulting in a polypeptide chain that ends prematurely and a protein product that is truncated and incomplete 
and usually nonfunctional. 
MISSENSE MUTATIO N: Point mutation where a single nucleotide is changed to cause substitution of a different  
amino acid. 
HETERO ZYGOSITY: Two d ifferent alleles for the same gene (in the case of our study one mutant allele - and 
one WT allele +). 
DO MINANT INHERITANCE: In the heterozygotic cells where both alleles are p resent but only one allele is 
dominant, meaning responsible for the phenotype and transmitted to the progeny.  
 
 
 
 
 
  
 
 
  
 
 
REVISION OF CONCEPTS 
 
1.Role of prefrontal cortex and medial-temporal lobe in cognitive functions 
 
1.THE PREFRONTAL CORTEX IN COGNITIVE FUNCTIONS  
 
The prefrontal cortex (PFC) is involved in higher- level cognitive processes including 
planning, motor control, language, reasoning, decision–making grouped under the more 
general term of “executive functions”, personality and social interaction (Kesner and 
Churchwell, 2011). Executive functions include the organization of the input from diverse 
sensory modalities, the maintenance of attention, the monitoring of information in working 
memory, and the coordination of goal-directed behaviors. From Baddeley’s definition, 
working memory is characterized by a limited capacity system for maintaining and 
manipulating information and it underpins the capacity for complex and flexible cognition 
(Baddeley, 1996). Working memory requires attention processes for temporary maintenance 
of domain-specific information over a brief period of time in a form that is fragile and 
vulnerable to distractions (Fuster, 2004; Miller et al., 2014). Given all the cognitive 
functions for which the PFC participates, it is not surprising that the PFC also contributes to 
higher-order cognitive functions such as social cognition. The term social cognition can 
encompass any cognitive process engaged to understand and interpret the self, others, and 
the self- in-relation-to-others within the social environment. Human social interaction 
requires knowledge and recognition of mental states, beliefs, desires, intentions in peers that 
guide our own behavior (Fiske, 1993; Macrae and Bodenhausen, 2000). 
 
2-THE MEDIAL-TEMPORAL LOBE IN COGNITIVE FUNCTION 
 
The major breakthrough in neurology that helped the neurobiologists in defining the 
role of medial- temporal function came in 1957 from a medical report written by Scoville 
and Milner, 1957 on the most famous neurological patient ever, Henry Molaison known by 
his initials H.M. This patient carried severe epileptic disease for several years. In an effort 
to alleviate his disease, the medial temporal lobe area (including hippocampi and 
parahippocampal girus) was removed, and the surgery could reduce considerably the seizure 
frequency. However, following the surgery H.M. patient became severely amnesic in 
 
 
selective memory types. This patient had severe anterograde amnesia and a partial 
retrograde amnesia focus on episodic memory. The discovery of a “pure” memory deficit 
following a selective brain damage also addressed how memory is compartmentalized in the 
brain. Memory is the faculty of the brain by which information is encoded, stored, and 
retrieved.  The time between memory acquisition and retrieval will dissociate between 
short-term and long-term memories: short time for working memory- memory-described in 
previous paragraph- (usually few seconds or minutes) and long-time for long-term memory 
(from hours to years) (Baddeley and Warrington, 1970). Squire and Knowlton, 1995 defined 
a taxonomy of human long term memory that can be classified in explicit/declarative 
(involving episodic and semantic memory) and implicit/non-declarative memory (involving 
implicit learning as procedure, priming, conditioning) (Morris et al., 1986; O’Keefe et al., 
1998) (FIGURE 1).  
Episodic memory characterizes episodes of personal life and its integration in a 
spatial and temporal context (Tulving, 2002). Semantic memories are those that we acquire 
by learning, like factual information and general knowledge. To distinguish between these 
two memories, it can be said that episodic memory requires recollection of a prior 
experience and semantic memory does not.  
Non-declarative memory includes information that is acquired during skill learning, 
habit formation, emotional learning, and other knowledge that is expressed through 
performance rather than recollection. Non-declarative memory is dissociated into 
procedural memory (required for the execution of integrated procedures involved in both 
cognitive and motor skills : associated to striatum and cerebellum functions) (Knowlton et 
al., 1996; Nagao and Kitazawa, 2008), priming memory (memory dependent on the 
neocortex through which an initial exposure is expressed unconsciously by improved 
performance at a later time) and conditioning memory (associated to emotional learning that 
implicates the amygdala) (Adolphs et al., 2005).  
 
 
 
 
FIGURE 1. TAXO NO MY O F HUMAN MEMORY (ADAPTED FRO M SQUIRE AND KNOWLTO N, 1995 FOR LONG 
TERM MEMO RY AND ATKINSON AND SHIFFRIN, 1968 FO R SHORT TERM MEMO RY) 
When a sensorial stimuli is received it can be converted in a short-term memory within a reduced period of 
time (<60 minutes). It can then be transformed into long-term memory or not and last for hours, days or 
years. Two type of long term memory have been proposed: explicit and implicit memory.  
 
3. HIPPOCAMPUS: ROLE, ORGANIZATION AND SYNAPTIC PLASTICITY  
 
The hippocampal formation (including the entorhinal cortex and hippocampal 
system) has been implicated as the major structure in the encoding, storage and retrieval of 
declarative memory (Eichenbaum, 2001; Morris et al., 1986; Squire, 1992). Also, the 
hippocampus is highly implicated in spatial memory, which stores information regarding 
the location of physical objects in space, in other words, the spatial properties of the 
environment (Morris et al., 1986; O’Keefe et al., 1998).  
The hippocampus is a complex structure of the brain located in the medial temporal 
lobe. It belongs to the limbic system, closely associated with the cerebral cortex. Humans 
and other mammals have two hippocampi, one in each side of the brain. The hippocampus 
contains two parts: the Ammons horn, which contains CA1, CA2, CA3 and CA4, and the 
dentate gyrus (DG) (FIGURE 2).  
Sensorial 
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FIGURE 2. HIPPOCAMPUS STRUCTURAL ORGANIZATIO N IN MOUSE BRAIN. 
The flow of information from the EC is largely unidirectional, with signals  propagation trough a series of tightly 
packed cell layers, first to the dentate gyrus, then to the CA3 layer, then to the CA1 layer, then to the subinculum and 
then out of the hippocampus to the EC. Image from (Deng et al., 2010).  
 
Synaptic plasticity plays an important role in neurochemical foundations of learning 
and memory. Hebb (1949) first said that memory formation is due to changes in the 
synaptic efficiency and that storage is made by cellular junctions that associate among them. 
In other words, synaptic plasticity is the ability of synapses between two neurons to change 
in strength, in response to the transmission of synaptic inputs (two active neurons at the 
same time strengthen their connection to ensure that future connections will be easier) 
(Purves, 2005). Long-term potentiation (LTP) reflects the strengthening of synapses and is 
believed to represent a major cellular mechanism at the basis of long term memory 
formation.  LTP was first described using artificial stimulation by (Bliss and Lomo, 1973). 
Whitlock et al., 2006 first observed a naturally- induced long-term potentiation in the 
hippocampus during a memory task in rats. LTP is now well admitted to represent a cellular 
correlate of long term memory.  
The association between the hippocampus and epilepsy has been often described, 
notably in seizure generation, abnormal electrophysiological properties, abnormal 
oscillatory rhythms and cognitive abnormalities. The effect of frequent early life seizures 
and hippocampal-dependent cognition has been well studied in rodent models and support 
the view that epileptic discharges disrupt normal development of hippocampal networks 
(reviewed in Holmes, 2016). The hippocampus seems to be frequently involved in seizures, 
even if they are not generated there. Also, the relatively simple histological construction and 
lamellar organization of the hippocampus makes it a structure of choice for experimental 
and clinical studies of epilepsy. 
 
 
 
4. EXCITATORY AND INHIBITORY BALANCE IN EPILEPSY: ROLE OF INTERNEURONS 
 
The brain balance is maintained through excitatory and inhibitory mechanisms 
handled by the main excitatory neurotransmitter glutamate counterbalanced by the main 
inhibitory neurotransmitter- γ-aminobutyric acid (GABA). The recurrent seizure activity is 
an electrographic hallmark of epilepsy, and consists in an excessive synchronous discharge 
of cerebral neurons, generated in one or more neuron populations. The electrical activity in 
the epileptic network is in general associated with a deficit in excitatory/inhibitory 
imbalance, which promotes neuronal hyperexcitability and hyper-synchronization, through 
an increase in excitatory neurotransmission or a decrease in inhibitory neurotransmission or 
both. Neurons are excitable cells that receive and transmit information trough electrical and 
chemical signals. Those electrical signals, received at the dendrites, generate action 
potentials at the axon initial segment (AIS) that are transmitted through the axon to the 
terminals. There, the synaptic boutons communicate with the other cells forming synapses. 
The structural organization of a neuron is represented in FIGURE 3. The work concerning 
the epileptic syndromes we will study here, focused mostly on two types of neurons: the 
excitatory neuron, releasing glutamate (eg hippocampal excitatory neurons described above) 
and the inhibitory interneuron releasing the neurotransmitter GABA.  
 
FIGURE 3. STRUCTURE O F THE NEURON. 
 
 
 
We will briefly describe the interneurons, a neuron type that is crucial for Scn1a 
mutant mouse models neurophysiopathology. Based on their network connectivity and 
intrinsic properties, the interneurons generate and control the rhythmic output of large 
populations of principal cells and other interneurons. In the central nervous system (CNS) 
they are primarily inhibitory, and use GABA or glycine as main neurotransmitters. They 
represent approximately 20-25% of cortical neurons and are highly diverse in morphology, 
connectivity, neurochemical and physiological properties (Kepecs and Fishell, 2014; Petilla 
Interneuron Nomenclature Group et al., 2008). FIGURE 4 represents the described subtypes 
of interneurons in the brain.  
The morphological appearance of interneurons is a source of important information 
regarding their specific role in a neuronal circuit. Using immunohistochemical tools, they 
can be marked by tagging the enzymes that synthesize GABA: GAD-65 and GAD-67. 
Various populations of interneurons were found to contain different peptides (e.i. 
somatostatin, cholecystokinin (CCK), calretinin, neuropeptide Y, parvalbumin, etc) 
(FIGURE 4) and these peptides gave the name to the interneuron subtypes. This has resulted 
in a neurochemical classification that is based on the cell-specific presence of these 
markers. Moreover, using electrophysiological tools, the interneurons have also been 
classified according to their firing properties and, for example, the termino logy fast spiking 
PV+ basket cells combines electrophysiological, biochemical and morphological 
characteristics.  
Several GABAergic cell types contribute to feedback circuits in the hippocampus. 
These include parvalbumin-positive (fast-spiking PV+) a major GABAergic type in 
contributing to the pathology in Scn1a mutant mouse models.  
 
 
 
FIGURE 4. SCHEMATIC O F INTERNEURO N DIVERSITY ACROSS THE BRAIN. FRO M (KEPECS AND FISHELL, 
2014) . 
They are mainly characterized according to morphology, type of connection, neuropeptide expressed and 
electrophysiological p roperties. 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 17th-century epileptic patient being restrained by another man is taken to see a priest to 
be blessed (in Madness (Porter, 2003). 
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I- INTRODUCTION  
Chapter 1- EPILEPSY AND GENETIC EPILEPSIES 
1. HISTORICAL,  DEFINITION AND EPIDEMIOLOGY.   
Epilepsy is the most common neurological disorder affecting 65 million persons 
worldwide and 0.5–1.0% of children younger than 16 years old (Shinnar and Pellock, 
2002; Thurman et al., 2011). The word epilepsy was derived from greek words that 
mean “seizure” or “attack” (Reynolds, 2002). The first known report of epilepsy was in 
a Babylonian medical report written 3000 years ago. The Babylonians described the 
seizures as invasions of the body by a particular evil spirit and characterized them 
similarly in what can be correlated with the seizures we know nowadays (Wilson and 
Reynolds, 1990). This supernatural view of the seizures has persisted until recently. In 
the 5th century, Hippocrates challenged this view by stating: “I do not believe that the 
Sacred Disease is any more divine than any other disease but, on the contrary, has 
specific characteristics and a definite cause. Nevertheless because it is completely 
different from other diseases it has been regarded as a divine visitation by those who, 
being only human, view it with ignorance and astonishment... The brain is the seat of 
this disease, as it is of other very violent diseases”. Interestingly, he already had some 
notions that the disease could be on the rise if not treated and become chronic and 
intractable, “Moreover it can be cured no less than other diseases so long as it has not 
become inveterate and too powerful for the drugs which are given. When the malady 
becomes chronic, it becomes incurable (Zanchin, 1992).” However Hippocrates’s view 
of the supernatural disease was not taken into account until the 17 th and 18th centuries. 
Thomas Wills, in 1961 first characterized epilepsy as a brain disorder (Willis and 
Pordage, 1681) and during the next two centuries very important debates took place to 
give rise to the first definitions of epilepsy in the 19th century. The works of Todd, 
influenced by Faraday and Jackson were very important in defining the electrical basis 
of seizures and in 1952, Hodgkin & Huxley (Hodgkin and Huxley, 1952) obtained the 
Nobel Prize for discoveries of the ionic basis of Todd’s nervous polarity/force. Thanks 
to the development of genetics, molecular biology, neurophysiology, functional imaging 
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and numerous neurochemical techniques for exploring the concepts of excitation, 
inhibition, modulation, neurotransmission and synchronization, the 20th century 
conferred the most important advance in epilepsy and seizures research.  
2. CLASSIFICATION OF SEIZURES, EPILEPSIES AND COMORBIDITIES  
2.1 Seizures Definit ion and Classif icat ion 
Epilepsy is characterized by the presence of epileptic seizures. They can be 
acutely provoked by head trauma or stroke (for example) or unprovoked as the result of 
a pathological condition. In 2014, the International League Against Epilepsy (ILAE) 
defined epilepsy as a “disease of the brain enduring predisposition to generate epileptic 
seizures, and by the neurobiological, cognitive, psychological, and social consequences 
of this condition.” An epileptic seizure is a “transient occurrence of signs and/or 
symptoms due to abnormal excessive or synchronous neuronal activity in the brain” 
(Fisher et al., 2014). The definition of epilepsy requires the occurrence of any of the 
following conditions: at least two unprovoked (or reflex) seizures occurring 24h apart, 
one unprovoked (or reflex) seizure and a probability of further seizures similar to the 
general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the 
next 10 years, or a diagnosis of an epilepsy syndrome (Fisher et al., 2014).  
Epileptic seizures arise from abnormal synchronization of neurons in the brain 
that disrupts normal patterns of neuronal signaling and results in electric discharges in 
the electroencephalogram (EEG). The brain hyperexcitability in epilepsy describes a 
general increase in response to a particular stimulus or enhanced tendency to generate 
repetitive synchronous neuronal discharges manifesting as a burst of population spikes.  
It is a very harmful disease leading to discrimination, misunderstanding, social stigma 
and the fear of living with a chronic unpredictable disease that can lead to loss of 
autonomy for daily activities.  
Seizures are divided in focal or generalized seizures according to the brain 
structure involved in the seizure origin.  
Focal (synonym=partial) seizures are those in which, in general, the first clinical 
and EEG alterations indicate initial activation of a system of neurons limited to a part of 
one cerebral hemisphere. The networks involved may be very discrete and highly 
localized or more broadly distributed within the hemisphere. Focal seizures are 
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classified primarily on the basis of whether or not consciousness is impaired during the 
attack (simple and complex respectively) and whether or not progression to generalized 
convulsions occurs. They are divided into motor and non motor focal seizures (FIGURE 
5).  
Generalized (synonym = bilateral) seizure are those in which the first clinical 
changes indicate initial involvement of both hemispheres. Consciousness may be 
impaired and this impairment may be the initial manifestation. The ictal EEG patterns 
are initially bilateral and presumably reflect neuronal discharge, which is widespread in 
both hemispheres. Generalized seizures may be motor or absence seizures and vary 
considerably. Motor manifestations of generalized seizures are bilateral. Motor 
generalized seizures can be tonic-clonic (GTC) or (previously called ‘grand mal’ 
seizures), and are characterized by bilateral symmetric tonic contraction and then 
bilateral clonic contraction of somatic muscles, usually associated with autonomic 
phenomena and loss of awareness. Alternatively generalized seizures can be purely 
tonic, purely atonic (sudden loss of muscle tone), purely myoclonic (sudden, brief (<100 
ms), involuntary, single, or multiple contractions of muscles or muscle groups of 
variable topography (axial, proximal limb, distal)), myoclonic-atonic (clonic seizures 
that results in falls), pure myoclonic, clonic-tonic-clonic (one or a few jerks of limbs 
bilaterally, followed by a tonic-clonic seizure) and epileptic spasms. Absence 
generalized seizures (previously called ‘petit mal’ seizures) are seizures characterized 
by a sudden onset, interruption of ongoing activities (a blank stare), and can be typical 
(brief loss of consciousness, normal EEG pattern), atypical (last longer than typical and 
can present irregular EEG pattern), myoclonic or characterized by eye- lid myoclonia 
(jerking of the eyelids at frequencies at least 3 per second, commonly with upward eye 
deviation) (FIGURE 5). Generalized seizures may be primarily (if they are generalized 
from the onset) or secondarily generalized (if they are focal at the onset but progress to 
generalized) (Berg, 2016; Berg et al., 2010; Blume et al., 2001; Fisher et al., 2014). 
Unclassified epileptic seizures or those with unknown onset are seizure types 
which cannot be classified because of inadequate or incomplete data (FIGURE 5).  
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FIGURE 5. OPERATIO NAL CLASSIFICATION OF SEIZURE TYPES BY THE INTERNATIO NAL LEAGUE 
AGAINST EPILEPSY (FISHER ET AL., 2016). 
 
The characterization of seizures types, origin and causes are the main focus of 
epilepsy care, due to their devastating effects on the quality of life and increasing 
stigmatism around the patients.  Also, high epileptic activity confers a high risk of 
sudden death in epilepsy, so it has to be taken seriously into account.  
2.2 Co-morbidit ies in epilepsy 
A good seizures control remains the main challenge in epilepsy. However, the 
epilepsy-associated comorbidities are very disabling for patients and sometimes more 
than seizures. Co-morbidities in epilepsy are pathological conditions that usually follow 
the epileptic onset and are present in addition to epilepsy. They can precede epilepsy 
and in this case are causative of the epilepsy (i.e. brain infection, trauma). However, in 
the majority of the cases they are a consequence of epilepsy, and are caused by 1) the 
negative effects of chronic epileptic abnormalities on brain development, 2) the anti-
epileptic drugs or 3) an independent effect of the physiological disturbances that 
predispose the brain to seizures (Wei and Lee, 2015). Depression and anxiety are the 
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most common comorbidities in epilepsy, encountered in 1/3rd of epileptic patients and 
are mainly caused by anti-epileptic drugs (Sankar and Mazarati, 2012). In children 
between 4 and 15 years, additional co-morbidities have been reported in 40% of 
patients. The co-morbidities identified in epileptic children are: neurological (cognitive 
and language impairment, migraine and headache or sleep problems), psychological 
(autism spectrum disorder, attention-deficit and hyperactivity disorder, mood disorders, 
sociability problems) and physical (bone loss, immunological disturbances, body weight 
retardation and others).  Among them, the most common are intellectual disabilities, 
speech and language difficulties or other specific cognitive disabilities (Holmes, 2015; 
Mula and Sander, 2016). Children with epilepsy have lower performances in school 
than children without epilepsy (Reilly et al., 2015) and their mental capacities tend to 
regress over time (Bailet and Turk, 2000). The children’s immature brain seems to be 
more prone to a poor cognitive outcome due to several reasons. The young age at 
seizure onset, the effects of the chronic treatments with anti-epileptic drugs (AEDs) and 
the presence of a symptomatic cause or epileptic encephalopathy are all negatively 
contributing to abnormal cognitive or psychological development.  However, whether 
poorly controlled epileptic activity is associated with progressive cognitive deterioration 
is still controversial, and this has been demonstrated only for some specific syndromes: 
mesial temporal lobe epilepsy and epileptic encephalopathies (reviewed in Avanzini et 
al., 2013).  
2.2.1 Epileptic Encephalopathies  
Epileptic encephalopathy (EE) carries the notion that “the epileptic activity itself 
may contribute to severe cognitive and behavioral impairment above and beyond what 
might be expected from the underlying pathology alone (e.g., cortical malformation), 
and that these can worsen over time” (Berg et al., 2010). EE are a group of 
heterogeneous brain disorders that occur in childhood and are characterized by 
pharmaco-resistance, focal and generalized seizures and severe cognitive and 
developmental delay often associated to premature death (Cross and Guerrini, 2013).  
The frequent and intense epileptic activity in young children interferes with normal 
brain development, induces delays in cognitive maturation and often cognitive 
regression. It can also have psychiatric and behavioral consequences. The different 
types of epileptic encephalopathies observed in children are listed in TABLE 1. 
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TABLE 1. LIST O F EPILEPTIC ENCEPHALOPATHIES ASSOCIATED TO  NEO NATAL PERIO D, INFANCY AND 
CHILDHOOD (ADAPTED FRO M CROSS AND GUERRINI, 2013). 
 
 
Conversely, an important part of the concept of EE treatment is that amelioration 
of epileptiform activity will improve the developmental consequences of the disorder 
(Jehi et al., 2015). It has been observed that individuals with EEs who are successfully 
treated with medications or surgery, display improvements in cognitive function. This 
demonstrates that seizures and an abnormal EEG play an important role in cognitive 
outcome (Asarnow et al., 1997; Lee et al., 2014; Matsuzaka et al., 2001).  
However, many, if not most, of these disorders are not solely associated with 
developmental or behavioral deterioration due to epileptiform activity. The term EE is 
currently being reviewed and debated, because it does not fit to all the EEs. In 
particular, whether Dravet Syndrome can be classified as an EE has been questioned 
recently, because development delay may occur in a period were seizures are not very 
frequent, so this suggests that this delay might have other underlying causes. In fact, the 
ILAE has recently proposed the new term “development encephalopathy” for particular 
EE cases (Scheffer et al., 2016).   
2.3 Etiology of  epilepsy 
Etiology describes the origin or causation of a problem, in this case epilepsy. 
The new classification recognizes three types of causes: 1) Genetic (idiopathic), 2) 
Structural/Metabolic, and 3) Unknown (Baxendale and Thompson, 2016; Berg et al., 
2010). Genetic epilepsies (1) are those in which there is a known or presumed genetic 
defect(s) and seizures are the symptoms of the disease. In structural/metabolic epilepsies 
(2), seizures appear subsequent to brain condition (as stroke, trauma, infection, 
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poisoning. etc). This type of etiology might also have a genetic variation, but, it is the 
brain condition that interferes between the genetic cause and epilepsy.  Unknown 
etiologies (3) are those that do not fit in the two previous characterizations, meaning 
that they are caused by non- identified factors. The majority of the gene in which 
mutations have been identified in epilepsy code for ion channels (Cossette, 2010). In my 
thesis, I will focus in the genetic epilepsies associated to SCN1A gene mutation that is 
the most commonly mutated gene in human epilepsies.  Due to the high number of 
mutations identified to date in SCN1A gene ( >900 different types), it has been referred 
to as a ‘super culprit’ gene (Lossin, 2009). 
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Chapter 2- GENETIC EPILEPSIES ASSOCIATED TO SCN1A  GENE MUTATION 
Voltage-gated sodium channels (SCN) genes code for voltage-gated sodium 
channels (NaV). In the first part of this chapter, I will review the importance of voltage-
gated channels in maintaining optimal neuronal excitability and introduce their different 
sub-types and molecular organization. In the second part, I will focus on the voltage-
gated sodium channel alpha subunit 1 (SCN1A) gene and NaV1.1 channel and the 
epileptic syndromes associated to this channel.  
1. SCN1A GENE AND TYPE-I VOLTAGE GATED SODIUM CHANNEL 
Excitation and electric signaling in the central nervous system involves the flow 
of ions (sodium, potassium, calcium and chloride) through ion channels. Voltage-gated 
ion channels underlie the electric properties of the neurons. They are membrane proteins 
with highly selective pores that can be in open or closed states according to the 
membrane electrical potential. Changes in membrane electrical potential induce 
modifications in channel conformation that allow ion transition between the 
extracellular and intracellular fluid - this property is called ion channel gating. Because 
these channels allow the ion flux down their electrochemical gradient in response to 
voltage-gating, they were called voltage-gated ion channels. There are three main types 
of voltage-gated ion channels with very conserved function similarities, but high 
selectivity for either sodium, potassium or calcium (Hille, 2001). They are composed by 
polytopic, transmembrane, pore forming and voltage-sensing α or α1 subunits (Catterall, 
1995). The work of Hodgkin and Huxley, 1952  was very important in the description of 
the action potential’s propagation. Action potentials propagate by voltage-gated 
activation of Na+ channels that conduct sodium ions inside neurons and allow for 
activation of potassium-gated channels that reestablish membrane charges by carrying 
K+ ions out of the cell (FIGURE 6). The authors defined three characteristics of sodium 
channels: voltage-dependent activation, rapid inactivation and selective ion 
conductance.  
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FIGURE 6. ACTIO N PO TENTIAL INITIATIO N AND PROPAGATIO N IN NERVE CELLS . 
When the voltage depolarizing stimulus arrives to the neuron (orange arrow), the voltage -gated sodium 
channels open allowing sodium ions to enter the cell (depolarizing state). The potassium (K
+
) channels 
open allowing potassium ions to exit the cell while Na
+
 channels became refractory (repolarizing state). 
After a period of hyperpolarization of the cell (hyperpolarizing state), the potential is normalized and the 
K
+
 channels close. 
 
The role of NaV channels in initiating and propagating action potentials became 
clear by that time and further research characterized these channels at the ir molecular 
and functional levels. NaV channels are composed by a large α subunit (260kDa) and 
smaller β subunits (30-40kDa) (FIGURE 7) (Lai and Jan, 2006). The α subunit is 
encoded by ten genes termed from SCN1A to SCN11A (Sodium Voltage-Gated Channel 
α Subunit 1-11). These genes code for nine NaV and one sodium channel involved in 
salt sensing (reviewed in Mantegazza and Catterall, 2012). The genes encoding the nine 
NaV, called NaV1.1 to Nav1.9, and their primary localization in human and rodent 
tissues are described in TABLE 2.  
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TABLE 2. VO LTAGE-GATED SODIUM CHANNELS SUBTYPES , ENCODING GENES AND LOCALIZATIO N IN 
PRIMARY TISSUE. REVIEWED IN (MANTEGAZZA AND CATTERALL, 2012) 
 
NaV1.1, Nav1.2, Nav1.3 and Nav1.6 are expressed in the central nervous system 
(CNS), while Nav1.7, Nav1.8, and Nav1.9 act mainly at the peripheral nervous system. 
Nav1.4 is found in the skeletal muscle and Nav1.5 is primary in the heart (Goldin, 1999). 
Less subtypes of NaV β-subunits where identified (β1, β2, β3, β4) and are characterized 
according to the type of ligation they present with the α subunit (noncovalent or 
disulfide) (Morgan et al., 2000; Yu et al., 2003). The NaV channel α-subunit consists of 
four domains (I–IV), with six transmembrane segments (S1–S6) each. The fourth 
transmembrane segment of each domain contains positively charged amino-acid 
residues in every third position that act as sensors for membrane depolarization and 
initiation of channel activation. The loop between S5-S6 segments form the selective 
pore domain through which sodium ions flow (FIGURE 7). One or more β-subunits, 
which are single transmembrane proteins with an extracellular immunoglobulin- like 
loop and an intracellular C terminus, co-assemble with the α-subunit and influence their 
functional properties. β2 and β4-subunits are covalently attached to the α-subunit while 
the β1 and β3-subunits are non-covalently attached (Messner and Catterall, 1985).  
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FIGURE 7. TRANSMEMBRANE O RGANIZATIO N O F NAV SUBUNITS AND 3-D STRUCTURE. 
NaV α-subunits represent a single polypeptide that consists of four domains  (D) (I–IV), with six 
transmembrane segments (S1–S6) each. The fourth transmembrane segment (S4) of each domain contains 
positively charged arginines (represented with + + + +) that are primarily responsible for voltage sensing, 
as well as the S5-pore loop-S6 region, which forms the pore domain  through which sodium ions flow. 
The β subunits, β 1/3 and β 2/4, are single transmembrane proteins that co-assemble with the α subunit. 
Three-dimentional structure of sodium channel (adapted from (Meisler and Kearney, 2005)).  
 
SCN1A codes for the Nav1.1 channel and, along with the NaV1.2, NaV1.3 and 
NaV1.6, it is primarily expressed in the CNS. As mutations in the SCN1A gene, and thus 
perturbations in the function of Nav1.1, are strongly associated with epilepsy (Claes et 
al., 2001), work has been carried out to deeply examine its developmental expression 
profile. NaV 1.1 expression becomes detectable at post-natal day (P) 7 in rats and around 
P10 in mice (Ogiwara et al., 2007) and at post-natal month one in humans (Cheah et al., 
2013a). They are predominantly localized in the caudal region and spinal cord (Gong et 
al., 1999; Gordon et al., 1987; Ogiwara et al., 2007; Westenbroek et al., 1989). Previous 
studies in rodents showed that high NaV1.1 expression was observed in the 
hippocampus, notably on the soma of DG cells and throughout the dentate hilus, in the 
stratum pyramidale of all hippocampal subfields, and within the stratum radiatum and 
statum oriens of the CA1 region.  Strong expression was also observed within the layer 
V of the cortex and in the cerebellum (Westenbroek et al., 1989). Similar distribution of 
NaV1.1 was found in human brain (Whitaker et al., 2001), indicating that the balance 
and distribution of this particular Na+ channel is highly conserved and thus probably 
important for brain function. At the microscopic level, the NaV1.1 was found primarily 
in cell bodies (Whitaker et al., 2001) and later, in depth analysis revealed a specific 
concentration of these channels at the axon initial segment (AIS) (proximal part of the 
axon, and the primary site for initiation of action potentials in neurons (FIGURE 3) 
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reviewed in (Kole and Stuart, 2012)) and in myelinated fibers, clustered at the nodes of 
Ranvier (Duflocq et al., 2008; Ogiwara et al., 2007). The creation of mouse models of 
NaV1.1 mutations confirmed that the NaV1.1 channels play an important role in the 
excitability of GABAergic interneurons (Ogiwara et al., 2007; Yu et al., 2006a) and 
confirmed concentrated localization of these channels at the AIS in fast-spiking 
parvalbumin basket cells (Hedrich et al., 2014) (FIGURE 4).  
Few NaV1.2 mutations have been identified which are also causing epilepsy 
(Howell et al., 2015; Misra et al., 2008; Ogiwara et al., 2009). Although even less 
frequent, mutations in NaV1.3, NaV1.6 and NaV1.8 were also reported in epilepsies 
(Estacion et al., 2014; Kambouris et al., 2016; Makinson et al., 2016; Malcolmson et al., 
2016; Meisler et al., 2001; Vanoye et al., 2014). For the purpose of this thesis, the next 
sections will focus on NaV1.1 channel-associated epileptic syndromes. 
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2. NAV 1.1 CHANNEL PHENOTYPIC/GENOTYPIC SPECTRUM  
2.1 A shared common feature: Febrile seizures 
It is described that around 5-12% of the children experience febrile seizures (FS) 
within the range of age 6-60 months with a peak at 2 years (Vestergaard and 
Christensen, 2009). FS are GTC seizures that happen in childhood associated to an 
increase in body temperature (~38,5ºC), without CNS infection. They occur in children 
without history of epilepsy or neurological dysfunction and might be due to a particular 
sensitivity to fever in the developing brain. It has been clearly demonstrated that there is 
an increased risk of FS incidence shortly after childhood vaccinations caused by 
vaccine- induced fever (Brown et al., 2007; Scheffer, 2015).  Simple FS last usually less 
than 15 minutes, are generalized with often loss of consciousness, shakes, and 
movements in limbs on both sides of the body and do not occur more than once within a 
24 hours period (Whelan et al., 2017). FS, first called benign but this term is not 
accepted anymore by the ILAE, is considered a self- limited condition different from 
epilepsy. Complex FS are classified in: 1) complex if they last between 15-30 minutes, 
happen more than once in a period of 24 hours and are focal or localized to a specific 
part of the brain or 2) febrile status epilepticus (SE) if they last more than 30 minutes 
(Whelan et al., 2017). FS plus (FS+) were considered as a simple FS that can occur 
more than once within a 24 hours period or that occur beyond the age of 6 (Grill and 
Ng, 2013). In terms of duration, the principal ictal* event (seizure) can be confused with 
the post-ictal events (tonic posture, eye deviation that last for some time post-seizure). 
So, basically, without EEG recording it is hard to delimitate the end of the seizure. The 
probability of recurrence after a simple FS is around 2%, while the probability is 2-3 
times higher after a complex FS (Camfield and Camfield, 2015). These long-
lasting/complex FS are better candidates to cause important modifications in the brain 
and epileptogenesis (Ellenberg and Nelson, 1978).  
The mechanism by which FS are generated is unknown. Yet four theories have 
been proposed for FS generation: 1) the neuronal hyperexcitability induced by the 
increased temperature (Fisher and Wu, 2002), possibly by acting directly on NaV gating 
at the AIS (Thomas et al., 2009), 2) the neuronal hyperexcitability caused by the release 
of inflammatory mediators during fever (eg.: Il-1β) (Alheim and Bartfai, 1998; Dubé et 
al., 2005), 3) the neuronal hyperexcitability caused by brain alkalosis during high 
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ventilation in hyperthermic conditions (Aram and Lodge, 1987; Balestrino and Somjen, 
1988; Schuchmann et al., 2006, 2011) or 4) a result from inefficient thermoregulation 
(Feng et al., 2014; Richmond, 2003).  
Among the many risk factors for FS, the genetic predisposition strongly confers 
the epidemiological link in many families (Baulac et al., 2004). Mantegazza et al., 2005  
identified a mild loss-of- function mutation in NaV1.1 responsible for the familial FS 
condition. Very few children exhibit more than three FS during their childhood 
(reviewed in Camfield and Camfield, 2015), and there is little evidence for a correlation 
of FS in these children with long- lasting consequences like brain damage or cognitive 
problems (Sillanpää et al., 2011). Also, the incidence of FS does not indicate that 
epilepsy will develop (15% of the children have a febrile seizure event and do not 
develop epilepsy). FS are common to all diseases characterized by NaV1.1 channel 
haploinsufficiency* thus it is considered that FS is a mild phenotypic consequence of the 
mutations in SCN1A gene. 
2.2 Epileptic syndromes associated to NaV1.1 channel mutation: 
genetic and phenotypic variants. 
SCN1A gene mutations associated to NaV1.1 loss of function cause a vast range 
of epilepsy syndromes in humans. The associated phenotypes range from simple FS as 
described in the previous part (Mantegazza et al., 2005), en passant par generalized 
epilepsy with febrile seizures plus (GEFS+), a mild epileptic syndrome with high 
phenotypic variability (Escayg et al., 2000a), to an extremely severe condition – Dravet 
Syndrome (DS) (Claes et al., 2001) (FIGURE 8C).  The diseases associated to the NaV1.1 
spectrum are categorized according to patient’s phenotype (mainly to seizures history). 
The first identified mutation in the NaV1.1 α-subunit was the SCN1A-R1648H missense 
mutation* in one large family presenting GEFS+ (Escayg et al., 2000a). Since then, 
more than 30 other missense mutations have been identified that cause GEFS+, a 
disease usually associated to the partial loss of the channel’s function. Most displayed 
GEFS+ cases present autosomal-dominant transmission with high variability of 
phenotypes. Following the first SCN1A mutations that accounted for 10% of GEFS+ 
patients, a new report of SCN1A mutation was described in children presenting the 
sporadic severe myoclonic epilepsy in infants (SMEI) later called Dravet Syndrome 
(DS) (Claes et al., 2001).  In SMEI children the mutations were de novo mutations since 
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none of the parents were affected. More than 80% of DS patients present SCN1A gene 
mutations and more than 900 different types had been described by 2013 (Parihar and 
Ganesh, 2013)(see also www.gzneurosci.com/scn1adatabase/). The types of mutation in DS 
are: 1) severe truncating mutations* (and less often splicing* or deletion* mutations) 
causing loss of NaV1.1 function or 2) severe missense mutations that prevent the 
channel’s expression or severely impair its function (Brunklaus et al., 2014). The 
duplication and deletion of sequences in the gene have also been pointed to impair the 
channel’s function (Marini et al., 2009).   
2.2.1 Type of mutat ions and the ir localizat ion in the SCN1A  
gene.  
FIGURE 8A&B represents some of the mutations found in GEFS+ and DS 
patients, respectively (but by now they are many more). In FIGURE 8B one can observe 
that the DS-causing missense mutations (green circles) are concentrated within the 
transmembrane segment where they probably prevent the channel’s folding and 
function. In fact, a recent study on large cohort of Japanese DS patients showed that the 
missense mutations found in DS were in the majority concentrated at the S4 voltage 
sensor and pore loops (S5 and S6) (Ishii et al., 2016). It was described that disease 
phenotype is worse when there is a substantial change in the physicochemical properties 
of the amino acids as measured by the Grantham score (A formula for the difference 
between amino acids that correlate better with protein residues substitution frequencies: 
composition, polarity, and molecular volume) (Grantham, 1974). 
The heritability of SCN1A is complex in GEFS+ and DS patients. The mutations 
reported for SCN1A-causing diseases were usually heterozygous as expected for a 
dominantly inherited disorder such as GEFS+ or with mutations that appears de novo as 
in DS. However, very interestingly, two new homozygous missense mutations of 
SCN1A gene were identified in 4 patients born from consanguineous parents (Brunklaus 
et al., 2015) and the phenotypic variability ranges from simple FS to DS. The 
heterozygous mutation in parents was conservative (preventing the channel from 
harboring functional changes) justifying why they remain unaffected. However, a 
change on both alleles had a cumulative and detrimental effect on the homozygous 
children. Basically, patients with heterozygous missense mutations can display a very 
mild phenotype if the mutation does not induce important conformational and functional 
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changes to the channel (mutation position and type of amino acid change), or very 
detrimental effects if it induces important modifications to the channel, justifying the 
heterogeneity of phenotypes in GEFS+ and DS patients.  
Another important feature is the possibly out-dated notion that inherited 
mutations are associated to GEFS+ and de novo mutations are associated to DS. Indeed, 
a recent study reported de novo mutations in 7 patients with GEFS+ (Myers et al., 
2017), again evidencing the importance of performing in depth genetic analysis in 
GEFS+ patients potentially carrying the de novo SCN1A gene mutations.  In parallel, 
DS patients carrying inherited mutations were also observed and will be described it in 
the next paragraph (Depienne et al., 2006). 
  
 
FIGURE 8. SO ME O F THE MUTATIO NS O F THE DISEASE SPECTRUM FOR NAV1.1-ASSOCIATED EPILEPSIES .  
A: Mutations in NaV1.1 channels in patients with generalized epilepsy with febrile seizures plus (GEFS+). 
B: Mutations in NaV1.1 channels in patients with Dravet syndrome (DS). The loss-of-function hypothesis for 
NaV1.1 genetic epilepsies (Mulley  et al., 2005). C:Increasing severity of loss-of-function mutations of 
NaV1.1 channels, noted above the arrow, causes progressively more severe epilepsy syndromes from 
familial febrile seizures to GEFS+and finally DS, noted below the arrow. Adatped from (Catterall, 2014). 
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2.2.2 Inher ited transmiss ion o f SCN1A-DS mutat ions. The 
concept of mosaic ism.  
DS mutations are mainly de novo mutations meaning that they appear for the 
first time in a given child and it is not transmitted from the parents. Another important 
issue contributing to the phenotypic variability in SCN1A gene-related epilepsies (and 
other types of genetic diseases) is the mosaicism*, phenomenon in which the person can 
have more than one population of cells with different genotypes. First cases of mosaic 
mutations were reported in DS families in 2006 (Depienne et al., 2006; Gennaro et al., 
2006; Marini et al., 2006, 2009) and it is now reported to account for 10% of all DS 
mutations (Depienne et al., 2010). These studies described many families in which the 
SCN1A mutation affected more than one sibling which led to genetic analysis of the 
parents. For example, a recent report showed a family with two affected DS children, 
and two unaffected parents. The in-depth genetic analyses of this family confirmed the 
diagnosis of affected father with mosaic DS-mutation (Tuncer et al., 2015). Mosaic 
parents of DS patients carry truncating mutations (Singh et al., 2001; Veggiotti et al., 
2001) and present phenotypes associated to the GEFS+ spectrum (explained by the 
lower number of affected cells). Depienne et al., 2010 reported 19 families (of which 6 
had GEFS+ spectrum) with inherited DS in the progeny (9 truncating, 9 missense and 1 
whole gene deletion mutation). The 6 families with GEFS+ were not mosaic, but there 
was one patient with DS in each family (Depienne et al., 2010). Mutations observed in 
DS patients were also previously reported in a GEFS+ families (Annesi et al., 2003; 
Escayg et al., 2000a). Therefore, truncating mutations cause DS in most of the cases if 
there is complete penetrance (not mosaic), and missense mutations can cause GEFS+ 
and DS according to the type of missense mutation and genetic modifiers. The authors 
therefore justify that DS disease can be at the severe end of the GEFS+ spectrum.  
2.2.3 Phenotyp ic var iability in GEFS+ and DS: genetic and 
environmenta l factors.  
Genetic and environmental factors also contribute to phenotypic variability in 
families with extreme phenotype distributions. Almost all the mutations in GEFS+ are 
missense mutations (Claes et al., 2009) that usually do not lead to complete ablation of 
channel function (Sugawara et al., 2002). However, complete truncating mutation can 
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cause GEFS+ or DS in two sibling brothers, indicating that genetic/environmental 
factors play a crucial role (e.i. family 12 in (Depienne et al., 2010)). It is apparent that 
the variability of phenotypes cannot be exclusively justified by the SCN1A mutation 
type, as in the same family, patients with the same mutation can have different 
phenotype severities (as observed in mutations transmitted from mosaic parents). 
Moreover, the same study reported a DS patient carrying the mild R1648H missense 
mutation first identified in the GEFS+ family (Depienne et al., 2010; Escayg et al., 
2000a).  Several genes have been identified for their involvement as genet ic modifiers 
(i.e. Scn8a in mice studies, SCN1B, SCN19, GABRG2 and CACNB4 in humans) 
(Gaily et al., 2013; Ohmori et al., 2008, 2013; Singh et al., 2009), possibly by 
compensating the NaV1.1 loss of function (Hawkins et al., 2016).  
All the reported genetic variables will be crucial determinants for the age of 
onset and the type/frequency of seizures that the patients present, and also in defining 
the outcome of the disease. The epileptic history of the patients in Na V1.1 mutation 
phenotypic spectrum is crucial for a correct diagnosis. It is therefore safe to assume that 
the genotype ↔ phenotype correlation is not applicable to all the cases.  Accord ing to 
this assumption, the diagnosis classification for a disease associated to the SCN1A 
mutation is given primarily according to the phenotypic spectrum, then taking into 
account the epileptic history (age at seizure onset, sensitivity to febrile seizures, 
type/duration of seizures and familial history of seizures) and the genetic profile (the 
type of mutation, the location in the gene, the genetic and environmental modifiers and 
the possibility of eventual mosaic caregivers). In the following section, an in-depth 
description about GEFS+ and DS diseases will be provided.  
3. GENETIC EPILEPSY WITH FEBRILE SEIZURES PLUS (GEFS+) 
3.1 GEFS+ historical, def init ion and epidemiology 
GEFS+ is the most variable syndrome of the SCN1A gene mutations spectrum 
and its prevalence in the world is unknown to date, but hundreds of cases have been 
reported in the literature. It was first described in 1997 by Scheffer and Berkovic, when 
they observed important correlations between generalized epilepsy and FS within 
several families, but with markedly different severity. The phenotypic spectrum in the 
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families was large, from FS, FS+ to GEFS+, and the genetic transmission trough 
autossomic dominance was clear.   
3.2 The genetics of  GEFS+ 
GEFS+ disease is divided into type 1 and type 2. Type 1 GEFS+ is associated to 
a mutation in the Nav ß1 subunit gene (SCN1B) and was first identified in 1998 
(Wallace et al., 1998). Type 2 GEFS+ is associated to mutations in the SCN1A gene, 
and cited earlier (Escayg et al., 2000a). Mutations in SCN2A, SCN9A, STX1B and 
GABRG2 have also been associated to GEFS+ (Meisler and Kearney, 2005). Escayg et 
al., 2000a found the first SCN1A mutations in GEFS+, in particular the R1648H 
missense mutation that was later also found in a patient with DS as mentioned earlier 
(Depienne et al., 2010). Nevertheless, genetic origin in the GEFS+ syndrome only 
accounts approximately for 10% of the cases (reviewed in (Lossin, 2009)), and the 
cause for the other 90% cases remain unknown.  
GEFS+ has long been associated to missense inherited mutations; however, due 
to the complex heritability of the SCN1A in GEFS+, some exceptions appeared.  In 
brief, not only heterozygous but also homozygous mutations have been observed 
(Brunklaus et al., 2015), not only missense mutations but also truncation mutations 
(mosaic or not) (Depienne et al., 2010; Singh et al., 2001; Veggiotti et al., 2001) and 
finally not only inherited mutations but also de novo mutations (Myers et al., 2017).  
3.3 Clinical characterizat ion of GEFS+:epilept ic history 
GEFS+ is a familial epilepsy syndrome where at least two family members have 
phenotypes consistent with the GEFS+ spectrum.  The patients usually present a first FS 
at a variable range of ages (6 months-6 years) (Singh et al., 1999). The most common 
feature in GEFS+ is the presence of FS+ (febrile seizures that persist beyond the age of 
6 years – until late childhood or adolescence) that tend to remit in adolescents when 
other seizure types take over. Patients with GEFS+ also present afebrile seizures within 
the range of FS (condition also considered as FS+) or after the period of FS remission 
(Scheffer and Berkovic, 1997; Singh et al., 1999). Both FS and FS+ may be associated 
with other seizure types. Often, GEFS+ also present GTC seizures, although focal 
seizures may occur and have been associated with more severe missense mutations and 
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poorer prognosis (Pineda-Trujillo et al., 2005; Sugawara et al., 2001). Because of the 
presence of focal seizures in some cases, the term was adapted to Genetic Epilepsy with 
Febrile Seizures plus (GEFS+) (Scheffer and Berkovic, 1997). In terms of generalized 
seizure types, absence seizures, myoclonic, atonic seizures, and myolonic-astatic are 
also observed in addition to GTC seizures (Scheffer and Berkovic, 1997; Singh et al., 
1999). GEFS+ patients with a mild phenotype display normal cognition upon 
neurological examination and normal EEG. However, more severe GEFS+ cases can 
present generalized epileptiform abnormalities in a normal EEG background.  
As far as we know, none had reported neuroimaging and neuropathological 
examinations in GEFS+ patients probably due to the generally positive long-term 
outcome in patients. 
3.4 Therapeutic strategy and long-term outcome 
The treatment is considered in the children if they have several individual 
episodes of FS. In the cases reported by Scheffer and Berkovic, 1997, most had febrile 
seizure onset in the first year of life and many had remittance of the seizures in the first 
or second decades, although some had seizures into adulthood. The treatment window 
and response can vary within the same family. It was reported that two GEFS+ 
mutations, that conferred a change in the NaV1.1 folding were partially rescued by 
treatment with anti-epileptic drugs (Rusconi et al., 2007, 2009). This might be the cause 
of successful treatment response in mild cases of GEFS+. However, GEFS+ patients 
with more severe phenotypes can present pharmaco-resistance (Grant and Vazquez, 
2005).  
Long-term outcome in GEFS+ children is usually self- limited and favorable. 
Seizures tend to decrease and in general, patients do not develop cognitive and 
behavioral deficits (Scheffer and Berkovic, 1997). However, some cases have been 
reported to exhibit mild psychiatric (Mahoney et al., 2009; Osaka et al., 2007) or 
cognitive deficits (Myers et al., 2017). On one hand, seizure intensity and severity have 
been pointed to contribute to the behavioral and cognitive outcomes, but on the other 
hand, the mutation severity might also be involved. GEFS+ spectrum is comparable to 
DS spectrum (Singh et al., 2001), and it has been suggested that DS could be a severe 
end of GEFS+ spectrum. 
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4. DRAVET SYNDROME (DS) 
4.1 DS historical, Definit ion and Epidemiology 
Severe myoclonic epilepsy of infancy (SMEI) was first described in 1978 in a 
French medical journal by doctor Charlotte Dravet, psychiatrist at Marseille Hospital 
(Dravet, 1978). An increased evidence of common cases emerged from all around the 
world, but myoclonic seizures were not always present in these patients (Ogino et al., 
1989; Yakoub et al., 1992). Also the disease was not limited to infants, because the 
epilepsy persisted in adults. The name of the disease was then adapted to Dravet 
Syndrome (DS) in 1989. DS is a rare and severe epileptic encephalopathy (Catarino et 
al., 2011) affecting around 1/30 000 patients in France (Yakoub et al., 1992) and 1/15 
000 in the USA (Wu et al., 2015). The gender incidence is equivalent, except for DS 
caused by mutations in the PCHD19 gene that affects a small percentage of females 
(Depienne et al., 2009). 
The diagnosis for DS is based on a first febrile or prolonged afebrile clonic 
seizure occurring during the first year of life in a normally developed child who can 
have or not family history of FS. If the patient presents two seizures associated to an 
increase in body temperature and if at least one of these seizures lasts more than five 
minutes possibly evolving to status epilepticus (SE)*, a diagnosis of DS is suspected 
and the genetic analysis is performed. Also, DS patients present sensitivity to fever and 
light.  
DS represents the epilepsy type with highest mortality incidence that can occur 
at any age, but mainly in childhood. The exact mortality incidence was not homogenous 
in all the studies. However, it varies from 5% to 10% at early age. The main causes of 
death reported were the Sudden Unexpected Death in Epilepsy (SUDEP), SE, accident, 
infection or unknown causes. SUDEP is generally defined as the sudden, unexpected, 
witnessed or unwitnessed, nontraumatic, and non-drowning death in patients with 
epilepsy with or without evidence for a seizure, and excluding documented SE, in which 
postmortem examination does not reveal a structural or toxicologic cause for death 
(Nashef, 1997). Mechanisms involved in SUDEP seem to be correlated with sudden 
cardio-respiratory arrest and the main risk factor seems to be the high level of GTC 
seizures (Hesdorffer et al., 2011; Sowers et al., 2013). It confers the highest reported 
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cause of death in DS, a condition that occurs mostly during sleep, in children who did 
not show a recent aggravation of the disease and under controlled medication.  
4.2 The genetics of  DS 
Since 2001, it is known that most of the DS cases are associated to SCN1A gene 
mutations (Claes et al., 2001). DS is the most severe disease of the NaV1.1 mutation 
spectrum, with 80% of the patients harboring a mutation in the SCN1A gene. Some 
patients who remain negative in genetic analysis have deletions or chromosomal 
rearrangements involving SCN1A. Mutations in other genes have also rarely been 
associated with DS, especially PCDH19 mutations (Depienne et al., 2009). SCN1A 
mutations arise usually de novo, but ~10% are inherited from mosaic parents, as 
described above (Gennaro et al., 2006). 
4.3 Clinical characterizat ion of DS: Epilept ic history 
Contrarily to GEFS+ that present a large spectrum of phenotypic severity, DS 
presents marked characteristics and a homogeneous phenotypic spectrum. The first 
febrile or afebrile seizure usually appears before the age of 1 year, within a range of 
ages from 2 to 12 months and the final diagnosis of DS disease is usually made between 
2 and 3 years of age (Bureau and Dalla Bernardina, 2011). Some studies suggested a 
correlation between the age of the first seizure with the severity o f the phenotype, i.e. 
lower ages of onset correlating with poorer prognosis (Cetica et al., 2017; Ragona et al., 
2010). The disease progression can be divided in three phases: the febrile phase, the 
worsening phase and the stabilization phase. The first seizure is usually clonic, 
generalized or focal triggered by fever or body temperature elevation (after a bath or 
high physical activity) and lasts longer than a simple FS (>15 minutes). The first seizure 
might also be afebrile in some cases (Ragona et al., 2010), but this is still controversial 
(Nieto-Barrera et al., 2000). These seizures can evolve into SE (seizures lasting longer 
than 30 minutes) that occurs at least once in each patient (Chipaux et al., 2010). The SE  
can be febrile (usually in the first year of life – duration >30 minutes) and obduntation 
(non-convulsive) between 4-8 years of age – duration can last for days. Isolated cases of 
focal myoclonic jerks were observed to precede the GTC seizures in a few children 
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(Dravet et al., 2005; Oguni et al., 2001). At the onset (febrile period), patients usually 
experience an average of one seizure per month or even less.  
Within the worsening seizure period, patients present multiple seizure types 
including: GTC seizures, generalized clonic seizures, myoclonic seizures, atypical 
absence seizures and simple and complex focal seizures (with or without secondary 
generalization). The end of the active period can vary from on child to another, usually 
until 3 years of life but sometimes extending up to 13 years of age. Later on, partial 
seizures, myoclonic seizures, atypical absenses and SE tend to disappear. GTC seizures 
persist, at least until reaching 25 years old when they tend to remit (Dravet, 2014). In 
adults, seizure-free periods of 1-5 years are low (>10%) (Akiyama et al., 2010; Jansen 
et al., 2006). 
At the onset, the EEG of DS children has a normal background, during awake 
and sleeping states. During GTC seizures patients show typical EEG pattern, 
characterized by a transient postictal flattening, which is rapidly replaced by diffuse 
delta waves (Bureau and Dalla Bernardina, 2011) (FIGURE 9).   
 
 
FIGURE 9. EEG TRACE O F A GENERALISED TO NIC-CLONIC SEIZURE IN AN 8-YEAR OLD DS PATIENT. 
FRO M (DRAVET AND GUERRINI, 2011) WITH JLE PUBLISHER AUTHO RIZATIO N TO  REPRODUCE. 
At the onset of the seizure, a brief burst of fast activity correlated to muscle tonus (R DELT, R EXT, L 
DELT), the clonic jerks progressed to GTC seizure and, at the ictal end, it is possible to see the brief 
flattening followed by low voltage theta* activity. 
R DELT = Right deltoid muscle, R EXT= right extensor muscle, L DELT = Left deltoid muscle  
 
With the disease progression, the EEG activity can be maintained at normal 
background level during awake phases in some patients, while in the others the 
background activity can become slower and poorly organized with presence of alpha-
rhythm, an increase in theta* activity and generalized or multifocal interictal spikes 
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(Bureau and Dalla Bernardina, 2011). During the night, the interictal* EEG is usually 
abnormal, due to the persistence of higher ictal* events during sleep.  
4.4 Neuroimaging and neuropathology 
There are not many studies about imaging or neuropathological studies in DS.  
No gross brain abnormalities using Magnetic Ressonance Imaging (MRI) or Computer 
Tomography (CT) have therefore been detected in the published studies. Only Dalla 
Bernardina et al., 1982 and  Dravet et al., 2005 reported a few cases presenting brain 
atrophy with increased white matter. In 2005, Dravet et al., reported that MRI changes 
were observed in 4 out of 35 DS patients  carrying SCN1A mutations, with one 
presenting hippocampal atrophy and another cerebellar atrophy (Dravet et al., 2005). 
Olivieri et al., 2016 analyzed a cohort of 20 patients, in which 4 patients presented 
either ventricular enlargement with corpus callosum thining, hippocampus atrophy, mild 
cerebellar atrophy or diffuse cortical atrophy.  Neither seizures frequency, age at seizure 
onset, nor the mutation was correlated with the neuroanatomical abnormalities in these 
patients.  
4.5 Therapeutic strategy and long term outcome 
DS is an intractable disease characterized by high pharmaco-resistance. The first 
therapeutical goal in DS consists of reducing the seizures frequency (in particular long-
lasting seizures - as SE) and to minimize the anti-epileptic drug toxicity. The second 
goal is to reduce the associated co-morbidities (reviewed in (Wirrell, 2016)).  
During the first years of DS progression, the seizures are extremely resistant to 
all treatments available until now, and seizure-free patients have rarely been described 
even after passing the worst epileptic period (Jansen et al., 2006). 
Na+ channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) 
have been used mainly before the SCN1A mutation identification, but appeared to 
clearly exacerbate the seizure phenotype in DS patients (Ceulemans, 2011; Chipaux et 
al., 2010; Guerrini et al., 1998; Wang et al., 1996).  It was then suggested to stop using 
them. Currently, first lines of treatments focus on benzodiazepines like clobazam, 
clonazepam, diazepan to increase GABAergic function and decrease brain excitability. 
Valproate is also used, but its mechanism of action is less specific including voltage-
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gated sodium channel and NMDA receptors blocker and enhancer of GABAergic 
function. 
Stiripentol is used as a second- line drug. Its use has clearly reduced the number 
of seizures including SE in patients, helping medical doctors to reduce the high 
mortality incidence caused by these prolonged seizures. Stiripentol is considered as the 
drug that, in combination with other drugs, has shown higher effectiveness in DS 
patients (Chiron et al., 2000; De Liso et al., 2016; Kassaï et al., 2008). It acts by 
increasing GABAergic function, but also increasing the effects of the other antiepileptic 
drugs on the GABAergic system (Fisher, 2011). Stiripentol is usually combined with 
topiramate that, as valproate, has a large spectrum of action (voltage-gated sodium 
channels and AMPA receptors blocker and enhancer of GABAergic function). In 
summary, the most common recent combined treatment comprises first of valproate 
with or without a benzodiazepine, and then of stiripentol with topiramate (Wirrell, 
2016).  
Yet, the seizures tend to be resistant even though multiple medications exhibit 
clinical evidence of efficacy (by reducing the number of seizures) in DS: stiripentol, 
valproic acid, clobazam, bromide and topiramate. 
Two recent treatments are in development (cannabidiol and fenfluramine). 
Cannabidiol was highly mediatic in the press however the very few studies who 
evaluated its efficacy in DS patients showed low level of responsiveness to the drug 
(O’Connell et al., 2017; Press et al., 2015). A current study is being done to test its 
efficacy.  
Fenfluramine is an agent that releases serotonin by disrupting vesicular storage 
and reversing serotonin transporter function, is actually on phase III of clinical trials, 
after showing remarkable efficacy in DS at low-dose concentration in seizures reduction 
(Ceulemans et al., 2016; Schoonjans et al., 2017). The effects of fenfluramide on 
cognition have not been assessed yet.  
Alternative non-pharmacological treatments have been proposed to combine 
with the anti-epileptic drugs notably: vagus nerve stimulation and ketogenic diet. Vagus 
nerve stimulation have been effective in treating several forms of refractory pediatric 
epilepsy (Cersósimo et al., 2011). However, the studies done in DS patients were not 
very promising (Zamponi et al., 2011). Only very recently, a new study showed 
improvement in seizure frequency (>50% of patients reduced significantly the seizure 
frequency) with behavioral and cognitive ameliorations in 75% of a small cohort of 
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patients submitted to vagus nerve stimulation in combination with anti-epileptic drugs 
(Fulton et al., 2017). The studies using ketogenic diet in combination with anti-epileptic 
drugs have been much more beneficial for patients than vagus nerve stimulation. 
Several studies reported seizure reduction from 50 to 99% in patients (Caraballo et al., 
2011; Korff et al., 2007), and even with improvement in behavioral phenotypes in some 
patients (Laux and Blackford, 2013; Nabbout et al., 2011) 
Other alternative treatments as immunotherapy have been tried without reaching 
significant conclusions to date (Chabardès et al., 2002). 
No published reports compared the effects of different anti-epileptic drug 
administration schedules for GTC seizures or SE in patients with DS. This could 
probably explain some worsening in the phenotypes, mainly in cases where Na+ channel 
blockers are still being administrated.  
Seizures importantly decrease the quality of life of DS patients and their 
relatives. In addition to seizures, important psychiatric, neurological and cognitive co-
morbidities are present in DS patients. To improve the comorbidities in DS, several 
therapies are used notably, occupational and speech therapy, social work and others.  
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Chapter 3- BEHAVIORAL AND COGNITIVE: LONG-TERM OUTCOME IN DRAVET 
SYNDROME :  
The long-term outcome in DS patients is always unfavorable.  The development 
is normal in the first year of life (before the severe period of high seizures intensity) and 
children can have a normal life. They usually start walking at normal age but then tend 
to show progressive development delay and regress, becoming severely impaired. 
Among the psychiatric and behavioral abnormalities shown in DS patients, it is always 
hard to say which ones are consequences of the disease and which ones result as side 
effects of the anti-epileptic drugs. DS patients develop neurological, psychiatric and 
cognitive abnormalities.  
1. NEUROLOGICAL ABNORMALITIES IN DRAVET SYNDROME 
Neurological signs progressively appear in DS children. They are characterized 
by hypotonia, ataxia, pyramidal signs, interictal myoclonus and “crouch” gait. 
Hypotonia, meaning low muscle strength, is observed very early in DS children (around 
one year of age). Patients have difficulty to stand up correctly and exhibit orthopedic 
problems later on (Dalla Bernardina et al., 1982). In addition to muscle strength 
abnormalities, DS children have also altered coordination of muscle movements.  
Pyramidal signs are the results of the activity of pyramidal cells in the motor cortex. It is 
usually present as voluntary, discrete and skilled movements that are observed in DS 
children by spasticity or walking on tiptoes. The frequency of these events is not 
continuous and is more frequent after severe seizure episodes (Caraballo and Fejerman, 
2006; Dalla Bernardina et al., 1982). In addition to the “voluntary” abnormal 
movements, the children also develop involuntary movements. Ataxia, the lack of 
muscle coordination, is reflected in DS children when they start walking, at around 12-
18 months (sometimes delayed) (Dalla Bernardina et al., 1982; Dravet et al., 2005). 
These neurological signs are observed in the majority of the patients and were 
hypothetically correlated to a cerebellar co-factor in DS disease progression (Battaglia 
et al., 2013). Additional involuntary movements are the interictal myoclonus 
(myoclonic jerks that appear independently to seizure events) that are more frequent 
after intense seizure activity and transitory in patients. They appear as involuntary facial 
or limb movements (Nabbout et al., 2003).  All these neurological signs and skeletal 
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abnormalities lead to a particular posture in DS patients. They usually maintain a 
normal or nearly normal gait in the first 5 years of age that then evolves into a “crouch” 
gait associated with skeletal misalignment in the lower limbs in the majority of patients 
after 13 years of age (Rilstone et al., 2012). This handicap is degenerative and 
irreversible prominently affecting all the motor skills which lead hence to the inability 
to realize the patient’s daily- life needs.  
2. COGNITIVE DELAY AND REGRESSION IN DRAVET SYNDROME 
Cognitive decline in DS has no specific age of onset. Visual functions seem to 
be primarily affected in DS children. Fine visuo-motor (i.e. object assembly, coding) 
and visuo-spatial (i.e. block design) skills through eye-hand coordination seem to be 
altered in the first year of life in children, even before the appearance of other cognitive 
symptoms and clinical confirmation of the syndrome (Battaglia et al., 2016; Chieffo et 
al., 2011a; Ricci et al., 2015; Wolff et al., 2006a).  Moreover, language is delayed in DS 
patients. The reported studies classify language capacities in three levels (average 
speech, isolated words but not the ability to construct sentences and complete lack of 
speech). These speech incapacities directly impact the school level of DS children, and 
some with lower prognosis can not even attend the school (Caraballo and Fejerman, 
2006; Fujiwara et al., 1992; Wolff et al., 2006a; Yakoub et al., 1992). Comparing to 
visual capacities, language seems to be more conserved or partially recover in late 
childhood in DS children (Chieffo et al., 2011b). However, Acha et al.,  showed that 
visual processing was preserved in their cohort of 8-14 years old DS patients, while 
verbal information was more affected (Acha et al., 2015).  
Memory function has not been as explored in DS study cases as behavioral 
phenotypes and visual skills, possibly due to the youth of patients. A study evaluating 
memory processing shows that verbal working memory was importantly impaired 
demonstrating, in the majority of DS children, an inability to integrate sensory serial 
events (Battaglia et al., 2013). This could also be correlated with the lack of visual and 
auditory attention demonstrated by the children, and other authors suggested a 
cerebellar role (Gottwald et al., 2003). However, as mentioned above, the PFC plays a 
crucial role in attention driven tasks (Clark et al., 2015), so alterations in the function of 
this structure in DS patients could also explain impairments in working memory tasks. 
Impaired executive function was reported in all the studies, which highlight an 
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important perturbation in the sequencing of activity plan (Acha et al., 2015; Chieffo et 
al., 2011a; Olivieri et al., 2016), again pointing to alterations in brain structures driving 
executive functions like the PFC.  
Sleep disturbances can importantly affect the cognitive profile in DS children 
but have been more controversial. There are not many studies that had a look into the 
sleeping patterns of DS children. Chieffo et al., 2011a reported sleep problems in all 5 
DS patients studied but did not specify the abnormalities observed. More recently,  
Dhamija et al., 2014 observed non-REM sleep abnormalities typical of immature 
cortical synaptic activity but no changes in the sleeping architecture in their cohort. The 
many hypothetical reports about sleeping abnormalities in DS children can be possibly 
due to the intense seizure activity during the night, and that certainly affects the norma l 
sleeping cycle during the night, but probably not inducing important architectural 
changes (Oguni et al., 2001). In sum, the major reports about cognitive dysfunctions in 
DS patients are about vision (visio-spatial, visio-motor), language, attention, working 
memory and executive functions, suggesting the role of PFC-mediated damage. Visuo-
spatial impairments were also reported (Chieffo et al., 2011b) indicating that the 
hippocampus might be affected in these children.  
3. PSYCHIATRIC/BEHAVIORAL ABNORMALITIES IN DRAVET SYNDROME 
As mentioned above, attention deficits frequently appear during the second year 
of life and are reflected in the many neuropsychological tests performed by clinicians.  
Correlated to the lack of attention, DS patients show increased activity and stereotypies. 
Thus, their attention deficits and hyperactivity reflect the poor eye-contact and the 
social integration difficulties (Battaglia et al., 2013). Autistic traits are often observed in 
DS patients, like difficulty to establish eye-contact, no emotional reciprocity, difficulty 
to establish friendships and to deal with social rules (Chieffo et al., 2011a, 2011b; 
Villeneuve et al., 2014). However, while many authors reinforce the fact that DS 
children are not autistic but have severely impaired social contact (Li et al., 2011; Wolff 
et al., 2006a), others promote autistic traits in these children (Berkvens et al., 2015). 
Along the same line, DS patients tend to be repetitive in their activities and to have 
obsessive attitudes. During adolescence, some DS cases can display internalized 
behaviors : anxiety, depression or exhibit externalized behaviors: becoming aggressive, 
hyperactive and rule-breaking (Akiyama et al., 2010; Battaglia et al., 2013; Olivieri et 
 
30 
al., 2016). Excessive familiarity with strangers, and poor danger awareness was reported 
by Villeneuve et al., 2014. In adulthood, however, patients seem to be calmer, but still 
maintain their tendency to perseverate, difficulty to communicate and exhibit motor 
impairments that render them socially isolated. In summary, the main behavioral 
features in DS patients are characterized by hyperactivity and social isolation and in 
some cases internalized or externalized behaviors. In the studies that performed 
continuous behavioral and cognitive analysis through life, there was high evidence that 
the phenotype tends to get worse. In adulthood, fully independent patients have rarely 
been reported, but some can become only partially dependent (Akiyama et al., 2010). 
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Chapter 4- ANIMAL MODELS OF EPILEPSY AND SEIZURES CONSEQUENCES ON 
COGNITION 
Several mouse and rat models of epilepsy have been developed and described in 
the literature. There are two types of models: 1) models of acute or chronic seizure 
induction in a normal brain that does not indicate the presence of an epileptogenic 
condition and 2) models that are associated with permanent “epileptic” disturbances (i.e. 
mice/rats carrying genetic mutations associated to epileptic phenotypes).  
Although experimental studies using animal models are crucial to understand the 
physiopathology of epilepsy and develop anti-epileptic drugs, they also have many 
limitations. The seizure types in humans are very diverse, and some of them might be 
hard to reproduce in the rodent models.  Accordingly, different epileptic syndromes are 
characterized by the typical seizures that the patients present. Although several mouse 
models seem to reflect human epilepsies, it is impossible to imagine that the mouse 
model will faithfully reflect all the aspects of the human epileptic syndrome 
(Guillemain et al., 2012).  In addition, the genetic heterogeneity of backgrounds 
observed in human cohorts does not reflect the homogeneity of a particular group of 
animals with very little genetic variability, under controlled house conditions in the 
animal facility.  Rodent models carrying genetic mutations found in epileptic patients 
are still one of the most accepted models by the epilepsy scientific community (Frankel, 
2009; Guillemain et al., 2012). They usually fulfill three criteria, namely face validity 
(analogy to the human symptoms), construct validity (conceptual analogy to the cause 
of the disease) and predictive validity (specific response to treatments in patients). The 
rodent models of epilepsy have contributed to important advances and knowledge of 
human epilepsies and the associated comorbidities, contributing to the drug-therapy 
improvement and the more accuracy in the diagnosis.  
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1. MODELS OF RECURRENT SEIZURES AT EARLY-AGE ON THE DEVELOPING 
BRAIN AND THEIR CONSEQUENCES ON BEHAVIORAL AND COGNITIVE 
PHENOTYPES 
1.1 Hyperthermia-induced seizures: the model of febrile seizures, 
its epilept ic and behav ioral consequences 
As stated earlier, FS are convulsions associated with fever and are typically 
elicited by temperature higher than 38.5ºC in humans (Ellenberg and Nelson, 1978). 
Fever, an adaptive host defense response to viral and bacterial infections, and other 
inflammatory stimuli, relies on coordinated neuro- immune interactions between the 
periphery and the brain (Alheim and Bartfai, 1998). Yet, FS are not identical to 
hyperthermia- induced seizures, because febrile seizures occur in response to fever that 
triggers the release of pro-inflammatory cytokines (interleukin (IL)-1, IL-6 and tumour 
necrosis factor (TNF)-α) (Alheim and Bartfai, 1998). It was previously described that 
inducing fever in rodents, through injection of established pyrogenic agents (i.e. 
lypopolysacharide) to provoke an increase of body temperature of more than 1ºC (in an 
inflammation context) is almost impossible (Cartmell et al., 1999; Fewell and Wong, 
2002; Heida and Pittman, 2005). However, while children present FS, they are also 
sensitive to hyperthermia in most cases. Moreover, FS and hyperthermic seizures share 
common mechanisms trough cytokines as mediators (i.e. Il-ß) (Dubé et al., 2005; Gatti 
et al., 2002).  
The rat model of experimental FS was largely described in the literature (Baram 
et al., 1997; Bender et al., 2003; Dubé et al., 2005, 2012). Simple FS, lasting less than 
15 minutes, are known to be self- limited, not causing brain damage and cognitive 
impairment (Berg and Shinnar, 1996). The effect of complex FS (lasting longer than 
15minutes), however, is more controversial. Briefly, FS are induced in P10-11 rats and 
P14-15 mice by elevating the body temperature at a rate of 0.5ºC every 2 minutes using 
hot air. Seizures are usually triggered at an average of 41ºC. Animals are maintained in 
hyperthermia (40-42ºC) from the initial behavioral sign of a seizure (time 0) to a total 
duration of 15 minutes for simple FS or 30 minutes for complex FS. Neither type of FS 
induces neuronal death (Bender et al., 2003; Chang et al., 2003). 
The occurrence of FS increases the probability of recurrent FS in children 
(Annegers et al., 1987) and in animal models (Dubé et al., 2010; McClelland et al., 
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2011; Yagoubi et al., 2015). In animal models, the occurrence of further epileptic 
seizures and the reduced thresholds to chemically induced seizures after one prolonged 
FS episode indicate that FS lead to epileptogenesis in the immature brain (Dubé et al., 
2010).  
Many studies in rodents addressed the neuropathological consequences of FS. It 
was clearly showed that FS perturb the neuronal network of the hippocampus rending it 
hyperexcitable throughout life without cell loss (Bender et al., 2003; Dube et al., 2000; 
Dubé et al., 2010). However, fewer reports investigated the long-term effects of FS in 
cognition. This can be associated to the benign or self- limited effect of these seizures in 
young children and the controversies about their effects. One prolonged hyperthermic 
seizure (~25-30 minutes) was shown to cause memory deficits in the spatial Morris 
water maze test in rats, however the effects were usually moderate or transient (Dubé et 
al., 2009; Rajab et al., 2014; Yagoubi et al., 2015). Also, the results in animal models of 
FS are contradictory. Indeed, after one prolonged hyperthermic seizure (30 minutes) in 
rats, some authors showed alterations in hippocampus synaptic plasticity (increased 
LTP and reduced LTD) but no spatial memory deficits (Lemmens et al., 2009; 
Notenboom et al., 2010). Interestingly, one study in mice has shown an age-dependent 
effect of FS on cognition. While FS induced at P10 cause cognitive problems, when 
induced at P14 they cause an enhancement in hippocampal-dependent memory 
performance (Tao et al., 2016). 
Simple episodes of hyperthermic seizures (5 minutes) have been induced 
chronically in rats (1, 3 and 9 episodes over 1, 3 and 3 days respectively) at P10 and the 
animals were tested for spatial memory at P35 and at P60. One simple FS did not 
change memory performance at P35 or at P60, however the animals who experienced 3 
or 9 seizures, respectively exhibited memory deficits at P35 and those where maintained 
at P60 (adulthood) in the group which experienced 9 seizures, whereas it recovered in 
the group with 3 seizures (Xiong et al., 2014).  
Thus it was concluded that one episode of brief hyperthermia- induced seizure 
(<15 minutes) does not cause memory deficits, but long- lasting or repeated episodes of 
these seizures seem to affect normal brain development. The behavioral results seem to 
indicate memory deficits caused by the seizures. Additional studies are however 
required to confirm these findings.   
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1.2 Flurothyl-induced seizures: its epilept ic and behav ioral 
consequences 
Flurothyl, a GABAA antagonist, is a volatile chemoconvulsant that was 
previously used to induce seizures in severely depressed patients as an alternative to 
electroconvulsive therapy (Fink, 2014) and has been used to induce repeated seizures in 
rats and mice (Holmes et al., 1998). It is a good model for repeated seizure induction, 
due to the low mortality level and the rapid reestablishment of the animals following the 
seizure episode.  
Flurothyl is infused into a plexiglass closed chamber usually at a rate of 
20µL/min, until the seizure occurs. The number of induced seizures usually varies. 
Holmes et al, reports a seizure-induction protocol of a minimum of 25 seizures and a 
maximum of 100 seizures induced during 5-10 days (5 -8 seizures p/day) (Holmes et al., 
1998). Seizures are induced at different ages from P1 to P70. A follow up study did not 
report spontaneous seizures following the protocol of flurothyl- induced seizures in 
neonatal rats (Holmes, 2009). However, recently, Kadiyala et al. 2016, induced seizures 
for 1, 5 and 8 days, at 7 weeks of age in C57BL/6 mice and observed the appearance of 
spontaneous seizures. The authors report that one single seizure does not induce the 
appearance of subsequent GTC seizures, 5 seizures and 8 seizures induced subsequent 
GTC seizures in 28% and 95% of mice respectively. These spontaneous seizures in 
remitted within 1 month (Kadiyala et al., 2016) 
At the neuronal network level, repeated flurothyl- induced seizures lead to 
persistent decreases in GABA currents in the hippocampus and neocortex (Isaeva et al., 
2009, 2010, 2013), enhanced short-term plasticity and LTP alterations (Hernan et al., 
2013; Isaeva et al., 2013; Karnam et al., 2009a).  
The effects of single or chronic induction of seizures by flurothyl during early 
life on cognition were also evaluated. One single flurothyl- induced seizure at P6 does 
not induce cognitive changes in rats in adulthood (Bo et al., 2004).  Karnam et al., 
2009a induced seizures from P0 to P10 and P15 to P25 (5seizures/day and 50 seizures 
in total) and the animals were tested for spatial memory 2 weeks following seizures. 
The authors observed that neonatal seizures impaired spatial memory with no 
differences between age of induction. Other studies used the following protocols: from 
P1 to P10 (7-8 seizures p/day:75 seizures in total), from P15-P37 (4-5 seizures 
p/day:100 seizures in total) or from P7-P11 (3 seizures p/day:15 seizures) and 
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behavioral testing was usually conducted 2 to 3 weeks following the seizures (P40). All  
the protocols above induced cognitive impairment in the different behavioral tasks 
tested (mainly spatial and working memory deficits) (Karnam et al., 2009b, 2009a; 
Kleen et al., 2011; Nishimura et al., 2011; Zhou et al., 2007). When tested at P90, 
almost 80 days following recurrent seizures induction from P0 to P9 (5seizures p/day – 
total of 50 seizures) no behavioral changes were observed in seizure- induced rats 
(Huang et al., 1999).  
Together, the data on flurothyl induced-seizures indicate that recurrent neonatal 
seizures (more than 15 seizures, and usually more than one seizure per day) induce 
cognitive defects in adulthood, with no difference between the ages at induction in 
childhood (P0-P10 or P15-P37), but that seizures induced in adulthood seem to be 
reversible long-time after seizures induction. 
The long-term effects of repeated seizures on the otherwise normally developing 
brain are still controversial. While it is clear that they increase epileptogenesis and alter 
neuronal circuits, their effects on cognition are not consistent. The majority of the 
studies suggest hippocampus-dependent memory deficits even though these effects 
seem to be transient or moderate.   
2. ANIMAL MODELS HARBORING THE SCN1A MUTATION 
2.1 Using animal models of  Scn1a mutation 
The first Scn1a+/- mutant mouse was created by (Yu et al., 2006a). This model 
carries a Scn1a knock-out (KO) gene mutation obtained by target deletion of the last 
coding exon of the Scn1a gene (encodes the domain 4 (D4) downstream of the segment 
3 (S3) and the cytoplasmic tail). Following this model, other models of DS pathology 
have been created (Miller et al., 2014; Ogiwara et al., 2007; Tsai et al., 2015) and two 
models of GEFS+ have also been developed in 2010 and carry missense mutations  
(Martin et al., 2010a; Mashimo et al., 2010) (TABLE 3). To more intensively describe 
the neurophysiopathology and address specific neuronal populations in specific brain 
areas, several conditional mouse models have been developed and are described in the 
bottom part of TABLE 3. 
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TABLE 3. SCN1A MUTANT MOUSE/RAT MO DELS (TYPE O F MUTATIO N, LOCATION, ASSOCIATED 
DISEASE). 
 
2.2 Impaired neuronal inhibit ion in Scn1a mouse models: Role of 
interneurons 
The creation of the Scn1a+/- KO model by (Yu et al., 2006a), was very important 
to better understand the neurophysiopathology in DS. The KO mutation caused the 
reduction of NaV1.1 staining by half in heterozygous animals and to 100% in 
homozygous animals. Homozygous mutant mice (Scn1a-/-) showed severe ataxia, 
seizures beginning at day 9 (coinciding with the beginning of the channel’s expression) 
and died by day 15 (Yu et al., 2006a), showing that NaV1.1 is essential for life. The 
NaV1.1 staining was observed in pyramidal neurons and inhibitory interneurons in the 
hippocampus but also in other brain areas. Using electrophysiogical tools, they showed 
that the NaV1.1 driven sodium current of the hippocampus pyramidal cells was lower 
than 10%, while it corresponded to approximately 75% in the interneurons.  Moreover, 
the number of interneurons was unaltered (anti-GAD antibody staining), and most of 
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them where positive for NaV1.1 in WT mice. The authors clearly illustrated a substantial 
decrease in sodium current levels of interneurons in the Scn1a+/- and Scn1a-/- mutant 
mice, correlated with a decrease in firing frequency (as seen by dec reased number of 
action potentials for a given current injection) in those interneurons. The results 
confirmed that NaV1.1 haploinsufficiency caused brain excitability rather than 
inhibition. The excitability was thus associated to a loss of inhibition med iated by 
interneurons, which suffered a massive NaV1.1 reduction. The excitability and sodium 
currents in pyramidal cells were unaffected in Scn1a+/- mice (Yu et al., 2006a). This 
study was a major discovery for the field because: 1) Scn1a+/- mice had striking 
phenotypic similarities to human DS pathology that varies according to the genetic 
background (as observed in humans), Thus, this model could be used in pre-clinical 
investigation of pharmacological treatments; and 2) the electrophysiological studies 
allowed the extrapolation of the cause of excitability and epileptic activity in DS 
patients based on the interneuron physiopathology. In sum, NaV1.1 are preferentially 
expressed in GABAergic neurons, although a small fraction was observed in the 
excitatory cells and this suggests that DS disease is caused by a loss of GABAergic-
driven inhibition.  
With the creation of other Scn1a mutant mouse models, these results were 
further confirmed (Martin et al., 2010a; Ogiwara et al., 2007). While further 
investigating the consequences of NaV1.1 reduction of function in the Scn1a
RH/+ mouse 
model (KI-missense mutation), Hedrich et al., 2014 showed that in addition to 
previously reported reduction in Na+ current in the cortex, there was reduction in the 
sodium current of GABAergic thalamus and hippocampus characterized by a deficit in 
action potential firing at the AIS (Hedrich et al., 2014). Using the Scn1a+/- mice, 
Kalume et al. 2007 observed that the firing rates of Purkinje neurons (a class of 
GABAergic cells in the cerebellum) from mutant (-/- and +/-) mice were substantially 
reduced, as seen previously in the hippocampus (Yu et al., 2006a), an alteration that 
could be responsible for ataxia observed in these mice. Later, the same authors reported 
reduced Na+ currents and action potential firing in GABAergic neurons of the reticular 
nucleus of the thalamus potentially related with the sleep abnormalities observed in the 
Scn1a+/- mice and reported in the same study (Kalume et al., 2015). 
The Scn1a-KI mouse model created by Ogiwara et al., 2007  showed that Nav1.1 
is primarily localized at the AIS, axons, and soma of parvalbumin (PV+) interneurons in 
the developing neocortex and hippocampus.   
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In 2012, Cheah and her collaborators, created a conditional mouse model with 
the specific ablation of NaV1.1 in the forebrain and observed that the mice had a severe 
DS-like phenotype similar to the Scn1a+/-KO mouse created before by the same 
laboratory (Cheah et al., 2012; Yu et al., 2006a).  
While the studies with the KO mouse evaluated the effect of the specific deletion 
on spontaneous seizures frequency and survival rate, the Scn1aRH/+ (model of GEFS+) 
was used to evaluate the seizure susceptibility that characterized the model because 
these mice do not otherwise present enough spontaneous seizures and the mortality is 
inexistent. Dutton et al. 2013 suggested that the phenotype could be due to a specific 
type of interneurons and studied the different contributions of the excitatory and 
inhibitory neurons. They showed that, in the hippocampus and neocortex, 69% of 
NaV1.1 immunoreactive neurons were also positive for PV. In contrast, 13% and 5% of 
NaV1.1 positive cells in the hippocampus and neocortex, respectively, were found to co-
localize with excitatory cells. Next, they reduced the expression of Scn1a in either a 
subset of interneurons (mainly PV interneurons) or excitatory cells by using conditional 
ablation of Scn1a gene in mice and observed that the reduction in interneurons of the 
neocortex and hippocampus was sufficient to reduce thresholds to induced-seizures, 
whereas thresholds were unaltered following inactivation in excitatory cells (Dutton et 
al., 2013).  
Ogiwara et al., 2013, using the DS mouse model, showed that NaV1.1 
haploinsufficiency in excitatory and inhibitory neurons are both involved in the 
pathology of DS. By using three conditional mouse models that had the conditional 
ablation of Nav1.1 specifically in forebrain interneurons, excitatory neurons or both, 
they observed that: 1) the ablation of NaV1.1 specifically in excitatory neurons did not 
change the phenotype; 2) the ablation of the NaV1.1 channel in the interneurons but not 
in the excitatory neurons caused a more severe phenotype (higher letha lity and 
spontaneous seizures) than observed before in the constitutive Scn1a-KI mouse model; 
3) but the severe lethality was rescued in the model by additional Nav1.1 deletion in 
excitatory neurons. Completing the results, the two major subtypes of interneurons in 
layer V of the neocortex, PV+-expressing and somatostatin (SST)-expressing, had 
impaired excitability, resulting in desinhibition of the cortical network (Tai et al., 2014). 
An important role of the impaired GABAergic ininhition in the DG in the Scn1aE1099X/+ 
DS mouse model have been proposed recently by Tsai et al., 2015. They also showed 
that the NaV1.1 staining is decreased in the DG at post-natal week 3, but not in CA1 or 
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CA3 areas, suggesting that the hippocampus gating might be primarily affected in these 
models in the critic epileptic period (Tsai et al., 2015).  
All together, the studies using animal models indicate that the neuronal cause for 
DS is a widespread loss of sodium currents in the inhibitory GABAergic neurons. The 
ablation of NaV1.1 in the forebrain is sufficient to cause the disease and while different 
interneuron types have been implicated (Purkinje neurons, reticular nucleus of the 
thalamus or SST, PV+ interneurons were consensually reported to play a major role in 
DS pathology. 
2.3 Strain and age dependent  - phenotypic severity: mortality, 
seizure frequency and electrophysiological propert ies. 
As described in the previous part, the creation of the first Scn1a+/- mutant mice 
(model of DS), revealed high dependency of the genetic strain to the severity of the 
phenotype, as observed in DS patients. (Yu et al., 2006a). They observed that the 
mortality was very high in Scn1a+/- mutant mice in pure C57BL/6 background and 
almost inexistant in the 129/SvJ genetic background (FIGURE 10B), and that the mice in 
the mixed 129:B6 hybrid background from F2 and F3 generations had an intermediate 
phenotype (FIGURE 10A). Showing striking correlation with mortality the spontaneous 
seizures were not observed in Scn1a+/- mutants in the 129 genetic background, but 
frequent in the hybrid 129:B6 and very frequent C57BL/6 backgrounds (Yu et al., 
2006a).  Thus, the Scn1a+/- mutation induced a severe DS-like phenotype in mouse 
models with B6 background and a mild phenotype (cannot be considered DS) in the 129 
background, possibly by compensatory genetic modifications. These results were 
further confirmed in other DS mouse models (Miller et al., 2014; Ogiwara et al., 2013; 
Tsai et al., 2015). In 2009, Oakley and his colleagues showed that the Scn1a+/- mutant 
mice in pure B6 background were sensitive to seizures- induced by hyperthermia (SIH), 
a phenomenon largely described in DS patients (Dravet et al., 2005). They saw that no 
P17-18 Scn1a+/- had SIH, but practically all P20-22 and P30-46 Scn1a+/- mice had 
myoclonic seizures followed by generalized seizures caused by elevated core body 
temperature. The seizure susceptibility and severity was worse in the P30-46 mice 
(Oakley et al., 2009a) (FIGURE 10C). In 2013, Cheah et al., interestingly showed that 
the timing at increase in NaV1.1 channel staining correlated with the decrease in NaV1.3, 
corresponds to the critical period of spontaneous seizure generation in Scn1a+/- channels 
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(around P20) (FIGURE 10D). The fact that the inefficient NaV1.1 activity is not able to 
take over the role of NaV1.3 can be responsible for the brain hyperexcitability in these 
mice. The same correlation was found in humans and corresponds to 5 months, the 
average of seizure onset in DS the patients (FIGURE 10E) (Cheah et al., 2013a).  
Spontaneous seizures start around P20-P21 in Scn1a+/- mice in pure B6 background 
(Kalume et al., 2013; Yu et al., 2006a). In the electrocorticogram (ECoG) recordings for 
spontaneous seizures in Scn1a+/- mice, studied in Kalume et al., 2013 the animals 
presented an average of spontaneous seizures per day that varied from 3 for animals 
who survived to 9 in animals who died following the intense seizure activity. They 
confirmed a striking correlation between high seizure activity and death in those mice, 
and a critical period of higher incidence of death from P23 to P27 (Cheah et al., 2013b). 
Mistry et al., 2014 showed that preserved hippocampus sodium current density in 
GABAergic interneurons contributes to the milder phenotype of Scn1a+/− 129 mutant 
mice. Also they reinforced the observations made first by Ogiwara et al., 2013, showing 
that excitatory pyramidal neurons contribute to severity of phenotype in Scn1a+/− mutant 
mice. They observed an increase in the Na+ current in hippocampal pyramidal cells that 
was age-dependent, and correlated with the higher spontaneous seizure activity in the 
Scn1a +/- 129:B6 mutant mice (Mistry et al., 2014). Later, it was demonstrated that 
Scn1a +/- 129 mice had a higher threshold for SIH, fewer myoclonic seizures when 
compared to Scn1a +/- B6 mice, similar to patients with GEFS+. Consistent with this 
mild phenotype, Scn1a+/- 129 mice had higher sodium currents in inhibitory GABAergic 
neurons, indicating less impaired excitability of those neurons (Rubinstein et al., 
2015a). Concerning the Scn1a-RH mouse model created by Martin et al. 2010, the 
authors observed that all the homozygous Scn1aRH/RH mice die by P25 following high 
frequency of spontaneous seizures while the heterozygous and WT mice presented the 
same survival proportion. The ECoG recordings for spontaneous seizures in the 
heterozygous Scn1aRH/+ were done between 3-5 months and only few spontaneous 
seizures were observed. However, they presented lower threshold for hyperthermia and 
flurothyl- induced seizures when compared to WT controls (Martin et al., 2010a).   
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FIGURE 10. SURVIVAL, EPILEPTIC PHENO TYPE AND TIMING FO R NAV EXPRESSION IN THE BRAIN. 
Survival percentage according to the genetic background in Scn1a
+/-
 mutant mice (A-mixed 129:B6 
background, B-129 and B6 backgrounds) and age-dependent seizure susceptibility (C). Expression of 
sodium channel proteins in developing mouse cerebral cortex (D).Expression of sodium channel proteins in 
developing human cerebral cortex (E). From (Cheah et al., 2013b; Oakley et al., 2009b; Yu et al., 2006a). 
 
All together, these studies showed a highly phenotypic correlation to the genetic 
background confirmed by the severity of the phenotype, and also, an age-dependent 
seizure susceptibility in the Scn1a+/- mutant mice. 
2.4 Behav ioral/cognit ive phenotypes in mouse models of Scn1a 
gene mutation  
The Scn1a mouse models have striking similarities to human diseases GEFS+ 
and DS. They show sensitivity to SIH, spontaneous seizures and high mortality as 
observed in DS patients. It was important to confirm if Scn1a mutant mice presented 
behavioral abnormalities.  
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2.4.1 DS mouse mode l 
The first behavioral observation in Scn1a mice was done in Yu et al., 2006 when 
they observed dramatic behavioral abnormalities in homozygous Scn1a-/- mice, prior to 
death (in the 3 genetic backgrounds:129; B6 and 129:B6) . From P9 the homozygous 
mice started showing progressive epileptic seizures phenotype and could easily be 
distinguished from the Scn1a+/- heterozygous and the WT mice. They develop severe 
ataxia, with limb tremors, side-to-side swaying and complete loss of postural control. 
The time to recover their righting reflex (between back and up-side position) was 
significantly higher in Scn1a-/- mice, they were progressively immobile and did not feed 
themselves leading to death by P15 (Yu et al., 2006b) (TABLE 4). In a later study, ataxic 
phenotype was confirmed in Scn1a-/- mice further by impaired gait, coordination and 
motor reflexes when compared to the Scn1a+/- and WT mice (Kalume et al., 2007a). 
These findings reported on young Scn1a-/- mice (TABLE 4) were correlated with the low 
firing rates of cerebellar Purkinje neurons, as mentioned earlier. Interestingly, the 
Scn1a+/- had a similar phenotype to WT mice at this age. The same ataxia profile was 
observed in the homozygous Scn1aRX/RX mice (Ogiwara et al., 2007). 
 
TABLE 4. BEHAVIO RAL ABNORMALITIES OBSERVED IN YOUNG SCN1A
-/-
 HOMO ZYGOUS MICE. 
 
 
In 2012, Han and his collaborators conducted a battery of behavioral and 
cognitive tasks using the Scn1a+/- mutant mice in the pure B6 background at adulth age. 
As illustrated in FIGURE 10B, the percentage of survival of these mice at 12 weeks is 
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20%. The animals were tested between 2 and 8 months of age. The authors reported 
profound behavioral and cognitive alterations in these animals (Han et al., 2012b) 
(TABLE 5). Scn1a+/- mice were hyperactive, anxious and presented stereotyped behavior 
when compared to the WT littermates. They also reported important autistic- like traits 
as social interaction deficits and social avoidance. To ensure that social deficits were not 
correlated to olfactory perception, they conducted different tests. Using olfactory tests, 
they showed that, while food perception and preference was not changed, they clearly 
avoid social and aversive odors. Hippocampus-dependent memory was assessed using 
the Barnes maze and contextual- fear conditioning (CFC) tests. The contextual- fear and 
spatial memories were impaired (TABLE 5). A reduction in NaV1.1 staining was 
confirmed in the Scn1a+/- animals in the medial prefrontal cortex, motor cortex, sensory 
cortex, parietal cortex and hippocampus CA1 region (Han et al., 2012b). Using 
electrophysiological recordings, they reported a deficit in GABAergic transmission, 
observed by a decrease in spontaneous inhibitory post-synaptic current frequency 
(sIPSC), and an increase in spontaneous excitatory post-synaptic current (sEPSC) in 
pyramidal cells of the CA1 region of the hippocampus and prefrontal cortex. The 
synaptic functions, measured with the miniature IPSP and EPSP, were unaltered.  
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TABLE 5. BEHAVIO RAL AND COGNITIVE ALTERATIO NS IN SCN1A
+/-
 MUTANT MICE IN PURE B6 
BACKGROUND. REPO RTED BY HAN ET AL.2012. 
 
 
Ito et al, 2013 also tested the DS mouse model Scn1aRX/+ created by (Ogiwara et 
al., 2007). Similar to the previous study (Han et al, 2012), the Scn1aRX/+ in pure B6 
background showed hyperactivity that normalized after habituation, normal anxiety 
profile, hippocampus-dependent memory deficits, and social interaction problems. They 
reported also, olfactory problems and normal motor coordination (Ito et al., 2013) 
(TABLE 6). 
To go further in the study, Han et al. 2012 also conducted behavioral tasks to 
test the conditional Scn1afl-Dlx-Cre/+ created by (Cheah et al., 2012) that has the specific 
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deletion of NaV1.1 in forebrain interneurons (represented in TABLE 3). The Scn1a
fl-Dlx-
Cre/+ mice with conditional NaV1.1 reduction showed similar behavior compared to the 
Scn1a+/- with ubiquitous NaV1.1 ablation indicating that the GABAergic 
interneuronopathy was responsible for the behavioral alterations observed. Using low-
dose clonazepan (enhancer of GABAergic transmission), they clearly rescued the social 
deficits and the contextual fear conditioning impairment observed in the Scn1a+/- mutant 
mice, without changing the hyperactive phenotype.  
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TABLE 6. BEHAVIO RAL ABNORMALITIES OBSERVED IN SCN1A
RX/+
 MICE IN ITO  EL AL. 2013 
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Although sleep disorders are still controversial in DS patients and are mainly 
attributed to side effects of anti-epileptic drugs, Kalume et al., 2015 showed sleep 
abnormalities (reduced delta wave power, reduced sleep spindles, increased brief wakes, 
and numerous interictal spikes in Non-Rapid-Eye-Movement sleep) in the Scn1a+/- DS 
mice in pure B6 background without drug treatment. With electrophysiological tools, 
they attributed those abnormalities to the GABAergic interneurons of the reticular 
nucleus of the thalamus. In line with the previous findings, Rubinstein et al. 2015 
recently published a work in which they dissected the contribution of two subclasses of 
interneurons affected in Scn1a+/- DS model :the PV+ and SST+ interneurons (Tai et al., 
2014) to the behavioral abnormalities observed by Han et al., 2012b. They used 
conditional mice with specific ablation of the Scn1a gene in the PV+, SST+ or both and 
investigated the behavioral effects. Selective deletion of Na V1.1 in PV+ or SST+-
expressing interneurons increases susceptibility to thermally- induced seizures, with a 
higher contribution of the PV+, and the deletion of both recapitulates the phenotype 
observed in the Scn1a+/- mutant mice. They also observed that the reduced excitability 
of PV-expressing neurons caused social interaction deficits, whereas impaired 
excitability of SST-expressing neurons resulted in hyperactivity. Deletion in both PV 
and SST interneurons impaired long-term spatial memory in context-dependent fear 
conditioning, but was not sufficient to recapitulate the full extent of the cognitive 
impairment observed in the Scn1a+/- mice by Han et al. 2012 (Rubinstein et al., 2015b).  
The most recent published study was done to test the behavioral effects caused 
by the genetic background in Scn1a+/- mice. As described earlier, the Scn1a+/- mutant 
mice in the 129 pure background did not develop spontaneous seizure activity nor 
premature death (Yu et al., 2006b) (FIGURE 10A). Rubinstein and her colleagues 
showed that the Scn1a+/- in 129 background have higher threshold for hyperthermia-
induced seizures, increased inhibitory Na+ currents in the hippocampus and preserved 
contextual- fear conditioning, when compared to the severe DS model in the B6 
background (Rubinstein et al., 2015c). Thus, the phenotypic severity is clearly affected 
by the genetic background.  
In conclusion, as shown in this section, the Scn1a+/- mutant mice in B6 
background present striking similarities to the human DS disease (Han et al., 2012a; Ito 
et al., 2013; Kalume et al., 2015; Oakley et al., 2009; Rubinstein et al., 2015b; Yu et al., 
2006b) in terms of spontaneous seizure activity and important behavior and cognitive 
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abnormalities, while the same mutant in 129 background has a mild phenotype 
comparable to GEFS+ patients (Rubinstein et al., 2015c; Yu et al., 2006a).  
2.4.2 GEFS+ mouse model 
The analysis of the behavioral phenotype in GEFS+ mouse models is more 
recent (Ohmori et al., 2014; Papale et al., 2013; Sawyer et al., 2016). The GEFS+ 
mouse model carrying the human R1648H mutation was developed by Martin et al., 
2010a. This mutation was found in a large family of GEFS+ disease (Escayg et al., 
2000a) and in one DS patient (Depienne et al., 2010). 
The Scn1aRH/+ mutant mice display a mild phenotype comparable to what is 
observed in GEFS+ patients. Sleep abnormalities, characterized by increased 
wakefulness and reduced non-rapid eye movement (NREM) and rapid eye movement 
(REM) sleep amounts during the dark phase, were reported in these mice at 3-4 months 
of age (Papale et al., 2013). Recently, Sawyer et al, had done a behavioral 
characterization of the Scn1aRH/+ model and reported very mild behavioral abnormalities 
when compared to WT controls. They observed that the Scn1aRH/+ mice have an 
increase in activity in the openfield and slightly impaired spatial object recognition 
memory and social interaction. They also reported an increase in the cued-fear 
conditioning and decreased sensory gating (Sawyer et al., 2016). The behavioral tests 
performed in the Scn1aRH/+ model are summarized in TABLE 7. 
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A rat carrying the homozygous Scn1a N1417H missense mutation in the third 
pore of the NaV channel, induced by gene-driven N-ethyl-N-nitrosourea mutagenesis 
(never observed in patients), was also generated (Mashimo et al., 2010). Homozygous 
mutations are lethal in all the mouse models of Scn1a mutation without exception, but 
this rat model survived normally. In humans, homozygous mutations have been reported 
recently only in one patient with GEFS+ and one patient with DS (Brunklaus et al., 
2015). The electrophysiological studies in the Scn1aNH/NH rat model showed a decreased 
inhibition in the GABAergic interneurons of the hippocampus. Also similar to the 
previous models, they are sensitive to hyperthermia- induced seizures (Mashimo et al., 
2010). However, the authors did not observe spontaneous seizures using EEG 
recordings from 5 weeks of age, suggestive of the mild phenotype carried by the model. 
The behavioral analysis showed that the rats present a slight increase in activity in the 
openfield and poorer spatial learning than the control WT. However, the anxiety level is 
normal in the elevated plus maze, the sociability skills are preserved and they reach the 
TABLE 7. BEHAVIO RAL CHARACTERIZATIO N O F THE SCN1A
RH/+
 MICE BY SAWYER ET AL. 2016 
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same level of performance in the last day of spatial learning as the controls. The 
behavioral skills are only mildly affected in the rats (Ohmori et al., 2014) (TABLE 8).  
 
TABLE 8. BEHAVIO RAL CHARACTERIZATIO N O F THE SCN1A
NH/NH
 RAT BY OHMORI ET AL. 2014. 
 
As expected, the two GEFS+ models (Scn1aRH/+ and Scn1aNH/NH) show very 
mild behavioral and cognitive abnormalities, as expected from animals with no 
mortality, low or inexistent seizure activity and mild mutations that do not severely 
impair the channels function. Compared to the Scn1a+/- mice in the B6 background 
(model of DS and severe phenotype), GEFS+ models offer a good opportunity to 
investigate the role of epileptic activity in cognitive and neurobiological outcomes 
presented by DS patients (see Chapter 5 below).  
The studies in animal models in the past 10 years have helped to clarify the 
physiopathology behind the SCN1A-related diseases and confer an excellent tool to 
investigate potential therapeutic strategies for patients.    
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Chapter 5- SEIZURES AND COGNITIVE PHENOTYPE IN DS: EPILEPTIC 
ENCEPHALOPATHY OR CHANNELOPATHY?  
While early- life seizures are the most striking feature of DS, the most 
debilitating consequences of the disease are often the associated cognitive and 
behavioral impairments. DS was classified as an EE; however there is still an ongoing 
debate about the variables affecting phenotype in these children. The concept of EE has 
recently been adapted to “the epileptic activity itself may contribute to severe cognitive 
and behavioral impairment above and beyond what might be expected from the 
underlying pathology alone”. Consequently, suppressing the seizures might have 
benefic effects in improving cognition and behavioral abnormalities (Berg et al., 2010). 
1. CAN SEIZURE SEVERITY BE CORRELATED WITH COGNITIVE/BEHAVIORAL 
OUTCOME IN DS  PATIENTS? 
Evidence from different epileptic syndromes suggests that seizure frequency and 
early age at onset could be crucial for cognitive delay. The main reason is that the 
immature brains are most sensitive to seizures and are certainly less able to develop a 
functional reserve capacity to cope with subsequent decline (reviewed in Hermann et al., 
2002). Also, the hypothesis that “seizures beget seizures” have been formulated in the 
basis of the occurrence of brain function modifications following seizures and 
consequently each seizure increases the risk for further seizures  (Gowers, 1881). 
However, this theory is still controversial (Allen Hauser and Lee, 2002; Ben-Ari et al., 
2008; Karoly et al., 2017).  
It is possible but not clear that the SCN1A mutation confers a particular epileptic 
profile in patients with DS. Nevertheless, the several seizure types inducing EEG 
abnormalities (ictal and post ictal), the age at onset and duration of the seizures 
observed in patients, the large therapeutic window applied and the high genotypic 
variability of the SCN1A gene spectrum associated with the infinite possible genetic and 
environmental modifiers accounting for the phenotypic variability, give rise to an 
unclassifiable range of inconsistent outcomes. 
Clinical studies have reported families carrying SCN1A gene mutations, where 
amongst affected patients, those who had lower seizures number had normal cognition, 
while those with intractable seizures were cognitively impaired (Guerrini et al., 2010; 
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Suls et al., 2010; Takayama et al., 2014) The age at seizure onset and the duration of the 
seizures events seemed also to correlate with the worst outcomes in some cases (Acha et 
al., 2015; Cetica et al., 2017; Wolff et al., 2006a). Moreover, it has been hypothesized 
that more complex seizures, as myoclonic seizures, focal seizures, absence seizures and 
prolonged SE could be responsible by worsening the phenotype (Ragona et al., 2011a).  
Chipaux and collaborators observed three unusual cases of SE. In these patients the 
long- lasting SE (2, 7 and 12 hours respectively), clearly caused  persistent and severe 
cognitive and motor deterioration following the event (Chipaux et al., 2010). 
Yet, adding to the debate, many clinical studies failed to correlate the seizure 
profile with the cognitive outcome and the reduction of seizures seems to not ameliorate 
the phenotype (Akiyama et al., 2010, 2012; Nabbout et al., 2013; Riva et al., 2009; 
Villeneuve et al., 2014). Some authors argue that the neurological signs observed in 
patients (i.e. ataxia, crouching gait) can hardly be explained by the epileptic activity and 
that mutations in PCDH19 do not cause this motor neuropathy. They better correlate 
them to the channel dysfunction at the motor neuron axon initial segment (Duflocq et 
al., 2008; Gitiaux et al., 2016). Guerrini and Striano, 2016 argued that this motor 
impairment might have a complex origin, which also includes ataxia, in line with 
evidence that SCN1A is also expressed in basal ganglia and cerebellar Purkinje neurons. 
In addition, a possible detrimental effect of a high seizure frequency and multiple 
anticonvulsants treatment should be taken into account (Guerrini and Striano, 2016).  
Despite the fact that seizures reduction did not ameliorate the phenotypes, there 
are very few “seizure- free” patients in response to therapy. Very few patients were 
reported. One study reported a case carrying the SCN1A de novo truncation mutation, 
and presenting a normal cognitive and developmental phenotype in adulthood after 
considerable reduction of seizures events after the age of 4 years old (Buoni et al., 
2006). Another case presenting a de novo frameshit mutation in a patient presenting 
refractory seizures until 5 years of age and who presented mild cognitive impairment at 
2 years of age showed normal cognitive functions by 10 years of age (Jiang et al., 
2016).  
With the exception of few truncation mutations found in patients presenting a 
mild phenotype (as described previously), the most impacting mutations for the NaV1.1 
function have been found in DS patients (Brunklaus et al., 2014). However, not many 
studies have correlated the severity of the mutation with the cognitive outcome. The 
presence of mosaicism and genetic modifiers make the correlations difficult to make.   
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Ricci et al, 2015 showed that visual functions can be affected shortly after 
seizure onset in DS patients, even before the diagnosis and the strong epileptic period. 
They reported that the language functions are more preserved in these children, and 
suggest a possible role of the NaV1.1 haploinsufficiency in impairing these primitive 
functions (Ricci et al., 2015). However, in this study only one patient (out of 5) had a 
confirmed SCN1A mutation and had a rare late cognitive impairment appearance. 
Nevertheless, the visual impairment was otherwise reported in the majority of DS 
patients.  Passamonti et al, 2015 reported one family carrying a splicing inherited 
mutation in the SCN1A gene and a large heterogeneity of epileptic and 
neuropsychological phenotypes (from non-affected to DS). All the affected patients 
(having epileptic history) shared common visual problems, and one of the non affected 
patients (never had a seizure, but carrying the mutation) had also mild visual problems 
(Passamonti et al., 2015).  Opposite observations (higher impairment in language than 
visual function in DS patients) have also been reported by Acha et al., 2015, where they 
correlate the worst epileptic phenotypes to the poorer cognitive outcomes.  
To date, all these clinical observations provide controversy as to the origins of 
the behavioral and cognitive deficits in DS. It would have been ideal to test whether 
children have entirely normal cognitive skills before seizure onset to clarify this issue. 
However, there are methodological limitations in planning prospective studies that 
would unequivocally demonstrate complete integrity of early development. Studying 
more simple/controlled models is crucial to understand the epileptic/cognitive and 
genetic/cognitive correlations in DS patients.  
2. DO NAV1.1  DYSFUNCTIONAL MICE SUPPORT THE CHANNELOPATHY THEORY? 
The induction of repeated early- life seizures in the normal rodent brain have 
suggested the appearance of important neuronal rearrangements and behavioral 
modifications in those animals (reviewed in Barry and Holmes, 2016). These studies 
suggest that seizures can induce long- lasting changes in an otherwise normally 
developing brain. 
Interestingly, the identical NaV1.1 truncation mutation is present in the B6 and 
129 mice, however they present very different behavioral phenotypes. The DS mouse 
model in the B6 background has striking similarities with the human DS disease, 
however the same mutation in 129 background induce a mild phenotype (Rubinstein et 
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al., 2015c; Yu et al., 2006b). Han et al, 2012 and Ito et al, 2013 submitted the Scn1a+/- 
mice in B6 background to a battery of behavioral tasks and observed important behavior 
and cognitive impairment. Unfortunately, the behavioral deficits observed in these mice 
cannot be dissociated from the negative impact of the strong recurrent epileptic activity 
that these mice present throughout life. Han et al., rescued the phenotype by treating the 
animals with GABAergic enhancer at low-dose to avoid sedation (Han et al., 2012b), 
and suggested that the disease was a pure consequence of the network dysfunction 
caused by NaV1.1 haploinsufficiency.  
In addition, there is now evidence in mice that the mutation of the sodium 
channel can result in cognitive deficits independent of seizures.  Bender et al, 2013 used 
an siRNA approach to knockdown NaV1.1 channels selectively in the basal forebrain 
region, were they could target a learning and memory network while avoiding the 
generation of spontaneous seizures. They showed that the reduction of NaV1.1 
expression, without epileptic seizures in the medial septum and diagonal band of Broca 
lead to a dysregulation of hippocampal oscillations in association with a spatial memory 
deficit (Bender et al., 2013). Using the same technique, they later confirmed that NaV1.1 
dysfunction impairs fast- and burst- firing properties of neurons in vivo altering brain 
rhythms by decreasing theta frequency during a working memory task (Bender et al., 
2016).  
These studies therefore strongly support the notion that NaV1.1 dysfunction per 
se can alter neuronal networks and associated brain oscillations and thus affect memory 
performance in DS. However these rodent models, in which the investigator can control 
the majority of the variables, do not account for the DS phenotypic and genetic 
variability and do not represent all the phenotypic spectrum present in patients. These 
experiments need further confirmation.  
It is clear that the genetic predisposition lead to seizures. However, it is not clear 
whether the comorbidities present in DS are pure consequence of epilepsy, whether both 
epileptic and cognitive phenotypes are pure consequences of the genetic defect or 
whether both the genetic defect and the epileptic activity build the resulting outcome. 
Thus, whether DS should be considered as an EE or a channelopathy remains an 
outstanding question that needs to be resolved.  
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II- PROBLEMATIC AND OBJECTIVES 
Clinical studies failed to correlate the epileptic severity with the cognitive 
outcome in DS (Battaglia et al., 2016; Chieffo et al., 2011b; Ragona et al., 2011a; Riva 
et al., 2009; Suls et al., 2010).  On another hand, genotype-phenotype correlations are 
blurred by the occurrence of genetic and environmental modifiers and the presence of 
genetic mosaicism.  
Experimental studies, using Scn1a mutant mice, push the fact that the mutation 
per se can be responsible for the long-term behavioral and cognitive outcome in DS 
patients, challenging its definition as an EE.  Yet, it was shown that recurrent seizures in 
the first weeks of life result in considerable cognitive impairment in adolescent or adult 
rodents (Holmes, 2009). 
In this controversial context, we designed a study to investigate the effect of 
seizures in the worsening of cognitive/behavioral phenotypes in mouse lines carrying 
the Scn1a gene mutation, an issue that had not yet been addressed. Our goal was to 
investigate if seizures in early life in DS and GEFS+ mutant mice can cause the 
developmental delay and cognitive regression observed in DS patients. Answering this 
question is crucial to adapt the definition of DS (as an EE or not) and for the 
development of adequate treatments in DS and other EEs.  
To do so, we used Scn1a mutant mice carrying mild phenotypes (no mortality 
and no spontaneous seizures). We first tested if the mutation per se could alter the 
behavioral and cognitive phenotypes. We then chronically induced seizures using 
hyperthermia for 10 days at post-natal day 21 and evaluated the long-term effects on: 
 
1) The evolution of the epileptic activity after the seizures induction protocol 
using EcoG recordings, and understand if “seizures beget seizures”; 
2) The long-term structural modifications in adulthood (P60) by analyzing 
neuronal mortality using immunohistochemical analysis; 
3) The long-term functional modifications in the hippocampus at later age 
(P60) using field and patch-clamp electrophysiological recordings; 
4) The cognitive and behavioral effects at later age (P60) using different 
behavioral and cognitive tasks. 
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III- MATERIAL AND METHODS 
1. ANIMAL MODELS , BREEDING AND HOUSING CONDITIONS 
1.1 Scn1a+/-  (NaV1.1 knock -out): Dravet Syndrome’s mouse model:  
The Scn1a+/- mice, model of Dravet Syndrome, and created by (Yu et al., 2006a) 
was used initially in this study. Summarizing, the Scn1a+/- mouse was obtained by 
disruption of the last coding exon of the gene that encodes for the NaV 1.1 channel 
(Scn1a gene) with a replacement-type construct. This exon encodes for the domain IV 
of the channel downstream of the S3 segment of the cytoplasmic tail. The mouse line 
was generated from stem cell clones and the founding chimeric male was bred to 
129/SvJ females in order to generate congenic Scn1a+/--129 SvJ mice. The line was then 
backcrossed in 129 SvJ background for more than 12 generations. After receiving the 
mutant males we crossed them with 129/SvJ females (Envigo, France) and used the 
litters obtained (results chapter 1). After observing a very low breeding performance we 
created a mixed 129/SvJ:C57BL/6 line in order to increase the number of animals to use 
in the experiments. We backcrossed the Scn1a+/- mutant mouse in 129 SvJ background 
with C57BL/6J females (Charles River, France) and used the F1 generation that were 
hybrid and 50% 129/SvJ: 50% C57BL/6J (Results Chapter 1 and 5).  
1.2 Scn1aRH/+ (NaV 1.1 knock-in): GEFS+ mouse model 
The knock-in GEFS+ mouse model harboring the human SCN1A-R1648H 
mutation was used in this study. This specific mutation was identified in a large and one 
of the first families with GEFS+ disease (Escayg et al., 2000a). This model was 
generated as described previously by Martin et al., 2010b. The targeting vector 
containing the human SCN1A-R1648H mutation was knocked- in into the exon 26 of the 
mouse Scn1a gene.  The mutation resulted in the replacement of the arginine residue 
with a histidine residue at the position 1648 of the gene (voltage sensor of domain 4).  
The B6 - Scn1aRH/+ heterozygous mutant male, maintained in C57BL/6J background for 
more than 10 generations was backcrossed with a 129/SvJ female. The F1 generation of 
the hybrid mixed 129/SvJxC57BL/6J background mice was used for this study (results 
chapter 3, 4). 
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1.3 Housing condit ions 
All experiments were done according to policies on the care and use of 
laboratory animals of European Communities Council Directive (2010/63). The 
protocols we approved by the French Research Ministry following evaluation by a 
specialized ethics committee (protocol number NCE/2014-216). All efforts were made 
to minimize animal suffering and reduce the number of animals used. The animals were 
housed under controlled laboratory conditions with a 12-h dark light cycle, a 
temperature of 22 ± 2°C and 55±10% humidity. Mice had free access to standard rodent 
diet and tap water. The number of animals per cage was maintained at 6 ± 1 containing 
the four test groups.  
2. EXPERIMENTAL TIMELINE 
To study the effect of early life seizures induced by hyperthermia on the 
phenotype of mouse models with Scn1a mutation, we organized the experimental 
approach as shown in TABLE 9. From postnatal day 8 (P8) the animals were identified 
and genotyped. At P21, after weaning, we induced seizures by hyperthermia (SIH) once 
a day for 10 days. Following the protocol of SIH 4 different cohorts of animals were 
prepared for: 1) Video electrocortigram (ECoG) recordings; 2) behavioral analysis; 3) 
electrophysiological recordings and 4) Immunohistochemistry staining. For ECoG 
recordings, electrophysiological recordings and immunohistochemistry males and 
females were used, however for behavioral studies, only males were studied to avoid 
hormonal interference. One cohort of animals was implanted with electrocortigram 
electrods immediately following the end of the SIH protocol and recorded from P34 to 
P90 to analyze the presence of spontaneous seizures.  In parallel, SIH was also induced 
in three other cohorts of animals, which were allowed to age in the stabulation room 
before being tested at P60 (adulthood) (TABLE 9).  
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TABLE 9. EXPERIMENTAL TIMETABLE. 
Sequence of experiments from P8 to P90. A ll g roups went through identification and genotyping, then SIH 
protocol followed by: either ECoG recordings (from P32 to P90), behavioral analysis, electrophysiological 
recordings or immunohistochemistry staining. 
 
2.1 Genotyping 
2.1.1 DNA extraction 
Genotyping for mutation screening in the offspring was performed using DNA 
obtained from tail biopsies acquired when the animals were identified (between P8-
P10). Tail biopsies were digested overnight at 56ºC and gentled shaking with lysis 
buffer (50 mM Tris-HCl pH 8, 100 mM EDTA pH 8, 100 mM NaCl 1% SDS) and 
proteinase K (10 mg/ML). After overnight incubation, samples were centrifuged for 10 
minutes at 15000 g to get rid of undigested tissues and supernatants were transferred 
into new eppendorf tubes. To lyse cells and access genomic DNA, saturated NaCl was 
added to samples and incubated for 10 minutes on a rocking platform. Samples were 
then centrifuged for 10 minutes at 15000g at 4ºC to get rid of cell debris. Supernatants 
were transferred into new eppendorf tubes and DNA was precipitated with 2-propanol. 
After centrifugation for 10 minutes at 15000g, the pellet was washed with 70% Ethanol. 
After air drying the pellet, DNA was resuspended in TE buffer (100 mM Tris-HCl pH 
7,5 and 1 mM EDTA). pThe DNA concentration of each sample was quantified by 
spectrophotometry (A260 and A280) and stored at - 20ºC.  
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2.1.2 DNA amplificat ion  
For PCR analysis, DNA was placed in PCR tubes and used as template for 
amplification by adding the Master Mix solution (each primer (presented on TABLE 10), 
ddH2O, Buffer 5X, dNTPS and Taq Polymerase). 268, 269 and 316 primers amplify 
mutated NaV1.1 fragment from the Scn1a
+/- mouse model, while 38S and 39S amplify 
mutated NaV1.1 fragment fom the Scn1a
RH/+ mouse model. All the primers were used at 
10 µM concentration. For the Scn1a+/- mouse the following polymerase-chain reaction 
(PCR) was used : denaturation of the DNA at 95ºC for 2 min, followed by 30 cycles of 
amplification: 95ºC for 30 sec, 67ºC for 30 sec, 72ºC for 45 sec and a final extension 
step at 72ºC for 7 min. The PCR-specific primers used are presented in (TABLE 10). For 
the Ki mouse model the PCR was done with minor modifications: 94ºC for 2 min, 
followed by 30 cycles of amplification: 94ºC for 30 sec, 56ºC for 30 sec, 72ºC for 45 
sec and a final extension step at 72ºC for 7 min. Immediately following this reaction 1µl 
was taken to a second reaction and mixed with ddH20, oligomers, DNA polymerase, 
primer 39S and buffer to prepare for DNA sequencing (the mutant fragment is usually 
obtained after EcoR1 cutting, but this reaction never worked in our hands so the entire 
fragment surrounding the mutation had to be sequenced systematically). The PCR 
reaction was the following: 96ºC for 1 min, followed by 30 cycles of amplification: 
96ºC for 30 sec, 50ºC for 30 sec, 60ºC for 150 sec. The sequencing was done in a 
platform in the institute. . 
TABLE 10. PRIMERS USED FO R DNA AMPLIFICATION IN SCN1A MOUSE LINES . 
 
2.1.3 DNA revelat ion and sequenc ing 
For Scn1a+/- mouse model, PCR products were visualized on a 1.5% agarose gel 
containing 2% of ethidium bromide to confirm the presence of DNA from the mutated 
mouse models. To allow band size estimation, 100 bp DNA ladder was added, as 
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demonstrated in (FIGURE 11). Gel was run for 20 minutes at 100 volts in an 
electrophoresis bath containing 1x Tris-Acetate-EDTA (TAE) buffer and then placed 
under UV light for band visualization. FIGURE 11A shows a typical progeny genotyping 
containing bands for mutant and WT mice. WT mice presents one single band of 291 
base pair (bp) that corresponds to non-mutant amplified band (lanes 2,4), while Scn1a+/- 
heterozygous mice exhibits two bands, one of 261bp (control band) and one at 141 bp 
that corresponds to the mutant band (lanes 1,3,5). Scn1a+/+ positive (+/+) littermates 
were used as controls (WT mice). After DNA sequencing the files were analysed and 
we searched for the mutation at around base number 130. WT animals present the 
sequence GAATCCTACG, while mutant animals have the sequence GAATYCTACR 
as illustrated in FIGURE 11B. 
 
 
FIGURE 11. GENO TYPING REVELATIO N. 
A: Agarose gel contaning NaV 1.1 KO progeny. WT animals are illustrated in white (+/+) and mutants in 
red (+/-). B: DNA sequencing of the Nav 1.1 KI progeny. On the left an example of the WT mouse and on 
the right the presence of the R1648H mutation surrounded by the blue circle.  
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2.2 Repeated Seizures induction 
2.2.1 Seizures induction by hyperthermia  
Acute seizure induction by hyperthermia (SIH) have been described previously 
(Oakley et al., 2009a). We optimized and developed a protocol of chronic SIH. SIH 
protocol started at P21 (weaning time), once a day for 10 days. The time at which 
seizures were induced during the day was randomized as well as the order for mice 
having the seizure. SIH protocol was done as described previously for acute 
hyperthermia induced seizures with minor modifications (Cheah et al., 2012). The 
mouse was placed in an incubator (Dominique Dutscher, France) (width (w) 23cm, 
length (l) 20cm, height (h) 20cm) and allowed to acclimatize for 10 minutes. The core 
body temperature was continuously monitored with a rectal temperature probe (type 
RET-4, Physitemp Instruments, Inc, USA) controlled by a temperature controller (type 
TCAT-2, Physitemp Instruments, Inc, USA). The temperature was increased 0.5°C 
every 2 minutes, until a seizure appearance or a maximum temperature of 42° was 
reached. The animal was then removed from the incubator and the temperature was 
decreased to 37°C before returning the mouse to the home cage. For mice having a 
seizure, the temperature threshold and behavioral characterization were noted. WT and 
Scn1aRH/+ mice were submitted to the protocol but only mutant animals had short-
lasting seizures (< 1 minute) at this temperature. Seizures were systematically video 
recorded to allow off line analysis. WT and Scn1aRH/+ control animals followed the 
same handling protocol but the temperature of the incubator was maintained at room 
temperature. 
 
2.2.2 Seizures induction by flurothyl 
As an internal control, a convulsant known to perturb the GABAergic system 
was used to induce seizures in WT and Scn1aRH/+ animals.  Flurothyl (Bis 2,2,2-
trifluoroethyl ether) (Sigma-Aldrich) induced seizures were described previously 
(Holmes et al., 1998). Animals were placed in a transparent plexiglas box (15 cm W, 10 
cm L, 12 cm H). Liquid flurothyl was delivered using a syringe pump injector at a rate 
 
67 
of 10 µl/min and allowed to volatilize. The animals were removed after the appearance 
of a generalized tonic clonic seizure. The latency to seizure was quantified.  
2.2.3 Behaviora l characterizat ion o f seizures 
The seizure characterization is important in order to fathom which brain areas 
are involved in the seizure development. According to different methods of seizure 
induction, the behavioral consequence in rodents will be different. SIH and Flurothyl-
induced seizures show common sequence and seizure type than seizures with limbic 
origin (Hashimoto et al., 2006; Liautard et al., 2013). The origin of clonic seizures 
(grade 1-4 TABLE 11) happens in the forebrain. The rapid and synchronized forelimb 
clonus usually accompanied by head nodding indicates the activation of zones beyond 
the limbic system (Velíšková et al., 2005). Following the forelimb clonus a tonic 
component appears and the mouse loose balance having a twist of the body (failing)  but 
a rapid effort to get back happens (grade 5 TABLE 11). This phase indicates the 
spreading of the seizure from the forebrain to brainstem. Seizures usually quickly 
develop to more complex seizures called generalized tonic-clonic (GTC) seizures. The 
GTC seizures that provoke the loss of consciousness announce the involvement of the 
brainstem areas (grade 6 TABLE 11) (Browning, 1985). This seizure event is 
characterized by wild run or jump with failing, followed by a tonic phase characterized 
by tonic flexion presenting forelimb and hind limb extension (most severe part of the 
seizure and sometimes culminating in death (grade 7 TABLE 11)) and finally long-
lasting clonus in all limbs. During all the GTC seizure phase the mouse doesn’t show 
efforts to regain balance. After passing all the steps if the seizure completely develops, 
the mouse regains the upright position.  
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TABLE 11. SEIZURES SEVERITY SCORING ADAPTED FO R SEIZURES WITH LIMBIC ORIGIN (ADAPTED FRO M 
VELISKOVA, 2007). 
 
 
2.3 Electrocort icogram recordings 
After SIH protocol, the mice were implanted with ECoG electrods. The 
electrods’ implantation and ECoG monitoring was done by Dr. Fabrice Duprat and Dr. 
Ingrid Bethus.   
2.3.1 Electrods imp lantat ion 
The animals were anesthetized with ketamine (11.25 mg/kg) Virbac/ xylasine 
(7.5 mg/kg) (Rompun 2%). After being placed in the stereotaxic support, ocular gel 
(Dexpanthénol , Bausch Lomb) was put into the mouse’s eyes to protect them from 
drying. The animals were maintained at 37ºC core body temperature for all the 
procedure duration. The head’s  hair was removed using depilatory cream. An incising 
was done to access the scull and a local anesthetic was applied under the exposed area 
(Lidocaïne 21,33 mg/ml, Xylovet). The skin was cleared using clippers. The bregma 
position was measured in order to then calculate the distance of the wholes to it 
(Antero-posterior; Lateral). Fives holes were made (diameter 0.95 mm) using a screw 
 
69 
driver (one placed in each hemisphere as recording electrodes and one placed above the 
cerebellum as ground reference). The coordinates for the recording electrodes were:  
 electrode 1: AP : 0.0 mm / Lat : + 3 mm;  
 electrode 2 : AP : - 3.5 mm / Lat : +3 mm;  
 electrode 3: AP : 0.0 mm / Lat : - 3 mm;  
 electrode 4 : AP : - 3.5 mm / Lat : -3 mm;  
 Reference electrode: AP : -6.0 mm / Lat : ±0.2 mm.  
The screws connected to the wires (Bilaney, Plastics One) were placed in the 
holes. The screws were fixed to the skull with a resin (Super Bond, Sun Medical) and 
the electrodes were placed in the connector and enveloped with dental cement 
(Dentalon, Phymep) forming the hat above the mouse’s head. The mice were surveyed 
until the recovering from anesthesia and then placed in their home cages with an anti-
inflammatory in the drinking-water (Ketofen 0.04 mg/mL of water). 
2.3.2 Video Electrocorticogram recordings  
After recovering from surgery, the animals were allowed to rest for 2 days. They 
were individualized in the appropriate recording cages and connected to an amplifier 
(Animal Bio Amp, AD Instruments) for ECoG recording. Each mouse was connected to 
the amplifier through a cable and a swivel to allow the mouse to freely move in the 
cage. The amplifiers were connected to an acquisition system (PowerLab 16/35, AD 
nstruments) that converted the analogic signal into a numeric signal recorded, and 
anlysed with the software (Labchart 8, ADInstruments). The system was equipped with 
16 amplifiers that connected 16 electrodes, which allowed us to record simultaneously 4 
mice with 4 recorded channels per mouse (FIGURE 12). Four infrared cameras 
(Day&Night, Ganz) were connected and synchronized to the ECoG leading to the 
analysis of the ECoG seizures and behavioral seizures, simultaneously. The animals 
were recorded for 2 months in regular windows of 3-days periods.  
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FIGURE 12. ECOG RECO DINGS SYSTEM. 
Top Figure: Recording cage.The mouse is connected to the signal collecting cable that has a rotator that 
allows the animal to freely move. Bottom figure: 16 amplifiers allowed the recording of 8 mice 
simultaneously. Photo from Doctor Lavigne PhD manuscript. 
2.3.3 Signa l ana lys is 
The recordings were analyzed with Labchart 8 (AD Instruments). ECoG traces 
were screened manually to identify the signal with a typical seizure pattern, and the 
generalized tonic-clonic seizure was confirmed by watching the corresponding video. 
We quantified the seizures’ frequency (number of seizures divided by time recorded) 
and their durations. All values were normalized to 24h in order to be compared. 
2.4 Electrophysiological recordings in the hippocampus 
Acute transverse hippocampal slices (350 µm thick for field recodings and 250 
µm thick for whole cell recordings) were obtained from mice 60-70 days of age. 
Animals were first anaesthetized with isoflurane and killed in accordance with the 
European Communities Council Directive (80/609/EEC). Slices were cut on a 
vibratome (Microm HM600V, Thermo Scientific) in ice-cold dissecting solution 
containing (in mM): 234 sucrose, 2.5 KCl, 0.5 CaCl2, 10 MgCl2, 26 NaHCO3, 1.25 
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NaH2PO4 and 11 D-glucose, oxygenated with 95% O2 and 5% CO2, pH 7.4. Slices were 
first incubated, for 60 min at 37°C, in an artificial CSF (aCSF) solution containing (in 
mM): 119 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 1.3 MgSO4, 2.5 CaCl2 and 11 D-
glucose, oxygenated with 95% O2 and 5% CO2, pH 7.4. Slices were used after 
recovering for another 30 min at room temperature. For all experiments, slices were 
perfused with the oxygenated aCSF at 31 ± 1 °C. fEPSPs were recorded in the stratum 
radiatum of the CA1 region using a glass electrode (RE) (filled with 1 M NaCl, 10 mM 
HEPES, pH 7.4) and the stimuli (30% of maximal fEPSP) were delivered to the 
Schaeffer Collateral pathway by a monopolar glass electrode (SE) (filled with ACSF) 
(FIGURE 13A). Whole-cell recordings were made using borosilicate glass pipettes of 3–
6 MΩ resistance containing (in mM) K-gluconate 120, KCl 15, MgCl2 2, EGTA 0.2, 
HEPES 10, QX-314 1.5, P-Creatine 20, GTP 0.2, Na2-ATP 2, leupeptin 0.1 and 
adjusted to pH 7.3 with KOH and osmolarity between 290 and 300 mOsm. Slices were 
visualized on an upright microscope with IR-DIC illumination and epi- fluorescence 
(Scientifica, Ltd).  After a tight seal (>1GΩ) on the cell body of the selected neuron was 
obtained, whole-cell patch clamp configuration was established, and cells were left to 
stabilize for 2-3 min before recordings began. ).  The recordings were performed using a 
Multiclamp 700B (Molecular Devices) amplifier, under the control of pClamp10 
software (Molecular Devices).  
2.4.1 Fie ld potentia l recordings  
LTP was induced using a high-frequency stimulation protocol (HFS) protocol 
with one pulse of 100 Hz or 4 pulses of 100Hz spaced by 5 minutes inter-stimulus 
interval (ISI). For LTP analysis, the first third of the fEPSP slope (FIGURE 13B) was 
calculated in baseline condition (20 minutes prior to induction protocol delivery and for 
45-60 minutes post- induction). The average baseline value was normalized to 100% and 
all values of the experiment were normalized to this baseline average (one minute bins).  
The paired-pulse ratio (PPR) was obtained by stimulating the Schaeffer 
collateral consecutively within a short-period of time. The PPR (P2/P1) was expressed as 
the peak amplitude of the second response (P2) relative to that of the first response (P1) 
at different ISI (150ms, 200ms, 250ms, 300ms, 350ms, 400ms, 450ms) (FIGURE 13C). 
Experiments were pooled per condition and presented as mean±s.e.m.  
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FIGURE 13. FIELD EXCITATO RY POST-SYNAPTIC PO TENTIALS IN THE HIPPOCAMPUS . 
A: Coronal hippocampus slice. The SE (stimulation  electrode) stimulates at the sch (Schaeffer collateral) 
and the signal is recorded by the RE (record ing electrode) in the CA1 pyramidal neurons. B: the fEPSPs 
for baseline and post-LTP induction are calcu lated as slope (represented in orange) placed at 1/3 of the 
peak amplitude of the response. C: The PPR are calculated as the rat io between the peak amplitude 2 and 
the peak amplitude 1.  
2.4.2 Patch-clamp recordings (performed by Doctor 
Pousinha)  
Current-clamp recordings were performed on CA1 pyramidal neurons or on 
dentate gyrus (DG) granule cells. The resting (Vm) membrane potential was first 
measured in the absence of any spontaneous firing, and only cells with Vm more 
negative than -55mV were considered. To study the relationship between firing 
frequency and current input, we first adjusted the membrane potential of CA1 pyramidal 
neurons at Vh=-70 mV and of DG granule cells at Vh=-60 mV and then injected pulses 
of increased intensity in steps of 20 pA (from 0 to 400 pA, 1 s duration).  
  
 
73 
2.5 Immunohistochemical analysis in brain slices 
After SIH, the mice from all the groups were collected at P60 for later 
immunohistochemical analysis. We fixed the brains with trans-cardiac perfusion of and 
shipped the brains to our collaborators. All the immunohistochemical analysis on these 
brains was done by Dr. Carolina Frassoni (team leader) and Dr. Cristina Regondi 
(researcher) in Instituto Carlo Besta in Milan.  
2.5.1 Intracardiac paraformaldeyde perfus ion  
At 2 months of age the mice were anaesthetized with 11.25 mg/kg ketamine/7.5 
mg/kg xylasine of body weight administered intraperitoneally, and then transcardially 
perfused with 4% paraformaldehyde in 0.1M phosphate buffer (PB), pH 7.2, using a 
peristaltic pump. The brains were removed from the skull, immersed overnight in 4% 
paraformaldehyde in PB and then transferred to 0.1M PB in 0.001 NaN3.  
2.5.2 Antibody staining 
The brains were removed from the skull, immersed in 4% PFA in PB for 1 day, 
cut into 50-μm-thick serial coronal sections in a Vibratome VT1000S (Leica, 
Heidelberg, Germany), stored in PB and processed for immunohistochemistry. Selected 
free-floating vibratome sections were incubated overnight at 4°C using the following 
anti-neuronal nuclei (NeuN, 1:3000, Chemicon, Temecula, CA, USA) primary 
antibody, in accordance with the standard immunoperoxidase protocol (Moroni et al., 
2008). After several rinses in PBS, the sections were incubated in biotinylated goat anti-
rabbit IgG (Vector Laboratories, Burlingame, CA, USA) diluted 1:200 in 1% NGS in 
PBS. The avidin-biotin-peroxidase protocol (ABC; Vector) was followed, with 3,  3’-
diaminobenzidine tetrahydrochloride (DAB; Sigma) being used as chromogen. For 
cytoarchitectonic analysis, selected sections were stained with Cresyl violet (2%). 
Finally, the sections were mounted, dehydrated, and coverslipped with DPX (BDH, 
Poole, Dorset, EN). 
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2.6 Behav ioral analysis 
A battery of behavioral tasks was done to assess behavioral abnormalities 
(anxiety, locomotor activity, sociability) and cognitive function (hippocampus and 
prefrontal cortex memory). For Scn1a+/- mice, model of DS, only control WT and 
mutant mice in one cohort of animals were tested. For Scn1aRH/+ mice the four groups of 
animals (WT control, WT submitted to hyperthermia, Scn1aRH/+ control and Scn1aRH/+ 
with SIH) were obtained. We ran four cohorts of animals that we pooled. The order of 
the memory tasks was counterbalanced between cohorts (Morris water maze-radial 
maze-contextual fear conditioning; radial maze- Morris water maze-contextual fear 
conditioning or Morris water maze- contextual fear conditioning- radial maze). The 
openfield, dark/light and social interaction tests were always done at the beginning of 
the test battery to avoid handling/habituation interferences and the placement for 72 
consecutive hours in the actimeter was always done at the end of the testing to prevent 
animal isolation-associated stress. For all the behavioral tasks’analysis the experimenter 
was blind to genotype.  
2.6.1 Openfie ld test  
 Apparatus  
Hall, 1934 first described the openfield test (OF) to study emotionality in rats. 
Nowadays, it is largely used to study novel environment exploration, general locomotor 
activity, and provide an initial screen for anxiety-related behavior in rodents. The 
reaction to novelty was assessed by studying the anxiety, locomotor activity and 
stereotyped behaviors as previously described (Crawley et al., 1992). The apparatus 
consisted in a white and opaque quadratic arena (40cm L (length) x40cm W (width) x30 
cm H (height)) (FIGURE 14). An imaginary central area (20cm Lx 20W) and a peripheral 
area (30 cm L, 10 cm W) were defined to study anxiety- like behavior. The light intensity 
was set at 300 lux.  
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FIGURE 14. OPENFIELD APPARATUS . 
 Procedure 
The mouse was placed in the center of the arena and allowed to explore for 10 
minutes. The apparatus was cleaned with 70% ethanol and rinsed with water between 
each animal. The trajectory of the animals was video recorded and tracked with 
ANYmaze software (Stoelting, Wood Dale, Il). The total distance travelled and average 
speeds were counted as measures of locomotor activity. The distance travelled in the 
center (anxious area) was divided by the total distance travelled to assess anxiety level.  
To evaluate stereotyped behaviors, the number of rearing episodes were scored 
manually, while the circling behavior was scored automatically by the video tracking 
software (ANYmaze software (Stoelting, Wood Dale, Il)). A complete 360-degree turn 
of nose angle with respect to the body center was counted as one circling event.  
2.6.2 Dark↔light exp lorat ion test  
 Apparatus: 
The dark↔light paradigm has been extensively used for testing anxiolytic 
properties of drugs in rodents (Crawley and Goodwin, 1980; Holmes et al., 2003). The 
apparatus consisted of a white and black cage separated in two compartments (light and 
dark) by a partition, which had a small opening at floor level. The dark/closed 
compartment was made with black opaque walls (less anxious) cover by an opaque top 
and a light/open compartment was made with white walls and was light exposed (more 
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anxious). The total dimensions of the box were 42 cm L, 18 cm W, 29 cm H, while the 
light compartment represents 28 cm L and the black compartment 14 cm L (FIGURE 15). 
The opening that allowed dark↔light transitions was 7cm L and 5 cm H. The open side 
was illuminated by 300 lux light intensity.  
 
 
FIGURE 15. DARK↔LIGHT BO X APPARATUS . 
 Procedure 
The animals were released in the center of the light compartment and allowed to 
explore the entire apparatus, notably entering and exiting the dark compartment for a 
period of 5 minutes. The apparatus was cleaned with 70% ethanol and rinsed with water 
between each animal.  The dark compartment represents the protected area while the 
light compartment represents the unprotected area. The test mouse has to deal with the 
conflict of explore the bright area or be safe in the protected area.  The time spent 
(seconds) in the light compartment and the number of dark↔light transitions represent a 
measure of anxiety and were counted manually.  
2.6.3 Three-chamber social interact ion 
 Apparatus  
Sociability and social novelty tests were performed as described previously with 
minor modifications (Moy, 2004). The three-chamber apparatus consisted in a 
rectangular non-transparent plexiglass box (60cm L x30 cm W). Two dividing walls 
were made with clear plexiglass containing one circular opening each (4 cm diameter) 
to allow the mouse to assess each chamber. Each chamber was 20 cm L, 30 cm W, 22 
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cm H (FIGURE 16). Light intensity was adjusted to 3.5 lux and the apparatus was 
cleaned with 70% ethanol and water between each mouse. The wire cages were 11 cm 
H, with a bottom diameter of 10.5 cm and bars spaced by 1cm (Galaxy Cup, Spectrum 
Diversified Designs, Inc, Streetsboro, OH).  
 
FIGURE 16. THREE-CHAMBER SOCIAL INTERACTION APPARATUS .  
 Procedure 
The test consisted in three phases: 1) Habituation, 2) Sociability test and 3) 
Social Novelty test. All the stages were recorded using a camera to allow offline 
analysis. In the habituation phase the test mouse was placed in the empty box for 10 
minutes, with the doors open in order to freely explore the 3 chambers and acclimated to 
the environment. The time spent in each chamber, the distance travelled and the average 
speed were measured using ANYmaze tracking software (Stoelting, Wood Dale, Il). 
After the habituation period, the test mouse was restrained in the central chamber for the 
time of the preparation of the next step. An unfamiliar mice (same strain/same age/same 
gender) (M) was enclosed in the round wire cup, which allowed sensory but not 
physical contact and placed in one of the side chambers and another empty wire cage 
(EC) was placed in the opposite side chamber. Emplacements of the unfamiliar stranger 
mouse cage and empty cage were counterbalanced between animals to avoid chamber 
side preferences. A weighted bottle was placed on top of the wire cages to avoid 
climbing from the test mouse. The test mouse was then allowed to explore for a 10-
minute session. After the sociability stage, the test mouse was again blocked in the 
central chamber. For the last phase (the social novelty phase), a novel unfamiliar mouse 
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(nM) was placed in the cage that was previously empty. The doors were open and the 
test mouse had now the opportunity to choose between the familiar mouse (fM) 
(previously seen in the sociability phase) or the nM. The time spent interacting 
with/exploring the cages (distance between the test mouse and the cage less than 2cm) 
and also the time spent and the number of entries in each chamber was measured for the 
sociability and social novelty phases.  
2.6.4 Morris water maze  
 Apparatus: 
The Morris Water Maze paradigm (MWM) was widely described for testing 
spatial learning and memory (Morris 1981, Morris 1984). The apparatus consisted in a 
circular tank (90 cm diameter) filled with opaque water (temperature 25°C±1). An 
escape platform (8cm diameter) was submerged 1.0 cm below the water surface. 
Extramaze cues were placed in the walls surrounding the maze to allow the animals to 
create a spatial map and find the platform. Light intensity was set at 30 lux. Animals 
were placed in the testing room 30 minutes prior to experiment in order to acclimatize.  
 Procedure 
The testing consisted in 3 phases: 1) Cue task training (2 days) 2) Spatial 
learning training (4 days) and 3) Long-term reference memory-probe test (1 day) 
(FIGURE 17). For the cue task and spatial trainings, all the animals received 4 trials/day 
with a maximum trial duration of 90 seconds (+30 seconds on the platform at the end of 
each trial) and an inter-trial interval of 10 minutes. For each trial, the animals were 
gently placed in the water facing the sidewalls in a different cardinal point (NWSE) and 
randomized between animals and training days.  If the animal did not find the platform 
within the trial it was gently guided to it. All the trials were video recorded and tracked 
using ANYmaze software (Stoelting, Wood Dale, IL).  
1) Cued task training: Cued task was done prior to spatial learning training to 
notice visual and motor problems and to accustom the mice to the testing rule (find the 
platform to escape). A visible object was placed on top of the platform and the maze 
was surrounded by opaque curtains. The mice were allowed to find the visible platform 
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for 2 consecutive days with 4 trials per day. If the animal did not find the platform 
within the trial it was gently guided to it. The platform emplacement was changed every 
day. The escape latency, average speed and distance travelled were recorded.   
2) Spatial Training: For the spatial learning, the curtains and the object on top of 
the platform were removed. The animals could guide their learning to find the hidden 
and invisible platform based on the extramaze cues.  If the animal did not find the 
platform within the trial it was gently guided to it. The escape latency for each trial was 
analysed.  
3) Probe: A probe trial was run, 24 hours after training completion to assess the 
strength of the memory for the platform location. The platform was removed and the 
test mouse was allowed to search for it for 60s. The time spent in each quadrant (target, 
left, right and opposite) were recorded. An imaginary zone was draw around the 
platform –“platform zone” with 24cm diameter (3 x the platform diameter), and the 
number of crosses in the “platform zone” were counted.  
 
 
FIGURE 17. MO RRIS WATER MAZE APPARATUS AND PRO TOCOL TIMELINE. 
A: Morris water maze apparatus. B: GEFS+ mouse trying to find the hidden platform. C: Scheduling of the task: 
the animals went trough two days of cue task, followed by 4 days of spatial learn ing (4 trials per day) and a probe 
day. Each day represents a 24 hours delay between them (D1 to D7 ). D= day  
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2.6.5 Contextua l-Fear condit ioning  
The hippocampus plays an important role in the representation of contextual 
information in the contextual- fear conditioning paradigm ) (Phillips and LeDoux, 1992). 
In this test, the mice are placed in a conditioning chamber and receive pairings of a 
conditioned stimulus (contextual chamber) and an aversive unconditioned stimulus (an 
electric foot-shock). After a time delay, the mice are re-exposed to the same 
conditioning chamber without receiving any shock and the freezing response observed 
in the mice expresses the memory association between the contextual stimulus and the 
foot-shock.  
 Apparatus: 
The CFC apparatus consisted in a cubic box (25cm L x25cm W, 25cm H) with 
black methacrylate walls, a transparent frond door and a metallic floor with bars spaced 
by 0,6 cm. The floor was connected to the electric shock generator and a control unit of 
signal amplification (Startel and Fear System, BIOSEB Allcat Instruments, France). The 
3 shocks delivered in the conditioning phase had duration of 2 seconds and an intensity 
of 0.7mA. The light intensity was maintained at 5lux for all the procedure duration. The 
signal generated by animal’s movement was analyzed using the automatic freezing 
software Panlab V1.3 (BIOSEB Allcat Instruments, France). All the experiments were 
video recorded using a camera connected to the top of the chamber. The chamber was 
cleaned between animals with 70% ethanol, water and finally wiped with paper towels.  
 Procedure 
The experiment was done in two days: 1) conditioning (D1), 2) retrieval (D2) as 
illustrated in FIGURE 18.  
1) Condtioning: The mouse was placed in the conditioning box. After exploring 
for 2 minutes, the first shock was delivered, followed by the two other shocks, at an 
inter-stimulus interval of 1 minute. One minute after the last shock, the mouse was 
returned to his home cage. The animal’s activity was recorded.  
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2) Test: Twenty-four hours after the conditioning, the animal was placed in the 
CFC box (same context as in the previous fear conditioning) for 5 minutes and no 
shocks were delivered.   
 
The activity generated by the testing mice in the box (high and low activities and 
freezing) was recorded using the floor sensors and the video recording.  The cumulated 
freezing time (s) was measured across the time.  
2.6.6 Eight-arm radia l maze  
The radial maze was developed by Olton and Samuelson, 1976 and is used to 
test working memory in rodents The protocol used in this study was adapted from 
(Etchamendy et al., 2003) and based in a win-shift strategy to discriminate between two 
arms-choice.  
 
FIGURE 18. CO NTEXTUAL FEAR CONDITIO NING PROCEDURE. 
Top table: The description of the protocol t imeline. At day 1 the animals went trough the conditioning 
phase. Here, after a period of 2 minutes of habituation the animals (as seen in the scheme in the bottom) 
received 3 shocks with a duration of 2 seconds and spaced by 1 minute inter-stimulus interval. 
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 Apparatus: 
The apparatus consisted in a black plexiglass 8-arm radial maze (Viewpoint, 
Lyon, France). The maze was placed in an infrared floor and connected to a video 
recording camera and tracking software (Videotrack/Viewpoint). Distal and proximal 
extramaze cues were placed respectively on the walls of the room and above the 
infrared floor (between the arms). The central platform (diameter of 24 cm) and 8 arms 
(35cm L, 5cm W, 2cm H) which project radially outward were elevated 8 cm above the 
floor (see diagram FIGURE 19). Each arm had a transparent Plexiglass door, placed 
between the end of the arm and the central area that could be open and closed according 
to the protocol. A metallic and weighted food cup was placed at the end of each arm and 
maintained there for all the protocol. The maze was cleaned with water between each 
trial and light intensity was set at 3.5 lux. The procedure was divided in 2 phases: 
habituation (3 days) and training (n days until reach the criterion). For the whole 
protocol course the animals were food deprivated to motivate the mice in getting the 
food reward. Chocoloops ® (1/6 of the cereal ring) were used as food reward.  
1) Food deprivation: Food deprivation started one day before the first day of the 
protocol. Daily feeding was adapted to maintain the level of 90% of the initial body 
weight. Water was provided ad libitum. 
2) Habituation: In the habituation phase the test mouse was placed in the center 
of the maze, with the 8 doors opened and allowed to explore the entire maze. The bait 
was initially available throughout the maze, but was gradually restricted to the food cup. 
Three food rewards (1 – 1 – 1) were placed in all the arms at day one, two rewards at 
day 2 (0 – 1 – 1) and 1 reward at day 3 (0 – 0 – 1) placed only in the food cup to 
incentive the mouse to go to the end of the arm (see FIGURE 19) 
3) Training: The protocol for the training was based in a win-shift strategy. We 
presented a sequence of 7 pairs of arms that was changed every day. The animal was 
placed in the center platform with all the arms closed for 30s. A first baited arm was 
opened while the other 7 arms were closed. After this first forced choice, the mouse had 
to return to the center for another 30s. For trial 2, the old arm and a new consecutive or 
non-consecutive (never more than 90° angle between the 2 arms) were open at the same 
time, allowing the choice between two arms of the maze. The previous (old) arm was 
this time unbaited while the new one was baited. When the animal went to an incorrect 
arm this one was immediately closed after returning to the center to avoid perseverance 
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errors. If his first choice is the correct arm, the two arms were immediately closed after 
returning to the center and the trial is ended. The animal had to wait 30s before the next 
trial. The protocol was repeated for 6 more trials for a total of 8 trials per day. The 
animal had to retain the rule that if, in a given arm, it won the reward, it had to shift the 
other one. The sequence was changed every day and the training was stopped when the 
control animals reached the criterion of having an average of 75% of correct choices for 
2 consecutive days (5.25 correct choices out of 7).  
FIGURE 19. RADIAL MAZE DIAGRAM AND PRO TOCOL TIMELINE 
A: Radial maze apparatus and proximal and d istal cues. B: Mouse returning to the center after having collected 
the reward from the arm. C: Protocol timeline. Food deprivation started one day before habituation. Then the 
animals went through habituation for 3 days with the 8 arms  open (white arms),and food was d istributed across 
the arms from D1 to D3 as illustrated in the diagram. Following habituation the training started until the 
criterion was reached. Each training day had 8 trials, with the sequence of open arms changed everyday  (an 
example of a sequence is illustarted in the figure).  
2.6.7 Actimeter  
We placed the animals in the actimeter (Imetronic Apparatus, Pessac, France) 
for 3 consecutive days (72 hours). The animals had free access to food and water and a 
12 hours light cycle. The actimeter box (20 cm L, 11 cm W, and 18 cm H - FIGURE 20) 
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was equipped with infrared sensors to detect locomotor activity (horizontal and vertical) 
and an infrared plane to detect rearing. The data was collected by bins of 30 minutes.  
 
 
FIGURE 20. ACTIMETER DIMENSIONS . 
3. THERAPEUTIC EFFECT OF DRUG X IN DECREASING THE SPONTANEOUS 
SEIZURES FREQUENCY IN SCN1A+/-  MOUSE MODEL 
3.1 Drug X administrat ion 
The Scn1a+/- -B6-129 mice were used for this study and the treatment started at 
P21. Drug X (name cannot be disclosed) was prepared at a concentration of 15 mg/kg in 
5% DMSO and 95% PBS. Drug X was intraperitoneally administrated at a volume of 
5.5 ml/kg once a day for 5 days (in parallel to the SIH protocol).  
3.2 Protocol of seizure induced by hyperthermia and monitoring 
Six hours after drug X administration, DS mice were submitted to the SIH 
protocol in order to increase the spontaneous seizure frequency. The protocol was 
repeated for 5 consecutive days. The threshold temperature for seizure induction and the 
seizure severity were measured. The animals were then grouped by 2 and video 
recorded to analyze the presence of spontaneous seizures. The seizures were detected 
with custom-made software designed by ULLO society (la Joliette) for this experiment.  
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4. STATISTICAL ANALYSIS 
All the data analysis was obtained and analyzed blind to genotype. Statistical 
analyses were performed with GraphPad Prism V6.01 (La Jolla, CA 92037 USA). The 
normality of the data distribution was verified with Shapiro-Wilk’s test.  
Differences between groups were measured using two-tailed t-test, one way 
analysis of variance (ANOVA), two-way ANOVA (Genotype x Treatment) or repeated 
measures ANOVA in the protocol of consecutive dependent variables ( i.e. Training 
days/time x Group (genotype-treatment)). The ANOVA was followed by Tukey’s (3 or 
more comparisions) or Sidak’s (2 comparisions) post hoc test. The one-sample t-test 
was used to compare the time spent in the target zone and the chance level (25%) and 
also to compare training performance and the chance level in the radial maze training 
(chance level = 3.5 correct choice). Survival curves were compared with Log-rank 
(Mantel-Cox) test and the analysis of the data concerning the SIH protocol was done 
with Kruskal-Wallis test. Details of each value and statistical test used are described in 
the statistic tables (VIII-1,0,VIII-3,VIII-4,VIII-5 page 185). Error bars represent s.e.m. 
Null hypotheses were rejected at the 0.05 level. Statistical significances are represented 
by the following P-values in all figures: * p<0.05; ** p<0.01; ***, p<0.001; 
****p<0.0001 and n=number of animals, n=number of fields for field electrophysiology 
recordings, n=number of cells for patch clamp recordings.  
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IV- RESULTS 
Chapter 1- PHENOTYPIC CHARACTERIZATION OF SCN1A+/- (DS  MODEL) 
1. SCN1A+/- (DS  MOUSE MODEL) IN 129 BACKGROUND (SCN1A+/--129) 
The Scn1a+/--129 mouse, model of DS, is characterized as described previously, 
with high variability of phenotypes according to the genetic background (Yu et al., 
2006a). Because of that, the model we chose preferentially was the Scn1a+/- in 129/SvJ 
background, which present the mild phenotype (high survival and no spontaneous 
seizures). We first wanted to see if the Scn1a+/- mutation per se affects the behavioral 
phenotype. With the first littermates obtained, we behaviorally characterized the control 
WT and mutant animals (this chapter). After getting the first results we could not get 
enough animals to continue and validate the experiments. We decided to start breeding 
the mutant line in a different background in order to increase the reproducibility. We  
crossed the Scn1a+/--129 male with a C57BL/6 female to get the F1 generation of a 50% 
B6:129 mice and increase the colony (results presented in the 2nd part of this chapter).  
1.1 The Scn1a+/- mouse in 129 background show normal spatial 
learning and memory in the Morris water maze task 
We submitted the Scn1a+/--129 mice and littermate controls to the MWM task.  
One of the most described cognitive perturbation in DS patients is the inability to 
integrate visual-motor and visual-spatial information (Chieffo et al., 2011a; Ragona et 
al., 2011b; Wolff et al., 2006a). It is believed that the visual function is affected before 
the cognitive problems. In the cue task phase, ran to decipher visual and motor 
problems the two groups showed a significant decrease in latency to find the platform 
from day D1 to D2 with no difference in the average between the groups (RM-two way 
ANOVA, main effect of Day). These first results allowed us to conclude that the 
Scn1a+/--129 had no major visual or motor dysfunctions. Following the cue task, the cue 
above the platform was removed and the animals had to learn the hidden platform 
location based on the spatial extra-maze cues. The Scn1a+/--129 mice and the WT 
controls showed no amelioration in learning performance from D1 to D2. However, the 
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latency significantly decreased from D2 to D3 (FIGURE 21). After D2, we could 
conclude that this amelioration indicated that the two groups learnt the platform 
emplacement (RM-two way ANOVA, main effect of Day). In line with the learning 
curve results, when removed the platform 24 hours following the training end, the two 
groups of mice persisted higher than chance in searching the platform in the target 
quadrant (where the hidden platform has been positioned during training) than in the 
other 3 quadrants (left, target, right, opposite) (FIGURE 21). The RM-two way ANOVA 
showed a Quadrant x Genotype interaction with a significant main effect of quadrant, 
and the Sidak’s post-hoc analysis revealed a better performance of the Scn1a+/--129 
mice than the WT mice in the probe test because the persistence of the Scn1a+/--129 
mice in the 60s probe is mainly focused in the target quadrant (presence in target 
quadrant is significantly higher than in the 3 other quadrants: left, right, opposite) while 
the WT animals could not significantly discriminate between the left and target 
quadrants.  With these results, we concluded that the spatial learning was preserved in 
the Scn1a+/--129 mice and that both groups remembered the platform emplacement 
though in the probe test, the memory strength was higher in Scn1a+/--129 mice. 
 
 
FIGURE 21. SCN1A
+/-
 MICE IN 129 BACKGROUND SHOW PRESERVED SPATIAL LEARNING AND MEMO RY 
IN THE MWM TASK.  
A: Latency to findthe platform in the cue task (days 1&2) and train ing (days 1-4). B: Percentage of 
presence in the four quadrants (left, target, right, opposite) in the probe test, 24 hours after the train ing 
ended. *p<0.05; ***p<0.001, n=number of an imals  
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1.2 The Scn1a+/-  mouse in the 129 background show normal 
contextual-fear condit ioning 
The Scn1a+/--129 mice were submitted to the CFC using two different protocols. 
In the conditioning phase, the first group of animals received one shock. Twenty-four 
hours after the conditioning, the animals were placed in the conditioning context 
without receiving any shock. The freezing percentage was measured and was lower than 
published control animals of the same background (Rubinstein et al., 2015a), so we 
decided to increase the number of shocks in the next group of animals to ensure that the 
low freezing could not be causative of masked differences between the groups. The next 
group of mice received three shocks. We did not see differences in the freezing 
percentage between the groups (FIGURE 22). Although the number of animals was low, 
the Scn1a+/- mutation does not seem to alter contextual fear memory.  
 
FIGURE 22. THE SCN1A
+/-
 AND WT LITTERMATES SHOW SIMILAR FREEZING PERCENTAGE AFTER 1 
SHOCK OR 3 SHOCKS IN THE CFC. 
We run 2 d ifferent pilot experiments: the first with one conditioning shock (left side of the graph) and 
the second with 3 conditiong shocks (right side of the graph). n=number of animals  
 
In sum, we could not observe differences in any of the hippocampus-dependent 
memory tasks tested (MWM and CFC). We cannot yet make major conclusions 
concerning the data due to the low number of animals and the poor performance of the 
control WT animals in the tasks. To validate our hypothesis that the mutation itself 
cannot affect the cognitive performance more animals would have been required. 
Although this Scn1a+/--129 mouse model was ideal due to its mild phenotype 
(characterized by high survival and low spontaneous seizures frequency) the low 
breeding rate did not allow us to pursue the experiments with this model. In the next 
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paragraphs I will present the first preliminary results we obtained in this model. We 
therefore decided to cross the Scn1a+/--129 mutant mouse with a C57BL/6J female and 
use the F1 generation of the Scn1a+/- B6:129 mice (50% B6, 50% 129). In the next 
paragraphs, I will present the results obtained with this Scn1a+/- B6:129 mice.  
2. SCN1A+/-  (DS MOUSE MODEL) IN B6:129  BACKGROUND 
The Scn1a+/- -B6:129 showed 100% survival from P0 to P90 if not submitted to 
SIH (data not shown). We continued our investigation about the effect of the mutation 
per se in affecting the phenotype. As the number of animals was sufficient, we ran 
different behavioral and cognitive tasks. 
2.1 The Scn1a+/--B6:129 mouse display normal act iv ity in the 
openfield 
After 10 minutes in the openfield, the automatic analysis allowed to us to 
evaluate some parameters. For locomotor activity, the distance travelled and average 
speeds were measured. The Scn1a+/--B6:129 mice had the same locomotor profile as the 
WT-control (FIGURE 23A&B) suggesting that the mutation per se did not cause 
changes in this parameter. The anxiety level was quantified by counting the time the test 
mouse spent in the center of the openfield. The two groups spent similar time in the 
center, suggesting again no changes in the anxiety profile induced by the mutation 
(FIGURE 23 C).  
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FIGURE 23. SCN1A
+/-
-B6:129 MICE HAVE NORMAL ACTIVITY AND ANXIETY IN TH E OPENFIELD.  
A: Distance travelled (m) in the openfield. B: Average speed (m/s). C: Time in the center area of the 
openfield. n=number of animals.  
2.2 The Scn1a+/--B6:129 have normal circadian rhythm and 
act iv ity 
The activity of Scn1a+/--B6:129 mice was normal in the openfield. However it 
was previously reported that mice carrying the Scn1a mutation in the pure C57BL/6 
background had sleep disturbances and exhibited increased activity (Han et al., 2012a; 
Ito et al., 2013; Papale et al., 2013). To further confirm our results from the open field 
and study the circadian rhythm and activity in the Scn1a+/--B6:129 mice, we placed the 
animals in the actimeter for 72 consecutive hours.  
The RM-two way ANOVA revealed a significant main effect o f Time for both 
horizontal and vertical activities. This is clear in FIGURE 24A&B as the WT and 
Scn1a+/--B6:129 mice present a preserved circadian cycle with low activity during the 
light/resting phase and high activity during the dark/active phase, but no differences 
between them were pointed by the post-hoc analysis. The increased activity reported in 
previous studies (Han et al., 2012a; Ito et al., 2013; Papale et al., 2013), was not 
observed in the Scn1a+/--B6:129, thus indicating that the mutation per se is not 
responsible for the hyperactivity in the model.  
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FIGURE 24. SCN1A
+/-
-B6:129 MICE HAVE NORMAL CIRCADIAN ACTIVITY IN THE ACTIMETER . 
A: Total horizontal activity for 72 consecutive hours. B: Total vertical activ ity (rearing episodes) for 72 
consecutive hours. The timeline in g ray represents the dark phase (20h00 to 8h00). n=number of animals . 
 
2.3 The Scn1a+/--B6:129 mouse have preserved social interact ion 
sk ills 
Social interaction skills are affected in Dravet Syndrome patients (Berkvens et 
al., 2015; Olivieri et al., 2016). Also Han et al., 2012b and Ito et al., 2013 reported 
severe social skill perturbations in Scn1a+/- mouse model in the pure C57BL/6 
background, which exhibits a severe phenotype (high mortality, high spontaneous 
seizures frequency). One day after the openfield test, the mice were tested for social 
interaction skills in the three-chambered test. Before starting, the habituation trial was 
run in order to detect if there was a preference for one of the chambers that could 
interfere with the results. The two groups explored equally the two chambers (1 and 2) 
being slightly longer time in the center (RM-Two way ANOVA, main Chamber effect) 
(FIGURE 25 C). Confirming normal locomotor activity, the WT and mutant animals 
presented similar average speed and distance travelled during the habituation phase 
(FIGURE 25 A&B). In the sociability phase, the test mouse had to choose between an 
unfamiliar mouse and the empty cage. A normal mouse is expected to interact 
preferentially with the mouse than with the empty cage, though the WT showed an 
important preference for the mouse, none of the groups significantly discriminate 
between the two (FIGURE 25D) (RM-Two-way ANOVA, the Genotype effect is very 
close to reach statistical significance but did not, and there is no Cage effect). We would 
need to increase the number of animals to understand if the test was working for the 
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controls. In the next phase however, the two way ANOVA revealed a significant main 
effect of cage and Tuckey’s post-hoc analysis showed that the two groups displayed 
higher preference for the new mouse than the familiar mouse as expected (FIGURE 
25E). We see that the empty cage and the mouse are not significantly discriminated, 
anticipating sociability problems in the Nav 1.1 KO mice, however as the control 
animals did not significantly discriminate the two cages very well, it does not allow us 
to conclude for the impairment. A 2nd cohort of animals would allow us to conclude 
about the validity of the test. In the second phase, both groups preferred the social 
novelty than the social familiarity suggesting normal sociability skills in the Scn1a+/--
B6:129 mice.  
 
 
FIGURE 25. SCN1A
+/-
-B6:129 MICE SHOW NORMAL ACTIVITY IN THE HABITUATIO N PHASE (A&B). TH E 
SOCIAL PREFERENCE WAS NO T STRONG IN THE SOCIABILITY PHASE FO R THE WT AND SCN1A
+/-
-B6:129 
MICE, BUT REACHED SIGNIFICANCE FOR THE SOCIAL NOVELTY PREFERENCE IN THE SECOND PHASE 
(D)  
A,B&C Habituation phase: A: Average speed (m/s). B: Distance travelled (m). C: Time in the 3 
chambers (s). D: Sociab ility phase: interaction time with the empty cage (EC) or the mouse (M). E:  
Social novelty phase: time interacting with the familiar mouse (fM) or the novel mouse (nM). *p<0.05;  
**<0.01;n=number of animals  
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2.4 The Scn1a+/--B6:129 express normal spatial memory 
In this Scn1a+/--B6:129 mouse model, we went further in the behavior 
characterization and assessed spatial memory in the MWM as described earlier. The 
results illustrated in FIGURE 26 demonstrate that mice carrying the Scn1a+/- gene 
mutation in the B6:129 background exhibit normal spatial learning and memory. In the 
cue task, as we had observed for the 129/SvJ background, the two groups significantly 
decreased their latencies from cue task D1 to cue task D2 being in the last day at a 
latency lower than 5 seconds (RM-Two way ANOVA, main effect of cue task day). 
Similarly, the training for spatial memory was achieved with success by the two groups 
of animals (RM-Two way ANOVA, main effect of training day) (FIGURE 26 A). A 
significant increase in performance was observed from training D1 to D2, suggesting 
that the two groups learnt the platform location. Twenty-four hours after the end of the 
training, the platform was removed and the long-term memory strength was measured. 
Considering that the WT and Scn1a+/- mice swam persistently in the target quadrant 
(FIGURE 26B RIGHT) where the hidden platform was normally located (higher than 
chance), it was interesting to see that while the WT animals significantly discriminate 
the target quadrant the Scn1a+/- mice did not show a preference between target and right 
quadrants (RM-Two way ANOVA, main effect of quadrant) (FIGURE 26B RIGHT). The 
same number of platform zone crosses again confirmed that both groups had preserved 
spatial learning and memory in the MWM task (FIGURE 26B LEFT).   
 
FIGURE 26. SCN1A
+/-
-B6:129 DISPLAY NORMAL LEARNING AND MEMO RY IN THE MWM TASK. 
A: Average of the four trials latencies to find the platform in the cue task and training. In the cue task, the 
platform is visible, while in the training the platform is hidden. B (left): 24 hours after training complet ion 
the platform is removed and the persistance in the four quandrants of the MWM is measured. The target 
quadrant (where the platform was located) is highlited with a different pattern. The persistence in the t arget 
quadrant is compared to  chance level (gray line) B (right): Number of crosses in the en larged p latform zone 
were measured. **p<0.01;n=number of an imals. 
 
97 
2.5 The Scn1a+/--B6:129 display normal contextual-fear memory 
The contextual fear conditioning was done in order to confirm that hippocampus-
dependent memories are preserved in the Scn1a+/- model. Twenty-four hours after 
receiving three electric shocks, the animals were placed in the conditioning context. The 
total freezing time over the 5 minutes of testing was counted and, as shown in FIGURE 27, 
the two groups exhibited similar freezing behaviors, suggesting that the contextual- fear 
memory is preserved. 
 
 
FIGURE 27. THE SCN1A
+/-
-B6:129 MICE HAVE NORMAL CO NTEXTUAL-FEAR MEMO RY. 
Freezing percentage showed during the 5 minutes test, 24 hours after the conditioning when replaced in the 
same context. N=number of an imals. 
Combining the two behavioral tasks that assessed hippocampus function, we 
conclude that the heterozygous NaV1.1 loss of function cannot per se affect spatial 
memory.  
2.6 The Scn1a+/--B6:129 show normal work ing memory 
DS patients were previously reported to display important working memory 
deficits (Chieffo et al., 2011a; Ragona et al., 2011b). After food deprivation, we trained 
the animals to learn the working memory rule in the radial maze. There were 7 trials per 
day and the learning criterion was achieved when the animals had 75% of correct 
choices (5.25) for two consecutive days.  The RM-Two way ANOVA showed a 
significant main effect of training day but no Training Day x genotype interaction. The 
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Sidak’s post-hoc analysis confirmed that the mutation per se was not inducing 
differences between the 2 genotypes. The number of correct choices analysis showed 
that the WT control animals passed the criterion at training D12 and the mutant animals 
at training D11. Similarly, the WT controls behaved better than chance level from D8 to 
the end while mutant animals were already better than chance at D7 (FIGURE 28). This 
indicates that all mice learned the 8-arm radial maze rule, and that the mutants with 
heterozygous loss of Scn1a gene showed no deficits in working memory compared with 
WT mice.  
 
 
FIGURE 28. WT AND SCN1A
+/-
-B6:129 MICE SHOWED PRESERVED WORKING MEMORY IN THE EIGHT-
ARM RADIAL MAZE. 
The animals were trained in the radial maze to learn the working memory rule for n training days until 
the criterion was reached. The chance level was 3.5 correct choices (gray line) and the criterion was 5.25 
correct choices (burgundy line). The controls reached the criterion at train ing day 11. The statistical 
difference from chance level is represented. **p<0.01;***p<0.001; D=training day, n=number of 
animals  
 
All together the data on the Scn1a+/- (DS mouse model) in the mixed B6:129 
background indicates that DS mice present a similar cognitive phenotype to the WT, 
strongly suggesting that the cognitive impairment is not related to the mutation per se. 
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Chapter 2- SEIZURES INDUCTION BY HYPERTHERMIA (SIH) IN SCN1A+/--B6:129 AND 
SCN1ARH/+-129:B6  MOUSE MODELS  
We wanted to induce seizures using hyperthermia at early age (developing brain) 
in Scn1a+/- mutant mice to study the long-term effects in adulthood. The first febrile 
seizure in Dravet patients occur at around 4-6 months of age (Chieffo et al., 2011a), and 
in Scn1a+/- mutant mice with pure C57BL/6 background at P10 (Yu et al., 2006a). It has 
been described previously that rat brain development at P10-15 might correspond to the 
age at which human infants are most susceptible to febrile seizures (Dobbing and Sands, 
1973). The corresponding age of the mouse brain is not clear (Andreollo et al., 2012; 
Quinn, 2005; Romijn et al., 1991) but the data tend more to the hypothesis that a rodent 
at P15 corresponds to one year of age in humans. As WT pups present SIH from P11-17 
we wanted to use animals elder than this age to avoid WT animals submitted to 
hyperthermia to have seizures (Hjeresen and Diaz, 1988). 
SIH have been acutely induced in Scn1a mutant models (Cheah et al., 2012; 
Martin et al., 2010b; Oakley et al., 2009a; Sawyer et al., 2016), but never chronically. 
We were therefore confronted with an important range of optimizations to the protocol.  
Our first question concerned the number of seizures that we should induce in the mice. 
Dravet patients can have more than 30 seizures for a period of 1 month in average but 
can have more than one seizure per day (Takayama et al., 2014). We first decided to 
induce 2 seizures per day for 10 days. The high level of mortality, rapidly persuade us 
to decrease the number of seizures previously established. We thus decided to induce 
only one seizure per day for 10 days. The next troubles concerned the technical method 
employed. Previous SIH were provoked using a red lamp heating, in a transparent 
cylinder and the temperature was controlled by a mouse rectal probe connected to a 
thermocouple (Oakley et al., 2009a). With the chronicity of the protocol, the mice 
suffered from some injuries caused by the red lamp (i.e. burning of the tail and ears) and 
we had to adapt the protocol by using a small incubator to cause hyperthermia. 
Following all these adaptions we started the SIH protocol.  
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1. SCN1A+/--B6:129 PRESENT HIGH SEIZURE SEVERITY AND HIGH MORTALITY 
DURING THE 10-DAYS PROTOCOL OF SEIZURES INDUCTION.   
After confirming that the heterozygous loss of function of the Scn1a gene did 
not seem to induce cognitive problems in this genetic background, our next goal was to 
induce seizures by hyperthermia in this model. We observed that the survival 
percentage of the Scn1a+/--B6:129 mice was 100% at post natal week 16 (data not 
shown). We induced one seizure per day by hyperthermia for 10 days. The percentage 
of mice alive after 10 days was 100% for control non-hyperthermia animals (WT-
B6:129 control and Scn1a+/--B6:129 control) (this animals underwent the same handling 
procedure but no hyperthermia), 72.72% in WT-B6:129 animals submitted to 
hyperthermia (WT B6:129 HYP) (WT mice, submitted to hyperthermia but did not 
present seizures) and 36.76% for Scn1a+/--B6:129 mice (FIGURE 29  A). All the Scn1a+/-
mice presented seizures when submitted to hyperthermia and the seizures last usually 
lower than 1 minute (short-lasting or simple hyperthermic seizures). The temperature 
required to induce seizures at protocol day 1 (41.17±0.106ºC), FIGURE 29 B, was higher 
than reported previously in mouse models with the same mutation (Scn1a+/--129, 
Scn1a+/--B6, Scn1a+/--129:B6) (Kalume et al., 2007a; Oakley et al., 2009a; Rubinstein et 
al., 2015a). When increasing the temperature to induce seizures in the incubator, the 
animals were immediately removed after the appearance of the first behavioral signs of 
a seizure (i.e. staring, head nodding and myoclonic jerks (grade 1-4) see TABLE 11 in 
material and methods). At D1 the majority of the animals presented a clonic seizure  
with a tonic component characterized by forelimb clonus with rearing and failing that 
indicates forebrain activation and the beginning of the seizures spreading from forebrain 
to brainstem. On the following days, the seizure severity significantly increased to GTC 
seizures indicating that the seizure had reached the brainstem, and was maintained at the 
same level for the following days (FIGURE 29C). 
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FIGURE 29. SEIZURES INDUCTION BY HYPERTHERMIA IN SCN1A
+/-
 -B6:129 MICE. 
A: Survival plot of Nav1.1 mutant mice in B6:129 genetic background, shown as the percentage of live 
mice at each day of the SIH protocol.. B: Temperature treshold for the appeareance of the 1
st
 behavioral 
sign of a seizure. C: Caracterization of the seizure severity according to the scale adapted for seizures 
with a limbic origin. n=number of animals, ***p<0.001 
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Due to the high level of mortality observed by Scn1a+/- mouse in B6:129 
background after SIH, we could not obtain a sufficient number of mice to perform 
behavioral tasks to test the effect of seizures on cognitive phenotype. As previously 
described, the NaV1.1 channel phenotypic spectrum is large and while truncating 
mutations are usually associated to the most severe phenotypes as DS, missense 
mutations are described to confer the higher variability of the spectrum (Volkers et al., 
2011). Although missense mutations have been found preferentially in GEFS+ patients 
they also cause DS (Escayg and Goldin, 2010), i.e. the R1648H missense mutation that 
was originally found in two families with GEFS+ spectrum (Escayg et al., 2000a) was 
present in one DS patient (Depienne et al., 2010). Thus, the R1648H mutation had 
clinical relevance in GEFS+ and DS diseases.  
We then decided to use the KI Scn1aRH/+ mouse, model of GEFS+, having the 
heterozygous R1648H missense mutation (available in the laboratory).  It was a good 
alternative because, the Scn1aRH/+ mouse, created by Martin et al., 2010 present a mild 
phenotype and almost no spontaneous seizures in the described pure C57BL/6 
background. Moreover, these mice are sensitive to SIH so we could induce our protocol 
as previously done in the Scn1a+/- mutant. Similar to Scn1a+/- mouse, (KO model) the 
homozygous mutation is lethal in the Scn1a-/- mice. The Scn1aRH/+ model was available 
in the pure C57BL/6 in the laboratory. To maintain the mixed background as in the 
previous Scn1a+/- line, the Scn1aRH/+ male in the pure C57BL/6 background was crossed 
with a 129/SvJ WT female and all the experiments were continued in this Scn1aRH/+ -
129:B6 model. 
2. SIH PROTOCOL IN SCN1ARH/+  -129:B6 MOUSE  
The SIH protocol was successful in the Scn1aRH/+ mutant. As described 
previously in material and methods, there are 4 groups in this study. The WT and 
Scn1aRH/+ control groups that underwent the same handling protocol but without 
hyperthermia were used to evaluate the effect of the Scn1aRH/+ mutation per se. The WT 
HYP mice were WT littermates that were submitted to the hyperthermia protocol (up to 
42°C) but did not display seizures and were used to evaluate the effect of hyperthermia 
per se when compared to WT control animals. Finally the Scn1aRH/+ SIH group was 
analysed to evaluate the effect of the seizures in the mutant mice.  At SIH protocol day 
10 the percentage of Scn1aRH/+-129:B6 mice alive was 65.07%, while 92.06% for WT-
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129:B6 HYP and 100% for WT-129:B6 and Scn1aRH/+-129:B6 control animals (FIGURE 
30A). The Scn1aRH/+ mice presented seizures when submitted to hyperthermia and the 
seizures last usually lower than 1 minute (short-lasting or simple hyperthermic 
seizures). The temperature threshold to induce seizure at day 1 was 41.63±0.04 and 
significantly increased at day 2 and 3 indicating an adaptive compensation in response 
of the SIH. Passed day 3, the animals returned to temperature thresholds similar to day 1 
for the following days (FIGURE 30 B). The seizure severity started at grade 5 for the 
first day, meaning that the animals were having forelimb clonus with a tonic component 
(rearing) and twist of the body (failing) – seizure with origin in the forebrain but 
spreading to brainstem. The severity was increasing across the days (FIGURE 30  C). By 
day 4, the majority of the animals were displaying GTC seizures (grade 6) indicating 
that the seizure was involving to the brainstem structures (FIGURE 30  C). 
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FIGURE 30. SEIZURES INDUCTION BY HYPERTH ERMIA (SIH) IN SCN1A
RH/+
-129:B6 MICE. 
A: Percentage of mice alive during the 10-days of seizures induction by hyperthermia. B: Temperature 
treshold for the appeareance of the 1
st
 behavioral sign of a seizure. C: Characterization of the seizure 
severity according to the scale adapted for s eizures that resultt from the disruption of the GABAergic 
system . n=number of animals, ***p<0.001  
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Chapter 3- LONG-TERM EFFECTS OF THE 10-DAYS SEIZURES INDUCTION BY 
HYPERTHERMIA PROTOCOL IN SCN1ARH/+-129:B6 MICE. 
Due to the reasonable reproduction and resistance of the Scn1aRH/+ -129:B6 
mouse (GEFS+ model) to the SIH, we decided to pursue our research using this mutant 
mouse and thus answer our main question i.e if seizures can worsen epileptic and 
cognitive phenotypes in mouse models carrying the Scn1a gene mutation.  
1. SIH WORSEN THE EPILEPTIC PHENOTYPE IN SCN1ARH/+-129:B6 MUTANT 
MOUSE 
It was previously reported that Scn1aRH/+ in C57BL/6J background present very 
low level of spontaneous seizure activity (Martin et al., 2010b). We wanted to test if it 
was the case for our animals that should exhibit even milder phenotype introduced by 
the 129/SvJ background, as previously reported for other Scn1a mutants (Rubinstein et 
al., 2015a; Yu et al., 2006a). For this we induced seizures by hyperthermia for 10 days 
on the Scn1aRH/+-129:B6 mice, as reported in the previous chapter. The animals were 
implanted with the 5 ECoG electrodes (FIGURE 31A) on the day following the last day 
of the protocol. Two days after the surgery, the animals were connected to the ECoG 
recording cables and recorded in time windows of three days during 2 months. The 
analysis of the ECoG signal was done simply by quantifying the number of GTC 
spontaneous seizures as illustrated in FIGURE 31B. We are conscious that a more 
profound analysis of the signal would a revealed more events and we plan to perform 
this analysis in due course.  
FIGURE 31C shows the results obtained. We did not observe any spontaneous 
GTC seizure in the Scn1aRH/+-129:B6 control mice during the period tested. It is 
possible that they exhibited more subtle ECoG alterations that we did not observe using 
our analysis method. However, it was clear that the SIH increased seizure frequency in 
the mutant animals. We observed the appearance of 0.5 to 1 seizure in average per day 
and per animal. We thus conclude that by inducing seizures for 10 days in the 
Scn1aRH/+-129:B6 model that normally presented no (or very low) epileptic history, we 
could convert its phenotype into a severe epileptic model.   
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FIGURE 31. SIH PRO TOCOL WORSENS THE EPILEPTIC PHENO TYPE IN SCN1A
RH/+
-129:B6
 
MUTANT MICE.  
A: Position of the elctrods implantation. B: ECoG signal showing a spontaneous GTC seizure, scale bars 
2mV, 2.5s. C: Spontaneous seizures frequency recorded two days following the last day of SIH 
(represented with the orange arrow) in Scn1a
RH/+
-129:B6 mice after 10 days of SIH compared to control 
WT-129:B6 and Scn1a
RH/+
-129:B6 and WT-129:B6 HYP
 
mice. LF (Feft frontal), RF (right frontal), LO 
(Left occip ital) RO (right occipital), Ref: Reference electrode. N=number of animals. 
2. CELLULAR AND MOLECULAR ALTERATIONS IN HIPPOCAMPUS AFTER SIH IN 
SCN1ARH/+-129:B6  MOUSE MODEL 
After successfully inducing the protocol of SIH, we wanted to first understand if 
important cellular and molecular rearrangements had occurred during the post-SIH 
resting time.  
2.1 Cytoarchitecture is preserved after seizures in Scn1aRH/+  mice 
in the hippocampus 
We first explored if seizures could induce neuronal damage and important 
cytoarchitecture changes. We induced seizures using the SIH protocol as described 
previously and allowed the animals to rest until they reached P60. The brains were  then 
fixed, sliced and stained with Nissl and NeuN antibodies to evaluate neuronal integrity 
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and organization. The hippocampal formation receives the major excitatory input from 
the entorhinal cortex via the perforant path to primarily terminate in the dentate gyrus. 
Dentate axons, the mossy fibers, project to the CA3 region and from there the Schaffer 
collaterals convey the processed input to the CA1 area. Thus, the dentate gyrus operates 
as a gate at the entrance to the hippocampus, filtering incoming excitation from the 
entorhinal cortex (Acsády and Káli, 2007; Henze et al., 2002). In other Scn1a mouse 
models the hippocampus has been shown to participate in the seizure onset (Liautard et 
al., 2013; Ohno et al., 2011) and it is also of major importance in memory processing 
(Neves et al., 2008). Therefore, it is conceivable to speculate that seizures induction in a 
mouse model carrying a Scn1aRH/+ mutation causes cellular alterations within the 
hippocampus. However, the neuropathological evaluations (Nissl and NeuN staining) 
showed no major cytoarchitecture modifications in the hippocampus of Scn1aRH/+-
129:B6 mice after the protocol of seizure induction.  
 
 
FIGURE 32. SIH DO NO T INDUCE IMPORTANT CYTOARCHITECTURE CHANGES IN THE HIPPOCAMPUS IN 
SCN1A
RH/+
-129:B6 MUTANT MICE.  
A,B: Photomicrographs illustrating Nissl staining in  Scn1a
RH/+
-129:B6 control and SIH mice. C,D: NeuN 
immunolabelling in Scn1a
RH/+
-129:B6 control and SIH mice and amplified to the dentate gyrus in E,F.  
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In conclusion, the seizures did not induce gross cytoarchitecture changes in the 
hippocampus in the Scn1aRH/+129:B6, suggesting that the SIH did not induce major 
neuronal death unlike other models of epilepsy (kainite, pilocarpine) (Kang et al., 2015; 
Kim et al., 2011, 2015; Wang et al., 2015). The results are therefore in line with what 
was observed in the Scn1a+/- mouse model in pure C57BL/6 background that present 
high spontaneous seizure activity but no neuronal death (Yu et al., 2006a).  
2.2 Long-term synaptic plast icity is maintained but not short -term 
synaptic plast icity in the CA1 region of the hippocampus after SIH 
in Scn1aRH/+129:B6 mice 
Long-term potentiation (LTP) has been described to underlie the synaptic basis 
of learning and memory in the hippocampus (Bliss and Collingridge, 1993; Morris et 
al., 1986; Whitlock et al., 2006). We tested whether the SIH protocol affected the ability 
of the CA1 neurons of the hippocampus to potentiate and maintain an LTP after a strong 
stimulus. After inducing seizures at P21, we sacrificed the animals at P60 and evaluated 
their synaptic properties in hippocampal slices. FIGURE 33A shows LTP of the field 
excitatory post-synaptic potentials recorded at the CA3 to CA1 synapse. After obtaining 
a stable baseline, averaged at 100%, a pulse of 100 Hz/1s was given to induce an LTP. 
The immediate response (1st 2 minutes), reflecting post-tetanic potentiation, was 
significantly increased in Scn1aRH/+-129:B6 mice submitted to SIH when compared to 
the 3 control groups. LTP was maintained after 60 minutes post- induction. The four 
groups showed similar LTPs with no changes in the LTP averages when measured 
during the last 15 minutes of the recording (FIGURE 33B). However, using this 
induction protocol (1 pulse at 100Hz/1s), the LTP obtained was not very strong (~115% 
in control WT-129:B6 animals). We thus decided to induce LTP with a stronger 
protocol (4 pulses of 100Hz/1s with 5 minutes inter stimulus interval (ISI)) to see if all 
the groups could equally respond to a stronger stimulus. As shown in FIGURE 33C&D, 
the LTP was higher (~150% in control WT-129:B6 animals) as compared to FIGURE 
33A&B with the stronger protocol. Yet, also with this protocol, all the groups displayed 
the same average LTP of fEPSP in the last 15 minutes of the recording. The increase in 
the immediate response (post-tetanic potentiation) after LTP induction was not observed 
this time, possibly due to the saturation after 20 minutes of the 1st induction pulse. As 
alterations in post-tetanic potentiation is generally due to functional alterations at the 
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pre-synapse (Balakrishnan et al., 2010; Colino et al., 2002; Voronin, 1982), we decided 
to also study paired-pulse facilitation, a measure of pre-synaptic plasticity (Zucker and 
Regehr, 2002). The fEPSP were evoked at different short ISI in order to study the pre-
synaptic release facilitation. As expected, the PPR (quantified as the peak amplitude of 
the 2nd response divided by the 1st) decreases with the increase of the ISI in all groups. 
Interestingly, we observed an increase in the PPR at different ISI (150, 250, 300, 350, 
400 ms) suggesting that SIH in Scn1aRH/+-129:B6 mice might alter the release 
probability of the presynaptic neuron. 
With these data we can conclude that SIH does not affect the LTP in CA1. We 
planned to test the LTP in the dentate gyrus (DG) that acts as first gatekeeper of the 
hippocampus (Acsády and Káli, 2007; Amaral et al., 2007; Treves et al., 2008), and has 
been stressed to have major importance in epiloptogenesis studies (reviewed in Dudek 
and Sutula, 2007). Also, Cheah et al., 2012 and Tsai et al., 2015 reported a higher 
reduction of NaV 1.1 protein in the DG than in CA1 or CA3 areas of the hippocampus in 
Scn1a mutant mice, and altered functional an structural properties of the DG region of 
the hippocampus (Tsai et al., 2015). According to previous results from the laboratory, 
reliable induction of LTP in the DG requires blocking the inhibitory function (Houeland 
et al., 2010). We could indeed obtain LTP in the DG using the GABAergic blocker 
picrotoxin (data not shown). Yet, this poised a conceptual problem regarding its use in 
the context of the Scn1a gene mice. Indeed, Nav 1.1 channel’s mutations mainly affect 
GABAergic neurons (Yu et al., 2006a), and the . It would thus have been more 
appropriate to avoid blocking GABAergic function during the study of this mo use 
model. Unfortunately, we could not obtain LTP in WT mice without picrotoxin leading 
us to give up on this experiment (data not shown).   
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FIGURE 33. SHORT-TERM PRE-SYNAPTIC BUT NO T LONG-TERM POST-SYNAPTIC PLASTICITY IN CA1 
REGION O F THE HIPPOCAMPUS IS ALTERED IN SCN1A
RH/+
129:B6
 
MICE. 
Long-term plasticity  : A,B: LTP of fEPSP induced with  one pulse of h igh-frequency stimulation  at 
100Hz/1s (orange arrow). B: Average of the last 15 minutes as % of baseline, from 45 minutes to 60 
after LTP induction. C: LTP of fEPSP indcued with four pulses of high-frequency stimulat ion at 
100Hz/1s with 5 min ISI (orange arrow). D: Average of the last 15 minutes as % of baseline, from 45 
minutes to 60 after LTP induction. E: Short-term pre-synaptic plasticity. E: Paired-pulse rat io (P2/P1) at 
different inter-stimulus intervals. Statistical significance is represented in vio let for difference between 
Scn1a
RH/+
 control and SIH mice and in b lack for differences between Scn1a
RH/+
 SIH mice and WT-HYP. 
* p<0.05; **p<0.01;  ***p<0.001 
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2.3 Scn1aRH/+  mice show an increase in f iring frequency in 
granular cells in the dentate gyrus but  not  in CA1 pyramidal 
neurons after SIH 
Field recordings of synaptic plasticity revealed the presence of modifications in 
short-term plasticity in CA1 area of the hippocampus. In addition previous studies in 
mouse models with Scn1a gene mutation had reported changes in DG granule cell’s 
properties (Tsai et al., 2015).  In collaboration with Dr Pousinha, we thus decided to 
pursue the analysis of DG granule cells and CA1 pyramidal neurons by whole cell 
current clamp recordings.  We first examined their passive and intrinsic excitability 
properties. The intrinsic excitability, as measured by the frequency of APs at a given 
current injection, of CA1 pyramidal neurons from Scn1aRH/+ SIH was slightly increased, 
though not statistically different, when compared to the other groups (FIGURE 34A). By 
contrast, DG granule neurons from Scn1aRH/+ SIH were strongly hyperexcitable 
(FIGURE 34B), than DG granule neurons from the other control groups. Importantly, 
neither the mutation itself (compare WT control and Scn1aRH/+ control) nor the 
hyperthermia induction (compare WT control and WT-HYP) affected, per se, the 
intrinsic excitability properties of the two neuron populations (FIGURE 34). Other 
membrane properties including resting membrane potential and membrane resistance 
did not significantly differ between genotypes/treatments in both CA1 and DG 
hippocampus regions (Statistic Table chapter VIII-3 page 190). 
 
FIGURE 34. FIRING FREQ UENCY O F EXCITATO RY NEURO NS IN THE DG BUT NO T IN THE CA1 IS 
INCREASED IN THE SCN1A
RH/+
-129:B6 MICE SUBMITTED TO  SIH. 
Firing Frequency measured as the number of action potentials per second (Hz) when neurons were 
depolarized by increasing current steps (20pA steps with 1s duration) in CA1 A and DG B . n= number of 
animals,   ***p<0.001. 
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3. SEIZURES INDUCED BY HYPERTHERMIA INDUCE LONG-LASTING CHANGES IN 
THE BEHAVIORAL AND COGNITIVE PHENOTYPES IN SCN1ARH/+-129:B6   MICE.  
As for the immunohistochemistry and electrophysiology analysis, another group 
of animals submitted or not to SIH at P21 went through a battery of behavioral tasks at 
P60. The order of the behavioral tasks was counterbalanced between cohorts of animals, 
except for openfield, social interaction and dark- light tests that were done at the 
beginning and for the analysis of activity in the actimeter that was done at the end. 
3.1 Scn1aRH/+-129:B6 mice with SIH have a novelty-associated 
increase in act iv ity in the openfield and stereotyped behav ior 
without changes in anx iety.  
Previously, Scn1a mutation’s carrying lines were reported to exhibit a novelty-
associated increase in activity (Han et al., 2012a; Ito et al., 2013; Purcell et al., 2013; 
Sawyer et al., 2016). We placed the 4 groups in the openfield. The parameters analyzed 
to evaluate locomotor activity were the speed of travelling and the distance travelled. 
The two-way ANOVA of the distance travelled and average speed in the openfield 
(treatment x genotype) revealed a significant main effect of genotype and treatment and 
a significant interaction between treatment and genotype (all the statistical values are 
described in the chapter VIII-page 185). Tuckey’s post hoc analysis showed that the 
WT-129:B6 (control and HYP) and Scn1aRH/+-129:B6 control mice travelled similar 
distances and at similar average speed. Scn1aRH/+-129:B6 mutants submitted to the SIH 
protocol travelled a greater total distance and travelled at a higher average speed than 
the 3 other groups FIGURE 35A&B. We could assume that the Scn1aRH/+ mutation per 
se does not induce novelty-associated locomotor changes, however, after chronic 
seizure induction by hyperthermia at early-age, the Scn1aRH/+-129:B6 was hyperactive 
when exposed to a novel environment (illustrated in the track-plot report  
FIGURE 35. SCN1ARH/+ -129:B6 SIH HAVE A NOVELTY associated increase in 
activity and stereotyped behavior.D)  
We wanted to go further in the analysis and we observed that the hyperactive 
mice had some repetitive behaviors. We counted the number of rotations of the animal’s 
body and the number of rearing episodes in the period tested. The ANOVA showed a 
main effect of genotype and treatment for both measures with an interaction between 
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treatment x genotype for the number of rearing episodes but not for the rotations of the 
animal’s body. The post-hoc analysis (Tuckey’s) indicated that the WT-129:B6, 
Scn1aRH/+-129:B6 control mice and WT-129:B6 HYP displayed similar number of these 
events, however the Scn1aRH/+-129:B6  mice submitted to SIH had exacerbated number 
of rotations of the animal’s body and rearings (FIGURE 35E&F). These two measures 
are associated to stereotyped behavior.  
 
 
FIGURE 35. SCN1A
RH/+
 -129:B6 SIH HAVE A NOVELTY ASSOCIATED INCREASE IN ACTIVITY AND 
STEREO TYPED BEHAVIOR. 
The animals were placed in the openfield for 10 minutes. A, B- Locomotor activity. A: average speed 
(m/s) and B: Distance travelled (m) caracterize the locomotor activity of the 4 groups. C: Anxiety 
measured as the distance travelled in the center dicided by the total distance travelled. D: Track plots of 
the locomotor activity o f a WT-129:B6 
 
HYP, a Scn1a
RH/+
-129:B6 control and a Scn1a
RH/+
-129:B6
 
SIH 
mice during the 10 minutes in the openfield. E, F Measures of stereotyped behavior: E: Rotations of the 
animals body (counted when the animal complete a 180° turn) and F: Number of rearing episodes. The 
legend presented on the bottom right is for all the graphs. n=number of animals, *p<0.05,***p<0.001. 
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The openfield can be used as a first screen for anxiety in rodents however it 
should be complemented with other paradigms (Prut and Belzung, 2003). This measure 
can easily be obtained by quantifying the time spent in the center or the latency to first 
entry in the center. However, the important changes in locomotion induce a bias in this 
measure, proposing a decrease in anxiety in the Scn1aRH/+-129:B6 mice submitted to 
SIH (data not shown). Another accepted measure for anxiety in the openfield is ratio: 
distance travelled in the center divided by the total distance travelled. We observed that 
all the groups had the same ratio of center exploration. This measure indicated that the 
SIH did not induce anxiety in the Scn1aRH/+-129:B6 mice. (FIGURE 35C) and all groups 
behaved equally. To complete the findings about anxiety obtained in the openfield we 
ran a trial: the dark↔light box (used to study anxiety in rodents). FIGURE 36 shows the 
time spent in the light compartment – more anxiogenic (A) and the number of entries in 
the same compartment (B). The Two-way ANOVA revealed a significant interaction 
between the treatment and genotype with a main effect of treatment for the number of 
entries in the light zone but not for the time in the light zone. The post hoc analysis 
show no differences between the groups for the time spent in the anxious light zone, but 
a difference between the WT-129:B6 and WT-129:B6 HYP in the number of entries. 
These results again suggest that there is no increase in anxiety caused by the seizures, 
even if this test is not very convincible due to the very low time spent by the WT-
129:B6 control mice in the light side (lower than 10 %) possibly due to the high light 
intensity used in the test and the large variability inside the groups as seen in the dot-
plot graphs.  
 
 
FIGURE 36. THE S IH DO ES NO T INDUCE ANXIETY IN SCN1A
RH/+
-129:B6 MUTANTS . 
A: time in the light side of the dark↔light box. B: Number of entries in the light side of the dark↔light 
box. n=numer of animals. **p<0.01.  
 
We could conclude that by confronting the 4 four groups to a novel and stressful 
environment, the WT-129:B6, WT-129:B6 HYP and Scn1aRH/+-129:B6 control mice 
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behave at the same level indicating that the mutation per se or the hyperthermia per se 
do not affect the novelty reaction, while, the 10-days of SIH clearly changed the 
reaction to novelty in Scn1aRH/+-129:B6 mice as demonstrated by a clear increase in 
activity, exacerbated stereotyped behavior but no changes in anxiety.  
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3.2 The novelty-associated hyperactiv ity normalizes after 
habituation in the act imeter in Scn1aRH/+-129:B6  SIH mice. 
Our first worry concerning the hyperactivity induced by the SIH was: is it 
associated to novelty or maintained chronically as home cage behavior? As we could 
not record the animals in their home cages, we placed them in the actimeter for 72 
hours. The sensors in the actimeter give the parameters represented in FIGURE 37. The 
measures are represented in bins of 30 minutes period (A&B) and 12 hours period (C). 
The animals were placed at 7 pm at day 1 and removed 3 days later. In FIGURE 
37A the horizontal activity measures the activity on the actimeter’s floor (movements at 
the back + movements in the front + number of crosses) of the 4 groups of animals. 
RM-two way ANOVA revealed a significant interaction (genotype-treatment x time) 
with a main effect of time but not genotype-treatment. This main effect is observed with 
the clear circadian cycle observed by the four groups. As the WT-129:B6 animals, the 
Scn1aRH/+-129:B6 control and Scn1aRH/+ -129:B6 SIH showed low activity during the 
light/resting phase and higher activity during the dark/active phase with no differences 
between the groups at any bin of time (pot-hoc analysis show no differences between 
the groups). The vertical activity, measuring the number of rear ing episodes also 
represents a measure of activity and it is illustrated in FIGURE 37A&B. The RM-Two-
way ANOVA of the vertical activity showed a significant main effect of time (as 
previously) but also of genotype-treatment and a significant interaction between the 
two. The four groups again showed a normal circadian cycle with low activity during 
the resting- light phase and high activity during the active-dark phase, confirming that 
neither the mutation nor the seizures induce important changes in the circadian cycle. 
Tuckey’s post-hoc analysis showed a significant increase in the vertical activity for the 
Scn1aRH/+-129:B6 SIH when compared to the 3 control groups during the first 12 hours 
in the actimeter (1st day and night). This activity tended to normalize and became 
similar to the controls for the following hours (FIGURE 37B), even if for 3 time points 
during the active phase this activity remained significantly increased. In FIGURE 37C 
the vertical activity is pooled in time bins of 12 hours and again we can see that the SIH 
significantly increases significantly the activity in the Scn1aRH/+-129:B6 group but not 
the mutation per se (no differences between the WT-129:B6 control and Scn1aRH/+-
129:B6 control). Yet, this increase in activity is temporary and normalizes within 24 
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hours, indicating that the hyperactivity in Scn1aRH/+-129:B6 with SIH is most probably 
associated to novelty.  
 
 
FIGURE 37. SCN1A
RH/+
-129:B6 MUTANT MICE EXHIBIT A NOVELTY-ASSOCIATED INCREASE IN REARING 
ACTIVITY IN THE ACTIMETER. 
A: Total horizontal act ivity (sum of the activ ity at the front + back + front-back crosses) scored for 69 
consecutive hours (data showed by half-an-hour periods). B: Total vertical activ ity (number of rearing 
episodes) for 69 consecutive hours (data showed by half-an-hour periods). C: Total vertical activ ity 
(number of rearing episodes) for 69 consecutive hours (data pooled by 12-hour periods). Statistical 
significance is shown in violet when the Scn1a
RH/+
-129:B6 SIH mice are different that Scn1a
RH/+
-129:B6 
control mice and WT-129:B6 HYP mice. *p<0.05, **p<0.01, ***p<0.001, n=number of an imals. 
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3.3 Scn1aRH/+-129:B6 SIH mice show impaired social interact ion 
ability in the three-chamber social interact ion test.  
The autistic- like phenotype of Scn1a mutation’s carrying mouse lines with 
severe phenotypes has been stressed previously (Han et al., 2012a; Ito et al., 2013). We 
then asked if the seizures could affect the sociability skills. The four groups were tested 
in the three chamber test.  
We first ran a 10-minutes habituation trial, in which the animals were placed in 
the central chamber and had to explore the two side chambers. This trial was crucial in 
order to detect chamber preferences and acclimatize the animals to the testing apparatus. 
All groups explored equally the two-side chambers FIGURE 38A, but the two-way 
ANOVA of distance travelled and speed in this phase showed a significant main effect 
of treatment and genotype and a significant interaction between them. The post-hoc 
analysis (Tuckey’s) highlighted that the Scn1aRH/+-129:B6 SIH mice travelled 
significantly longer and at higher speed than the 3 other groups, confirming again the 
novelty-associated increase in activity seen in the openfield and actimeter. This increase 
in activity normalized and was comparable to other groups’ level during the sociability 
and social novelty phases (data not shown, statistic values in the chapter VIII-page 185).  
The sociability phase consisted in the choice between and empty wire cage or a 
wire cage containing a stranger mouse. We analyzed the social interaction with a RM-
two way ANOVA and it revealed a significant main effect of the cage chosen for 
exploration by the test mouse.  The post hoc analysis (Sidak’s) indicated that the WT-
129:B6 control, WT-129:B6 HYP and Scn1aRH/+-129:B6 control mice interacted 
significantly longer with the M than with the EC, demonstrating preserved sociability 
skills. However, Scn1aRH/+-129:B6 with SIH had no preference between the EC and the 
M, demonstrating a perturbation in the sociability skills after SIH (FIGURE 38D). In the 
social novelty phase, again the analysis revealed a significant main effect of the cage, 
and the post-hoc analysis showed that the WT-129:B6, WT-129:B6 HYP and the 
Scn1aRH/+-129:B6 control interacted significantly longer with the nM as expected. For 
Scn1aRH/+-129:B6 mice with SIH, the time exploring the nM and the fM was equivalent, 
showing no preference between the nM (FIGURE 38E). These results of the two phases 
demonstrate that the social skills were importantly affected after experiencing early life 
seizures in this mouse model. All together these results show that seizures in infancy 
can promote long- lasting alterations in social skills during adulthood. 
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FIGURE 38. SIH IMPAIRS SOCIABILITY IN SCN1A
RH/+
-129:B6
 
MICE. 
A, B & C: Habituation phase. A: Time spent by the test mouse in each empty chamber (C1- chamber 1, 
C-center, C2- chamber 2). B: Average speed (m/s) during habituation phase.  C: Distance travelled (m) 
during habituation phase. D: Sociability phase. Time spent by the test mouse interacting with the empty 
cage (EC) or the stranger mouse (M). E: Social novelty phase. Time spent by the test mouse interacting 
with the familiar mouse (fM) or the novel mouse (nM).  *p<0.05, **p<0.01, ***p<0.001, n=number of 
animals. The bar legend is common for all the figures.  
3.4 Scn1aRH/+-129:B6 mice with SIH have impaired learning and 
memory in the Morris water maze task .  
Mental retardation is a main consequence of DS disease progression (Olivieri et 
al., 2016; Ragona et al., 2011b). We observed alteration in neuronal function in the 
hippocampus so it was important to test the memory functions (FIGURE 33 ; FIGURE 34) 
dependent on this structure. We submitted the control and hyperthermia/SIH mice to a 
protocol of spatial learning and memory in the MWM apparatus. This test was divided 
in two phases: the cue task to confirm no visual and motor impairment and the spatial 
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task (4 training days and a 24h probe) to test learning and long-term memory. 
Scn1aRH/+-129:B6 SIH mice were initially impaired having higher latency to approach a 
visible platform at cue task D1, but reached the same level of performance as Scn1aRH/+-
129:B6 control and WT groups by cue task D2. All groups significantly decreased the 
latency to find the visible platform from D1 to D2 (RM-ANOVA with significant main 
effect of Cue task day and Group), being all at an average of escape latency lower than 
10 seconds (FIGURE 39A). The increased latency to find the cued/visible platform at D1 
was associated to a significant increase in the distance travelled by the Scn1aRH/+-
129:B6 SIH mice (TABLE 13) with a decrease in the average speed when compared to 
the WT-129:B6 HYP but not to the Scn1aRH/+-129:B6 control mice (TABLE 12), so we 
could not say that the higher latency was justified by motor problems in the SIH 
submitted mice. We did not observe the novelty-associated increase in locomotion in 
the MWM (as in the openfield and actimeter) possibly of the water be something that 
they never experience before, and probably they do not know how to reac t and try to 
escape. This first observation indicated that even if the Scn1aRH/+-129:B6 SIH mice took 
longer time to understand the rule (D1), by the end of the cue task they equalize to the 
other groups latency’s and prove that they did not have sensorimotor problems that 
could impede the animals to perform the MWM task. Only one animal of the Scn1aRH/+-
129:B6 SIH group that never escape by him self to the platform was removed from the 
study.  
The spatial training proceeded by removing the cue from the pla tform and 
opening the curtains to expose the visual cues. The RM-two way ANOVA revealed a 
significant main effect of training day and group, the group x training day interaction 
did not, however, quite reach significance. The tuckey’s post-hoc analysis showed that 
at training D1 the Scn1aRH/+-129:B6 SIH mice showed higher escape latency than the 3 
control groups (FIGURE 39A). However, it is important to note that, as described in the 
material and methods, each training day results in the average of 4 trials. We could 
believe that in training 1 the Scn1aRH/+-129:B6 SIH group started from a higher latency 
than the 3 other groups justifying why they never equalized their performance. 
However, on trial 1 of training day 1 all 4 groups had the same latency to find the 
platform suggesting that the Scn1aRH/+-129:B6 SIH had a similar behavior as the other 
groups and that the within-day learning was not as good in this group as the 3 control 
groups (FIGURE 39B). 
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FIGURE 39. THE SCN1A
RH/+
-129:B6 SUBMITTED TO  SIH DISPLAY IMPAIRED SPATIAL LEARNING AND 
MEMO RY IN THE MWM TASK. 
A: Each cue task and training day represents the average of the four trials latencies to find the platform. 
In the cue task, the platform is visible, while in the train ing the platform is hidden. B: representation of 
the four trials of the spatial training day  1. C: 24 hours after training completion the p latform is re moved 
and the proportion of time spent searching each of the four quadrants of the pool during 60 sec of 
swimming in the absence of the hidden platform is reported. The target quadrant (where the platform was 
located) is h ighlited with a d ifferent pattern. The persistence in the target quadrant is compared to chance 
level (considered at 25%) (dotted line) D (right): Number of crosses in the enlarged platform zone (the 
smaller orange circle represents the platform in the track plots while the bigger circle is the enlarged zone 
E) were measured. *p<0.05, ***p<0.001, ****p<0.0001;n=number of an imals. 
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TABLE 12. AVERAGE SPEED (M/S) IN THE MWM FO R CUE TASK AND SPATIAL LEARNINGS . 
Mean±S.E.M of the swim speed across the cue task and training days by the 4 groups. Statistical 
significance is represented in the last column of the table. The 3 control groups did not differ in any day 
so we represented the statistics when the Scn1a
RH/+
-129:B6
 
SIH mice (co lumn in bold) are significantly 
different than the WT-HYP or Scn1a
RH/+
-129:B6
 
control groups.  *p<0.05, **p<0.01, ***p<0.001.  
 
 
 
 
TABLE 13. DISTANCE TRAVELLED (M) IN MWM FO R CUE TASK AND SPATIAL LEARNING TRAINING 
DAYS. 
Mean±S.E.M of the distance travelled across the cue task and training days by the 4 groups. Statistical 
significance is represented in the last column of the table. The 3 control groups did not differ in any day 
so we represented the statistics when the Scn1a
RH/+
-129:B6
 
SIH mice (co lumn in bold) are significantly 
different than the WT-HYP or Scn1a
RH/+
-129:B6
 
control groups.  *p<0.05,  ***p<0.001 
 
 
 
The post-hoc analysis also showed that all the groups significantly decreased 
their latencies to find the platform from training D1 to D2, and then maintained their 
performance levels (D2-D4). Even if this indicate that all the groups understood that 
there was an escape rule to follow, the latency to escape was significantly higher in the 
Scn1aRH/+-129:B6 SIH mice (FIGURE 39A) during the 4 training days. In addition, we 
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see in FIGURE 39A that by training D4 the WT-129:B6 control, WT-129:B6 HYP and 
Scn1aRH/+-129:B6 control had an escape latency lower than 10 seconds as seen in the 
cue task D2, while the Scn1aRH/+-129:B6  SIH did not (like they had a cue task D2). The 
poorer performance of the Scn1aRH/+-129:B6 SIH mice is unlikely to be due to effects 
on motor function as the swim speed was significantly increased when compared to the 
Scn1aRH/+-129:B6 control mice for all the training days and to WT-129:B6 HYP at D1 
and D4 (TABLE 12). The distance travelled was also increased during all the training 
days (TABLE 13).  
Twenty-four hours after training completion, we ran a probe trial to test the 
strength of the long-term memory when removing the platform, as explained previously.  
The one sample t-test comparing the percentage of time in the target zone, where the 
platform was located, to the chance level (25%) indicated that all the groups persisted 
longer than chance in this quadrant; By contrast, the Scn1aRH/+-129:B6 SIH persisted 
lower time in this quadrant than the other 3 groups (FIGURE 39C) (RM-ANOVA main 
effect of Quadrant and significant Group (treatment-genotype) x Quadrant interaction). 
The post-hoc analysis of within group quadrant persistence revealed that the WT-
129:B6 and Scn1aRH/+-129:B6 controls persist significantly higher in the target quadrant 
than in the other 3 quadrants (left, right and opposite). By contrast, the Scn1aRH/+-
129:B6 SIH mice did not significantly discriminate between the target and left 
quadrants. In addition, we counted the number of crosses in the platform zone area. The 
two-way ANOVA revealed a significant Genotype x Treatment interaction with main 
effects of Genotype and Treatment. We observed that the number of crosses in the 
platform zone was significantly decreased in the Scn1aRH/+-129:B6 SIH mice compared 
to the other groups (FIGURE 39D). The tracking plots of the probe trial illustrated in 
FIGURE 39E clearly indicate that the Scn1aRH/+-129:B6 SIH are less precise in 
remembering the previous emplacement of the spatial platform.  
We conclude that, although Scn1aRH/+ SIH mice showed a learning improvement 
in the latency to find the platform from training D1 to D2, they show poorer learning 
performance (within days and across days) and memory strength (long-term memory) 
than the control WT-129:B6 and Scn1aRH/+-129:B6 and the WT-129:B6 HYP. 
Accordingly, the results suggest that SIH protocol in the mutant mice also induce 
perturbations in hippocampal learning and memory during adulthood.  
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3.5 Scn1aRH/+-129:B6 mice show decreased contextual-fear 
condit ioning 
On the first day of the CFC the animals were placed in the conditioning box. 
After 2 minutes of habituation to the box, 3 consecutive shocks with 60s interval were 
delivered. FIGURE 40A illustrates the freezing percentage during the 5 minutes of 
conditioning. The RM-two way ANOVA (Genotype x Treatment) showed a significant 
main effect of genotype but not of treatment. The Scn1aRH/+-129:B6 mutation seemed to 
decrease the freezing percentage in the control and SIH mice when compared to the 
controls. This decrease did not reach statistical significance  when doing the post-hoc 
analysis (FIGURE 40A). Twenty-four hours later, the mice were placed in the 
conditioning box, but this time without receiving any shock. The RM-two way ANOVA 
revealed a significant main effect of Genotype and Treatment but no significant 
interaction between the 2. Considering this conditioning phase, it is interesting to see 
that, in the test phase, the Scn1aRH/+-129:B6 control mice show reduced contextual- fear 
memory that is excacerbated in the SIH mice, but did not reach statistical significance. 
Nevertheless, this difference was not statistically significant when compared to the WT-
129:B6 control and WT-129:B6 HYP respectively, and between them (Scn1aRH/+-
129:B6 control vs. SIH) (FIGURE 40B). By analyzing the results, we cannot assume 
perturbations in the contextual- fear conditioning for the Scn1aRH/+-129:B6 SIH because 
the mutation per se seems to decrease the freezing response to fear, in the conditioning 
and test phases.  
 
 
FIGURE 40. CO NTEXTUAL FEAR CONDITIO NING IS NO T CHANGED IN SCN1A
RH/+
-129:B6
 
MICE. 
A: Freezing time (%) during the 5 minutes’ conditioning. B: Freezing time (%) during the 5 minutes of 
testing, 24 hours after the conditioning. n=number of animals  
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3.6 Scn1aRH/+-129:B6 mice with SIH show an impairment  in 
work ing memory.  
Short-term memory associated with attention deficits has been observed in DS 
children at an early age (Villeneuve et al., 2014). To test this type of memory, we set up 
a protocol to test working memory in an 8-arm radial maze, a test dependent of the pre-
frontal cortex. The protocol consisted in a choice between 2 arms (one rewarded and 
one non-rewarded) in a sequence of 7 consecutive trials that was changed every day. 
The training was continued until the control WT mice reached the criterion level, 
meaning more that 75% correct choices (5.25) for 2 consecutive days. Chance level was 
considered as 50% correct choices (3.5).  
The first main observation we had was that the WT-129:B6 control, WT-129:B6 
HYP and Scn1aRH/+-129:B6 control mice reached the criterion for two consecutive days 
at training days D9 and D10 when the Scn1aRH/+-129:B6 SIH never did. The RM two-
way ANOVA revealed an interaction (training day x Group) with main effect of 
Training day and Group. The post-hoc analysis indicated that at training D9 and D10 
the 3 control groups had higher number of correct arm choices than the Scn1aRH/+-
129:B6  SIH mice (FIGURE 41A). 
Also, the three control groups performed significantly higher than chance for the 
2 last days of training. The RM two-way ANOVA revealed an interaction (training day 
x Group) with main effect of Training day and Group. Considering the chance level, 
using one sample t-test comparing to 3.5 correct choices, we observed that the 3 control 
groups were importantly better than chance from D8 until the end of the protocol. 
Considering the Scn1aRH/+-129:B6 with SIH, we observed that they were slightly better 
than chance at training D8 and D10 but not at D9. This suggested that this group might 
have started to learn the rule but with lower performance than the 3 control groups and 
never reached the criterion for the 10 days tested.  
Once again, the poor learning capacity of Scn1aRH/+-129:B6 with SIH was 
apparent in this task, Indeed, for the same training duration, this group they had never 
reached the criterion and their better performance than chance was not consistent, 
meaning than their choices were mainly random during the protocol. Working memory 
was therefore also clearly affected in the Scn1aRH/+-129:B6  mice after submission to 
early- life seizures.  
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FIGURE 41. SCN1A
RH/+
-129:B6 MUTANT MICE SUBMITTED TO  SIH EXHIBIT AN IMPAIRMENT IN 
WORKING MEMO RY. 
A: Number o f correct choices per day during  the working memory training. The pink dotted line 
represents the criterion corresponding to 75% of 7 correct choices (5.25). Gray dotted line at  chance level 
corresponds to 50% of 7 choices (3.5). Statistical significance is represented with black stars for 
differences between the Scn1a
RH/+
-129:B6
 
SIH group and the 3 other control groups. Gray stars and 
associated dotted traces correspond to the statistical significance between groups and the chance level. 
N=number of animal, *p<0.05, **p<0.01 and p<0.001.   
 
Together, these results allow us to conclude that the learning and memory 
abilities of the hippocampus and the pre-frontal cortex are disrupted after experiencing 
epileptic activity in Scn1aRH/+-129:B6 mice. 
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Chapter 4- IS THE SCN1A MUTATION IMPLICATED IN THE BEHAVIORAL/COGNITIVE 
EFFECTS CAUSED BY SEIZURES? ROLE OF FLUROTHYL-INDUCED SEIZURES. 
After observing important changes induced by the SIH in the mutant Scn1aRH/+ 
mice, many questions rose up. Notably, is the genetic background (i.e. Scn1a gene 
mutation) necessary for early life seizure-induced cognitive impairments? Or could 
early life seizures alone produce the same effect in WT animals? We could not test this 
question using the SIH protocol because the WT-129:B6 animals that were submitted to 
hyperthermia never presented seizures. However, we organized another experiment that 
could answer this question. We submitted to WT-129:B6 and Scn1aRH/+-129:B6 mice to 
a protocol that could induce seizures in the two genotypes, using flurothyl (a convulsant 
known to act on GABAergic functions and used previously in the Scn1aRH/+ mice 
(Martin et al., 2007, 2010b)). The WT-129:B6 group was first submitted to 
hyperthermia to ensure that the effect that we observed in the Scn1aRH/+ SIH 
(hyperthermia + seizures) was not an effect of seizures and exacerbated by the brain 
consequences of hyperthermia. This group was called WT-129:B6-HYP-FLU. The 
Scn1aRH/+-129:B6 FLU (Scn1aRH/+ with seizures induced by flurothyl) was not 
submitted to hyperthermia because it would have developed additional seizures with the 
increase in temperature. This chapter of results only presents very preliminary data. 
These experiments were done in the end of my PhD when we had a very important lack 
in breeding performance amplified by the fact that the 129/SvJ females (mothers of the 
Scn1aRH/+-129:B6 mutant line) were not available commercially. We only obtained 5 
WT-129:B6-HYP and 6 Scn1aRH/+ -129:B6 FLU males to test for behavior.  
1. FLUROTHYL-INDUCED SEIZURES PRODUCE HIGHER MORTALITY IN THE 
SCN1ARH/+-129:B6  MICE THAN IN THE WT-129:B6. 
Our first worry was about the mortality that the seizures- induced by flurothyl 
would cause. We induced seizures with flurothyl for 10 days from P21 to mimick as 
closely as possible the SIH protocol. As one can see in FIGURE 42 88.23% of the WT-
129:B6 HYP-FLU survived comparing to only 61.53% for Scn1aRH/+-129:B6  FLU. The 
log-rank (Mantel-Cox) test for curve comparison indicated that the survival curves were 
not significantly different.  
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FIGURE 42. FLURO THYL-INDUCED SEIZURES IN WT-129:B6 AND SCN1A
RH/+
-129:B6 MICE. 
A: Percentage alive of WT-129:B6-HYP-FLU and Scn1a
RH/+
-129:B6
 
FLU during the 10-days of sezure 
induction.  
 
Even if the number of mice tested was very limited, we ran 3 behavioral tasks to 
see if major behavioral effects were appearing at P60 after P21 flurothyl- induced 
seizures. We did not apply statistical analysis to the data because the number of animals 
was very limited. We ran the openfield, social interaction test and MWM. FIGURE 43 
shows the data obtained in the 3 tasks. In FIGURE 43-1 the average speed, distance 
travelled and ratio distance travelled in the center/total distance in the openfield are 
presented. The average speed and distance travelled seem to be increased in the 
Scn1aRH/+-129:B6  FlU but not in the WT-129:B6-HYP FLU when compared to the 
WT-129:B6-HYP controls. For the anxiety measure (ratio between the distance 
travelled in the center and the total distance travelled) the 3 groups seem to have similar 
ratio. For the social interaction task, the WT-129:B6 HYP mice clearly prefer the mouse 
than the empty cage as shown in the previous chapter. The WT-129:B6-HYP-FLU mice 
seem to prefer the mouse than the empty cage as well and the Scn1aRH/+-129:B6 FLU 
explore the two equally. For the social novelty phase, the exploration difference 
between the nM and the fM was higher in the WT-129:B6 HYP than in the Scn1aRH/+-
129:B6  FLU.  
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FIGURE 43. BEHAVIO RAL/COGNITIVE TASKS IN SEIZURES-INDUCED WITH FLURO THYL ANIMALS . 
1.Openfield. A: Average speed (m/s). B: Distance travelled (m). C: Ratio d istance in the center/total 
distance travelled. 2.Three-chamber social Interaction. D:Social interaction. E: Social novelty. 3. Morris 
water maze. F:Cue task and spatial learning latencies. G: Probe retrieval memory. n=number of an imals.  
1. O
P 
2.  
For the MWM task, the cue task is equivalent for the groups, even if at D1 the 
Scn1aRH/+ FLU seem to have higher latency to escape to the platform. The spatial 
learning curve indicates that the 3 groups decrease their latencies across the training 
days. However from D1 to D2 the learning improvements appear to be more important 
in the WT groups. Following the training, the probe task indicated that the WT-HYP 
FLU persisted longer in the target quadrant than the other groups. The poor performance 
of the WT HYP is due to the low number of animals, as we already demonstrated 
previously the ability of this group in remembering the platform location. The Scn1aRH/+ 
FLU group did not seem to really discriminate between the left and target quadrants.  
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We cannot yet make hard conclusions from this very preliminary data. However, 
all together, it seems that the flurothyl- induced seizures affect more importantly the 
Scn1aRH/+ mutant animals than the WT animals.  
Chapter 5- COLLABORATIVE WORK USING SCN1A+/-B6:129  (DS) MOUSE MODEL 
(DOCTOR INNA SLUTSKY ,  UNIVERSITY OF TEL AVIV,  ISRAEL) 
In collaboration with Doctor Inna Slutsky, professor and principal investigator at 
the University of Tel Aviv, Israel, we benefited from the SIH protocol we had 
previously set up to run a pharmacological trial to try to reduce the epileptic phenotype 
in DS mice (Scn1a+/- mouse model) (mixed B6:129 background).  For intellectual 
property reasons, I am unable to disclose the name of the drug studied and will therefore 
call it X in this chapter.  
1. DRUG X DECREASE THE MORTALITY OF SCN1A+/-B6:129 MOUSE BUT NOT 
THE SPONTANEOUS GTC SEIZURE FREQUENCY 
The drug injection started at P21 and delivered one time per day (10 AM) during 
5 days In the first day of injection, 6 hours later, we started the SIH protocol for 5 days 
to increase the phenotype severity and have a more challenging number of spontaneous 
seizures (very low otherwise). The SIH protocol induced high mortality in the Scn1a+/-
B6:129 vehicle mice. However, the high mortality was prevented by the drug in the 
treated animals (FIGURE 44A). The log-rank (Mantel-Cox) test to compare survival 
curves indicated a significant difference between the curves.  
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FIGURE 44. DRUG X ADMINISTRATIO N IN SCN1A
+/-
B6:129 MOUSE DECREASES THE MO RTALITY DURING 
TH E SIH PRO TOCOL BUT NO T TH E SPONTANEOUS SEIZURE FREQ UENCY.  
A: Percentage of vehicle and drug-treated Scn1a
+/-
B6:129 alive during the SIH protocol. B: Temperature 
threshold required to induce seizures by hyperthermia during the 5-days of the protocol.  
 
The RM-two way ANOVA of the temperature threshold to induce the seizure 
revealed a significant main effect of protocol day, as one can see the temperature 
reaches the minimum level at induction D3, but no differences were observed between 
the groups (FIGURE 44B).  
We video-recorded the spontaneous seizures during all the SIH protocol days. 
The animals were individualized and placed above an infrared floor connected to a 
camera fixed on the ceiling. Using a C++ custom made software, designed by ULLO 
SAS (la Rochelle, France) for this experiment, the number of seizures was 
automatically counted and divided by bins of 12 hours-periods and per animal (day and 
night; defined as D and N respectively). The RM-Two way ANOVA revealed a 
significant main effect of Day and Treatment but no Treatment x Day interaction. No 
differences were detected by the post-hoc analysis for the number of spontaneous GTCs 
seizures across the days (FIGURE 45).  
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FIGURE 45. SPONTANEO US SEIZURE ACTIVITY DURING THE 5 DAYS O F SIH WITH OR WITHOUT DRUG 
TREATMENT IN SCN1A
+/-
B6:129 MICE. 
A: Numer of generalized tonic-clonic seizures from D1 to N5 (day and night respectively). n=number of 
animals. Seizures were detected with a custom made software designed by ULLO SAS (La Rochelle, 
France). 
 
The treatment clearly reduces the mortality in the Scn1a+/-B6:129 mice, however 
the numbers of seizures seem to stay at the vehicle level and no differences in the 
temperature threshold were also observed.  
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V- DISCUSSION 
Identifying the cause of the cognitive and behavioral comorbidities in DS 
remains a major challenge for the field. While some studies investigated the role of 
NaV1.1 dysfunction in neuronal networks and behavior, none had yet studied the role of 
epileptic activity on Scn1a mutant mouse models. In this study, we wanted to 
understand the role of epileptic activity on behavioral and cognitive phenotypes in 
Scn1a mouse models. To address this question, we used mouse models carrying Scn1a 
mutations and presenting mild epileptic phenotypes. We used the Scn1a+/-, model of DS, 
in two genetic backgrounds (129 and B6-129) and observed that the mutation per se 
does not impact cognition in these models. We then tested the Scn1aRH/+, model of 
GEFS+, and confirmed that the mutation per se does not change the behavioral and 
cognitive phenotypes in the model. We submitted the Scn1aRH/+ mice to the SIH 
protocol during early life, once a day for 10 days, and observed a worsening in the 
epileptic phenotype with the appearance of spontaneous seizures. In adulthood, the 
Scn1aRH/+ mice submitted to SIH displayed an increase in activity, sociability 
impairment and hippocampus and prefrontal cortex-dependent memory problems. Our 
study thus demonstrates that hyperthermic seizures can change a mild GEFS+ mouse 
model into a severe DS mouse model.  
1. THE SCN1A+/-  MUTATION PER SE  IS NOT RESPONSIBLE FOR THE COGNITIVE 
AND BEHAVIORAL PHENOTYPE OBSERVED IN DS  PATIENTS. 
The SCN1A gene mutations are associated with a vast range of phenotypic 
severity progressing from GEFS+ to DS. GEFS+ patients usually present missense 
mutations and DS patients present missense and truncating mutations. While in GEFS+ 
the missense mutations cause the partial loss of the NaV1.1 function, in DS patients 
these mutations severely impair or cause the complete loss of channel function.  There 
are many exceptions to this generality as described in the introduction (I-Chapter 2-2.2), 
and the modifications introduced by different genetic backgrounds account for this 
variability.  
Our first goal was to understand if the Scn1a truncating mutation (that causes the 
channel loss of function and is usually associated to DS) per se can be responsible for 
the cognitive phenotype observed in DS mice, as suggested by other recent studies (Han 
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et al., 2012a; Ito et al., 2013). We first used the Scn1a+/- mouse model in the 129 
background. As detailed in the introduction (I-Chapter 4-2.3), the Scn1a+/- -129 mice do 
not present spontaneous seizures and exhibit a survival rate comparable to WT 
littermates (Rubinstein et al., 2015d; Yu et al., 2006a). Due to its mild phenotype (no 
mortality, no epileptic activity) in presence of a truncation mutation, and its sensibility 
to SIH, this DS model was ideal to address our question. We observed that Scn1a +/--129 
mice displayed similar performance to WT littermates in the MWM and the CFC tasks. 
Rubinstein and colleagues showed similar results in the CFC (Rubinstein et al., 2015d). 
Together, these results indicate that the mutation per se in this Scn1a mutant mouse is 
not sufficient to induce cognitive problems.  
The main observation arguing against a role of this truncation mutation per se in 
the cognitive outcome in DS is the lack of behavioral phenotype observed in the DS-
129 mice. These mice do not show spontaneous seizures activity, which could suggest 
that without the presence of epileptic seizures, the DS mice will not develop 
comorbidities. However, we do not know the effects of the genetic modifiers in the 129 
background that could compensate for the NaV1.1 loss of function in this model, so the 
role of seizures had to be addressed separately.  
Klassen et al., showed one control patient (no epileptic or behavioral 
manifestations) carrying a severe missense mutation (associated with severe DS 
phenotype) (Klassen et al., 2011). Similarly, truncating mutations have been detected in 
patients with mild phenotypes comparable to the ones found in GEFS+ patients (Jiang et 
al., 2016; Takaori et al., 2017). The mechanisms underlying phenotypic heterogeneity 
within patients are not known. It may, however, involve variable expressivity of the 
single causative gene (mosaicism), modifying genes (i.e. other voltage-gated channel 
genes) or epigenetic factors. 
Cognitive deficits and autistic- like behavior were reported before by Han et al., 
2012 and Ito et al., 2013 in the Scn1a+/- in the C57BL/6J background. Due to high 
frequency of spontaneous seizures and important mortality level in this model (see 
FIGURE 10), it is hard to dissociate between the role of seizures and mutation per se in 
these mutant mice. Also it is hard to assume that the 20% surviving animals (the more 
resilients), on which the behavior analysis was performed, are representative of the total 
colony. As explained above, the Scn1a+/- mutation in the 129 background confers a mild 
phenotype in the mouse model. This mouse model would have been ideal to understand 
our question regarding the role of seizures when induced in these mice with the SIH, but 
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the low breeding performance led us to choose the B6:129 F1 background, which 
allowed for better breeding.  This model did not therefore behave as we expected, 
according to the previous publications with this model (Kalume et al., 2007b; Yu et al., 
2006a).  It was previously reported in Yu et al. 2006 that the Scn1a mutant mice 
resulting from mixed B6 and 129 background crossings had an intermediate phenotype 
(same mutant as used in our study). The authors report that these animals show 40% 
mortality at post-natal week 16, however, they have used the 2nd and 3rd generations, 
while we used the 1st generation and had no mortality (0%) in these animals when 
comparing the same age. The different generations could have exp lained the phenotype 
because of the genetic variability observed in generations 2 or 3.  Kalume et al 2007 
used the F1 generation (as used by us in this study) and reported subtle signs of ataxia at 
P21 in Scn1a+/- mice. Before our study, behavior abnormalities were not further 
explored in this mixed B6:129 genetic background.  
Consistent with the absence of mortality in the Scn1a+/-B6:129 mice used in our 
work, the behavioral and cognitive phenotypes in adulthood were normal. The Scn1a+/- 
B6:129 that were not submitted to SIH had normal activity in the openfield as well as 
normal circadian cycle in the actimeter. They also displayed normal spatial memory and 
working memory. We could not conclude on the state of sociability skills because the 
WT controls did not behave as expected. We would need to repeat this experiment to 
conclude.  Another important parameter missing in our study with Scn1a+/- B6:129 mice 
is the analysis of the epileptic history at early-age by ECoG that could be correlated to 
the adult behavioral/cognitive phenotype. We, however, did not perform this experiment 
and it has never been reported by others in this genetic background before.  
As in our study the Scn1a+/--B6:129 mice present a similar cognitive phenotype 
to the WT, this strongly suggests that cognitive deficits in adulthood are not related to 
the mutation per se. These data are in contrast to the previous report using the Scn1a+/- 
in the B6 background, where seizure frequency is very high and not controlled (Han et 
al., 2012c; Ito et al., 2013). Also, it is known that the Scn1a+/- mice have a seizure onset 
at P20-21 and high seizure intensity at their fourth week of life that tend to regress 
(Kalume et al., 2013), but no one has studied the later epileptic phenotype in these 
models. As we could not test the effect of seizures on the Scn1a+/- mutant mice in the 
129 background (low breeding performance) nor the B6:129 (high mortality in the SIH 
protocol, described in next section), we used the Scn1aRH/+ mutant mice (GEFS+ model) 
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in the 129:B6 background presenting a mild phenotype and sensibility to SIH (described 
in the next section). 
We tested first the effect of the R1648H missense mutation per se on the 
behavioral and cognitive phenotypes in mice not submitted to SIH. We did not except 
behavioral abnormalities consistent with the favorable outcome as reported in the first 
human family carrying this mutation by (Escayg et al., 2000b). Yet, one patient has 
been described as having the same mutation and presenting DS (Depienne et al., 2010), 
suggesting that in particular cases this mutation could be associated to bad cognitive 
outcome. We observed that, in adulthood, the Scn1aRH/+-129:B6 mice exhibited normal 
activity, social interaction and memory, similar to WT littermates.  
Thus, when probing the Scn1a+/--B6:129 and the Scn1aRH/+-129:B6 mice in a 
similar background, we evidence that neither the mild missense (Scn1aRH/+) nor the 
truncation mutation (Scn1a+/-) per se induced behavioral/cognitive deficits. Sawyer et 
al. 2016 had previously studied the behavioral phenotype of the Scn1aRH/+ mutant in the 
pure B6 background (I-Chapter 4-2.4.2 Table 7). They reported a slight increase in 
activity and mild spatial memory impairments, while the anxiety, the contextual fear 
conditioning, the sociability skills and the olfactory and visual abilities were normal.  
These subtle differences between this recent study and our results might be related to 
the difference in the genetic background. Indeed, as discussed before, pure B6 
background can significantly impact the behavioral phenotype in Scn1a mutants (Yu et 
al., 2006b). All together, our results show that Scn1a mutations per se do not 
significantly contribute to cognitive and behavioral modifications in the mouse models 
carrying mild phenotypes. These data are arguing against the concept that DS could 
fully be explained as a channelopathy.  
2. DS  MICE DISPLAY SUSCEPTIBILITY TO HYPERTHERMIA INDUCED SEIZURES 
WITH HIGHER MORTALITY THAN GEFS+  MICE IN THE 10-DAYS PROTOCOL. 
The protocol of repeated seizures induction by hyperthermia (SIH) in Scn1a 
models presented here has not yet been published elsewhere. There are several types of 
seizures induction in rodents, notably the two protocols of repeated seizures induction 
described in the introduction: hyperthermia- induced seizures and flurothyl- induced 
seizures. Other models of chemically (injection of piocarpine, kainate) or electrically 
(implantation of electrodes in the brain that are then electrically stimulated)- induced 
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seizures have been extensively reported as models of acute and long- lasting seizure 
induction more often classified into SE (i.e kainate, pilocarpine). As described in the 
introduction (I-Chapter 2-2.1), FS represent typical hallmarks of epilepsies associated to 
NaV1.1 mutations. Indeed, GEFS+ and DS patients usually display a FS at disease onset 
and then febrile and afebrile seizures classified in different types. Therefore, the closest 
seizure induction protocol to FS is the hyperthermia- induced seizure protocol. For this 
reason, it was the model of choice for us to study the consequences of epileptic activity 
in early life in the Scn1a mutant models. To control for hyperthermia side-effects that 
could interfere with interpretation of our results, we systematically included a 
hyperthermia WT group (WT-HYP) in our study.  
We faced two major concerns while setting up the protocol. The first concern 
was age of mice to be used at SIH onset. The second concern was the frequency of SIH 
episodes that could be clinically relevant without causing drastic mortality.  
Regarding our first concern, data comparing rodent and human brain 
development are very limited. In addition, different brain regions develop at variable 
rates and chronological ages, in terms of neurogenesis, migration, connectivity and 
function, and these processes are not necessarily parallel in human and rodents.  
However, some studies show that P14-P16 in mice correspond to approximately 6 
months in humans, and P21 corresponds to 1-2 years in humans (Avishai-Eliner et al., 
2002; Dobbing and Sands, 1973; Gottlieb et al., 1977). To be closer to the earlier age at 
onset of seizures in patients (5 to 11 months of age on average) we could have chosen 
P14-15 as the age to start the SIH protocol. As described earlier, P14-15 WT rodents 
have been used as models of FS, with efficient induction of seizures by hyperthermia 
(Dubé et al., 2009). If we could induce seizures at P14 in WT as well as in Scn1a 
mutant mice, these WT + seizure group would have been an ideal control to test for 
combination of seizure ± Scn1a mutation on behavioral/cognitive outcome. Yet, for 
several reasons, we decided to start the SIH protocol later, at P21. First, Martin et al., 
2010 induced seizures by hyperthermia in Scn1aRH/+ mice and WT controls at P14. The 
mean temperature threshold for seizure in WT was 44°C and 43° in Scn1aRH/+. The mice 
did not develop the typical GTC hyperthermic seizures, but only tonic hyperthermic 
seizures. The high temperature threshold and the lack of GTC hyperthermic seizures 
show the high resistance of the mice to hyperthermia- induced seizures at this age. 
Second, body temperature higher than 43°C is known to provoke brain injury (Burger 
and Fuhrman, 1964). Moreover, the previous results on the Scn1a+/- mouse model (in 
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the most severe background – B6) show that P17-18 mice do not show seizures under 
hyperthermia conditions to a maximum temperature of 42.5°C. The authors reported 
that the sensitivity to hyperthermia- induced seizures in Scn1a+/- mice coincides with the 
appearance of spontaneous seizures at P20-21 (Kalume et al., 2013; Oakley et al., 
2009b). Finally, NaV1.1 expression rising and NaV1.3 failing in human and mice brain 
correspond to seizure onset in both human and mouse species at 5 months of age and 
P21, respectively, suggesting that the perfectly correlated timing of the channels 
expression could be a better indication to accurately target NaV dysfunction- induced 
brain susceptibility (Cheah et al., 2013b).  For all the reasons cited above, we chose to 
start the SIH protocol at P21. 
Regarding our second concern, the average seizure frequency in DS patients is 
usually categorized from “daily or more” in the more severe periods to “yearly or less” 
when seizures tend to decrease. Patients can have several seizures per day. We first 
decided to induce 2 seizures per day for 10 days. Due to the very high mortality in the 
two mouse lines (data not shown), we decided to induce only one seizure per day for 10 
days. 
The Scn1a+/- -129 mice were not tested in the SIH protocol due to the very low 
number of animals obtained from the breeding pairs. The Scn1a+/- -B6:129, however, 
showed very high mortality (±70% after SIH protocol), leading to 30% of mice alive at 
P31. The high mortality was provoked by SIH and spontaneous seizures in the night 
during the 10 days of the protocol. The high mortality and increase in spontaneous 
seizure frequency (as seen in vehicle-treated Scn1a+/- -B6:129 animals of the IV-Chapter 
5-1- FIGURE 44, suggests that SIH brings this model closer to the Scn1a+/- B6 mice with 
severe phenotype reported previously (Kalume et al., 2013; Yu et al., 2006b). The 
observed phenomenon is very interesting. While it is possible that the genetic modifiers 
introduced by the 129 background allow for a mild phenotype (100% survival and no 
cognitive deficits) of the Scn1a+/-_B6:129 model, our data suggest that the induction of 
repeated seizures by hyperthermia is enough to convert this into the more severe DS 
mouse model (like a model of Scn1a+/- in pure B6 background). Can the seizures 
episodes be the ON/OFF trigger to the severe phenotype observed in DS patients? 
While we meant to fully address this question, we unfortunately could not pursue our 
investigations in this model due to the high mortality observed in mice after SIH.  
We therefore carried the final optimization of the SIH protocol on the Scn1aRH/+ 
129:B6 mice carrying the R1648H mutation present in the first identifies GEFS+ family 
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and in one DS patient. As discussed above, the model exhibited good sensitivity to 
seizures and presented a mild phenotype without SIH. The SIH protocol in this model 
conferred lower mortality rate at protocol day 10 (35 % mortality). In terms of seizure 
severity, the Scn1a+/- B6:129 mice reached the severity score 6 (for GTC seizure) at D2, 
while the Scn1aRH/+ 129:B6 mice only reached this threshold at day 4. The temperature 
threshold to induce a seizure slightly increases until D3, possib ly indicating that some 
compensations are taking place, and reaches a plateau from the following days to the 
end of the protocol.  
Intriguingly, we also observed higher mortality in the WT-HYP control group 
from the Scn1a+/- B6:129 study than in the WT-HYP control group from the Scn1aRH/+ 
129:B6 study (92% survival and 72% survival, respectively).  This difference could 
have interfered with the interpretation of our results if we had succeeded in comparing 
both sets of data in these two models after SIH (not done because of high mortality of 
Scn1a+/- B6:129 group after SIH). This different outcome of the WT-HYP group after 
SIH could be related to the fact that the two lines result from different breeding pairs, 
even if both bred on 50:50 129/B6 mixed background,. Indeed, Scn1a+/-- B6:129 mice 
were always born from a WT B6 mother, which generally harbors large litters but 
provide little care leading to P21 pups rather weak and small in size. By contrast, 
Scn1aRH/+-129:B6 mice were always born from a WT 129 mother, which generally 
harbor small litters but provide better care than B6 mothers resulting in bigger/stronger 
pups at P21. These differences in size of litters and maternal behavior displayed by B6 
and 129 mothers have been reported previously (Champagne et al., 2007).  Thus this 
apparently trivial difference in the breeding strategy we adopted in the two models, 
resulting in P21 pups with slightly different developmental profiles, could very well 
account for the increased death toll observed in WT-HYP in the B6 background 
(Banbury, 1997). Yet, we did not observe the occurrence of spontaneous seizures in 
these WT-HYP mice, so we do not think that death was caused by seizures per se 
provoked by SIH. Others causes of death might be associated with the negative 
consequences of hyperthermia on brain function, as inflammation (Mcilvoy, 2005). We 
did not try to pinpoint the accurate cause of death in these WT-HYP mice.  
Together, the results of the SIH protocol survival rates suggest that this protocol 
induced more severe consequences in mice presenting the complete loss of the function 
(Scn1a+/- mice) than in the mice with reduced Nav1.1 function (Scn1a
RH/+ mice). Also, it 
is likely that the type of Scn1a mutation confers a differential modulatory effect on the 
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seizure severity induced by SIH. Indeed, it is possible that seizures acting on a brain 
with a severe Nav1.1 mutation confer a worst survival outcome than seizures acting on a 
brain carrying a milder Nav1.1 mutation. These data thus reveal the complexity of the 
question addressed in this study, suggesting that both epileptic history and underlying 
genetic profile intervene in phenotypic outcomes.  
3. LONG-TERM EFFECTS OF THE 10-DAYS SEIZURES INDUCTION BY 
HYPERTHERMIA PROTOCOL IN SCN1ARH/+-129:B6 MICE. 
The behavioral and cognitive testing was done using the Scn1aRH/+-129:B6 mice 
submitted to SIH and respective controls. We did not proceed to the behavioral testing 
in Scn1a+/--B6:129 mice due to the low number of animals remaining after the SIH 
protocol. 
3.1  “Seizures beget seizures” in Scn1a  RH/+ mice 
We first wanted to clarify the epileptic profile of the Scn1aRH/+ controls and test 
whether the SIH protocol changes the epileptic severity in this model. After the SIH 
protocol, the animals were implanted for ECoG recordings (P34-35). Martin et al, 2010  
reported the presence of few spontaneous seizures in the Scn1aRH/+ in pure B6 
background (out of 14 mice aged 3-5 months they reported that two exhibited 
spontaneous seizures). We did not observe any GTC seizures in the 4 control Scn1aRH/+ 
mice tested between 1-3 months of age. Lack of observed seizures in our conditions 
might be justified by the introduction of 50% of the129 genetic background that has 
been described in the Scn1a+/- to promote a milder phenotype or by the low number of 
animals tested. It is also possible that these Scn1aRH/+ -129:B6 mice harbor milder 
ECoG abnormalities that were not detected with our analysis. All the Scn1aRH/+ 
submitted to our SIH protocol, however, developed spontaneous GTCs, which persisted 
until end of ECoG recordings (3 months of age). Previous literature supports the notion 
that appearance of spontaneous seizures subsequent to seizure induction is generally 
correlated to the intensity/duration of the induced seizures and to the age at which these 
are induced in the rodent brain. Indeed, induction of seizures using kainate led to 
spontaneous seizures in adult rats, while rats submitted to the same seizures at early age 
did not develop spontaneous seizures (Stafstrom et al., 1993).  Also, in the adult mouse 
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brain, repeated seizures induction using flurothyl led to appearance of spontaneous 
seizures that then tended to remit after one month (Kadiyala et al., 2016). Concerning 
early ages, studies have previously shown that induction of one prolonged FS (~24 
minutes) in immature rats, led to appearance of spontaneous seizures in 37% of the 
animals at later ages (Dubé et al., 2006). The results regarding outcome of short- lasting 
febrile/flurothyl- induced seizures at early age on spontaneous seizure appearance are 
more controversial and many studies show that these short- lasting protocols do not 
cause the appearance of spontaneous seizures (Bender et al., 2004a; Liu et al., 1999). In 
our model, we clearly show that a short- lasting (once a day, less than 1 minute) but 
repeated SIH protocol at early-age triggers the appearance of GTCs, worsening the 
epileptic severity in our model. While it is a very controversial notion in the epilepsy 
scientific community, we thus observed that “seizures beget seizures” in the Scn1aRH/+ 
mouse model.  
3.2 SIH does not induce neuronal death in Scn1aRH/+mutant mouse 
Long- lasting seizure episodes as pilocarpine or kainate- induced SE have been 
associated to important neuronal death in the hippocampus in mature rats (Deshpande et 
al., 2008; Kim et al., 2011, 2015; Wang et al., 2015; Williams et al., 2009). However 
the same seizures in young rats before postnatal day (P18) are less likely to cause cell 
death or recurrent epileptic activity (Albala et al., 1984; Mlsna and Koh, 2013; Sperber 
et al., 1991; Stafstrom et al., 1992). Our immunohistochemical investigation, performed 
in collaboration with Dr. Frassoni in Milan, showed that SIH in Scn1aRH/+-129:B6 mice 
does not induce neuronal death nor important cytoarchitectural changes in the 
hippocampus.  The results are consistent with previous findings in Scn1a mutant mouse 
models. Indeed, There was no evidence of neuronal death in hippocampi of the Scn1a+/- 
mouse model in pure B6 background, a model known to exhibit intense spontaneous 
epileptic seizure activity,  (Yu et al., 2006b). Moreover, repeated flurothyl- induced 
seizures do no cause neuronal death (Liu et al., 1999) and similarly repeated or 
prolonged FS have not been associated to neuronal death (Bender et al., 2004b) in WT 
rodents. 
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3.3 Increased f iring propert ies of DG granule cells after SIH in 
Scn1aRH/+ mice 
The DG is seen as the first stage or “gate” into the trisynaptic circuit of the 
hippocampus, leading to an increased focus in this sub-region of the hippocampus by 
the epilepsy research (Dudek and Sutula, 2007). Sustained firing of GABAergic 
inhibitory interneurons is critical to the ‘gate-keeper’ function of the DG in filtering 
neocortical and entorhinal excitatory inputs that converge into the CA3 region (Buhl et 
al., 1994; Lothman et al., 1992). Yet, while most of the hippocampus-related research in 
Scn1a models focuses on the hippocampal CA1 area, the pathological consequence of 
Scn1a dysfunction in the DG has been largely disregarded. 
In human temporal lobe epilepsy, GABAergic neuronal cell loss and reduced 
inhibition of granule cells in the DG are associated with enhanced susceptibility to 
seizures (de Lanerolle et al., 1989).  The loss of seizure-sensitive neuronal populations 
can critically alter the balance of excitation and inhibition in the hippocampus. 
However, whether hyperthermia- induced seizures or short- lasting repeated seizures 
induction (that are not associated with neuronal loss) cause DG damage has been less 
studied. Early- life FS have been associated to similar abnormalities in DG granule cells 
(Kwak et al., 2008). Koyama et al. 2012 showed that after a prolonged FS, there was the 
aberrant migration of neonatal-generated granule cells  and altered GABA receptors 
signaling (Koyama et al., 2012). In a similar experiment, Swijen et al, 2012 showed 
reduced inhibitory currents in the DG 10 days after the FS event (Swijsen et al., 2012). 
Interestingly the DG filter was shown to be disrupted (impaired synaptic integration and 
increased excitability) 10 days following the FS seizure event but not later (Pathak et 
al., 2007).  
Following recurrent seizures (i.e. flurothyl- induced seizures), important synaptic 
reorganization and impaired neurogenesis of DG granule cells have been observed 
(Holmes et al., 1998; McCabe et al., 2001). The previous studies indicate that FS or 
recurrent seizures events per se can be related to the abnormal properties of the DG.  
However, recently, a study correlated the Scn1a-associated phenotype with DG 
abnormalities. Indeed, Tsai et al, 2015 reported the first study using Scn1a models in 
which the DG properties where investigated. The authors observed that, while at 4 
weeks of age the Scn1aE1099X/+ in a mixed 129:B6 background mice (model of DS) had a 
substantial reduction in NaV1.1-expressing neurons in CA1, CA3 and DG, at 3 weeks of 
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age (representing the critical epileptic period), there was a specific reduction of NaV1.1-
expressing neurons in the DG but not in other hippocampal areas (CA1 and CA3) when 
compared to WT littermates. The number of GABAergic interneurons was unchanged in 
any areas. Also, the electrophysiological properties in the DG PV+ GABAergic neurons 
were altered in the Scn1aE1099X/+ mice (altered action potential kinetics, reduced 
excitability, and fewer spontaneous inhibitory currents). In addition to these functional 
deficits, they observed morphological abnormalities of DG granule cells.  
In light of this literature regarding DG in epilepsy, we thus decided to 
investigate the effects of repeated SIH in both CA1 and DG function in our Scn1aRH/+-
129:B6 mice at P60 and correlate these with behavioral abnormalities. We only 
analysed the firing properties of the excitatory neurons, because of the difficulty in the 
identification of the interneurons without markage ((GAD-67)-GFP). They present high 
variability of types/shapes and organization within the hippocampus. However, it would 
have been very relevant to analyse them due to their main role in Scn1a models 
physiopathology. The firing properties of the pyramidal cells of the CA1 region of the 
hippocampus were similar in the four groups (WT and Scn1aRH/+ control and submitted 
to hyperthermia). By contrast, Scn1aRH/+ mice submitted to the SIH protocol exhibited a 
strong increase in firing frequency in DG granule cells compared to other groups.  
These data clearly revealed that SIH produces an increase in the excitability of the 
“gate” region of the hippocampus.  Thus, it is possible that the increase in DG firing 
frequency observed in the Scn1aRH/+ after SIH underlies the impairment in the spatial 
memory task we observed in these mice.  Direct causality cannot, however, be proven 
with our study. The exact role of the DG in subserving memory processes has been 
controversial for many years. Recently it has been shown that the DG might be 
associated to spatial pattern separation (dissociation between similar contexts) in tasks 
like the eight-arm radial maze (Gilbert et al., 2001; Kesner and Rolls, 2015). However, 
the majority of the studies published correlate a decrease in firing frequency with DG-
related memory problems. Blocking DG granule cells have been correlated with 
impaired hippocampal-dependent memory aquisition and maintenance (Lassalle et al., 
2000; Lee and Kesner, 2004; Madroñal et al., 2016). Also, impaired synaptic 
transmission and excitability in the DG have been associated to hippocampus-dependent 
memory deficits (Morice et al., 2013). We observed an opposite effect, characterized by 
increased excitability in DG granule cells. However, it is possible that this excitation in 
 
146 
the DG, characterized by an excitation/inhibition imbalance results in abnormal sensory 
information reception and impaired memory formation within the hippocampus.  
Still, as described previously, DS patients show visual-spatial memory deficits 
indicating that the hippocampus functions might be altered in the patients (Chieffo et 
al., 2011c) and animal models showed that seizure generation might initiate in the 
hippocampus in the Scn1a+/- mouse model (Liautard et al., 2013). Thus, the alteration of 
DG excitation profile we observed is in line with these previous observations.  
3.4 The behavioral phenotypes observed in Scn1aRH/+-129:B6 mice 
after SIH correlate with Scn1a+/-  DS mouse models  
For the behavioral and cognitive assessment following the SIH protocol in 
Scn1aRH/+ mutant mice, we wanted to evaluate the largest panel of behavior and 
cognitive parameters, perturbations of which are well described in DS patients. As 
described in the introduction (I-Chapter 3-page 27), DS patients present neurological, 
cognitive and psychiatric/behavioral abnormalities. The main observations pointed out 
through the numerous DS clinical studies are the neurological problems: ataxia, lack of 
motor coordination, crouch gait; the behavioral problems: hyperactivity and social 
interaction problems; and the cognitive problems: language delay, visual deficits, 
attention deficits, working memory and visual-spatial memory deficits.  
 No major motor/visual impairment in Scn1aRH/+ after SIH 
We did not extensively address the neurological problems. However, through the 
different behavioral tasks tested we were able to record and analyse the global 
locomotor activity and speed in different contexts (openfield, actimeter, MWM, social 
interaction test) and, there were no signs of ataxia or nor important abnormalities in 
their posture and motor coordination. The only assessment of motor coordination and 
visual function was done during the MWM task, when mice were submitted to the cue 
task training. The cue task was done during two days with four trials per day, just before 
the spatial training. The escape strategy was exclusively based on the swim speed and 
visual integrity, as all the animals could identify the platform location marked with a 
flag. We observed that the Scn1aRH/+ -SIH displayed higher latency to find the platform 
on the first day, but rapidly normalized their performance on the second day.  Similarly, 
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they swam as fast as the three other groups on the second day (see TABLE 12). These 
results thus indicate that, during this cue task, the Scn1aRH/+-SIH mice took longer to 
understand the escape rule. They surprisingly showed lower average speed in the D1 of 
the cue task, and normalized by D2 where they swam as fast as the three other groups.  
Yet, as their performance normalized rapidly, we can conclude that they do not exhibit 
important motor or visual problems following the SIH protocol.  
In the other tasks (openfield, social interaction), the Scn1aRH/+-SIH mice 
travelled longer distances and with higher speed on average than the other 3 groups 
indicating that they are definitely not affected by major motor problems. Kalume et al, 
2007 observed a motor impairment in the P13-P21 Scn1a-/- and a mild motor 
dyscoordination in Scn1a+/- mice, which they correlated with NaV1.1 loss of function 
observed in the cerebellar purkinje interneurons. In patients, cerebellar dysfunctionhas 
also been suggested to justify the motor impairment, language delay, attention-deficits 
and working-memory problems observed in DS (Battaglia et al., 2013). Our Scn1aRH/+  
mice submitted to SIH in early life do not show overt signs of important cerebellar 
impairment at 2 months of age, indicating that SIH might not cause long- lasting 
behavioral effects on this area. Similarly to our work, Ito et al. 2013 did not detect 
motor impairment in Scn1aRX/+ mice (DS model) using the foot-print test and rotarod at 
9 weeks of age (Ito et al., 2013). Visual dysfunction is another major characteristic in 
DS patients.  Yet, we observed normal performance of the Scn1aRH/+ -SIH mice on the 
D2 of the cue task, arguing against major alterations in visual function after SIH. 
However, this task cannot detect slight visual deficits, which could be addressed using 
more specific techniques as tests for visual attention, optomotor function, infrared 
photorefraction (Abdeljalil et al., 2005; Fitzpatrick et al., 2017; Schaeffel, 2008). 
 Hyperactivity but no anxiety profile following SIH in Scn1aRH/+  
The development of behavioral abnormalities was the most obvious observation 
made in Scn1aRH/+ mice following recurrent seizure activity. Hyperactivity was evident 
as measured by the distance travelled in the openfield and during the habituation phase 
in the three-chamber social interaction. The same increase in activity was reported in 
DS mouse models in the openfield (Han et al., 2012c; Ito et al., 2013). We confirmed 
the novelty-associetd hyperactivity by measuring the circadian activity at D1 in the 
actimeter. Interestingly, we observed that this increased activity was particularly present 
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when the mice were first exposed to the actimeter (mainly first 24 hours), i.e. when 
confronted to a novel environment, but their activity normalized after habituation. This 
novelty-associated reaction was also observed in Scn1aRX/+ mice (model of DS), while 
in a familiar environment these mice tended to exhibit lower activity than WT 
littermates (Ito et al., 2013). Together, these data confirm that SIH induces a 
hyperactive profile in our GEFS+ mouse model, mimicking a phenotype observed in DS  
mouse models and DS patients. More specifically, the hyperactivity observed in 
different tasks seems to be exacerbated in new environments which highlits the 
neophobia present in these mice, probably related to a higher anxiety profile or 
increased impulsive and risk-taking behavior. In the openfield (by measure of time in 
the center), we observed that the Scn1aRH/+ did not present higher anxiety levels that the 
three other groups. As said before the openfield measure of anxiety alone is not 
sufficient to detect anxiety levels, we thus tested the animals in the dark- light paradigm. 
Again the anxiety levels were unchanged in the Scn1aRH/+ with SIH. So in conclusion, 
we observed that the Scn1aRH/+ submitted to SIH mice had a normal anxiety level when 
compared to the three other groups, and even a tendency for lower anxiety levels in the 
dark-light. The results were not in accordance with the study of Han et al, 2012 who 
showed increased activity in the openfield and elevated-plus maze test. The results in 
the Scn1aRX/+ by Ito et al, 2013 were not clear because they show an increase in anxiety 
in the openfield (contrasting to our study) but a decrease in anxiety in the elevated-plus 
maze (similar to our study even if not significant for our study FIGURE 36). The 
tendency for a decrease in anxiety ans high activity can be associated to an increase in 
impulsivity and risk-taking in the Scn1aRH/+-SIH mice. These measures could have been 
assessed using the five-choice serial test however due the low number of animals that 
we always had, we could not optimize the technique (reviewed in Dent and Isles, 2014).  
 Scn1aRH/+-SIH mice had an increase in stereotyped behavior  
In addition to the hyperactivity, we observed, in the openfield test, an increase in 
the number of body rotations and rearing events specifically in the Scn1aRH/+ –SIH 
group. These measures are considered as stereotyped behaviors, motor responses that 
are repetitive, invariant, and seemingly without purpose or goal in rodents (Kelley, 
2001). Similarly, Han et al, 2012 reported an increase in the number of body rotations 
and an increase in grooming time in the Scn1a+/--B6 mice. In addition to the repetitive 
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behavior, we observed that the Scn1aRH/+ had an impairment in social interaction after 
experiencing SIH. Both measures are associated to measures of the autistic- like 
spectrum (Berkvens et al., 2015). Again the social impairment is a typical characteristic 
observed in DS mouse models (Han et al., 2012c; Ito et al., 2013). Han et al, 2012, 
stressed the fact that the Scn1a+/- presented an autistic-like behavior. However, whether 
or not DS patients are autistic is controversial. Clinical studies suggest that the autistic 
traits are not complete in DS patients and their difficulties in socializing might be due to 
their motor problems and language impairment (Li et al., 2011; Villeneuve et al., 2014; 
Wolff et al., 2006b).  Again, these data suggest that SIH in early life is sufficient to turn 
a GEFS+ phenotype (neither stereotyped behaviors nor impairments in social 
interations) into a more severe DS phenotype with these autistic- like traits. These traits 
have been associated to PFC dysfunction, however more recently cerebellar function 
has also been correlated to these types of behavioral alterations through the cerebellum-
PFC projections (Cupolillo et al., 2016; Wang et al., 2014). Thus, these two structures 
could be implicated in the phenotypes observed. Instead of autistic- like behavior, the 
phenotype observed, repetitive behaviors with hyperactivity can also be correlated to a 
spectrum of attention-deficit hyperactivity disorder (Leo and Gainetdinov, 2013). More 
analysis would have been required to address this issue.  
 Scn1aRH/+-SIH mice had working and spatial memory impairment  
Regarding cognitive deficits, we tested the effects of SIH on long-term spatial 
memory. We observed an impairment in spatial learning and long-term memory in the 
MWM task, confirming that hippocampal function is importantly affected after SIH 
protocol in Scn1aRH/+ mice. Again, the results were in accordance with the findings in 
the DS mouse models reported previously (Han et al., 2012c; Ito et al., 2013).  
Concerning CFC, Han et al. 2012 reported lower freezing in Scn1a+/- :B6 mice when 
compared to controls, demonstrating contextual- fear memory impairment. At present, 
we cannot conclude on our results obtained in the CFC. We observed lower freezing in 
the Scn1aRH/+-SIH mice, but this trend was not significantly different from the other 
groups, although the number of mice per group was already consequent. The lack o 
memory impairment in the CFC task, after seeing changes in the spatial memory tasks, 
can be associated with the participation of different complementar structures in addition 
to the hippocampus in the memory tasks. The spatial memory in the MWM task, is 
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known to involve the hippocampus and upper cortical areas (Tse et al., 2011), whereas 
the CFC recruits the hippocampus and subcortical areas like the hippocampus and the 
amygdala (Phillips and LeDoux, 1992).   
Finally, we tested the prefrontal cortex integrity using a working memory task. 
We observed that the Scn1aRH/+-SIH mice exhibit lower working memory capacities and 
never reach the performance level of the other three groups. The two published studies 
using DS mouse models have not tested PFC dependent memory tasks so a comparison 
to a DS phenotype in this task is not possible. However, in DS patients, working 
memory problems have been reported in the majority of cases (Chieffo et al., 2011c; 
Ragona et al., 2011a). The results obtained in the behavioral/cognitive tasks in the 
Scn1aRH/+-SIH mouse model are summarized in TABLE 14  and compared to the results 
published in the DS mouse models.  All together, the results clearly illustrate that the 
repeated SIH induction at early-age in a mild Scn1aRH/+ model induces long- lasting 
behavioral/cognitive defects similar to those observed in the DS mouse models 
presenting severe phenotypes.  
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TABLE 14. SIH CONVERTS A MILD SCN1A MOUSE MODEL INTO  A SEVERE SCN1A MO USE MODEL. 
Results observed in the battery of behavioral/cognitive tasks after SIH in the Scn1a
RH/+
 mouse and 
comparison to the results published in DS mouse models with severe phenotype. 
 
4. THE MUTATION IS REQUIRED FOR THE SEIZURES EFFECTS (PRELIMINARY 
RESULTS) 
After obtaining these very interesting results we were confronted with two main 
questions.  
Firstly, the only group which had seizures among the 4 groups tested was the 
Scn1aRH/+ -SIH mice. Could the repeated seizures induce the same behavioral and 
cognitive defects in the WT mice? In other words, is the Scn1aRH/+ mutation required for 
the behavioral and cognitive effects observed in the Scn1aRH/+ -SIH mice? This is an 
important point to address as result interpretation of our study will depend on its 
answer.  
Secondly, in many publications, it has been stressed that the effects of the 
hyperthermia per se must be distinguished from those of the associated seizures (Bender 
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et al., 2004b; Dubé et al., 2009). The potential effects of hyperthermia may not be 
inconsequential and, in some other epileptic models, hyperthermia enhances seizure 
severity and neuronal loss induced by kainic acid  (Liu et al., 1993). However, this is 
controversial and no worsening of kainate-induced seizures have also been reported 
following hyperthermia (Hamelin et al., 2014). Also, when extreme, hyperthermia can 
result in neuronal injury by itself (Germano et al., 1996). Considering the hyperthermia 
itself, we address this issue with the WT HYP group and we observed that, except for 
the spatial probe test, where the WT control are significantly better than the WT-HYP, 
the two groups did not differ in any of the other tasks tested. This slight decrease in 
memory strength in the MWM in the WT HYP mice might be due to the hyperthermia 
effects, however, this group still performed well in this task and considerably better than 
the Scn1aRH/+-SIH group. Considering the Scn1aRH/+ -SIH group, we do not know if the 
seizures effects are exacerbated by the hyperthermia itself.  
To address these two important points, we thus organized an additional 
experiment in which:  
1) Seizures where induced by flurothyl in hyperthermia treated WT animals to 
verify if seizures (worsened or not by hyperthermia) could cause long- lasting 
behavioral/cognitive alterations in WT mice;  
2) Flurothyl seizures where induced in Scn1aRH/+ mice in the absence of 
hyperthermia to test if we could also observe long- lasting changes in the Scn1aRH/+ mice 
using a different seizure induction protocol.  
We first optimized the flurothyl/hyperthermia seizure induction protocol in our 
lab to mimic as closely as possible the SIH protocol. Of note, in our hands, the seizures 
induced by this new protocol are very similar to SIH induced seizures (i.e. behavioral 
seizure phenotype – starting from head nodding, rearing and failing, forelimb clonus 
and progression to GTC seizures).This is an ongoing experiment. However, the first 
preliminary results indicate that the Scn1aRH/+ with flurothyl induced seizures exhibit 
increased activity, lower sociability skills and poor memory performance, while WT 
littermates submitted to flurothyl- induced seizures/ hyperthermia remain cognitively 
and behaviorally intact (FIGURE 43).  The results suggest that repeated seizures are not 
sufficient to lead to important behavioral changes in the WT mice.  If these results are 
confirmed, this would strongly support the hypothesis that it is the combination of early 
life epileptic activity + SCN1A mutation that is at the origin of behavioral/cognitive 
deficits in DS patients. Also, our first data suggest that, similarly to Scn1aRH/+-SIH 
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mice, Scn1aRH/+ mice submitted to flurothyl- induced seizures seem to display impaired 
behavioral and cognitive phenotypes. These results need to be confirmed but are very 
interesting because they suggest that, while a normal young WT brain is able to cope 
with the effect of repeated seizures, probably by somehow restoring homeostasis, an 
NaV1.1-dysfonctional brain is not capable of coping with recurrent seizure activity 
(independent of type of induction protocol), leading to behavioral and cognitive 
abnormalities in adulthood. 
5. IS DS A CHANNELOPATHY? 
In our study, we observed that SIH, not only causes the appearance of 
subsequent spontaneous seizures, worsening the epileptic phenotype, but also 
importantly impairs the behavioral and cognitive functions in the Scn1aRH/+ mice.  
The works of Han et al. 2012 and Ito et al. 2013 show that the Scn1a+/- and the 
Scn1aRX/+ mouse models in pure B6 background exhibit very severe epileptic and 
behavioral/cognitive phenotypes comparable to those observed in the DS patients. 
Given these behavioral abnormalities, the two studies did not dissociate the strong 
epileptic activity presented in these mice from the network abnormalities caused by the 
mutation per se. Neither group investigated the epileptic profile of the animals from 
early-age to the adulthood and during behavioral tasks.  
With these results in Scn1a+/--B6 mice, Han et al. 2012 challenged the DS 
definition of EE, suggesting that DS phenotype might solely be due to the SCNA1 gene 
mutation i.e. a channelopathy, when they rescued some of the behavioral impairments 
(CFC and social interaction deficits) with low-dose clonazepan without causing 
sedation. However, the animals used in this study resulted from the 20% survivors 
following recurrent spontaneous seizure activity. It is thus possible that these remaining 
mice represent a sub-population of the colony most resilient to the seizures, which could 
also be most receptive to pharmacotherapy. Moreover, benzodiazepines might be 
effective in reducing the seizures in DS but rapidly become ineffective and the cognitive 
deficits are not overcome via the use of benzodiazepines (Connolly, 2016; Genton et al., 
2011; Inoue et al., 2015). 
Using a knock-down model to selectively reduce the NaV1.1 function without 
causing seizures, Bender et al. 2013,2016 had shown network abnormalities (reduction 
of neurons that fired phase-locked to hippocampal theta oscillations and dysruption of 
 
154 
medial septal regulation of theta rhythm) correlated with memory deficits, arguing again 
for the notion that DS might actually rather be a channelopathy. However this knock-
down strategy was not sufficient to cover the severe behavioral/cognitive/neurological 
abnormalities presented in DS patients, thus questioning the validity of this model as a 
through DS model. 
To date, there has been a general consensus that epileptic activity cannot be 
excluded in accounting from the severity of the phenotype in DS (Guerrini and Striano, 
2016; Guzzetta, 2011; Wolff et al., 2006b). And very recently, a study showed that age at 
seizure onset appears to predict outcome better than mutation type in DS patients 
carrying SCN1A gene muatations (Cetica et al., 2017).  However, the correlation 
between epileptic activity and behavioral/cognitive phenotype has never been fully 
established (Nabbout et al., 2013; Villeneuve et al., 2014).   
Considering the clinical studies, recent evidences point to a possible role of 
network dysfunction to cause the very early visual impairments observed in DS patients  
(arguing for the channelopathy theory). Indeed, the study proposed by Ricci et al. 2015 
comprises five DS cases, that are visually impaired early in life, but only one patient 
carries the SCN1A gene mutation. However, it is difficult to conclude on one patient 
diagnosis. Also, a similar progressive neurocognitive decline was observed in two 
children with DS, carrying de novo SCN1A truncations and different epileptic 
phenotype severity (Riva et al., 2009).  Passamonti et al. 2015 shows a family with 
inherited transmission where all the members have visual problems, even one patient 
who carries the mutation, but never had seizures. However, this patient was tested at 74 
years of age, and the visual problems could be a consequence of normal aging 
(Passamonti et al., 2015). No study thus far evaluated visual problems before the 
appearance of the first febrile/afebrile seizure. Therefore, it is possible that the visual 
impairment is the first behavioral consequence of seizures. Interestingly, however, 
visual deterioration has rarely been reported following a GTC event (Subash et al., 
2010).  In animal models, the visual-spatial memory is affected following neo-natal 
seizures in normal brains (Holmes et al., 1998; Neill et al., 1996). Also attention 
importantly influences visual perception (Sundberg et al., 2012) and attention deficits 
(associated with PFC dysfunction) are present in DS children at the onset.  
Thus as some studies pointed the possible role of the SCN1A gene mutation per 
se in generating the behavioral and cognitive impairment in DS, it was important to 
address the question in the opposite way i.e. could we exclude seizures as aggravating 
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factors in disease progression.  Our data presented here strongly argument against this 
possibility. Thus, we propose that DS is probably not only due to the effect of SCN1A 
mutations on network dysfunction per se, arguing against DS as a channelopathy. We 
argue that SCN1A mutations set the developing brain into a fragile condition probably 
by altering network connection and synchronization upon which repeated seizures 
during early life will provoke irreversible network alterations at the basis of long-term 
behavioral and cognitive dysfunction.  Thus, early life epileptic history is likely to play 
a major role in the progression of the disease.  
6. THE IMPORTANCE OF UNDERSTANDING THE ROLE OF SEIZURES FOR THE 
DEVELOPMENT OF ADEQUATE TREAMENTS. 
The NaV1.1 dysfunction, by rendering the brain fragile to epileptic insults, has 
consequences in behavioral and cognitive phenotypes in DS. Indeed, it is clear from our 
study that the lack of NaV1.1 causes the appearance of spontaneous seizures in mouse 
models associated with hyper-sensitivity to hyperthermia- induced seizures. Some 
studies show that more severe missense mutations (impacting changes in aminoacids 
polarity – inducing higher Grantham Score) and truncating mutations might be 
associated to earlier onset of seizures in DS (Brunklaus et al., 2014; Zuberi et al., 2011). 
However the mutation severities per se have not been successfully correlated with the 
behavioral and cognitive abnormalities in DS (Ishii et al., 2017; Jiang et al., 2016; 
Takaori et al., 2017).  
We observe that seizures aggravate the epileptic and cognitive phenotypes in the 
Scn1aRH/+ mice carrying a missense mutation inducing a DS phenotype. One possibility 
is that seizures might have more severe consequences for cognition and behavior in 
patients carrying more severe mutations (we saw for example that the same SIH 
protocols induce higher mortality in animals presenting a truncation mutation than a 
missense mutation). Ishii, et. al 2016 suggested that the missense vs. truncation 
mutations in DS might have independent ways to induce cognitive deficits. Truncation 
mutations were associated with a more rapid rate of cognitive decline, regardless of age 
at seizure onset, while the age at seizure onset was a predictor for the rate of cognitive 
decline for missense mutations (Ishii et al., 2016).Yet, the fact that the mutations found 
in DS can occasionally cause GEFS+ if present only in some neurons (Depienne et al., 
2006; Gennaro et al., 2006; Marini et al., 2006) and that mutations present in GEFS+ 
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can cause DS (Depienne et al., 2010), as it is the case for the R1648H mutation, show 
the limit between the clinical dissociation of GEFS+ and DS with respec t to mutation 
type.  Also, it reveals that DS and GEFS+ share major features, including FS, sensitivity 
to hyperthermic seizures and polymorphous seizure types. Thus, these observations fit 
well with our current data, demonstrating that DS disease could be a severe end of 
GEFS+ (Scheffer et al., 2001; Singh et al., 2001; Veggiotti et al., 2001; Wallace et al., 
2003). The R1648H mutation was found in GEFS+ patients and in one DS patient, 
suggesting that factors other than the mutation type account for the severity of the 
phenotype. Thus, our study is the reflect of a clinical observation associated to the 
R1648H mutation that confers two different phenotypes in the presence or absence of 
epileptic activity.  Indeed, our results clearly show that early life repeated seizures 
worsen behavioral and cognitive phenotypes in the Scn1aRH/+, thus transforming a mild 
GEFS+ model into a severe DS mouse model (schematized in FIGURE 46). Overall, this 
work stresses the importance of treating the early life epileptic seizures for a better 
outcome in DS patients. 
 
FIGURE 46. SCHEMATIC ILLUSTRATIO N OF THE STATE O F THE ART KNOWLEDGE AFTER O UR STUDY. 
The role of epileptic activity and NaV1.1 dysfunction in contributing to the cognitive and behavioral 
phenotype in the DS mouse model (Left). The part ial loss of the NaV1.1 channel function and no 
spontaneous epileptic act ivity do not induce behavioral and cogntitive changes in the Scn1a
RH/+
 mice, but 
when challenged with early life SIH, is converted into the phenotype observed in DS mouse models.   
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VI- CONCLUSION AND PERSPECTIVES 
SCN1A gene mutations, encoding for NaV1.1, are associated to a large spectrum 
of epileptic disorders. GEFS+, the milder syndrome, is usually caused by mild missense 
mutations. The patients present seizures with no cognitive deficits and in general,  
respond well to therapy. DS, the most severe disease of the spectrum, is a drug-resistant 
EE. GEFS+ and DS share common mutations and the distinction between the two is 
sometimes blurred. The cause of the cognitive decline in DS has never been proven 
clinically, questioning the definition of EE. In particular, the definition of DS as an EE 
has recently been challenged by experimental studies using animal models. In these 
studies, it has been suggested that the mutation per se, irrespective of epileptic history, 
causes the cognitive deficits in DS, thus proposing DS as a genetic channelopathy.  
Understanding the origin of cognitive impairment in DS and other EE is crucial 
for a better quality of treatment and daily life of patients and caregivers. The type of 
mutation in the SCN1A gene is an important predictor of the seizure onset and 
development of epilepsy in DS patients. However, the strong epileptic activity might 
play a role in worsening the phenotype and in the appearance of the behavioral and 
cognitive comorbidities in DS.  
The main goal of our work was to study the effect of repeated seizures induced 
by hyperthermia to the cognitive and behavioral phenotypes in mouse models carrying 
Scn1a gene mutations observed in DS patients or in GEFS+ patients, but which display 
little phenotypes in terms of spontaneous epileptic activity. Using the Scn1aRH/+ mice 
(mouse model carrying a missense mutation that causes GEFS+ and DS in one patient), 
we disclosed an important role of early life seizures in the appearance  of subsequent 
behavioral and cognitive phenotypes in adulthood. The results clearly indicate that early 
life seizures can change a mild phenotype (similar to the one found in GEFS+ patients) 
into a severe form (closer to DS patients), by increasing spontaneous seizure occurrence 
and inducing important behavioral and cognitive abnormalities. We observed that the 
same seizure induction protocol did not perturb WT animals. Finally, we observed 
specific alterations in DG neuron function in the Scn1aRH/+ mice submitted to this 
seizure induction protocol.  These results indicate that a developing brain carrying the 
Scn1aRH/+ mutation, when submitted to repeated early life seizures, is not able to cope 
with seizures effects, thus developing DG neuron network abnormalities and additional 
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spontaneous seizures. These alterations change brain function inducing long- lasting 
behavioral and cognitive changes.  
Our findings indicate a negative role of early life epileptic seizures in the 
progression/worsening of cognitive deficits in Scn1a mutant mice. It is therefore 
important to develop treatments that can completely block the seizures in the patients in 
order to expect better outcomes.  
In terms of perspectives, the main perspective for now is to complete the 
behavioral analysis in the flurothyl- induced seizures as it represents an important 
control of our experiment. Flurothyl- induced seizures are also currently being induced 
in WT and Scn1aRH/+ mice to investigate the development of spontaneous seizures using 
ECoG recordings and the electrophysiological properties of DG granule cells to 
complete our study.  
We also need to complete the electrophysiological analysis by investigating the 
interneurons’ properties in CA1 and DG areas of the hippocampus in the Scn1aRH/+SIH 
and control mice, as play a key role in Scn1a mouse models neuropathology. 
Later on, it would have been interesting to investigate if there is an age-
dependent effect of seizures to the phenotype (e.g.  Induce SIH at earlier age P17-P18 
and later age P30 or P60).  
Another interesting investigation would have been to use  the severe DS mouse 
model in pure B6 background and block the spontaneous seizures from the very onset 
(probably with stiripentol+clonazepan (Inoue et al., 2015) or fenfluramine (Ceulemans 
et al., 2016; Schoonjans et al., 2017)) to evaluate if the animals still display behavioral 
abnormalities at later ages.  
Considering the long-term future perspective, it consists in understanding why 
and how early life seizures can produce a severe phenotype in a model that was 
previously normal.  Understanding the cellular and molecular mechanisms implicated in 
this conversion will provide new research avenues for innovative treatment therapies. 
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VIII- STATISTIC TABLES  
1. RESULTS – CHAPTER 1  –  SCN1A
+/-
 -129  MICE AND SCN1A
+/- -B6:129 
 
 
 
Mouse 
model and 
genetic 
backgroun
d
E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatment/
protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistical 
test
Source of 
variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
D1 33.250 4.343 24 12 Interaction F (1, 90) = 0,3028 0.5835
D2 13.010 2.576 24 12 Day F (1, 90) = 25,89 < 0,0001
D1 29.850 4.376 20 10
D2 13.560 3.351 20 10
WT 33.250 4.343 24 12 Interaction F (1, 90) = 0,3028 0.5835
Scn1a+/- 29.850 4.376 24 12 Day F (1, 90) = 25,89 < 0,0001
WT 13.010 2.576 20 10
Scn1a+/- 13.560 3.351 20 10
D1 54.931 4.540 48 12 WT: D1 vs. D2 t(258)=1,436 0.4779
D2 47.485 4.591 48 12 WT: D1 vs.D3 t(258)=4,666 < 0,0001
12 WT: D1 vs. D4 t(258)=5,761 < 0,0001
12 WT: D2 vs. D3 t(258)=3,23 0.0076
12 WT: D2 vs. D4 t(258)=4,325 0.0001
12 WT: D3 vs. D4 t(258)=1,095 0.6926
D1 53.220 5.239 40 10 Scn1a+/-:D1 vs. D2 t(258)=1,754 0.298
D2 43.258 5.022 40 10 Scn1a+/-:D1 vs.D3 t(258)=5,169 < 0,0001
10 Scn1a+/-:D1 vs. D4 t(258)=5,615 < 0,0001
10 Scn1a+/-:D2 vs. D3 t(258)=3,415 0.0041
10 Scn1a+/-:D2 vs. D4 t(258)=3,861 0.0008
10 Scn1a+/-:D3 vs. D4 t(258)=0,4464 0.9703
WT - 54.931 4.540 48 12
Scn1a+/- - 53.220 5.239 40 10
WT - 47.485 4.591 48 12
Scn1a+/- - 43.258 5.022 40 10
WT - 30.742 3.780 48 12
Scn1a+/- - 23.865 3.269 40 10
WT - 25.063 3.064 48 12
Scn1a+/- - 21.330 2.659 40 10
WT: LEFT - 25.916 3.690 12 12
WT: TARGET - 35.223 3.559 12 12
WT: RIGHT - 19.126 3.189 12 12
WT: OPPOSITE - 11.029 2.281 12 12
Scn1a+/-: LEFT - 13.335 1.489 10 10
Scn1a+/-: TARGET - 46.751 5.036 10 10
Scn1a+/-: RIGHT - 28.084 3.812 10 10
Scn1a+/-: OPPOSITE - 8.723 3.031 10 10
WT: LEFT - 25.916 3.690 12 12 WT: LEFT vs. TARGET t(60)=1,792 0.3866
Scn1a+/-: LEFT - 13.335 1.489 10 10 WT:  TARGET vs. RIGHT t(60)=3,099 0.0176
WT: TARGET - 35.223 3.559 12 12
Scn1a+/-: TARGET - 46.751 5.036 10 10
WT: RIGHT - 19.126 3.189 12 12
Scn1a+/-: RIGHT - 28.084 3.812 10 10
WT: OPPOSITE - 11.029 2.281 12 12
Scn1a+/-:  TARGET vs. 
RIGHT
t(60)=3,281 0.0103
Scn1a+/-: OPPOSITE - 8.723 3.031 10 10
Scn1a+/-:  TARGET vs. 
OPPOSITE
t(60)=6,683 < 0,0001
WT - 35.223 3.559 12 12 -
Chance level - 25.000 - - - -
Nav 1.1 KO +/- - 46.751 5.036 10 10 -
Chance level - 25.000 - - - -
 Morris Water Maze (MWM)
 < 0,0001 WT vs. Scn1a+/- +/-
:RIGHT
< 0,0001
Genotype F (1, 20) = 2,126 0.1603
M
W
M Probe 
test
One 
sample t-
test
t(11)=2,873 0.0152 - - - -
t(9)=4,319 0.0019 - - - -
Target 
quadrant:Diff
erence to 
chance level
M
W
M Probe 
test
RM-Two 
Way 
ANOVA
Interaction F (3, 60) = 4,144 0.0098
Sidak's
WT: TARGET vs. 
OPPOSITE
t(60)=4,658 0.0001
Quadrant F (3, 60) = 22,75  < 0,0001
Scn1a+/-:  LEFT vs. 
TARGET
t(60)=5,873
Presence in 
quadrant (%)
Presence in 
quadrant (%)
t(80)=2,395
t(80)=2,613
25.063 3.064
t(344)=0,6374
t(344)=1,174
t(344)=0,722
t(344)= 0,2922
Tuckey's
Two-Way 
RM ANOVA
Day
Genotype
M
W
M
M
W
M
Genotype
SPATIAL-
latency
Scn1a+/-
0.1603
S
c
n
1
a
+
/-
-1
2
9
Sidak's
SPATIAL-
latency
RM-Two 
Way 
ANOVA
0.0422
WT vs. Scn1a+/-+/-: 
TARGET
D3
Day
Interaction
0.9488
0.6682
0.9215
0.9972
0.0738
< 0,0001
Quadrant
F (3, 258) = 29,10
D1
D2
D3
D4
t(80)=1,861 0.2405
Genotype
F (1, 86) = 1,413
Probe 
test
F (1, 86) = 1,413
D1: WT vs. Scn1a+/-
Two-Way 
RM ANOVA
Genotype
F (1, 90) = 0,1317
WT vs. Scn1a+/- +/-: 
OPPOSITE
t(80)=0,479 0.9819
Tuckey's
Two-Way 
RM ANOVA
2.65921.330
3.26923.865
0.2378F (1, 86) = 1,413
0.9278F (3, 258) = 0,1529
 < 0,0001
F (3, 258) = 0,1529
0.2378
Day
Interaction
M
W
M
D4
 < 0,0001
Interaction
3.78030.742
D3
D4
Interaction F (3, 60) = 4,144 0.0098
WT vs. Scn1a+/-+/-: LEFT
F (3, 258) = 29,10
F (3, 60) = 22,75
48
48
40
40
M
W
M CUE TASK -
latency
WT
0.2378
F (3, 258) = 29,10
D4: WT vs. Scn1a+/-
D3: WT vs. Scn1a+/-
D2: WT vs. Scn1a+/-
F (1, 20) = 2,126
21B
21B
21B
RESULTS Chapter 1- Phenotypic characterization of Scn1a+/--129 (DS model)
-
-
M
W
M CUE TASK -
latency
Two-Way 
RM ANOVA
Sidak's 21A
Genotype F (1, 90) = 0,1317 0.7176
21A
- Genotype D2: WT vs. Scn1a+/- t(180)=0,1039 0.9932
D1
D2
WT
Scn1a+/-
21A
21A
21A
-
-
WT: D1 vs. D2
Scn1a+/-: D1 vs. D2
t(90)=4,276 < 0,0001
0.0066t(90)=3,018
0.7176
-
Two-Way 
RM ANOVA
D1: WT vs. Scn1a+/-
Sidak's
t(180)=0,6392 0.773
0.9278F (3, 258) = 0,1529
0.9278
Tuckey's
Mouse 
model and 
genetic 
backgroun
Experime
nt
Measurment
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) 
value / 
q(dF) 
value
p value Figure
WT - 29,530 8,770 6 6 - - - - -
Scn1a+/- - 32,230 7,362 8 8 - - - - -
WT - 43,010 9,192 9 9 - - - - -
Scn1a+/- - 42,470 10,340 7 7 - - - - -
0,9695
22
U=21,50 0,7799
t(14)=0,038
 1 shock
 3 shocksS
c
n
1
a
+
/-
-1
2
9
Mann-
Withney 
test
Unpaired 
two-tailed 
t-test
Freezing %
Freezing %
CFC
Contextual Fear-Conditioning (CFC)
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Mouse 
model and 
genetic 
backgroun
E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
WT - 75,330 4,540 - 12 - - - - -
Scn1a+/- - 74,790 2,819 - 10 - - - - -
Unpaired 
two-tailed 
t-test
t(20)=09533 0,925 27
S
c
n
1
a
+
/-
-
B
6
:1
2
9
C
o
n
te
x
tu
a
l 
F
e
a
r 
C
o
n
d
it
io
n
i
Conditioning  
3 shocks
Freezing %
Contextual Fear Conditioning
Mouse 
model and 
genetic 
backgroun
E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
WT - 25,040 1,248 12 12 - - - - -
Scn1a+/- - 26,560 1,731 10 10 - - - - -
WT - 0,042 0,002 12 12 - - - - -
Scn1a+/- - 0,044 0,003 10 10 - - - - -
C1:WT - 167,800 14,390 12 12 WT: C1 vs. Center
t(40)=3,605
0,0026
C:WT - 240,000 12,030 12 12 WT: C1 vs. C2
t(40)=1,127
0,605
C2:WT - 190,400 15,380 12 12 WT: Center vs. C2
t(40)=2,478
0,0517
C1: Scn1a+/- - 192,700 9,190 10 10 Scn1a+/-: C1 vs. Center
t(40)=2,614
0,0372
C: Scn1a+/- - 250,000 8,510 10 10 Scn1a+/-: C1 vs. C2
t(40)=1,648
0,2884
C2: Scn1a+/- - 156,600 6,930 10 10 Scn1a+/-: Center vs. C2 t(40)=4,262 0,0004
EC: WT - 92,218 10,069 11 11 Interaction F (1, 20) = 0,4825 0,4953
M:WT - 136,046 13,254 11 11 Genotype F (1, 20) = 4,335 0,0504
EC:Scn1a+/- - 118,067 9,197 9 9
M: Scn1a+/- - 142,000 18,660 9 9
familiar mouse: WT - 49,836 7,939 11 11 Interaction F (1, 18) = 0,4089 0,5306
novel mouse: WT - 87,273 9,653 11 11 Genotype F (1, 18) = 2,990 0,1009
familiar mouse: Scn1a+/- - 62,656 6,549 9 9
novel mouse: Scn1a+/- - 112,889 16,492 9 9
25E
25D
25C
25B
S
c
n
1
a
+
/-
-B
6
:1
2
9
T
h
re
e
 c
h
a
m
b
e
r 
s
o
c
ia
l 
in
te
ra
c
ti
o
 t
e
s
t
Unpaired 
two-tailed 
t-test
t(20)=0,7283
t(18)=2,303EC - M: WT 
Sidak's
0,0668
Cage F (1, 20) = 2,429 0,1348 EC - M: Scn1a+/- t(18)=1,138 0,5404
Social 
Novelty 
phase
RM-Two 
Way 
ANOVA
fM - nM: WT 
Sidak's
t(18)=2,789 0,0243
Cage F (1, 18) = 19,19 0,0004 fM - nM: Scn1a+/- t(18)=3,385 0,0066
Sociability 
phase
0,4749
Unpaired 
two-tailed 
t-test
t(20)=0,7597 0,4653
Two-way 
ANOVA
Interaction F (2, 40) = 2,114
RM-Two 
Way 
ANOVA
Tuckey's
Tuckey's
Chamber F (2, 40) = 14,15 < 0,0001
Genotype F (1, 20) = 2,034 0,1692
Distance 
travelled (m)
Average 
speed (m/s)
Time in the 
room (s)
Interaction 
time (s)
Interaction 
time (s)
Habituation 
phase
Habituation 
phase
Habituation 
phase
0,1341
25A
Three-chamber social 
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Mouse 
model and 
genetic 
backgroun
E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
Cue task 1 - 23,540 3,927 48 12
Cue task 2 - 2,652 0,272 48 12
Cue task 1 - 23,790 4,838 40 10
Cue task 
Day
F (1, 86) = 42,51  < 0,0001
Cue task 2 - 4,640 0,980 40 10 Genotype F (1, 86) = 0,1250 0,7245
WT - 23,540 3,927 48 12
Scn1a+/- - 23,790 4,838 40 10
WT - 2,652 0,272 48 12
Cue task 
Day
F (1, 86) = 42,51  < 0,0001
Scn1a+/- - 4,640 0,980 10 40 Genotype F (1, 86) = 0,1250 0,7245
Training 1 - 31,631 4,972 48 12
WT: Training 1 vs. 
Training 2
t(258)=5,925 < 0,0001
Training 2 - 9,240 2,288 48 12
WT: Training 1 vs. 
Training 3
t(258)=6,444 < 0,0001
WT: Training 1 vs. 
Training 4
t(258)=6,267 < 0,0001
WT: Training 2 vs. 
Training 3
t(258)=0,5193 0,9961
WT: Training 2 vs. 
Training 4
t(258)=0,3423 0,9996
WT: Training 3 vs. 
Training 4
t(258)=0,177 > 0,9999
Training 1 - 27,195 4,827 40 10
Scn1a+/-: Training 1 vs. 
Training 2
t(258)=4,042 0,0004
Training 2 - 10,460 1,545 40 10
Scn1a+/-:Training 1 vs. 
Training 3
t(258)=3,894 0,0008
Scn1a+/-:Training 1 vs. 
Training 4
t(258)=4,882 < 0,0001
Scn1a+/-:Training 2 vs. 
Training 3
t(258)=0,148 > 0,9999
Scn1a+/-:Training 2 vs. 
Training 4
t(258)=0,8394 0,9543
Scn1a+/-:Training 3 vs. 
Training 4
t(258)=0,9874 0,9049
WT - 31,631 4,972 48 12
Scn1a+/- - 27,195 4,827 40 10
WT - 9,240 2,288 48 12
Scn1a+/- - 10,460 1,545 40 10
WT - 7,277 1,008 48 12
Scn1a+/- - 11,073 1,756 40 10
WT - 7,946 1,754 48 12
Scn1a+/- - 6,985 1,160 40 10
WT: LEFT - 21,930 3,385 12 12 WT: LEFT vs. TARGET t(60)=4,12 0,0007
WT: TARGET - 40,260 3,795 12 12 WT:  TARGET vs. RIGHT t(60)=3,137 0,0158
WT: RIGHT - 26,310 2,558 12 12
WT: TARGET vs. 
OPPOSITE
t(60)=6,486 <0,0001
WT: OPPOSITE - 11,400 1,813 12 12
Scn1a+/-: LEFT - 14,230 1,906 10 10
Scn1a+/-: TARGET - 38,680 2,917 10 10
Scn1a+/-:  TARGET vs. 
RIGHT
t(60)=1,566 0,5439
Scn1a+/-: RIGHT - 31,050 3,485 10 10
Scn1a+/-: 
OPPOSITE
- 15,980 1,607 10 10
WT: LEFT - 21,930 3,385 12 12
Scn1a+/-: LEFT - 14,230 1,906 10 10
WT: TARGET - 40,260 3,795 12 12
Scn1a+/-: TARGET - 38,680 2,917 10 10
WT: RIGHT - 26,310 2,558 12 12
Scn1a+/-: RIGHT - 31,050 3,485 10 10
WT: OPPOSITE - 11,400 1,813 12 12
Scn1a+/- OPPOSITE - 15,980 1,607 10 10
WT - 40,260 3,795 12 12 -
Chance level - 25 - -
Scn1a+/- - 38,680 2,917 10 10 -
Chance level - 25 - -
WT - 10,330 0,742 12 12
Nav 1.1 KO +/- - 9,700 0,746 10 10
26A
26A
Scn1a+/-
Training 3
Sidak's
M
o
rr
is
 W
a
te
r 
M
a
z
e
26A
t(344)=0,9345 0,8223
Genotype F (1, 86) = 0,001928 0,9651
Interaction F (3, 258) = 0,7736 0,5097
WT
Two-Way 
RM 
ANOVA
Interaction F (3, 258) = 0,7736 0,5097
Scn1a+/-
Two-Way 
RM 
ANOVA
0,9969
26B
26B
26A
26A
26B
26B
Two-Way 
RM 
ANOVA
F (1, 86) = 0,001928
-
M
o
rr
is
 W
a
te
r 
M
a
z
e
WT
Cue task1
M
o
rr
is
 W
a
te
r 
M
a
z
e
Probe test
RM-Two 
Way 
ANOVA
Interaction F (3, 60) = 1,610 0,1965
WT vs. Scn1a+/-: LEFT
Sidak's
t(80)=1,904 0,2209
WT vs. Scn1a+/-: 
TARGET
t(80)=0,3912 0,9915
Quadrant F (3, 60) = 24,41  < 0,0001
WT vs.Scn1a+/-:RIGHT t(80)=1,174 0,6733
Genotype
F (1, 20) = 
0,5451
0,4689
WT vs. Scn1a+/-: 
OPPOSITE
<0,0001
0,7013t(80)=1,133
-
M
o
rr
is
 W
a
te
r 
M
a
z
e
Probe test
RM-Two 
Way 
ANOVA
Interaction F (3, 60) = 1,610 0,1965
Quadrant F (3, 60) = 24,41  < 0,0001
Genotype F (1, 20) = 0,5451 0,4689
- -
0,0001t(60)=4,657
-
t (9)=4,690 0,0011 -
M
o
rr
is
 W
a
te
r 
M
a
z
e
Probe test
One 
sample t-
test
t(11)=4,022 0,002 -
S
c
n
1
a
+
/-
-B
6
:1
2
9
--
Sidak's t(60)=5,015
Presence in 
quadrant (%) 
Quadrant 
discriminatio
n by group
Presence in 
quadrant (%) 
Quadrant 
discriminatio
n between 
the groups
Target 
quadrant:Diff
erence to 
chance level
Training 4
Training 4: WT vs. 
Scn1a+/-
Scn1a+/-:  LEFT vs. 
TARGET
Scn1a+/-:  TARGET vs. 
OPPOSITE
M
o
rr
is
 
W
a
te
r 
M
a
z
e Mann 
Whitney 
test
0,8332U=10,5-
Training 3: WT vs. 
Scn1a+/-
0,9651
M
o
rr
is
 W
a
te
r 
M
a
z
e
t(344)=0,3005
< 0,0001
Genotype F (1, 86) = 0,001928 0,9651
Training 3 - 7,277 1,008 12 Training Day F (3, 258) = 27,22
Sidak's
M
o
rr
is
 W
a
te
r 
M
a
z
e
Training 1
Training 2
Training Day F (3, 258) = 27,22 < 0,0001
Training 2: WT vs. 
Scn1a+/-
11,073 1,756 10 Training Day F (3, 258) = 27,22 < 0,0001
Training 4 -
Latency to 
find the cued 
platform (s)
Training 4 - 7,946 1,754 12
Cue task 2
Training 3
---
48
48
40
40
Latency to 
find the cued 
platform (s)
Latency to 
find the 
hidden 
platform (s)
Latency to 
find the 
hidden 
platform
6,985 1,160 10 Genotype
t(344)=1,092Interaction F (3, 258) = 0,7736 0,5097
Training 1: WT vs. 
Scn1a+/-
Probe test
Number of 
platform 
crosses
0,7244
t(344)=0,2366
Sidak's-
0,9988
Two-Way 
RM 
ANOVA
0,7779F (1, 86) = 0,08006Interaction
Cue task 2: WT vs. 
Scn1a+/-
Sidak's t(172)=0,87 0,8794
0,998t(172)=0,056Sidak's
Cue task 1: WT vs. 
Scn1a+/-
0,0001
< 0,0001t(86)=5,045Sidak's
WT: Cue task 1 vs. Cue 
task 2
26A
Two-Way 
RM 
ANOVA
0,7779F (1, 86) = 0,08006Interaction
Scn1a+/-: Cue task 1 vs. 
Cue task 2
Sidak's t(86)=4,223
Morriw Water Maze
Mouse 
model and 
genetic 
backgroun
E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
WT - 75,330 4,540 - 12 - - - - -
Scn1a+/- - 74,790 2,819 - 10 - - - - -
Unpaired 
two-tailed 
t-test
t(20)=09533 0,925 27
S
c
n
1
a
+
/-
-
B
6
:1
2
9
C
o
n
te
x
tu
a
l 
F
e
a
r 
C
o
n
d
it
io
n
i
Conditioning  
3 shocks
Freezing %
Contextual Fear Conditioning
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Mouse 
model and 
genetic E
x
p
e
ri
m
e
n
t
Measurment
Protocol 
phase
Genotype
treatm
ent/pro
tocol
average S.E.M
# 
values/sli
ces/cells
# 
animals
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) 
value/U/χ²/H
p value Comparision
post 
hoc test
t(dF) value / 
q(dF) value
p value Figure
WT - 2.917 0.260 12 12
Scn1a+/- - 2.900 0.314 10 10
WT - 3.917 0.379 12 12
Scn1a+/- - 3.800 0.327 10 10
WT - 3.333 0.396 12 12
Scn1a+/- - 3.500 0.401 10 10
WT - 3.833 0.423 12 12
Scn1a+/- - 3.600 0.371 10 10
WT - 3.667 0.256 12 12
Scn1a+/- - 3.800 0.359 10 10
WT - 3.750 0.429 12 12
Scn1a+/- - 3.800 0.359 10 10
WT - 4.083 0.468 12 12
Scn1a+/- - 4.400 0.267 10 10
WT - 5.000 0.389 12 12
Scn1a+/- - 5.100 0.407 10 10
WT - 5.250 0.524 12 12
Scn1a+/- - 5.200 0.359 10 10
WT - 5.167 0.386 12 12
Scn1a+/- - 5.600 0.400 10 10
WT - 5.583 0.288 12 12
Scn1a+/- - 5.900 0.407 10 10
WT - 5.500 0.359 12 12
Scn1a+/- - 5.600 0.267 10 10
D1 WT - 2.917 0.260 12 12 D1 : WT vs. Chance level t(11)=2,244 0.0463 - - - -
D2 WT - 3.917 0.379 12 12 D2 : WT vs. Chance level t(11)=1,101 0.2945 - - - -
D3 WT - 3.333 0.396 12 12 D3 : WT vs. Chance level t(11)=0,4212 0.6817 - - - -
D4 WT - 3.833 0.423 12 12 D4 : WT vs. Chance level t(11)=0,7872 0.4478 - - - -
D5 WT - 3.667 0.256 12 12 D5 : WT vs. Chance level t(11)=0,6504 0.5288 - - - -
D6 WT - 3.750 0.429 12 12 D6 : WT vs. Chance level t(11)=0,5833 0.5715 - - - -
D7 WT - 4.083 0.468 12 12 D7 : WT vs. Chance level t(11)=1,246 0.2385 - - - -
D8 WT - 5.000 0.389 12 12 D8 : WT vs. Chance level t(11)=3,854 0.0027 - - - -
D9 WT - 5.250 0.524 12 12 D9 : WT vs. Chance level t(11)=3,339 0.0066 - - - -
D10 WT - 5.167 0.386 12 12 D10 : WT vs. Chance level t(11)=4,318 0.0012 - - - -
D11 WT - 5.583 0.288 12 12 D11 : WT vs. Chance level t(11)=7,244 < 0,0001 - - - -
D12 WT - 5.500 0.359 12 12 D12 : WT vs. Chance level t(11)=5,573 0.0002
Chance 
level
- 3.500 - - -
D1 Scn1a+/- - 2.900 0.314 10 10 D1 : Scn1a+/- vs. Chance level t(9)=1,908 0.0887 - - - -
D2 Scn1a+/- - 3.800 0.327 10 10 D2 : Scn1a+/- vs. Chance level t(9)=0,9186 0.3823 - - - -
D3 Scn1a+/- - 3.500 0.401 10 10 D3 : Scn1a+/- vs. Chance level t(9)=0,0 1 - - - -
D4 Scn1a+/- - 3.600 0.371 10 10 D4 : Scn1a+/- vs. Chance level t(9)=0,2694 0.7937 - - - -
D5 Scn1a+/- - 3.800 0.359 10 10 D5 : Scn1a+/- vs. Chance level t(9)=0,8356 0.425 - - - -
D6 Scn1a+/- - 3.800 0.359 10 10 D6 : Scn1a+/-vs. Chance level t(9)=0,8356 0.425 - - - -
D7 Scn1a+/- - 4.400 0.267 10 10 D7 : Scn1a+/- vs. Chance level t(9)=3,375 0.0082 - - - -
D8 Scn1a+/- - 5.100 0.407 10 10 D8 : Scn1a+/- vs. Chance level t(9)=3,932 0.0034 - - - -
D9 Scn1a+/- - 5.200 0.359 10 10 D9 : Scn1a+/- vs. Chance level (9)t=4,735 0.0011 - - - -
D10 Scn1a+/- - 5.600 0.400 10 10 D10 : Scn1a+/- vs. Chance level t(9)=5,250 0.0005 - - - -
D11 Scn1a+/- - 5.900 0.407 10 10 D11 : Scn1a+/-vs. Chance level t(9)=5,898 0.0002 - - - -
D12 Scn1a+/- - 5.600 0.267 10 10 D12 : Scn1a+/- vs. Chance level t(9)=7,875 < 0,0001
Chance 
level
- 3.500 - - -
Radial Maze
Number of 
correct 
choices
F (1, 20) = 0,2325
F (11, 220) = 
13,69
F (11, 220) = 
0,1394
D3:WT vs. Scn1a+/-
S
c
n
1
a
+
/-
-B
6
:1
2
9
R
a
d
ia
l 
M
a
z
e
One 
sample t-
test
Differences 
to chance 
level
-
D11:WT vs. Scn1a+/-
D10:WT vs. Scn1a+/-
D5:WT vs. Scn1a+/-
-- -
> 0,9999t(240)=0,218
> 0,9999t(240)=0,031
R
a
d
ia
l 
M
a
z
e
Two-Way 
RM ANOVA
  Interaction
Training Day
Genotype
> 0,9999t(240)=0,591
> 0,9999t(240)=0,093
> 0,9999t(240)=0,249
> 0,9999t(240)=0,435
> 0,9999t(240)=0,311
t(240)=0,186
t(240)=0,591
0.9985
D9:WT vs. Scn1a+/-
D8:WT vs. Scn1a+/-
D7:WT vs. Scn1a+/-
S
c
n
1
a
+
/-
-B
6
:1
2
9
D12
D11
D10
D9
D8
D7
D6
D5
D4
D3
D2
D1
> 0,9999
> 0,9999
t(240)=0,809
> 0,9999t(240)=0,093
t(240)=0,186 > 0,9999
D2: WT vs. Scn1a+/-
D1: WT vs. Scn1a+/-
 < 0,0001
0.9995
D6:WT vs. Scn1a+/-
D12:WT vs. Scn1a+/-
Sidak's
0.6349
28
28
D4:WT vs. Scn1a+/-
28
-
---
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2. RESULTS – CHAPTER 2  –  SCN1A+/- -B6:129 MICE AND SCN1ARH/+ 
 
Mouse 
model 
and 
genetic 
Experime
nt
Measurm
ent
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / 
t (dF) 
value/U/χ²/H
p value
Comparis
ion
post hoc 
test
t(dF) 
value / 
q(dF) 
value
p value Figure
WT - 100,000 - 12 12
Scn1a+/- - 100,000 - 10 10
WT Hyperthermia 72,720 13,428 11 11
Scn1a+/- SIH 36,769 12,800 13 13
D1 41,173 0,106 11 11 1 vs. 2 - > 0,9999
D2 41,320 0,213 10 10 1 vs. 3 - > 0,9999
D3 40,122 0,514 9 9 1 vs. 4 - 0,624
D4 40,017 0,481 6 6 1 vs. 5 - > 0,9999
D5 40,717 0,257 6 6 1 vs. 6 - 0,6634
D6 40,240 0,385 5 5 1 vs. 7 - > 0,9999
D7 40,350 0,328 4 4 1 vs. 8 - > 0,9999
D8 41,160 0,308 5 5 1 vs. 9 - > 0,9999
D9 40,925 0,439 4 4
D10 41,900 0,058 3 3
D1 5,091 0,091 11 11 1 vs. 2 - 0,0004
D2 5,900 0,100 10 10 1 vs. 3 - < 0,0001
D3 6,000 0,000 9 9 1 vs. 4 - < 0,0001
D4 6,167 0,167 6 6 1 vs. 5 - 0,0007
D5 6,000 0,000 6 6 1 vs. 6 - 0,0018
D6 6,000 0,000 5 5 1 vs. 7 - 0,009
D7 6,000 0,408 4 4 1 vs. 8 - 0,0018
D8 6,000 0,000 5 5 1 vs. 9 - 0,0002
D9 6,250 0,250 4 4
D10 6,000 0,000 3 3
RESULTS Chapter 2- Seizures induction by hyperthermia (SIH) in Scn1a +/--B6:129 and Scn1a RH/+-129:B6 mouse models
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3. RESULTS – CHAPTER 3  –  SCN1ARH/+ -SIH 
 
 
  
Mouse 
model 
and 
genetic 
Experime
nt
Measurm
ent
Protocol 
phase
Genotype
treatment
/protocol
average S.E.M
# 
values/sli
ces/cells
# animals
Statistica
l test
Source of 
variation
F(DFn,DFd) / 
t (dF) 
value/U/χ²/H
p value
Comparis
ion
post hoc 
test
t(dF) 
value / 
q(dF) 
value
p value Figure
WT - 100,000 - 20 20
Scn1a
RH/+ - 100,000 - 20 20
WT Hyperthermia 92,063 3,406 33 33
Scn1a
RH/+ SIH 65,079 6,006 63 63
D1 41,632 0,049 63 63 1 vs. 2 - 0,0092
D2 41,918 0,057 56 56 1 vs. 3 - 0,0001
D3 42,042 0,048 57 57 1 vs. 4 - > 0,9999
D4 41,475 0,168 53 53 1 vs. 5 - > 0,9999
D5 41,486 0,130 50 50 1 vs. 6 - > 0,9999
D6 41,298 0,147 48 48 1 vs. 7 - > 0,9999
D7 41,292 0,108 48 48 1 vs. 8 - 0,8898
D8 41,200 0,132 45 45 1 vs. 9 - 0,7714
D9 41,240 0,120 43 43
D10 41,605 0,116 41 41
D1 4,804 0,059 46 46 1 vs. 2 - 0,968
D2 5,093 0,056 43 43 1 vs. 3 - < 0,0001
D3 5,581 0,089 43 43 1 vs. 4 - < 0,0001
D4 5,925 0,066 40 40 1 vs. 5 - < 0,0001
D5 5,865 0,079 37 37 1 vs. 6 - < 0,0001
D6 6,059 0,041 34 34 1 vs. 7 - < 0,0001
D7 5,971 0,029 34 34 1 vs. 8 - < 0,0001
D8 6,030 0,030 33 33 1 vs. 9 - < 0,0001
D9 6,032 0,032 31 31
D10 5,929 0,071 28 28
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Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 0.40 0.17 11 11 - - - -
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 1.03 0.09 7 7 - - - -
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 0.89 0.21 10 10 - - - -
Scn1a
RH/+ - 0.00 0.00 4 4 - - - -
Scn1a
RH/+ SIH 0.70 0.09 8 8 - - - -
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 0.56 0.12 8 8 - - - -
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 0.51 0.13 10 10 - - - -
Scn1aRH/+ - 0.00 0.00 4 4 - - - -
Scn1aRH/+ SIH 0.64 0.13 7 7 - - - -
Scn1aRH/+ - 0.00 0.00 3 3 - - - -
Scn1aRH/+ SIH 0.63 0.17 7 7 - - - -
Scn1aRH/+ - 0.00 0.00 3 3 - - - -
Scn1aRH/+ SIH 0.55 0.21 4 4 - - - -
Scn1a
RH/+ - 0.00 0.00 3 3 - - - -
Scn1a
RH/+ SIH 0.75 0.15 4 4 - - - -
t(12)=2,458
t(10)=3,217
t(10)=5,466
t(12)=2,570
t(9)=8,412
t(13)=1,370
Holm-Sidak correction for multiple 
comparision
31C
Post SIH 
week 10
Post SIH 
week 9
Post SIH 
week 8
Post SIH 
week 7
Post SIH 
week 6
Post SIH 
week 5
Post SIH 
week 4
Post SIH 
week 3
Post SIH 
week 2
Post SIH 
week 1
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test
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< 0,0001
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0.0050108
0.0512169
0.078416
0.0082818t(5)=4,225
t(5)=2,206
t(8)=2,290
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RESULTS Chapter 3- Long-term effects of the 10-days seizures induction by hyperthermia protocol in Scn1a
RH/+
-129:B6 mice
Spontaneous seizure analysis  in Scn1aRH/+ -129:B6
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Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 202.61 9.79 14 7 WT control vs. Scn1aRH/+ control t(3840)=1.471 0.5996
Scn1aRH/+ - 215.63 9.50 11 8 WT control vs. WT HYP t(3840)=1.58 0.5168
WT HYP 215.73 11.52 14 8 Scn1aRH/+ control vs. Scn1aRH/+ SIH t(3840)=4.915 < 0.0001
Scn1aRH/+ SIH 259.85 20.28 13 8 WT HYP vs. Scn1aRH/+ SIH t(3840)=5.216 < 0.0001
WT - 192.56 10.77 14 7 WT control vs. Scn1aRH/+ control t(3840)=3.57 0.0022
Scn1aRH/+ - 224.15 12.66 11 8 WT control vs. WT HYP t(3840)=2.962 0.0183
WT HYP 217.16 12.75 14 8 Scn1aRH/+ control vs. Scn1aRH/+ SIH t(3840)=2.826 0.0281
Scn1aRH/+ SIH 249.58 25.66 13 8 WT HYP vs. Scn1aRH/+ SIH t(3840)=3.833 0.0008
WT - 166.06 5.91 14 7 WT control vs. Scn1aRH/+ control t(3840)=2.514 0.0698
Scn1aRH/+ - 188.31 8.92 11 8 WT control vs. WT HYP t(3840)=1.956 0.2674
WT HYP 182.30 9.45 14 8 Scn1aRH/+ control vs. Scn1aRH/+ SIH t(3840)=2.277 0.1296
Scn1aRH/+ SIH 208.79 21.24 13 8 WT HYP vs. Scn1aRH/+ SIH t(3840)=3.132 0.0105
WT - 153.78 4.79 14 7 WT control vs. Scn1a
RH/+ 
control t(3840)=2.409 0.0924
Scn1aRH/+ - 175.11 7.44 11 8 WT control vs. WT HYP t(3840)=1.581 0.5163
WT HYP 166.91 7.77 14 8 Scn1aRH/+ control vs. Scn1aRH/+ SIH t(3840)=1.958 0.2665
Scn1aRH/+ SIH 192.72 17.57 13 8 WT HYP vs. Scn1aRH/+ SIH t(3840)=3.051 0.0137
WT - 147.60 4.60 14 7 WT control vs. Scn1aRH/+ control t(3840)=1.792 0.3661
Scn1aRH/+ - 163.46 6.23 11 8 WT control vs. WT HYP t(3840)=1.364 0.6795
WT HYP 158.93 8.02 14 8 Scn1aRH/+ control vs. Scn1aRH/+ SIH t(3840)=2.121 0.1874
Scn1aRH/+ SIH 182.55 15.89 13 8 WT HYP vs. Scn1aRH/+ SIH t(3840)=2.792 0.0311
WT - 117.91 5.31 14 7 WT control vs. WT HYP q(48)=1,669 0.6419
Scn1aRH/+ - 124.72 4.24 11 8 WT control vs. Scn1aRH/+ control q(48)=1,086 0.8684
WT HYP 127.91 6.58 13 8 Genotype F (1, 48) = 0,8656 0.3568 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(48)=1,244 0.8155
Scn1aRH/+ SIH 132.51 7.17 14 8 Treatment F (1, 48) = 2,107 0.1532 WT HYP vs. Scn1aRH/+ SIH q(48)=0,7678 0.948
WT - 149.79 8.42 14 8 WT control vs. WT HYP q(54)=0,7188 0.9568
Scn1aRH/+ - 140.59 7.77 14 8 WT control vs. Scn1aRH/+ control q(54)=1,112 0.8603
WT HYP 155.64 9.06 15 8 Genotype F (1, 54) = 0,2123 0.6468 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(54)=2,059 0.4706
Scn1aRH/+ SIH 157.35 7.11 15 8 Treatment F (1, 54) = 1,930 0.1705 WT HYP vs. Scn1aRH/+ SIH q(54)=0,2132 0.9988
 Long-term potentiation in CA1 area of the hippocampus  in Scn1aRH/+ -129:B6
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Mouse model 
and genetic 
background
Experi
ment
Meas
urme
nt
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of 
variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 1.579 0.053 12 5 WT control vs. WT HYP q(43)=0,6265 0.9706
Scn1aRH/+ - 1.510 0.045 11 4 WT control vs. Scn1aRH/+ control q(43)=1,370 0.7676
WT HYP 1.548 0.032 12 5 Treatment F (1, 43) = 0,9651 0.3314 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(43)=2,556 0.2839
Scn1aRH/+ SIH 1.639 0.062 12 4 Genotype F (1, 43) = 0,04681 0.8297 WT HYP vs. Scn1aRH/+ SIH q(43)=1,839 0.5678
WT - 1.473 0.047 12 6 WT control vs. WT HYP q(43)=0,4022 0.9919
Scn1aRH/+ - 1.457 0.021 12 6 WT control vs. Scn1aRH/+ control q(43)=0,4208 0.9907
WT HYP 1.488 0.039 12 5 Treatment F (1, 43) = 3,421 0.0712 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(43)=3,266 0.1118
Scn1aRH/+ SIH 1.584 0.044 11 5 Genotype F (1, 43) = 1,073 0.306 WT HYP vs. Scn1aRH/+ SIH q(43)=2,461 0.3161
WT - 1.380 0.030 12 6 WT control vs. WT HYP q(44)=1,578 0.6817
Scn1aRH/+ - 1.313 0.010 12 7 WT control vs. Scn1aRH/+ control q(44)=2,466 0.3138
WT HYP 1.338 0.024 12 5 Treatment F (1, 44) = 2,951 0.0928 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(44)=5,014 0.005
Scn1aRH/+ SIH 1.450 0.037 12 5 Genotype F (1, 44) = 0,6886 0.4111 WT HYP vs. Scn1aRH/+ SIH q(44)=4,126 0.0274
WT - 1.256 0.025 13 7 WT control vs. WT HYP q(43)=0,4675 0.9874
Scn1aRH/+ - 1.252 0.026 12 6 WT control vs. Scn1aRH/+ control q(43)=0,1419 0.9996
WT HYP 1.269 0.033 12 6 Treatment F (1, 43) = 1,402 0.2429 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(43)=1,855 0.5606
Scn1a
RH/+ SIH 1.308 0.032 10 6 Genotype F (1, 43) = 0,3546 0.5547 WT HYP vs. Scn1a
RH/+ 
SIH q(43)=1,285 0.8002
WT - 1.210 0.021 12 7 WT control vs. WT HYP q(41)=2,008 0.4946
Scn1aRH/+ - 1.175 0.019 11 7 WT control vs. Scn1aRH/+ control q(41)=1,641 0.6548
WT HYP 1.168 0.021 12 6 Treatment F (1, 41) = 2,005 0.1643 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(41)=4,617 0.0114
Scn1aRH/+ SIH 1.280 0.028 10 7 Genotype F (1, 41) = 3,009 0.0903 WT HYP vs. Scn1aRH/+ SIH q(41)=5,026 0.0052
WT - 1.132 0.014 12 5 WT control vs. WT HYP q(44)=0,1466 0.9996
Scn1aRH/+ - 1.116 0.015 11 7 WT control vs. Scn1aRH/+ control q(44)=0,9341 0.9113
WT HYP 1.130 0.012 13 7 Treatment F (1, 44) = 6,953 0.0115 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(44)=5,307 0.0028
Scn1aRH/+ SIH 1.204 0.022 12 7 Genotype F (1, 44) = 3,338 0.0745 WT HYP vs. Scn1aRH/+ SIH q(44)=4,707 0.0093
WT - 1.103 0.021 12 8 WT control vs. WT HYP q(42)=0,3697 0.9936
Scn1aRH/+ - 1.101 0.017 11 6 WT control vs. Scn1aRH/+ control q(42)=0,08919 > 0,9999
WT HYP 1.110 0.015 12 6 Treatment F (1, 42) = 5,196 0.0278 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(42)=4,109 0.0287
Scn1aRH/+ SIH 1.180 0.021 11 8 Genotype F (1, 42) = 3,344 0.0746 WT HYP vs. Scn1aRH/+ SIH q(42)=3,746 0.0531
WT - 1.088 0.019 12 7 WT control vs. WT HYP q(41)=1,117 0.8587
Scn1aRH/+ - 1.065 0.011 11 7 WT control vs. Scn1aRH/+ control q(41)=1,454 0.7341
WT HYP 1.105 0.016 11 6 Treatment F (1, 41) = 18,13 0.0001 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(41)=7,333 < 0,0001
Scn1aRH/+ SIH 1.183 0.016 11 7 Genotype F (1, 41) = 2,939 0.094 WT HYP vs. Scn1aRH/+ SIH q(41)=4,816 0.0078
WT - 1.065 0.021 12 7 WT control vs. WT HYP q(45)=2,642 0.2562
Scn1a
RH/+ - 1.069 0.018 11 5 WT control vs. Scn1a
RH/+ 
control q(45)=0,2418 0.9982
WT HYP 1.111 0.014 12 5 Treatment F (1, 45) = 10,82 0.002 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(45)=3,944 0.0374
Scn1aRH/+ SIH 1.137 0.017 14 7 Genotype F (1, 45) = 0,7715 0.3844 WT HYP vs. Scn1aRH/+ SIH q(45)=1,555 0.6918
WT - 1.054 0.017 12 5 WT control vs. WT HYP q(44)=1,988 0.5025
Scn1aRH/+ - 1.047 0.014 11 6 WT control vs. Scn1aRH/+ control q(44)=0,4376 0.9896
WT HYP 1.085 0.011 12 5 Treatment F (1, 44) = 18,64  < 0,0001 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(44)=6,639 0.0001
Scn1aRH/+ SIH 1.150 0.018 13 8 Genotype F (1, 44) = 3,559 0.0658 WT HYP vs. Scn1aRH/+ SIH q(44)=4,311 0.0196
33E
0.0017
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0.0619
Tuckey's
Two-way 
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Two-way 
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 Paired-pulse ratio in CA1 area of the hippocampus  in Scn1aRH/+ -129:B6
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Mouse model 
and genetic 
background
Experi
ment
Meas
urme
nt
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of 
variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 0.00 0.00 13 3 WT control vs. Scn1a RH/+ control q(1290)=0 > 0,9999
Scn1a RH/+ - 0.00 0.00 12 3 WT control vs. WT HYP q(1290)=0 > 0,9999
WT HYP 0.00 0.00 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=0,077 > 0,9999
Scn1a RH/+ SIH 0.30 0.21 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=0,077 > 0,9999
WT - 1.85 0.82 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,02658 > 0,9999
Scn1a RH/+ - 1.75 1.22 12 3 WT control vs. WT HYP q(1290)=0,1116 0.9998
WT HYP 2.25 0.99 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,305 0.7927
Scn1a RH/+ SIH 6.80 1.53 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=1,176 0.8395
WT - 5.31 1.46 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,4536 0.9886
Scn1a RH/+ - 3.67 1.52 12 3 WT control vs. WT HYP q(1290)=0,01595 > 0,9999
WT HYP 5.25 1.60 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,154 0.4241
Scn1a RH/+ SIH 12.00 2.44 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=1,744 0.6056
WT - 8.23 1.86 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,7087 0.9588
Scn1a RH/+ - 5.67 1.70 12 3 WT control vs. WT HYP q(1290)=0,01772 > 0,9999
WT HYP 8.17 2.08 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,722 0.2181
Scn1a RH/+ SIH 16.20 2.99 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,076 0.4573
WT - 11.00 2.10 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8522 0.9312
Scn1a RH/+ - 7.92 1.94 12 3 WT control vs. WT HYP q(1290)=0,1612 0.9995
WT HYP 11.58 2.44 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,252 0.0987
Scn1a RH/+ SIH 20.50 3.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,304 0.3624
WT - 10.85 2.10 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,349 0.9947
Scn1a RH/+ - 9.58 2.20 12 3 WT control vs. WT HYP q(1290)=0,8948 0.9215
WT HYP 14.08 2.98 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,191 0.0164
Scn1a RH/+ SIH 25.80 3.97 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,028 0.1408
WT - 12.38 2.49 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,01417 > 0,9999
Scn1a RH/+ - 12.33 2.47 12 3 WT control vs. WT HYP q(1290)=1,091 0.8672
WT HYP 16.33 3.57 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,385 0.0106
Scn1a RH/+ SIH 29.30 4.38 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,351 0.0836
WT - 14.23 3.12 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1099 0.9998
Scn1a RH/+ - 13.83 2.70 12 3 WT control vs. WT HYP q(1290)=0,7424 0.9531
WT HYP 16.92 3.14 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,772 0.0042
Scn1a RH/+ SIH 32.30 4.85 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,975 0.0258
WT - 14.62 3.00 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,4057 0.9918
Scn1a RH/+ - 16.08 2.92 12 3 WT control vs. WT HYP q(1290)=0,6821 0.963
WT HYP 17.08 3.10 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,328 0.001
Scn1a RH/+ SIH 36.70 5.01 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,069 0.002
WT - 17.00 3.42 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1843 0.9992
Scn1a RH/+ - 17.67 3.11 12 3 WT control vs. WT HYP q(1290)=0,4837 0.9862
WT HYP 18.75 3.61 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,642 0.0004
Scn1a RH/+ SIH 39.50 5.05 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,362 0.0009
WT - 18.46 3.74 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,0567 > 0,9999
Scn1a RH/+ - 18.67 2.85 12 3 WT control vs. WT HYP q(1290)=0,1506 0.9996
WT HYP 17.92 3.66 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,056 0.0001
Scn1a RH/+ SIH 42.10 4.90 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,249 < 0,0001
WT - 19.08 3.90 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,14 0.9997
Scn1a RH/+ - 19.58 2.75 12 3 WT control vs. WT HYP q(1290)=0,1134 0.9998
WT HYP 18.67 4.11 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,336 < 0,0001
Scn1a RH/+ SIH 44.10 4.91 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,572 < 0,0001
WT - 18.62 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,6821 0.963
Scn1a RH/+ - 21.08 2.62 12 3 WT control vs. WT HYP q(1290)=0,815 0.9392
WT HYP 15.67 3.80 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,051 0.0001
Scn1a RH/+ SIH 44.50 5.12 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=7,451 < 0,0001
WT - 16.46 3.22 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,485 0.72
Scn1a RH/+ - 21.83 2.50 12 3 WT control vs. WT HYP q(1290)=0,2658 0.9976
WT HYP 15.50 4.22 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,16 0.0016
Scn1a RH/+ SIH 41.80 5.35 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,796 < 0,0001
WT - 16.85 3.52 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,448 0.7356
Scn1a RH/+ - 22.08 2.67 12 3 WT control vs. WT HYP q(1290)=0,3721 0.9936
WT HYP 15.50 4.72 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,147 0.0016
Scn1a RH/+ SIH 42.00 6.36 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,848 < 0,0001
WT - 16.15 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,224 0.8225
Scn1a RH/+ - 20.58 2.97 12 3 WT control vs. WT HYP q(1290)=0,2959 0.9968
WT HYP 15.08 4.59 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,94 0.0028
Scn1a RH/+ SIH 39.70 7.02 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,361 < 0,0001
WT - 16.85 3.85 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8257 0.937
Scn1a RH/+ - 19.83 3.16 12 3 WT control vs. WT HYP q(1290)=0,6024 0.974
WT HYP 14.67 4.47 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,134 0.0017
Scn1a RH/+ SIH 39.70 7.69 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,469 < 0,0001
WT - 15.54 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,9568 0.906
Scn1a RH/+ - 19.00 3.33 12 3 WT control vs. WT HYP q(1290)=0,0567 > 0,9999
WT HYP 15.33 4.99 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,117 0.0018
Scn1a RH/+ SIH 38.80 8.12 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,064 0.0001
WT - 16.77 4.17 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1329 0.9997
Scn1a RH/+ - 17.25 3.56 12 3 WT control vs. WT HYP q(1290)=0,8345 0.9351
WT HYP 13.75 4.41 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,285 0.0011
Scn1a RH/+ SIH 37.70 8.70 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,189 < 0,0001
WT - 15.00 3.91 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,5989 0.9745
Scn1a RH/+ - 17.17 3.77 12 3 WT control vs. WT HYP q(1290)=0,8292 0.9362
WT HYP 12.00 3.93 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,911 0.0294
Scn1a RH/+ SIH 32.30 8.37 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,246 0.0012
WT - 13.23 3.77 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,6272 0.9709
Scn1a RH/+ - 15.50 3.80 12 3 WT control vs. WT HYP q(1290)=0,5014 0.9847
WT HYP 11.42 3.57 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,057 0.0218
Scn1a RH/+ SIH 31.20 8.40 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,112 0.0018
WT - 10.92 3.08 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8274 0.9366
Scn1a RH/+ - 13.92 3.87 12 3 WT control vs. WT HYP q(1290)=0,4624 0.9879
WT HYP 9.25 2.66 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,743 0.041
Scn1a RH/+ SIH 28.40 7.97 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=4,949 0.0027
WT - 9.69 2.89 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,122 0.8576
Scn1a RH/+ - 13.75 3.92 12 3 WT control vs. WT HYP q(1290)=0,652 0.9675
WT HYP 7.33 2.46 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,088 0.1283
Scn1a RH/+ SIH 25.70 7.48 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=4,746 0.0045
WT - 7.54 2.39 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,51 0.7095
Scn1a RH/+ - 13.00 3.68 12 3 WT control vs. WT HYP q(1290)=0,010 > 0,9999
WT HYP 7.50 2.75 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,429 0.3148
Scn1a RH/+ SIH 22.40 7.23 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,85 0.0332
WT - 6.77 1.91 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,63 0.6569
Scn1a RH/+ - 12.67 3.93 12 3 WT control vs. WT HYP q(1290)=0,1329 0.9997
WT HYP 7.25 2.81 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,024 0.4799
Scn1a RH/+ SIH 20.50 6.30 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,424 0.0736
WT - 5.69 1.59 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,237 0.8181
Scn1a RH/+ - 10.17 3.24 12 3 WT control vs. WT HYP q(1290)=0,1541 0.9995
WT HYP 6.25 2.54 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,309 0.3607
Scn1a RH/+ SIH 19.10 6.20 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,321 0.0879
WT - 5.08 1.54 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,084 0.8694
Scn1a RH/+ - 9.00 2.96 12 3 WT control vs. WT HYP q(1290)=0,3242 0.9958
WT HYP 6.25 2.93 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,68 0.6347
Scn1a RH/+ SIH 15.50 5.57 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,39 0.3292
WT - 4.85 1.31 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8717 0.9269
Scn1a RH/+ - 8.00 2.82 12 3 WT control vs. WT HYP q(1290)=0,2268 0.9985
WT HYP 5.67 2.42 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,628 0.6578
Scn1a RH/+ SIH 14.30 6.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,231 0.3918
WT - 4.77 1.29 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8009 0.9421
Scn1a RH/+ - 7.67 2.72 12 3 WT control vs. WT HYP q(1290)=0,06378 > 0,9999
WT HYP 5.00 2.29 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,559 0.6881
Scn1a RH/+ SIH 13.70 6.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,248 0.3848
WT - 4.15 1.05 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8327 0.9355
Scn1a RH/+ - 7.17 2.74 12 3 WT control vs. WT HYP q(1290)=0,01949 > 0,9999
WT HYP 4.08 1.61 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,533 0.6993
Scn1a RH/+ SIH 13.10 6.42 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,33 0.3523
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WT - 0.00 0.00 13 3 WT control vs. Scn1a RH/+ control q(1290)=0 > 0,9999
Scn1a RH/+ - 0.00 0.00 12 3 WT control vs. WT HYP q(1290)=0 > 0,9999
WT HYP 0.00 0.00 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=0,077 > 0,9999
Scn1a RH/+ SIH 0.30 0.21 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=0,077 > 0,9999
WT - 1.85 0.82 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,02658 > 0,9999
Scn1a RH/+ - 1.75 1.22 12 3 WT control vs. WT HYP q(1290)=0,1116 0.9998
WT HYP 2.25 0.99 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,305 0.7927
Scn1a RH/+ SIH 6.80 1.53 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=1,176 0.8395
WT - 5.31 1.46 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,4536 0.9886
Scn1a RH/+ - 3.67 1.52 12 3 WT control vs. WT HYP q(1290)=0,01595 > 0,9999
WT HYP 5.25 1.60 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,154 0.4241
Scn1a RH/+ SIH 12.00 2.44 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=1,744 0.6056
WT - 8.23 1.86 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,7087 0.9588
Scn1a RH/+ - 5.67 1.70 12 3 WT control vs. WT HYP q(1290)=0,01772 > 0,9999
WT HYP 8.17 2.08 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,722 0.2181
Scn1a RH/+ SIH 16.20 2.99 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,076 0.4573
WT - 11.00 2.10 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8522 0.9312
Scn1a RH/+ - 7.92 1.94 12 3 WT control vs. WT HYP q(1290)=0,1612 0.9995
WT HYP 11.58 2.44 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,252 0.0987
Scn1a RH/+ SIH 20.50 3.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,304 0.3624
WT - 10.85 2.10 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,349 0.9947
Scn1a RH/+ - 9.58 2.20 12 3 WT control vs. WT HYP q(1290)=0,8948 0.9215
WT HYP 14.08 2.98 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,191 0.0164
Scn1a RH/+ SIH 25.80 3.97 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,028 0.1408
WT - 12.38 2.49 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,01417 > 0,9999
Scn1a RH/+ - 12.33 2.47 12 3 WT control vs. WT HYP q(1290)=1,091 0.8672
WT HYP 16.33 3.57 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,385 0.0106
Scn1a RH/+ SIH 29.30 4.38 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,351 0.0836
WT - 14.23 3.12 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1099 0.9998
Scn1a RH/+ - 13.83 2.70 12 3 WT control vs. WT HYP q(1290)=0,7424 0.9531
WT HYP 16.92 3.14 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,772 0.0042
Scn1a RH/+ SIH 32.30 4.85 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,975 0.0258
WT - 14.62 3.00 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,4057 0.9918
Scn1a RH/+ - 16.08 2.92 12 3 WT control vs. WT HYP q(1290)=0,6821 0.963
WT HYP 17.08 3.10 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,328 0.001
Scn1a RH/+ SIH 36.70 5.01 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,069 0.002
WT - 17.00 3.42 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1843 0.9992
Scn1a RH/+ - 17.67 3.11 12 3 WT control vs. WT HYP q(1290)=0,4837 0.9862
WT HYP 18.75 3.61 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,642 0.0004
Scn1a RH/+ SIH 39.50 5.05 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,362 0.0009
WT - 18.46 3.74 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,0567 > 0,9999
Scn1a RH/+ - 18.67 2.85 12 3 WT control vs. WT HYP q(1290)=0,1506 0.9996
WT HYP 17.92 3.66 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,056 0.0001
Scn1a RH/+ SIH 42.10 4.90 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,249 < 0,0001
WT - 19.08 3.90 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,14 0.9997
Scn1a RH/+ - 19.58 2.75 12 3 WT control vs. WT HYP q(1290)=0,1134 0.9998
WT HYP 18.67 4.11 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,336 < 0,0001
Scn1a RH/+ SIH 44.10 4.91 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,572 < 0,0001
WT - 18.62 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,6821 0.963
Scn1a RH/+ - 21.08 2.62 12 3 WT control vs. WT HYP q(1290)=0,815 0.9392
WT HYP 15.67 3.80 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=6,051 0.0001
Scn1a RH/+ SIH 44.50 5.12 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=7,451 < 0,0001
WT - 16.46 3.22 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,485 0.72
Scn1a RH/+ - 21.83 2.50 12 3 WT control vs. WT HYP q(1290)=0,2658 0.9976
WT HYP 15.50 4.22 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,16 0.0016
Scn1a RH/+ SIH 41.80 5.35 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,796 < 0,0001
WT - 16.85 3.52 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,448 0.7356
Scn1a RH/+ - 22.08 2.67 12 3 WT control vs. WT HYP q(1290)=0,3721 0.9936
WT HYP 15.50 4.72 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,147 0.0016
Scn1a RH/+ SIH 42.00 6.36 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,848 < 0,0001
WT - 16.15 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,224 0.8225
Scn1a RH/+ - 20.58 2.97 12 3 WT control vs. WT HYP q(1290)=0,2959 0.9968
WT HYP 15.08 4.59 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,94 0.0028
Scn1a RH/+ SIH 39.70 7.02 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,361 < 0,0001
WT - 16.85 3.85 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8257 0.937
Scn1a RH/+ - 19.83 3.16 12 3 WT control vs. WT HYP q(1290)=0,6024 0.974
WT HYP 14.67 4.47 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,134 0.0017
Scn1a RH/+ SIH 39.70 7.69 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,469 < 0,0001
WT - 15.54 3.53 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,9568 0.906
Scn1a RH/+ - 19.00 3.33 12 3 WT control vs. WT HYP q(1290)=0,0567 > 0,9999
WT HYP 15.33 4.99 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,117 0.0018
Scn1a RH/+ SIH 38.80 8.12 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,064 0.0001
WT - 16.77 4.17 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,1329 0.9997
Scn1a RH/+ - 17.25 3.56 12 3 WT control vs. WT HYP q(1290)=0,8345 0.9351
WT HYP 13.75 4.41 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=5,285 0.0011
Scn1a RH/+ SIH 37.70 8.70 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=6,189 < 0,0001
WT - 15.00 3.91 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,5989 0.9745
Scn1a RH/+ - 17.17 3.77 12 3 WT control vs. WT HYP q(1290)=0,8292 0.9362
WT HYP 12.00 3.93 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,911 0.0294
Scn1a RH/+ SIH 32.30 8.37 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,246 0.0012
WT - 13.23 3.77 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,6272 0.9709
Scn1a RH/+ - 15.50 3.80 12 3 WT control vs. WT HYP q(1290)=0,5014 0.9847
WT HYP 11.42 3.57 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=4,057 0.0218
Scn1a RH/+ SIH 31.20 8.40 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=5,112 0.0018
WT - 10.92 3.08 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8274 0.9366
Scn1a RH/+ - 13.92 3.87 12 3 WT control vs. WT HYP q(1290)=0,4624 0.9879
WT HYP 9.25 2.66 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,743 0.041
Scn1a RH/+ SIH 28.40 7.97 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=4,949 0.0027
WT - 9.69 2.89 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,122 0.8576
Scn1a RH/+ - 13.75 3.92 12 3 WT control vs. WT HYP q(1290)=0,652 0.9675
WT HYP 7.33 2.46 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=3,088 0.1283
Scn1a RH/+ SIH 25.70 7.48 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=4,746 0.0045
WT - 7.54 2.39 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,51 0.7095
Scn1a RH/+ - 13.00 3.68 12 3 WT control vs. WT HYP q(1290)=0,010 > 0,9999
WT HYP 7.50 2.75 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,429 0.3148
Scn1a RH/+ SIH 22.40 7.23 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,85 0.0332
WT - 6.77 1.91 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,63 0.6569
Scn1a RH/+ - 12.67 3.93 12 3 WT control vs. WT HYP q(1290)=0,1329 0.9997
WT HYP 7.25 2.81 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,024 0.4799
Scn1a RH/+ SIH 20.50 6.30 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,424 0.0736
WT - 5.69 1.59 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,237 0.8181
Scn1a RH/+ - 10.17 3.24 12 3 WT control vs. WT HYP q(1290)=0,1541 0.9995
WT HYP 6.25 2.54 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=2,309 0.3607
Scn1a RH/+ SIH 19.10 6.20 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=3,321 0.0879
WT - 5.08 1.54 13 3 WT control vs. Scn1a RH/+ control q(1290)=1,084 0.8694
Scn1a RH/+ - 9.00 2.96 12 3 WT control vs. WT HYP q(1290)=0,3242 0.9958
WT HYP 6.25 2.93 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,68 0.6347
Scn1a RH/+ SIH 15.50 5.57 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,39 0.3292
WT - 4.85 1.31 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8717 0.9269
Scn1a RH/+ - 8.00 2.82 12 3 WT control vs. WT HYP q(1290)=0,2268 0.9985
WT HYP 5.67 2.42 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,628 0.6578
Scn1a RH/+ SIH 14.30 6.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,231 0.3918
WT - 4.77 1.29 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8009 0.9421
Scn1a RH/+ - 7.67 2.72 12 3 WT control vs. WT HYP q(1290)=0,06378 > 0,9999
WT HYP 5.00 2.29 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,559 0.6881
Scn1a RH/+ SIH 13.70 6.43 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,248 0.3848
WT - 4.15 1.05 13 3 WT control vs. Scn1a RH/+ control q(1290)=0,8327 0.9355
Scn1a RH/+ - 7.17 2.74 12 3 WT control vs. WT HYP q(1290)=0,01949 > 0,9999
WT HYP 4.08 1.61 12 4 Scn1a RH/+ control vs. Scn1a RH/+ SIH q(1290)=1,533 0.6993
Scn1a RH/+ SIH 13.10 6.42 10 4 WT HYP vs. Scn1a RH/+ SIH q(1290)=2,33 0.3523
Excitability in DG area of the hippocampus  in Scn1aRH/+ -129:B6
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0 Tuckey's
20 Tuckey's
40 Tuckey's
60
520 Tuckey's
540 Tuckey's
560 Tuckey's
Tuckey's
460
 < 0,0001F (87, 1247) = 1,774
380 Tuckey's
Two-way 
ANOVA
Genotype
Treatment
Interaction
320 Tuckey's
340 Tuckey's
360 Tuckey's
< 0,0001F (29, 1247) = 27,58
0.0002F (3, 43) = 8,369
260 Tuckey's
280 Tuckey's
300 Tuckey's
200 Tuckey's
220 Tuckey's
240 Tuckey's
140 Tuckey's
Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 17.375 1.012 19 19 WT control vs. Scn1aRH/+ control q(64)=2,064 0.4676
Scn1aRH/+ - 20.946 1.338 22 22 WT control vs. WT HYP q(64)=2,749 0.2203
WT HYP 22.841 1.808 13 13 Treatment F (1, 64) = 45,01  < 0,0001 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(64)=10,88 < 0,0001
Scn1aRH/+ SIH 41.498 3.492 14 14 Genotype F (1, 64) = 32,85  < 0,0001 WT HYP vs. Scn1aRH/+ SIH q(64)=8,768 < 0,0001
WT - 0.029 0.002 19 19 WT control vs. Scn1a
RH/+ 
control q(64)=62,033 0.4808
Scn1a
RH/+ - 0.035 0.002 22 22 WT control vs. WT HYP q(64)=2,762 0.2167
WT HYP 0.038 0.003 13 13 Treatment F (1, 64) = 45,97  < 0,0001 Scn1a
RH/+ 
control vs. Scn1a
RH/+
 SIH q(64)=11,01 < 0,0001
Scn1aRH/+ SIH 0.069 0.006 14 14 Genotype F (1, 64) = 33,20 < 0,0001 WT HYP vs. Scn1aRH/+ SIH q(64)=8,849 < 0,0001
WT - 20.632 1.575 19 19 WT control vs. Scn1aRH/+ control q(64)=1,463 0.7298
Scn1aRH/+ - 23.364 1.244 22 22 WT control vs. WT HYP q(64)=1,928 0.5266
WT HYP 24.769 1.680 13 13 Treatment F (1, 64) = 14,73 0.0003 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(64)=5,85 0.0006
Scn1aRH/+ SIH 35.286 3.739 14 14 Genotype F (1, 64) = 10,02 0.0024 WT HYP vs. Scn1aRH/+ SIH q(64)=4,58 0.01
WT - 26.385 5.112 13 13 WT control vs. Scn1aRH/+ control q(47)=1,145 0.8495
Scn1aRH/+ - 33.500 4.350 16 16 WT control vs. WT HYP q(47)=2,118 0.4472
WT HYP 40.818 7.499 11 11 Treatment F (1, 47) = 27,00  < 0,0001 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(47)=8,419 < 0,0001
Scn1aRH/+ SIH 88.364 10.098 11 11 Genotype F (1, 47) = 16,80 0.0002 WT HYP vs. Scn1aRH/+ SIH q(47)=6,702 0.0001
WT - 0.162 0.020 18 18 WT control vs. Scn1aRH/+ control q(64)=1,244 0.8155
Scn1aRH/+ - 0.181 0.014 23 23 WT control vs. WT HYP q(64)=0,2553 0.9979
WT HYP 0.158 0.018 13 13 Treatment F (1, 64) = 1,623 0.2072 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(64)=2,37 0.3449
Scn1aRH/+ SIH 0.142 0.013 14 14 Genotype F (1, 64) = 0,01061 0.9183 WT HYP vs. Scn1aRH/+ SIH q(64)=0,8281 0.9361
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Interaction F (1, 64) = 15,13 0.0002
0.0039
Tuckey's
Interaction F (1, 64) = 15,58 0.0002
Two-way 
ANOVA
Two-way 
ANOVA
Two-way 
ANOVA
Tuckey's
Tuckey's
F (1, 64) = 3,460 0.0675
F (1, 64) = 1,020 0.3164
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ANOVA
Interaction
Two-way 
ANOVA
Interaction
Interaction
Tuckey's
F (1, 47) = 9,191
Openfield  in Scn1aRH/+ -129:B6
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Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 4.621 2.049 8 8 WT control vs. Scn1aRH/+ control q(40)=2,893 0.1887
Scn1aRH/+ - 13.343 3.374 10 10 WT control vs. WT HYP q(40)=2,945 0.1764
WT HYP 13.031 2.347 13 13 Treatment F (1, 40) = 1,725 0.1965 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(40)=0,4277 0.9902
Scn1aRH/+ SIH 12.200 2.671 13 13 Genotype F (1, 40) = 2,035 0.1615 WT HYP vs. Scn1aRH/+ SIH q(40)=0,3332 0.9953
WT - 2.875 0.833 8 8 WT control vs. Scn1aRH/+ control q(40)=2,042 0.4802
Scn1a
RH/+ - 7.100 1.616 10 10 WT control vs. WT HYP q(40)=5,181 0.0039
WT HYP 6.538 1.169 13 13 Treatment F (1, 40) = 8,361 0.0062 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(40)=0,4486 0.9888
Scn1aRH/+ SIH 7.923 1.579 13 13 Genotype F (1, 40) = 0,05405 0.8174 WT HYP vs. Scn1aRH/+ SIH q(40)=2,985 0.1671
Interaction
Tuckey's
Tuckey's
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Two-way 
ANOVA
F (1, 40) = 2,982 0.0919Interaction
Dark-light in Scn1aRH/+ -129:B6
Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 11.378 2.046 5 5 D1:WT control vs. WT HYP q(162)=1,201 0.9519
Scn1a
RH/+ - 16.495 4.277 8 8 D1:WT control vs. Scn1aRH/+ control q(162)=1,636 0.8207
WT HYP 18.198 3.381 9 9 D1:WT HYP vs. Scn1aRH/+ SIH q(162)=7,625 < 0,0001
Scn1aRH/+ SIH 44.186 8.787 9 9 D1:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=7,376 < 0,0001
WT - 8.933 0.994 5 5 N1:WT control vs. WT HYP q(162)=1,306 0.9293
Scn1aRH/+ - 14.500 2.054 8 8 N1:WT control vs. Scn1aRH/+ control q(162)=2,182 0.5508
WT HYP 18.028 2.064 9 9 N1:WT HYP vs. Scn1aRH/+ SIH q(162)=4,996 0.0032
Scn1aRH/+ SIH 32.644 8.853 9 9 N1:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=4,148 0.0228
WT - 1.467 0.346 5 5 D2:WT control vs. WT HYP q(162)=0,2853 > 0,9999
Scn1a
RH/+ - 2.682 0.583 8 8 D2:WT control vs. Scn1a
RH/+ 
control q(162)=0,4933 0.9996
WT HYP 3.523 0.749 9 9 D2:WT HYP vs. Scn1aRH/+ SIH q(162)=0,7185 0.9966
Scn1aRH/+ SIH 5.292 1.631 9 9 D2:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=0,502 0.9995
WT - 8.883 1.512 5 5 N2:WT control vs. WT HYP q(162)=0,8329 0.9924
Scn1aRH/+ - 12.432 1.509 8 8 N2:WT control vs. Scn1aRH/+ control q(162)=2,371 0.4525
WT HYP 18.769 3.980 9 9 N2:WT HYP vs. Scn1aRH/+ SIH q(162)=3,308 0.1172
Scn1aRH/+ SIH 24.444 4.954 9 9 N2:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=1,611 0.8308
WT - 1.583 0.433 5 5 D3:WT control vs. WT HYP 0.3032 > 0,9999
Scn1a
RH/+ - 2.875 0.326 8 8 D3:WT control vs. Scn1aRH/+ control 0.5897 0.9989
WT HYP 4.042 0.620 9 9 D3:WT HYP vs. Scn1a
RH/+ 
SIH q(162)=0,02932 > 0,9999
Scn1aRH/+ SIH 2.981 0.552 9 9 D3:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=0,3009 > 0,9999
WT - 7.158 1.287 5 5 N3:WT control vs. WT HYP q(162)=1,083 0.9708
Scn1aRH/+ - 11.771 1.119 8 8 N3:WT control vs. Scn1aRH/+ control q(162)=1,339 0.9211
WT HYP 12.741 1.942 9 9 N3:WT HYP vs. Scn1aRH/+ SIH q(162)=1,813 0.741
Scn1aRH/+ SIH 18.356 2.967 9 9 N3:Scn1aRH/+ control vs. Scn1aRH/+ SIH q(162)=1,594 0.8376
ACTIMETER in Scn1aRH/+ -129:B6
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Mouse model 
and genetic 
background
Experi
ment
Meas
urme
nt
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of 
variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 20.718 1.470 13 13 Interaction F (1, 59) = 4,910 0.0306 WT control vs. WT HYP q(59)=0,5149 0.9833
Scn1aRH/+ - 26.629 1.373 16 16 Treatment F (1, 59) = 7,535 0.008 WT control vs. Scn1aRH/+ control q(59)=2,685 0.2398
WT HYP 21.909 1.530 17 17 WT HYP vs. Scn1aRH/+ SIH q(59)=7,555 < 0,0001
Scn1aRH/+ SIH 37.617 3.314 16 16 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(59)=5,106 0.0034
WT - 0.035 0.002 13 13 Interaction F (1, 58) = 5,256 0.0255 WT control vs. WT HYP q(59)=0,5149 0.9833
Scn1aRH/+ - 0.044 0.002 16 16 Treatment F (1, 58) = 8,120 0.006 WT control vs. Scn1aRH/+ control q(59)=2,685 0.2398
WT HYP 0.036 0.003 17 17 WT HYP vs. Scn1aRH/+ SIH q(59)=7,555 < 0,0001
Scn1aRH/+ SIH 0.062 0.005 17 17 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(59)=5,106 0.0034
C1:WT - 124.985 17.737 13 13
C:WT - 302.292 33.575 13 13
C2:WT - 169.739 21.850 13 13
C1: Scn1aRH/+ - 173.400 17.391 16 16
C: Scn1aRH/+ - 254.125 21.591 16 16
C2: Scn1a
RH/+ - 168.594 11.535 16 16
C1:WT HYP 146.712 13.545 17 17
C:WT HYP 292.965 25.432 17 17
C2:WT HYP 152.106 15.605 17 17
C1: Scn1a
RH/+ SIH 178.712 10.768 17 17
C: Scn1aRH/+ SIH 226.194 10.895 17 17
C2: Scn1aRH/+ SIH 188.824 9.170 17 17
EC:WT - 111.170 12.998 10 10
M:WT - 167.830 20.922 10 10
EC: Scn1aRH/+ - 96.100 9.994 15 15
M: Scn1aRH/+ - 144.840 12.114 15 15
EC:WT HYP 112.444 9.542 16 16
M:WT HYP 160.219 11.413 16 16
EC: Scn1aRH/+ SIH 147.471 18.404 14 14
M: Scn1aRH/+ SIH 146.186 12.129 14 14
WT - 0.038 0.002 10 10 Interaction F (1, 51) = 0,4221 0.5188 WT control vs. WT HYP q(51)=1,381 0.7633
Scn1aRH/+ - 0.045 0.003 15 15 Treatment F (1, 51) = 4,350 0.042 WT control vs. Scn1aRH/+ control q(51)=1,666 0.6431
WT HYP 0.043 0.002 16 16 WT HYP vs. Scn1aRH/+ SIH q(51)=2,854 0.1949
Scn1aRH/+ SIH 0.055 0.006 14 14 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(51)=3,235 0.1143
fM:WT - 80.500 9.741 10 10
nM:WT - 117.360 9.051 10 10
fM: Scn1aRH/+ - 68.007 6.451 15 15
nM: Scn1aRH/+ - 103.000 7.704 15 15
fM:WT HYP 68.325 5.244 16 16
nM:WT HYP 100.725 6.523 16 16
fM: Scn1aRH/+ SIH 101.679 12.268 14 14
nM: Scn1aRH/+ SIH 102.336 11.979 14 14
WT - 0.050 0.008 10 10 Interaction F (1, 51) = 6,241 0.0157 WT control vs. WT HYP q(51)=2,689 0.2402
Scn1aRH/+ - 0.041 0.003 15 15 Treatment F (1, 51) = 0,08887 0.7668 WT control vs. Scn1aRH/+ control q(51)=1,994 0.4993
WT HYP 0.039 0.002 16 16 WT HYP vs. Scn1aRH/+ SIH q(51)=2,295 0.3751
Scn1aRH/+ SIH 0.050 0.003 14 14 Scn1aRH/+ control vs. Scn1aRH/+ SIH q(51)=3,069 0.1454
38D
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38B
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38E
not shown
D
is
ta
n
c
e
 t
ra
v
e
ll
e
d
 (
m
)
A
v
e
ra
g
e
 s
p
e
e
d
 (
m
/s
)
T
im
e
 i
n
 t
h
e
 c
h
a
m
b
e
r 
(s
) 
In
te
ra
c
ti
o
n
 t
im
e
 (
s
)
In
te
ra
c
ti
o
n
 t
im
e
 (
s
)
Two-way 
ANOVA
RM- Two 
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ANOVA
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ANOVA
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ANOVA
F (6, 177) = 3,213Interaction
0.9994
F (3, 177) = 
0,005712
Group 
(Treatment-
genotype)
 < 0,0001F (2, 177) = 46,72Chamber
F (3, 102) = 2,157 0.0977
Two-way 
ANOVA
t(177)=0,4147
0.2957
0.9965
0.9947
0.9669
0.0051
WT HYP: C1 vs. C2
Scn1aRH/+ control : C1 vs. C2
WT control: C1 vs. C2 t(177)=1,605
t(177)=0,1912
t(177)=0,2212
Sidak's
Tuckey's
Tuckey's
< 0,0001F (1, 59) = 25,12Genotype
 < 0,0001F (1, 58) = 25,59Genotype
Scn1aRH/+ SIH: C1 vs. C2
0.0457
0.0314
0.0286
0.1277F (3, 102) = 1,941
0.0001F (1, 102) = 15,79
0.2277F (3, 102) = 1,468
Scn1aRH/+ control : EC vs. M
WT HYP: EC vs. M
Scn1aRH/+ SIH: EC vs. M
Sidak's
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Scn1aRH/+ SIH: fM vs. nM t(102)=0,05357 > 0,9999
Group 
(Treatment-
genotype) > 0,9999
Sidak's
t(102)=2,540 0.0495
Scn1aRH/+ control : fM vs. nM t(102)=2,953 0.0155
WT HYP: fM vs. nM t(102)=2,824 0.0226
Interaction F (3, 102) = 1,905 0.1335
WT control: fM vs. nM
Cage F (1, 102) = 17,38 < 0,0001
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Three-chamber social interaction test in Scn1aRH/+ -129:B6
Social 
Novelty 
phase
 
197 
 
Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
D1 17.554 2.501 76 19
D2 5.293 0.683 76 19
D1 16.296 2.391 92 23
D2 6.296 0.910 92 23
D1 17.810 2.353 88 22
D2 3.463 0.332 88 22
D1 29.068 3.569 84 21
D2 9.340 1.617 84 21
WT - 17.554 2.501 76 19 Cue task 1: WT control vs. WT HYP q(672)=0,6033 0.9739
Scn1aRH/+ - 17.810 2.353 88 22
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,08600 > 0,9999
WT HYP 16.296 2.391 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=6,290 < 0,0001
Scn1aRH/+ SIH 29.068 3.569 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=5,485 0.0007
WT - 5.293 0.683 76 19 Cue task 2: WT control vs. WT HYP q(672)=0,4805 0.9865
Scn1aRH/+ - 3.463 0.332 88 22
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=0,6144 0.6144
WT HYP 6.296 0.910 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=1,499 0.7138
Scn1aRH/+ SIH 9.340 1.617 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,864 0.1798
WT - 0.128 0.006 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 1: WT control vs. WT HYP q(672)=0,8557 0.9305
Scn1aRH/+ - 0.132 0.006 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,5562 0.1121
WT HYP 0.134 0.006 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=4,211 0.0159
Scn1aRH/+ SIH 0.104 0.006 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=3,867 0.0324
WT - 0.146 0.009 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 2: WT control vs. WT HYP q(672)=1,016 0.8897
Scn1aRH/+ - 0.138 0.008 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=1,068 0.8745
WT HYP 0.138 0.009 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=2,460 0.3039
Scn1aRH/+ SIH 0.121 0.007 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,370 0.3371
WT - 2.970763 0.4965251 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 1: WT control vs. WT HYP q(664)=0,7936 0.9435
Scn1aRH/+ - 2.653614 0.3747214 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(664)=0,7803 0.9461
WT HYP 2.644679 0.4470432 84 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(664)=4,279 0.0137
Scn1aRH/+ SIH 4.338921 0.6543971 88 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=4,307 0.0129
WT - 1.223474 0.2069968 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 2: WT control vs. WT HYP q(664)=0,3639 0.994
Scn1aRH/+ - 0.5581932 0.075622 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(664)=1,637 0.654
WT HYP 1.073941 0.2038943 84 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(664)=1,62 0.6616
Scn1aRH/+ SIH 1.715159 0.3986418 88 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=2,957 0.1571
D1 32.04473 3.67175 76 19 WT: Training 1 vs. Training 2 q(1008)=9,827 < 0,0001
D2 8.242105 0.8416948 76 19 WT: Training 1 vs. Training 3 q(1008)=10,24 < 0,0001
WT: Training 1 vs. Training 4 q(1008)=9,948 < 0,0001
WT: Training 2 vs. Training 3 q(1008)=0,4107 0.9915
WT: Training 2 vs. Training 4 q(1008)=0,1211 0.9998
WT: Training 3 vs. Training 4 q(1008)=0,2896 0.997
D1 32.22717 3.422416 92 23 WT HYP: Training 1 vs. Training 2 q(1008)=9,399 < 0,0001
D2 11.53696 1.807323 92 23 WT HYP: Training 1 vs. Training 3 q(1008)=10,77 < 0,0001
WT HYP: Training 1 vs. Training 4 q(1008)=11,46 < 0,0001
WT HYP:  Training 2 vs. Training 3 q(1008)=1,374 0.7658
WT HYP: Training 2 vs. Training 4 q(1008)=2,061 0.4637
WT HYP: Training 3 vs. Training 4 q(1008)=0,6878 0.9621
D1 29.22955 3.296376 88 22
Scn1aRH/+ control: Training 1 vs. 
Training 2
q(1008)=7,948 < 0,0001
D2 11.33977 1.36383 88 22
Scn1aRH/+control: Training 1 vs. 
Training 3
q(1008)=9,127 < 0,0001
Scn1aRH/+ control: Training 1 vs. 
Training 4
q(1008)=10,2 < 0,0001
Scn1aRH/+ control: Training 2 vs. 
Training 3
q(1008)=1,179 0.8383
Scn1aRH/+ control: Training 2 vs. 
Training 4
q(1008)=2,254 0.3827
Scn1aRH/+ control: Training 3 vs. 
Training 4
q(1008)=1,074 0.8725
D1 57.88572 3.629017 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 2 q(1008)=12,54 < 0,0001
D2 28.98571 3.359673 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 3 q(1008)=13,56 < 0,0001
Scn1aRH/+ SIH: Training 1 vs. Training 4 q(1008)=14,02 < 0,0001
Scn1aRH/+ SIH: Training 2 vs. Training 3 q(1008)=1,014 0.8903
Scn1aRH/+ SIH: Training 2 vs. Training 4 q(1008)=1,472 0.7256
Scn1aRH/+ SIH: Training 3 vs. Training 4 q(1008)=0,4573 0.9883
WT -
67.88421 6.222804 19 19
Interaction F (9, 246) = 1,007 P = 0,4351 Trial 1: WT control vs. WT HYP q(328)=1,16 0.845
Scn1aRH/+ -
64 6.950537 22 22
Trial F (3, 246) = 58,27 P < 0,0001
Trial 1: WT control vs. Scn1aRH/+ 
control
q(328)=0,6534 0.9672
WT HYP
61.06087 6.284087 23 23
Trial 1: WT HYP vs. Scn1aRH/+ SIH q(328)=3,356 0.0844
Scn1aRH/+ SIH
80.05454 4.602327 22 22
Trial 1: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(328)=2,805 0.1962
t1-D1
67.88421 6.222804 19 19
t2-D1
27.94737 7.072909 19 19
t1-D1
64 6.950537 22 22
t2-D1
24.32727 5.898617 22 22
t1-D1
61.06087 6.284087 23 23
t2-D1
32.18696 7.241072 23 23
t1-D1
80.05454 4.602327 22 22
t2-D1
55.62727 7.725384 22 22
WT - 32.04473 3.67175 76 19 Training 1: WT control vs. WT HYP q(1344)=0,07479 > 0,9999
Scn1aRH/+ - 32.22717 3.422416 92 23
Training 1: WT control vs. Scn1aRH/+ 
control
q(1344)=1,142 0.8508
WT HYP 29.22955 3.296376 88 22 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1344)=10,8 < 0,0001
Scn1aRH/+ SIH 57.88572 3.629017 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=11,94 < 0,0001
WT - 8.242105 0.8416948 76 19 Training 2:  WT control vs. WT HYP q(1344)=1,351 0.775
Scn1aRH/+ - 11.53696 1.807323 92 23
Training 2: WT control vs. Scn1aRH/+ 
control
q(1344)=1,257 0.8107
WT HYP 11.33977 1.36383 88 22 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,347 < 0,0001
Scn1aRH/+ SIH 28.98571 3.359673 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,351 < 0,0001
WT - 7.247368 1.002153 76 19 Training 3:  WT control vs. WT HYP q(1344)=0,5188 0.9831
Scn1aRH/+ - 8.513043 1.087739 92 23
Training 3:WT control vs. Scn1aRH/+ 
control
q(1344)=0,5834 0.9763
WT HYP 8.685227 1.229834 88 22 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1344)=7,636 < 0,0001
Scn1aRH/+ SIH 26.64881 3.134997 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,483 < 0,0001
WT - 7.948684 1.358431 76 19 Training 4: WT control vs. WT HYP q(1344)=0,3893 0.9927
Scn1aRH/+ - 6.998913 1.016919 92 23
Training 4: WT control vs. Scn1aRH/+ 
control
q(1344)=0,6824 0.963
WT HYP 6.267045 0.7822427 88 22 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,83 < 0,0001
Scn1aRH/+ SIH 25.59524 3.211734 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=8,051 < 0,0001
WT - 0.1731 0.0064 76 19 Training 1: WT control vs. WT HYP q(1296)=1,406 0.7528
Scn1aRH/+ - 0.1573 0.0058 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=2,347 0.3455
WT HYP 0.1634 0.0069 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,189 0.0164
Scn1aRH/+ SIH 0.1915 0.0056 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=5,224 0.0013
WT - 0.1398 0.0066 76 19 Training 2:  WT control vs. WT HYP q(1296)=0,6093 0.9732
Scn1aRH/+ - 0.1388 0.0061 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=0,1489 0.9996
WT HYP 0.1440 0.0078 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=3,484 0.0662
Scn1aRH/+ SIH 0.1673 0.0063 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,361 0.0112
WT - 0.1197 0.0073 76 19 Training 3:  WT control vs. WT HYP q(1296)=4,268 0.0138
Scn1aRH/+ - 0.1390 0.0067 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=2,881 0.175
WT HYP 0.1490 0.0079 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=3,127 0.1207
Scn1aRH/+ SIH 0.1699 0.0062 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,727 0.0047
WT - 0.1255 0.0065 76 19 Training 4: WT control vs. WT HYP q(1296)=2,341 0.3479
Scn1aRH/+ - 0.1299 0.0073 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,6571 0.9667
WT HYP 0.1416 0.0076 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,775 0.0042
Scn1aRH/+ SIH 0.1735 0.0057 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=6,674 < 0,0001
WT - 6.460737 0.7937213 76 19 Training 1: WT control vs. WT HYP q(1296)=0,4226 0.9907
Scn1aRH/+ - 5.556216 0.6823414 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=1,65 0.6481
WT HYP 6.23138 0.6989641 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=10,46 < 0,0001
Scn1aRH/+ SIH 11.68935 0.8374145 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=11,62 < 0,0001
WT - 1.315329 0.1638174 76 19 Training 2:  WT control vs. WT HYP q(1296)=1,384 0.7616
Scn1aRH/+ - 1.921886 0.2769157 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=1,106 0.8625
WT HYP 2.066435 0.364425 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,731 < 0,0001
Scn1aRH/+ SIH 6.10242 0.7526377 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,921 < 0,0001
WT - 1.139329 0.2044359 76 19 Training 3:  WT control vs. WT HYP q(1296)=0,8549 0.9307
Scn1aRH/+ - 1.435739 0.2222679 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=0,5407 0.981
WT HYP 1.603261 0.2461549 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=8,188 < 0,0001
Scn1aRH/+ SIH 5.877432 0.7365466 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=8,416 < 0,0001
WT - 1.295526 0.2833215 76 19 Training 4: WT control vs. WT HYP q(1296)=0,1389 0.9997
Scn1aRH/+ - 1.025261 0.1717624 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,493 0.9855
WT HYP 1.22013 0.2120321 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,513 < 0,0001
Scn1aRH/+ SIH 5.142352 0.7405574 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,801 < 0,0001
WT: LEFT 17.11351 1.590523 19 19 WT: LEFT vs. TARGET q(243)=14,33 < 0,0001
WT: TARGET 56.76281 3.567275 19 19 WT:  TARGET vs. RIGHT q(243)=14,91 < 0,0001
WT: RIGHT 15.52632 2.157894 19 19
WT: OPPOSITE 10.5 2.111683 19 19
WT: LEFT 24.55077 2.435804 23 23 WT HYP: LEFT vs. TARGET q(243)=10,46 < 0,0001
WT: TARGET 50.85536 2.845297 23 23 WT  HYP:  TARGET vs. RIGHT q(243)=14,58 < 0,0001
WT: RIGHT 14.20072 1.664953 23 23
WT: OPPOSITE 10.05507 1.590904 23 23
Scn1aRH/+: LEFT 19.53106 1.379024 22 22 Scn1aRH/+:  LEFT vs. TARGET q(243)=13,82 < 0,0001
Scn1aRH/+: 
TARGET
55.06091 3.040268 22 22 Scn1aRH/+:   TARGET vs. RIGHT q(243)=15,49 < 0,0001
Scn1aRH/+: 
RIGHT
15.24242 2.271501 22 22
Scn1aRH/+: 
OPPOSITE
10.03061 1.408996 22 22
Scn1aRH/+: LEFT 26.3889 2.395459 21 21 Scn1aRH/+ SIH:  LEFT vs. TARGET q(243)=3,55 0.0608
Scn1aRH/+: 
TARGET
35.73079 2.968656 21 21 Scn1aRH/+ SIH:   TARGET vs. RIGHT q(243)=6,508 < 0,0001
Scn1aRH/+: 
RIGHT
18.60619 1.648541 21 21
Scn1aRH/+: 
OPPOSITE
19.00603 1.901427 21 21
WT: TARGET - 56.76281 3.567275 19 19 Interaction F (9, 243) = 6,353 < 0,0001 Target: WT control vs. WT HYP q(324)=2,58 0.3488
Scn1aRH/+: 
TARGET
- 50.85536 2.845297 23 23 Quadrant F (3, 243) = 166,1 < 0,0001
Target: WT control vs. Scn1aRH/+ 
control
q(324)=0,7359 0.9961
WT: TARGET HYP 55.06091 3.040268 22 22 Target: WT HYP vs. Scn1aRH/+ SIH q(324)=6,786 < 0,0001
Scn1aRH/+: 
TARGET
SIH 35.73079 2.968656 21 21
Target: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(324)=8,58 < 0,0001
WT - 56.76281 3.567275 19 19 -
Chance level 25.000 -
WT HYP 55.06091 3.040268 22 22 -
Chance level 25.000 -
Scn1aRH/+ - 50.85536 2.845297 23 23 -
Chance level 25.000 -
Scn1aRH/+ SIH 35.73079 2.968656 21 21 -
Chance level 25.000 -
WT - 13.737 0.908 19 19 Interaction F (1, 81) = 8,504 0.0046 WT control vs. WT HYP q(81)=2,722 0.2259
Scn1aRH/+ - 13.182 0.755 22 22 Treatment F (1, 81) = 32,03  < 0,0001  WT control vs. Scn1aRH/+ control q(81)=0,626 0.9709
WT HYP 11.348 1.055 23 23 WT HYP vs. Scn1aRH/+ SIH q(81)=6,593 < 0,0001
Scn1aRH/+ SIH 5.714 0.673 21 21  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(81)=8,646 < 0,0001
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Probe test
RM-Two 
Way 
ANOVA
Tuckey's
Training Day F (3, 1008) = 117,0 < 0,0001
Group (Treatment-genotype) F (3, 336) = 55,50
0.15F (3, 81) = 1,820
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D3 3.134997 84 21
D4 25.59524
F (9, 1008) = 1,063
Tuckey's
D1
< 0,0001
Scn1aRH/+:  TARGET vs. OPPOSITE q(243)=17,52 < 0,0001
Scn1aRH/+SIH :  TARGET vs. 
OPPOSITE
0.0001
0.3877
< 0,0001
Two-Way 
RM ANOVA
23
Tuckey's
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Scn1aRH/+
F (3, 336) = 7,057
< 0,0001F (1, 336) = 101,8
F (3, 336) = 55,50
8.513043 1.087739 92
3.211734 84 21
22
Scn1aRH/+
19761.0021537.247368
Tuckey's26.64881
D2
Tuckey's
SIH
- Tuckey's
Tuckey's
921.0169196.998913
Training Day
Interaction
8.685227
D3
Group (Treatment-genotype) F (3, 340) = 54,81 < 0,0001
D4
Two-Way 
RM ANOVA
Interaction F (9, 1008) = 1,063 0.3877
D1
Tuckey's
Group (Treatment-genotype) F (3, 332) = 4,410 0.0047
Group (Treatment-genotype)
< 0,0001F (3, 1008) = 117,0
Tuckey's
P < 0,0001F (3, 82) = 15,95Seizures
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0.0001F (3, 336) = 7,057
< 0,0001F (1, 336) = 101,8
-
Group (Treatment-genotype)
Seizures F (3, 336) = 4,919 0.0023
t(20)=3,615 0.0017 - - -
- -
F (1, 81) = 12,63
Tuckey's
Scn1aRH/+ SIH: Cue task 1 vs. Cue 
task 2
Sidak's t(336)=7,042 < 0,0001
< 0,0001t(336)=5,242Sidak's
Scn1aRH/+ control : Cue task 1 vs. Cue 
task 2
t(336)=4,163 0.0002
0.0009t(336)=3,736Sidak'sWT HYP: Cue task 1 vs. Cue task 2
WT control : Cue task 1 vs. Cue task 2
q(246)=7,257
q(246)=6,789
0.0096
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< 0,0001
< 0,0001
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39B
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Trial
Interaction
P < 0,0001F (3, 82) = 15,95
P < 0,0001F (3, 246) = 58,27
P = 0,4351F (9, 246) = 1,007
WT control: Trial1 vs.Trial 2
Scn1aRH/+ control : Trial1 vs.Trial 2
WT HYP : Trial1 vs.Trial 2
Scn1aRH/+ SIH: Trial1 vs.Trial 2
Tuckey's
q(246)=4,468
q(246)=5,400
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Mouse model 
and genetic 
background
Experi
ment
M
e
a
s
u
r
m
e
n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
D1 17.554 2.501 76 19
D2 5.293 0.683 76 19
D1 16.296 2.391 92 23
D2 6.296 0.910 92 23
D1 17.810 2.353 88 22
D2 3.463 0.332 88 22
D1 29.068 3.569 84 21
D2 9.340 1.617 84 21
WT - 17.554 2.501 76 19 Cue task 1: WT control vs. WT HYP q(672)=0,6033 0.9739
Scn1aRH/+ - 17.810 2.353 88 22
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,08600 > 0,9999
WT HYP 16.296 2.391 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=6,290 < 0,0001
Scn1aRH/+ SIH 29.068 3.569 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=5,485 0.0007
WT - 5.293 0.683 76 19 Cue task 2: WT control vs. WT HYP q(672)=0,4805 0.9865
Scn1aRH/+ - 3.463 0.332 88 22
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=0,6144 0.6144
WT HYP 6.296 0.910 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=1,499 0.7138
Scn1aRH/+ SIH 9.340 1.617 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,864 0.1798
WT - 0.128 0.006 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 1: WT control vs. WT HYP q(672)=0,8557 0.9305
Scn1aRH/+ - 0.132 0.006 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,5562 0.1121
WT HYP 0.134 0.006 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=4,211 0.0159
Scn1aRH/+ SIH 0.104 0.006 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=3,867 0.0324
WT - 0.146 0.009 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 2: WT control vs. WT HYP q(672)=1,016 0.8897
Scn1aRH/+ - 0.138 0.008 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=1,068 0.8745
WT HYP 0.138 0.009 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=2,460 0.3039
Scn1aRH/+ SIH 0.121 0.007 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,370 0.3371
WT - 2.970763 0.4965251 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 1: WT control vs. WT HYP q(664)=0,7936 0.9435
Scn1aRH/+ - 2.653614 0.3747214 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(664)=0,7803 0.9461
WT HYP 2.644679 0.4470432 84 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(664)=4,279 0.0137
Scn1aRH/+ SIH 4.338921 0.6543971 88 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=4,307 0.0129
WT - 1.223474 0.2069968 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 2: WT control vs. WT HYP q(664)=0,3639 0.994
Scn1aRH/+ - 0.5581932 0.075622 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(664)=1,637 0.654
WT HYP 1.073941 0.2038943 84 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(664)=1,62 0.6616
Scn1aRH/+ SIH 1.715159 0.3986418 88 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=2,957 0.1571
D1 32.04473 3.67175 76 19 WT: Training 1 vs. Training 2 q(1008)=9,827 < 0,0001
D2 8.242105 0.8416948 76 19 WT: Training 1 vs. Training 3 q(1008)=10,24 < 0,0001
WT: Training 1 vs. Training 4 q(1008)=9,948 < 0,0001
WT: Training 2 vs. Training 3 q(1008)=0,4107 0.9915
WT: Training 2 vs. Training 4 q(1008)=0,1211 0.9998
WT: Training 3 vs. Training 4 q(1008)=0,2896 0.997
D1 32.22717 3.422416 92 23 WT HYP: Training 1 vs. Training 2 q(1008)=9,399 < 0,0001
D2 11.53696 1.807323 92 23 WT HYP: Training 1 vs. Training 3 q(1008)=10,77 < 0,0001
WT HYP: Training 1 vs. Training 4 q(1008)=11,46 < 0,0001
WT HYP:  Training 2 vs. Training 3 q(1008)=1,374 0.7658
WT HYP: Training 2 vs. Training 4 q(1008)=2,061 0.4637
WT HYP: Training 3 vs. Training 4 q(1008)=0,6878 0.9621
D1 29.22955 3.296376 88 22
Scn1aRH/+ control: Training 1 vs. 
Training 2
q(1008)=7,948 < 0,0001
D2 11.33977 1.36383 88 22
Scn1aRH/+control: Training 1 vs. 
Training 3
q(1008)=9,127 < 0,0001
Scn1aRH/+ control: Training 1 vs. 
Training 4
q(1008)=10,2 < 0,0001
Scn1aRH/+ control: Training 2 vs. 
Training 3
q(1008)=1,179 0.8383
Scn1aRH/+ control: Training 2 vs. 
Training 4
q(1008)=2,254 0.3827
Scn1aRH/+ control: Training 3 vs. 
Training 4
q(1008)=1,074 0.8725
D1 57.88572 3.629017 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 2 q(1008)=12,54 < 0,0001
D2 28.98571 3.359673 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 3 q(1008)=13,56 < 0,0001
Scn1aRH/+ SIH: Training 1 vs. Training 4 q(1008)=14,02 < 0,0001
Scn1aRH/+ SIH: Training 2 vs. Training 3 q(1008)=1,014 0.8903
Scn1aRH/+ SIH: Training 2 vs. Training 4 q(1008)=1,472 0.7256
Scn1aRH/+ SIH: Training 3 vs. Training 4 q(1008)=0,4573 0.9883
WT -
67.88421 6.222804 19 19
Interaction F (9, 246) = 1,007 P = 0,4351 Trial 1: WT control vs. WT HYP q(328)=1,16 0.845
Scn1aRH/+ -
64 6.950537 22 22
Trial F (3, 246) = 58,27 P < 0,0001
Trial 1: WT control vs. Scn1aRH/+ 
control
q(328)=0,6534 0.9672
WT HYP
61.06087 6.284087 23 23
Trial 1: WT HYP vs. Scn1aRH/+ SIH q(328)=3,356 0.0844
Scn1aRH/+ SIH
80.05454 4.602327 22 22
Trial 1: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(328)=2,805 0.1962
t1-D1
67.88421 6.222804 19 19
t2-D1
27.94737 7.072909 19 19
t1-D1
64 6.950537 22 22
t2-D1
24.32727 5.898617 22 22
t1-D1
61.06087 6.284087 23 23
t2-D1
32.18696 7.241072 23 23
t1-D1
80.05454 4.602327 22 22
t2-D1
55.62727 7.725384 22 22
WT - 32.04473 3.67175 76 19 Training 1: WT control vs. WT HYP q(1344)=0,07479 > 0,9999
Scn1aRH/+ - 32.22717 3.422416 92 23
Training 1: WT control vs. Scn1aRH/+ 
control
q(1344)=1,142 0.8508
WT HYP 29.22955 3.296376 88 22 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1344)=10,8 < 0,0001
Scn1aRH/+ SIH 57.88572 3.629017 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=11,94 < 0,0001
WT - 8.242105 0.8416948 76 19 Training 2:  WT control vs. WT HYP q(1344)=1,351 0.775
Scn1aRH/+ - 11.53696 1.807323 92 23
Training 2: WT control vs. Scn1aRH/+ 
control
q(1344)=1,257 0.8107
WT HYP 11.33977 1.36383 88 22 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,347 < 0,0001
Scn1aRH/+ SIH 28.98571 3.359673 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,351 < 0,0001
WT - 7.247368 1.002153 76 19 Training 3:  WT control vs. WT HYP q(1344)=0,5188 0.9831
Scn1aRH/+ - 8.513043 1.087739 92 23
Training 3:WT control vs. Scn1aRH/+ 
control
q(1344)=0,5834 0.9763
WT HYP 8.685227 1.229834 88 22 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1344)=7,636 < 0,0001
Scn1aRH/+ SIH 26.64881 3.134997 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,483 < 0,0001
WT - 7.948684 1.358431 76 19 Training 4: WT control vs. WT HYP q(1344)=0,3893 0.9927
Scn1aRH/+ - 6.998913 1.016919 92 23
Training 4: WT control vs. Scn1aRH/+ 
control
q(1344)=0,6824 0.963
WT HYP 6.267045 0.7822427 88 22 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,83 < 0,0001
Scn1aRH/+ SIH 25.59524 3.211734 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=8,051 < 0,0001
WT - 0.1731 0.0064 76 19 Training 1: WT control vs. WT HYP q(1296)=1,406 0.7528
Scn1aRH/+ - 0.1573 0.0058 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=2,347 0.3455
WT HYP 0.1634 0.0069 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,189 0.0164
Scn1aRH/+ SIH 0.1915 0.0056 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=5,224 0.0013
WT - 0.1398 0.0066 76 19 Training 2:  WT control vs. WT HYP q(1296)=0,6093 0.9732
Scn1aRH/+ - 0.1388 0.0061 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=0,1489 0.9996
WT HYP 0.1440 0.0078 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=3,484 0.0662
Scn1aRH/+ SIH 0.1673 0.0063 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,361 0.0112
WT - 0.1197 0.0073 76 19 Training 3:  WT control vs. WT HYP q(1296)=4,268 0.0138
Scn1aRH/+ - 0.1390 0.0067 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=2,881 0.175
WT HYP 0.1490 0.0079 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=3,127 0.1207
Scn1aRH/+ SIH 0.1699 0.0062 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,727 0.0047
WT - 0.1255 0.0065 76 19 Training 4: WT control vs. WT HYP q(1296)=2,341 0.3479
Scn1aRH/+ - 0.1299 0.0073 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,6571 0.9667
WT HYP 0.1416 0.0076 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,775 0.0042
Scn1aRH/+ SIH 0.1735 0.0057 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=6,674 < 0,0001
WT - 6.460737 0.7937213 76 19 Training 1: WT control vs. WT HYP q(1296)=0,4226 0.9907
Scn1aRH/+ - 5.556216 0.6823414 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=1,65 0.6481
WT HYP 6.23138 0.6989641 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=10,46 < 0,0001
Scn1aRH/+ SIH 11.68935 0.8374145 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=11,62 < 0,0001
WT - 1.315329 0.1638174 76 19 Training 2:  WT control vs. WT HYP q(1296)=1,384 0.7616
Scn1aRH/+ - 1.921886 0.2769157 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=1,106 0.8625
WT HYP 2.066435 0.364425 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,731 < 0,0001
Scn1aRH/+ SIH 6.10242 0.7526377 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,921 < 0,0001
WT - 1.139329 0.2044359 76 19 Training 3:  WT control vs. WT HYP q(1296)=0,8549 0.9307
Scn1aRH/+ - 1.435739 0.2222679 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=0,5407 0.981
WT HYP 1.603261 0.2461549 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=8,188 < 0,0001
Scn1aRH/+ SIH 5.877432 0.7365466 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=8,416 < 0,0001
WT - 1.295526 0.2833215 76 19 Training 4: WT control vs. WT HYP q(1296)=0,1389 0.9997
Scn1aRH/+ - 1.025261 0.1717624 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,493 0.9855
WT HYP 1.22013 0.2120321 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,513 < 0,0001
Scn1aRH/+ SIH 5.142352 0.7405574 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,801 < 0,0001
WT: LEFT 17.11351 1.590523 19 19 WT: LEFT vs. TARGET q(243)=14,33 < 0,0001
WT: TARGET 56.76281 3.567275 19 19 WT:  TARGET vs. RIGHT q(243)=14,91 < 0,0001
WT: RIGHT 15.52632 2.157894 19 19
WT: OPPOSITE 10.5 2.111683 19 19
WT: LEFT 24.55077 2.435804 23 23 WT HYP: LEFT vs. TARGET q(243)=10,46 < 0,0001
WT: TARGET 50.85536 2.845297 23 23 WT  HYP:  TARGET vs. RIGHT q(243)=14,58 < 0,0001
WT: RIGHT 14.20072 1.664953 23 23
WT: OPPOSITE 10.05507 1.590904 23 23
Scn1aRH/+: LEFT 19.53106 1.379024 22 22 Scn1aRH/+:  LEFT vs. TARGET q(243)=13,82 < 0,0001
Scn1aRH/+: 
TARGET
55.06091 3.040268 22 22 Scn1aRH/+:   TARGET vs. RIGHT q(243)=15,49 < 0,0001
Scn1aRH/+: 
RIGHT
15.24242 2.271501 22 22
Scn1aRH/+: 
OPPOSITE
10.03061 1.408996 22 22
Scn1aRH/+: LEFT 26.3889 2.395459 21 21 Scn1aRH/+ SIH:  LEFT vs. TARGET q(243)=3,55 0.0608
Scn1aRH/+: 
TARGET
35.73079 2.968656 21 21 Scn1aRH/+ SIH:   TARGET vs. RIGHT q(243)=6,508 < 0,0001
Scn1aRH/+: 
RIGHT
18.60619 1.648541 21 21
Scn1aRH/+: 
OPPOSITE
19.00603 1.901427 21 21
WT: TARGET - 56.76281 3.567275 19 19 Interaction F (9, 243) = 6,353 < 0,0001 Target: WT control vs. WT HYP q(324)=2,58 0.3488
Scn1aRH/+: 
TARGET
- 50.85536 2.845297 23 23 Quadrant F (3, 243) = 166,1 < 0,0001
Target: WT control vs. Scn1aRH/+ 
control
q(324)=0,7359 0.9961
WT: TARGET HYP 55.06091 3.040268 22 22 Target: WT HYP vs. Scn1aRH/+ SIH q(324)=6,786 < 0,0001
Scn1aRH/+: 
TARGET
SIH 35.73079 2.968656 21 21
Target: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(324)=8,58 < 0,0001
WT - 56.76281 3.567275 19 19 -
Chance level 25.000 -
WT HYP 55.06091 3.040268 22 22 -
Chance level 25.000 -
Scn1aRH/+ - 50.85536 2.845297 23 23 -
Chance level 25.000 -
Scn1aRH/+ SIH 35.73079 2.968656 21 21 -
Chance level 25.000 -
WT - 13.737 0.908 19 19 Interaction F (1, 81) = 8,504 0.0046 WT control vs. WT HYP q(81)=2,722 0.2259
Scn1aRH/+ - 13.182 0.755 22 22 Treatment F (1, 81) = 32,03  < 0,0001  WT control vs. Scn1aRH/+ control q(81)=0,626 0.9709
WT HYP 11.348 1.055 23 23 WT HYP vs. Scn1aRH/+ SIH q(81)=6,593 < 0,0001
Scn1aRH/+ SIH 5.714 0.673 21 21  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(81)=8,646 < 0,0001
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Probe test
RM-Two 
Way 
ANOVA
Tuckey's
Training Day F (3, 1008) = 117,0 < 0,0001
Group (Treatment-genotype) F (3, 336) = 55,50
0.15F (3, 81) = 1,820
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D3 3.134997 84 21
D4 25.59524
F (9, 1008) = 1,063
Tuckey's
D1
< 0,0001
Scn1aRH/+:  TARGET vs. OPPOSITE q(243)=17,52 < 0,0001
Scn1aRH/+SIH :  TARGET vs. 
OPPOSITE
0.0001
0.3877
< 0,0001
Two-Way 
RM ANOVA
23
Tuckey's
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Scn1aRH/+
F (3, 336) = 7,057
< 0,0001F (1, 336) = 101,8
F (3, 336) = 55,50
8.513043 1.087739 92
3.211734 84 21
22
Scn1aRH/+
19761.0021537.247368
Tuckey's26.64881
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Tuckey's
921.0169196.998913
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Interaction
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Group (Treatment-genotype) F (3, 340) = 54,81 < 0,0001
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Tuckey's
Group (Treatment-genotype) F (3, 332) = 4,410 0.0047
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P < 0,0001F (3, 82) = 15,95Seizures
Two-Way 
RM ANOVA
WT D3
D4
D3 1.229834 88
D1
Tuckey's
Tuckey's
D2
F (3, 972) = 17,11  < 0,0001
D3
Group (Treatment-genotype) F (3, 324) = 20,77
Tuckey's
Tuckey's
22
23D4
-
D2
Two-Way 
RM ANOVA
Tuckey's
Group (Treatment-genotype) F (3, 336) = 4,919 0.0023
M
o
rr
is
 W
a
te
r 
M
a
z
e
D
is
ta
n
c
e
 t
ra
v
e
ll
e
d
 (
m
) 
-C
U
E
T
A
S
K
Seizures F (3, 332) = 4,410 0.0047
Two-Way 
RM ANOVA
P
re
s
e
n
c
e
 i
n
 q
u
a
d
ra
n
t 
(%
)
Probe test
D1
Tuckey's
Tuckey's
Tuckey's
Tuckey's
Two-Way 
RM ANOVA
Tuckey's
D2
< 0,0001q(243)=16,23WT HYP: TARGET vs. OPPOSITE
< 0,0001q(243)=16,72WT: TARGET vs. OPPOSITE
< 0,0001F (9, 243) = 6,353
Sidak's
Sidak's
Sidak's
Sidak's
M
o
rr
is
 W
a
te
r 
M
a
z
e
L
a
te
n
c
y
 t
o
 f
in
d
 t
h
e
 h
id
d
e
n
 
p
la
tf
o
rm
 (
s
)
t1-D1 Tuckey's
-
Quadrant
Interaction
Group (Treatment-genotype)
Tuckey's
Tuckey's
M
o
rr
is
 W
a
te
r 
M
a
z
e
0.15F (3, 81) = 1,820
< 0,0001F (3, 243) = 166,1
Probe test
M
o
rr
is
 W
a
te
r 
M
a
z
e
T
a
rg
e
t 
q
u
a
d
ra
n
t:
D
if
fe
re
n
c
e
 t
o
 c
h
a
n
c
e
 l
e
v
e
l
One 
sample t-
test
-
HYP
-
SIH
RM-Two 
Way 
ANOVA
M
o
rr
is
 W
a
te
r 
M
a
z
e
< 0,0001t(22)=9,087 
< 0,0001t(18)=8,904 - -
- -
D
is
ta
n
c
e
 t
ra
v
e
ll
e
d
 (
m
)
D1
-
- -
-
t(21)=9,888 < 0,0001 -
Probe test
Two-Way  
ANOVA
Genotype 0.0006
N
u
m
b
e
r 
o
f 
p
la
tf
o
rm
 c
ro
s
s
e
s
Two-Way 
RM ANOVA
Interaction F (9, 1020) = 0,8253 0.5928
D2
Training Day F (3, 1020) = 99,83  < 0,0001
 < 0,0001
D4
Sidak's
Tuckey's
D3
19761.3584317.948684
Two-Way 
RM ANOVA
< 0,0001
Tuckey's
S
c
n
1
a
R
H
/+
-1
2
9
:B
6
M
o
rr
is
 W
a
te
r 
M
a
z
e
0.0814F (3, 336) = 2,259Interaction
Cue task Day
Group (Treatment-genotype)
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< 0,0001F (1, 336) = 101,8
-
Group (Treatment-genotype)
Seizures F (3, 336) = 4,919 0.0023
t(20)=3,615 0.0017 - - -
- -
F (1, 81) = 12,63
Tuckey's
Scn1aRH/+ SIH: Cue task 1 vs. Cue 
task 2
Sidak's t(336)=7,042 < 0,0001
< 0,0001t(336)=5,242Sidak's
Scn1aRH/+ control : Cue task 1 vs. Cue 
task 2
t(336)=4,163 0.0002
0.0009t(336)=3,736Sidak'sWT HYP: Cue task 1 vs. Cue task 2
WT control : Cue task 1 vs. Cue task 2
q(246)=7,257
q(246)=6,789
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39B
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Trial
Interaction
P < 0,0001F (3, 82) = 15,95
P < 0,0001F (3, 246) = 58,27
P = 0,4351F (9, 246) = 1,007
WT control: Trial1 vs.Trial 2
Scn1aRH/+ control : Trial1 vs.Trial 2
WT HYP : Trial1 vs.Trial 2
Scn1aRH/+ SIH: Trial1 vs.Trial 2
Tuckey's
q(246)=4,468
q(246)=5,400
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Mouse model 
and genetic 
background
Experi
ment
M
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t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
D1 17.554 2.501 76 19
D2 5.293 0.683 76 19
D1 16.296 2.391 92 23
D2 6.296 0.910 92 23
D1 17.810 2.353 88 22
D2 3.463 0.332 88 22
D1 29.068 3.569 84 21
D2 9.340 1.617 84 21
WT - 17.554 2.501 76 19 Cue task 1: WT control vs. WT HYP q(672)=0,6033 0.9739
Scn1aRH/+ - 17.810 2.353 88 22
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,08600 > 0,9999
WT HYP 16.296 2.391 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=6,290 < 0,0001
Scn1aRH/+ SIH 29.068 3.569 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=5,485 0.0007
WT - 5.293 0.683 76 19 Cue task 2: WT control vs. WT HYP q(672)=0,4805 0.9865
Scn1aRH/+ - 3.463 0.332 88 22
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=0,6144 0.6144
WT HYP 6.296 0.910 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=1,499 0.7138
Scn1aRH/+ SIH 9.340 1.617 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,864 0.1798
WT - 0.128 0.006 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 1: WT control vs. WT HYP q(672)=0,8557 0.9305
Scn1aRH/+ - 0.132 0.006 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(672)=0,5562 0.1121
WT HYP 0.134 0.006 92 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(672)=4,211 0.0159
Scn1aRH/+ SIH 0.104 0.006 84 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=3,867 0.0324
WT - 0.146 0.009 76 19 Interaction F (3, 336) = 0,5145 0.6726 Cue task 2: WT control vs. WT HYP q(672)=1,016 0.8897
Scn1aRH/+ - 0.138 0.008 88 22 Cue task Day F (1, 336) = 5,212 0.0231
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(672)=1,068 0.8745
WT HYP 0.138 0.009 92 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(672)=2,460 0.3039
Scn1aRH/+ SIH 0.121 0.007 84 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(672)=2,370 0.3371
WT - 2.970763 0.4965251 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 1: WT control vs. WT HYP q(664)=0,7936 0.9435
Scn1aRH/+ - 2.653614 0.3747214 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 1:WT control vs. Scn1aRH/+ 
control
q(664)=0,7803 0.9461
WT HYP 2.644679 0.4470432 84 23 Cue task 1: WT HYP vs. Scn1aRH/+ SIH q(664)=4,279 0.0137
Scn1aRH/+ SIH 4.338921 0.6543971 88 21
Cue task 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=4,307 0.0129
WT - 1.223474 0.2069968 76 19 Interaction F (3, 332) = 0,7880 0.5013 Cue task 2: WT control vs. WT HYP q(664)=0,3639 0.994
Scn1aRH/+ - 0.5581932 0.075622 88 22 Cue task Day F (1, 332) = 57,91 < 0,0001
Cue task 2:WT control vs. Scn1aRH/+ 
control
q(664)=1,637 0.654
WT HYP 1.073941 0.2038943 84 23 Cue task 2: WT HYP vs. Scn1aRH/+ SIH q(664)=1,62 0.6616
Scn1aRH/+ SIH 1.715159 0.3986418 88 21
Cue task 2:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(664)=2,957 0.1571
D1 32.04473 3.67175 76 19 WT: Training 1 vs. Training 2 q(1008)=9,827 < 0,0001
D2 8.242105 0.8416948 76 19 WT: Training 1 vs. Training 3 q(1008)=10,24 < 0,0001
WT: Training 1 vs. Training 4 q(1008)=9,948 < 0,0001
WT: Training 2 vs. Training 3 q(1008)=0,4107 0.9915
WT: Training 2 vs. Training 4 q(1008)=0,1211 0.9998
WT: Training 3 vs. Training 4 q(1008)=0,2896 0.997
D1 32.22717 3.422416 92 23 WT HYP: Training 1 vs. Training 2 q(1008)=9,399 < 0,0001
D2 11.53696 1.807323 92 23 WT HYP: Training 1 vs. Training 3 q(1008)=10,77 < 0,0001
WT HYP: Training 1 vs. Training 4 q(1008)=11,46 < 0,0001
WT HYP:  Training 2 vs. Training 3 q(1008)=1,374 0.7658
WT HYP: Training 2 vs. Training 4 q(1008)=2,061 0.4637
WT HYP: Training 3 vs. Training 4 q(1008)=0,6878 0.9621
D1 29.22955 3.296376 88 22
Scn1aRH/+ control: Training 1 vs. 
Training 2
q(1008)=7,948 < 0,0001
D2 11.33977 1.36383 88 22
Scn1aRH/+control: Training 1 vs. 
Training 3
q(1008)=9,127 < 0,0001
Scn1aRH/+ control: Training 1 vs. 
Training 4
q(1008)=10,2 < 0,0001
Scn1aRH/+ control: Training 2 vs. 
Training 3
q(1008)=1,179 0.8383
Scn1aRH/+ control: Training 2 vs. 
Training 4
q(1008)=2,254 0.3827
Scn1aRH/+ control: Training 3 vs. 
Training 4
q(1008)=1,074 0.8725
D1 57.88572 3.629017 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 2 q(1008)=12,54 < 0,0001
D2 28.98571 3.359673 84 21 Scn1aRH/+ SIH: Training 1 vs. Training 3 q(1008)=13,56 < 0,0001
Scn1aRH/+ SIH: Training 1 vs. Training 4 q(1008)=14,02 < 0,0001
Scn1aRH/+ SIH: Training 2 vs. Training 3 q(1008)=1,014 0.8903
Scn1aRH/+ SIH: Training 2 vs. Training 4 q(1008)=1,472 0.7256
Scn1aRH/+ SIH: Training 3 vs. Training 4 q(1008)=0,4573 0.9883
WT -
67.88421 6.222804 19 19
Interaction F (9, 246) = 1,007 P = 0,4351 Trial 1: WT control vs. WT HYP q(328)=1,16 0.845
Scn1aRH/+ -
64 6.950537 22 22
Trial F (3, 246) = 58,27 P < 0,0001
Trial 1: WT control vs. Scn1aRH/+ 
control
q(328)=0,6534 0.9672
WT HYP
61.06087 6.284087 23 23
Trial 1: WT HYP vs. Scn1aRH/+ SIH q(328)=3,356 0.0844
Scn1aRH/+ SIH
80.05454 4.602327 22 22
Trial 1: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(328)=2,805 0.1962
t1-D1
67.88421 6.222804 19 19
t2-D1
27.94737 7.072909 19 19
t1-D1
64 6.950537 22 22
t2-D1
24.32727 5.898617 22 22
t1-D1
61.06087 6.284087 23 23
t2-D1
32.18696 7.241072 23 23
t1-D1
80.05454 4.602327 22 22
t2-D1
55.62727 7.725384 22 22
WT - 32.04473 3.67175 76 19 Training 1: WT control vs. WT HYP q(1344)=0,07479 > 0,9999
Scn1aRH/+ - 32.22717 3.422416 92 23
Training 1: WT control vs. Scn1aRH/+ 
control
q(1344)=1,142 0.8508
WT HYP 29.22955 3.296376 88 22 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1344)=10,8 < 0,0001
Scn1aRH/+ SIH 57.88572 3.629017 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=11,94 < 0,0001
WT - 8.242105 0.8416948 76 19 Training 2:  WT control vs. WT HYP q(1344)=1,351 0.775
Scn1aRH/+ - 11.53696 1.807323 92 23
Training 2: WT control vs. Scn1aRH/+ 
control
q(1344)=1,257 0.8107
WT HYP 11.33977 1.36383 88 22 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,347 < 0,0001
Scn1aRH/+ SIH 28.98571 3.359673 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,351 < 0,0001
WT - 7.247368 1.002153 76 19 Training 3:  WT control vs. WT HYP q(1344)=0,5188 0.9831
Scn1aRH/+ - 8.513043 1.087739 92 23
Training 3:WT control vs. Scn1aRH/+ 
control
q(1344)=0,5834 0.9763
WT HYP 8.685227 1.229834 88 22 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1344)=7,636 < 0,0001
Scn1aRH/+ SIH 26.64881 3.134997 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=7,483 < 0,0001
WT - 7.948684 1.358431 76 19 Training 4: WT control vs. WT HYP q(1344)=0,3893 0.9927
Scn1aRH/+ - 6.998913 1.016919 92 23
Training 4: WT control vs. Scn1aRH/+ 
control
q(1344)=0,6824 0.963
WT HYP 6.267045 0.7822427 88 22 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1344)=7,83 < 0,0001
Scn1aRH/+ SIH 25.59524 3.211734 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1344)=8,051 < 0,0001
WT - 0.1731 0.0064 76 19 Training 1: WT control vs. WT HYP q(1296)=1,406 0.7528
Scn1aRH/+ - 0.1573 0.0058 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=2,347 0.3455
WT HYP 0.1634 0.0069 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,189 0.0164
Scn1aRH/+ SIH 0.1915 0.0056 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=5,224 0.0013
WT - 0.1398 0.0066 76 19 Training 2:  WT control vs. WT HYP q(1296)=0,6093 0.9732
Scn1aRH/+ - 0.1388 0.0061 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=0,1489 0.9996
WT HYP 0.1440 0.0078 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=3,484 0.0662
Scn1aRH/+ SIH 0.1673 0.0063 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,361 0.0112
WT - 0.1197 0.0073 76 19 Training 3:  WT control vs. WT HYP q(1296)=4,268 0.0138
Scn1aRH/+ - 0.1390 0.0067 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=2,881 0.175
WT HYP 0.1490 0.0079 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=3,127 0.1207
Scn1aRH/+ SIH 0.1699 0.0062 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=4,727 0.0047
WT - 0.1255 0.0065 76 19 Training 4: WT control vs. WT HYP q(1296)=2,341 0.3479
Scn1aRH/+ - 0.1299 0.0073 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,6571 0.9667
WT HYP 0.1416 0.0076 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=4,775 0.0042
Scn1aRH/+ SIH 0.1735 0.0057 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=6,674 < 0,0001
WT - 6.460737 0.7937213 76 19 Training 1: WT control vs. WT HYP q(1296)=0,4226 0.9907
Scn1aRH/+ - 5.556216 0.6823414 88 22
Training 1: WT control vs. Scn1aRH/+ 
control
q(1296)=1,65 0.6481
WT HYP 6.23138 0.6989641 80 20 Training 1: WT HYP vs. Scn1aRH/+ SIH q(1296)=10,46 < 0,0001
Scn1aRH/+ SIH 11.68935 0.8374145 84 21
 Training 1:  Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=11,62 < 0,0001
WT - 1.315329 0.1638174 76 19 Training 2:  WT control vs. WT HYP q(1296)=1,384 0.7616
Scn1aRH/+ - 1.921886 0.2769157 88 22
Training 2: WT control vs. Scn1aRH/+ 
control
q(1296)=1,106 0.8625
WT HYP 2.066435 0.364425 80 20 Training 2: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,731 < 0,0001
Scn1aRH/+ SIH 6.10242 0.7526377 84 21
Training 2: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,921 < 0,0001
WT - 1.139329 0.2044359 76 19 Training 3:  WT control vs. WT HYP q(1296)=0,8549 0.9307
Scn1aRH/+ - 1.435739 0.2222679 88 22
Training 3:WT control vs. Scn1aRH/+ 
control
q(1296)=0,5407 0.981
WT HYP 1.603261 0.2461549 80 20 Training 3:WT HYP vs. Scn1aRH/+ SIH q(1296)=8,188 < 0,0001
Scn1aRH/+ SIH 5.877432 0.7365466 84 21
Training 3: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=8,416 < 0,0001
WT - 1.295526 0.2833215 76 19 Training 4: WT control vs. WT HYP q(1296)=0,1389 0.9997
Scn1aRH/+ - 1.025261 0.1717624 88 22
Training 4: WT control vs. Scn1aRH/+ 
control
q(1296)=0,493 0.9855
WT HYP 1.22013 0.2120321 80 20 Training 4: WT HYP vs. Scn1aRH/+ SIH q(1296)=7,513 < 0,0001
Scn1aRH/+ SIH 5.142352 0.7405574 84 21
Training 4: Scn1aRH/+ control vs. 
Scn1aRH/+ SIH
q(1296)=7,801 < 0,0001
WT: LEFT 17.11351 1.590523 19 19 WT: LEFT vs. TARGET q(243)=14,33 < 0,0001
WT: TARGET 56.76281 3.567275 19 19 WT:  TARGET vs. RIGHT q(243)=14,91 < 0,0001
WT: RIGHT 15.52632 2.157894 19 19
WT: OPPOSITE 10.5 2.111683 19 19
WT: LEFT 24.55077 2.435804 23 23 WT HYP: LEFT vs. TARGET q(243)=10,46 < 0,0001
WT: TARGET 50.85536 2.845297 23 23 WT  HYP:  TARGET vs. RIGHT q(243)=14,58 < 0,0001
WT: RIGHT 14.20072 1.664953 23 23
WT: OPPOSITE 10.05507 1.590904 23 23
Scn1aRH/+: LEFT 19.53106 1.379024 22 22 Scn1aRH/+:  LEFT vs. TARGET q(243)=13,82 < 0,0001
Scn1aRH/+: 
TARGET
55.06091 3.040268 22 22 Scn1aRH/+:   TARGET vs. RIGHT q(243)=15,49 < 0,0001
Scn1aRH/+: 
RIGHT
15.24242 2.271501 22 22
Scn1aRH/+: 
OPPOSITE
10.03061 1.408996 22 22
Scn1aRH/+: LEFT 26.3889 2.395459 21 21 Scn1aRH/+ SIH:  LEFT vs. TARGET q(243)=3,55 0.0608
Scn1aRH/+: 
TARGET
35.73079 2.968656 21 21 Scn1aRH/+ SIH:   TARGET vs. RIGHT q(243)=6,508 < 0,0001
Scn1aRH/+: 
RIGHT
18.60619 1.648541 21 21
Scn1aRH/+: 
OPPOSITE
19.00603 1.901427 21 21
WT: TARGET - 56.76281 3.567275 19 19 Interaction F (9, 243) = 6,353 < 0,0001 Target: WT control vs. WT HYP q(324)=2,58 0.3488
Scn1aRH/+: 
TARGET
- 50.85536 2.845297 23 23 Quadrant F (3, 243) = 166,1 < 0,0001
Target: WT control vs. Scn1aRH/+ 
control
q(324)=0,7359 0.9961
WT: TARGET HYP 55.06091 3.040268 22 22 Target: WT HYP vs. Scn1aRH/+ SIH q(324)=6,786 < 0,0001
Scn1aRH/+: 
TARGET
SIH 35.73079 2.968656 21 21
Target: Scn1aRH/+ control vs. Scn1aRH/+ 
SIH
q(324)=8,58 < 0,0001
WT - 56.76281 3.567275 19 19 -
Chance level 25.000 -
WT HYP 55.06091 3.040268 22 22 -
Chance level 25.000 -
Scn1aRH/+ - 50.85536 2.845297 23 23 -
Chance level 25.000 -
Scn1aRH/+ SIH 35.73079 2.968656 21 21 -
Chance level 25.000 -
WT - 13.737 0.908 19 19 Interaction F (1, 81) = 8,504 0.0046 WT control vs. WT HYP q(81)=2,722 0.2259
Scn1aRH/+ - 13.182 0.755 22 22 Treatment F (1, 81) = 32,03  < 0,0001  WT control vs. Scn1aRH/+ control q(81)=0,626 0.9709
WT HYP 11.348 1.055 23 23 WT HYP vs. Scn1aRH/+ SIH q(81)=6,593 < 0,0001
Scn1aRH/+ SIH 5.714 0.673 21 21  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(81)=8,646 < 0,0001
39A
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Probe test
RM-Two 
Way 
ANOVA
Tuckey's
Training Day F (3, 1008) = 117,0 < 0,0001
Group (Treatment-genotype) F (3, 336) = 55,50
0.15F (3, 81) = 1,820
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D3 3.134997 84 21
D4 25.59524
F (9, 1008) = 1,063
Tuckey's
D1
< 0,0001
Scn1aRH/+:  TARGET vs. OPPOSITE q(243)=17,52 < 0,0001
Scn1aRH/+SIH :  TARGET vs. 
OPPOSITE
0.0001
0.3877
< 0,0001
Two-Way 
RM ANOVA
23
Tuckey's
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Scn1aRH/+
F (3, 336) = 7,057
< 0,0001F (1, 336) = 101,8
F (3, 336) = 55,50
8.513043 1.087739 92
3.211734 84 21
22
Scn1aRH/+
19761.0021537.247368
Tuckey's26.64881
D2
Tuckey's
SIH
- Tuckey's
Tuckey's
921.0169196.998913
Training Day
Interaction
8.685227
D3
Group (Treatment-genotype) F (3, 340) = 54,81 < 0,0001
D4
Two-Way 
RM ANOVA
Interaction F (9, 1008) = 1,063 0.3877
D1
Tuckey's
Group (Treatment-genotype) F (3, 332) = 4,410 0.0047
Group (Treatment-genotype)
< 0,0001F (3, 1008) = 117,0
Tuckey's
P < 0,0001F (3, 82) = 15,95Seizures
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RM ANOVA
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0.15F (3, 81) = 1,820
< 0,0001F (3, 243) = 166,1
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RM-Two 
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ANOVA
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< 0,0001t(22)=9,087 
< 0,0001t(18)=8,904 - -
- -
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c
e
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d
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m
)
D1
-
- -
-
t(21)=9,888 < 0,0001 -
Probe test
Two-Way  
ANOVA
Genotype 0.0006
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s
Two-Way 
RM ANOVA
Interaction F (9, 1020) = 0,8253 0.5928
D2
Training Day F (3, 1020) = 99,83  < 0,0001
 < 0,0001
D4
Sidak's
Tuckey's
D3
19761.3584317.948684
Two-Way 
RM ANOVA
< 0,0001
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0.0814F (3, 336) = 2,259Interaction
Cue task Day
Group (Treatment-genotype)
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WT
L
a
te
n
c
y
 t
o
 f
in
d
 t
h
e
 c
u
e
d
 p
la
tf
o
rm
 (
s
) 
- 
C
U
E
 T
A
S
K
0.0001F (3, 336) = 7,057
< 0,0001F (1, 336) = 101,8
-
Group (Treatment-genotype)
Seizures F (3, 336) = 4,919 0.0023
t(20)=3,615 0.0017 - - -
- -
F (1, 81) = 12,63
Tuckey's
Scn1aRH/+ SIH: Cue task 1 vs. Cue 
task 2
Sidak's t(336)=7,042 < 0,0001
< 0,0001t(336)=5,242Sidak's
Scn1aRH/+ control : Cue task 1 vs. Cue 
task 2
t(336)=4,163 0.0002
0.0009t(336)=3,736Sidak'sWT HYP: Cue task 1 vs. Cue task 2
WT control : Cue task 1 vs. Cue task 2
q(246)=7,257
q(246)=6,789
0.0096
0.001
< 0,0001
< 0,0001
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SIHScn1aRH/+
HYPWT
-Scn1aRH/+
-WT
39B
Two-Way 
RM ANOVA
Group (Treatment-genotype)
Trial
Interaction
P < 0,0001F (3, 82) = 15,95
P < 0,0001F (3, 246) = 58,27
P = 0,4351F (9, 246) = 1,007
WT control: Trial1 vs.Trial 2
Scn1aRH/+ control : Trial1 vs.Trial 2
WT HYP : Trial1 vs.Trial 2
Scn1aRH/+ SIH: Trial1 vs.Trial 2
Tuckey's
q(246)=4,468
q(246)=5,400
Mouse model 
and genetic 
background
Experi
ment
M
e
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r
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n
t
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 21.09296 3.291269 18 18 Interaction F (1, 63) = 0,2228 0.6385 WT control vs. WT HYP q(63)=1,237 0.818
Scn1aRH/+ - 11.52091 2.292139 22 22 Treatment F (1, 63) = 0,6443 0.4252  WT control vs. Scn1aRH/+ control q(63)=3,373 0.0904
WT HYP 17.07436 4.300251 13 13 WT HYP vs. Scn1aRH/+ SIH q(63)=0,3415 0.995
Scn1aRH/+ SIH 10.47857 2.789497 14 14  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(63)=1,918 0.5311
WT - 75.07111 4.162738 18 18 Interaction F (1, 64) = 0,1338 0.7157 WT control vs. WT HYP q(63)=1,633 0.4939
Scn1aRH/+ - 56.56424 4.336703 22 22 Treatment F (1, 64) = 7,673 0.0073  WT control vs. Scn1aRH/+ control q(63)=2,422 0.1048
WT HYP 60.77692 7.499846 13 13 WT HYP vs. Scn1aRH/+ SIH q(63)=2,316 0.1345
Scn1aRH/+ SIH 37.91956 8.232697 15 15  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(63)=2,509 0.0848
Tuckey's
Tuckey's
CONDITIO
NING
TEST 
F
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z
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g
 %
Two-Way  
ANOVA
Two-Way  
ANOVA
0.0009F (1, 64) = 12,10
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Contextual-fear conditioningin Scn1aRH/+ -129:B6
40B
40A
Genotype
F (1, 63) = 6,576 0.0127Genotype
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Mouse model 
and genetic 
background
Experi
ment
Meas
urme
nt
Protocol 
phase
Genotype
treatme
nt/proto
col
average S.E.M
# 
values/sli
ces/cells
# 
animal
s
Statistical 
test
Source of variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
WT - 3.308 0.1748 13 13 WT control vs. WT HYP q(600)=1,833 0.5658
Scn1aRH/+ - 3.5 0.3416 16 16  WT control vs. Scn1aRH/+ control q(600)=0,549 0.9801
WT HYP 3.941 0.2496 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=2,967 0.155
Scn1aRH/+ SIH 3 0.2915 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=1,551 0.6916
WT - 3.692 0.5705 13 13 WT control vs. WT HYP q(600)=1,492 0.7168
Scn1aRH/+ - 3.875 0.3276 16 16  WT control vs. Scn1aRH/+ control q(600)=0,5216 0.9829
WT HYP 3.176 0.2743 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=1,895 0.5376
Scn1aRH/+ SIH 3.778 0.2977 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=0,3016 0.9966
WT - 3.923 0.2878 13 13 WT control vs. WT HYP q(600)=1,65 0.6483
Scn1aRH/+ - 4 0.3873 16 16  WT control vs. Scn1aRH/+ control q(600)=0,2196 0.9987
WT HYP 3.353 0.2704 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=0,2369 0.9983
Scn1aRH/+ SIH 3.278 0.2532 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=2,241 0.3883
WT - 3.231 0.3608 13 13 WT control vs. WT HYP q(600)=2,736 0.2146
Scn1aRH/+ - 3.5 0.2739 16 16  WT control vs. Scn1aRH/+ control q(600)=0,7686 0.9483
WT HYP 4.176 0.2606 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=0,206 0.9989
Scn1aRH/+ SIH 4.111 0.3223 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=1,896 0.5373
WT - 3.846 0.3553 13 13 WT control vs. WT HYP q(600)=0,7462 0.9524
Scn1aRH/+ - 3.438 0.3648 16 16  WT control vs. Scn1aRH/+ control q(600)=1,167 0.8426
WT HYP 3.588 0.3644 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=1,154 0.847
Scn1aRH/+ SIH 3.222 0.384 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=0,6679 0.9651
WT - 3.077 0.5122 13 13 WT control vs. WT HYP q(600)=2,501 0.2898
Scn1aRH/+ - 4 0.3651 16 16  WT control vs. Scn1aRH/+ control q(600)=2,635 0.245
WT HYP 3.941 0.3685 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=1,916 0.5284
Scn1aRH/+ SIH 3.333 0.2425 18 18  Scn1a
RH/+
 control vs. Scn1a
RH/+
 SIH q(600)=2,068 0.4609
WT - 4 0.4385 13 13 WT control vs. WT HYP q(600)=2,893 0.1725
Scn1aRH/+ - 4.5 0.3291 16 16  WT control vs. Scn1aRH/+ control q(600)=1,427 0.744
WT HYP 5 0.3835 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=3,502 0.0647
Scn1aRH/+ SIH 3.889 0.3419 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=1,896 0.5373
WT - 4.923 0.3662 13 13 WT control vs. WT HYP q(600)=0,05237 > 0,9999
Scn1aRH/+ - 4.813 0.3561 16 16  WT control vs. Scn1aRH/+ control q(600)=0,3157 0.9961
WT HYP 4.941 0.3262 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=2,616 0.251
Scn1aRH/+ SIH 4.111 0.2668 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=2,176 0.4149
WT - 5.538 0.2912 13 13 WT control vs. WT HYP q(600)=0,995 0.8957
Scn1aRH/+ - 5.375 0.301 16 16  WT control vs. Scn1aRH/+ control q(600)=0,4667 0.9876
WT HYP 5.882 0.2556 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=6,459 < 0,0001
Scn1aRH/+ SIH 3.833 0.3547 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=4,783 0.0043
WT - 5.769 0.3028 13 13 WT control vs. WT HYP q(600)=1,034 0.8845
Scn1aRH/+ - 5.813 0.3319 16 16  WT control vs. Scn1aRH/+ control q(600)=0,1235 0.9998
WT HYP 5.412 0.3328 17 17 WT HYP vs. Scn1aRH/+ SIH q(600)=3,925 0.029
Scn1aRH/+ SIH 4.167 0.2712 18 18  Scn1aRH/+ control vs. Scn1aRH/+ SIH q(600)=5,106 0.0019
D1 WT - 3.308 0.1748 13 13 D1 : WT control vs. Chance level t(12)=1,100 0.293 - - - -
D2 WT - 3.692 0.5705 13 13 D2 : WT control vs. Chance level t(12)=0,3371 0.7419 - - - -
D3 WT - 3.923 0.2878 13 13 D3  : WT control vs. Chance level t(12)=1,470 0.1673 - - - -
D4 WT - 3.231 0.3608 13 13 D4 : WT  control vs. Chance level t(12)=0,7462 0.4699 - - - -
D5 WT - 3.846 0.3553 13 13 D5 : WT  control vs. Chance level t(12)=0,9743 0.3491 - - - -
D6 WT - 3.077 0.5122 13 13 D6 : WT  control vs. Chance level t(12)=0,8260 0.4249 - - - -
D7 WT - 4 0.4385 13 13 D7 : WT   control vs. Chance level t(12)=1,140 0.2765 - - - -
D8 WT - 4.923 0.3662 13 13 D8 : WT  control vs. Chance level t(12)=3,886 0.0022 - - - -
D9 WT - 5.538 0.2912 13 13 D9 : WT  control vs. Chance level t(12)=7,000 < 0,0001 - - - -
D10 WT - 5.769 0.3028 13 13 D10 : WT  control vs. Chance level t(12)=7,493 < 0,0001 - - - -
3.500
D1 Scn1aRH/+ - 3.5 0.3416 16 16 D1 : Scn1aRH/+ control vs. Chance level t(15)=0,0 1 - - - -
D2 Scn1aRH/+ - 3.875 0.3276 16 16 D2 :Scn1aRH/+ control  vs. Chance level t(15)=1,145 0.2702 - - - -
D3 Scn1aRH/+ - 4 0.3873 16 16 D3 :Scn1aRH/+ control  vs. Chance level t(15)=1,291 0.2162 - - - -
D4 Scn1aRH/+ - 3.5 0.2739 16 16 D4 :Scn1aRH/+ control  vs. Chance level t(15)=0,0 1 - - - -
D5 Scn1aRH/+ - 3.438 0.3648 16 16 D5 : Scn1aRH/+ control vs. Chance level t(15)=0,1713 0.8663 - - - -
D6 Scn1aRH/+ - 4 0.3651 16 16 D6 : Scn1aRH/+ control  vs. Chance level t(15)=1,369 0.1911 - - - -
D7 Scn1aRH/+ - 4.5 0.3291 16 16 D7 : Scn1aRH/+ control  vs. Chance level t(15)=3,038 0.0083 - - - -
D8 Scn1aRH/+ - 4.813 0.3561 16 16 D8 : Scn1aRH/+ control  vs. Chance level t(15)=3,686 0.0022 - - - -
D9 Scn1aRH/+ - 5.375 0.301 16 16 D9 : Scn1aRH/+ control  vs. Chance level t(15)=6,228 < 0,0001 - - - -
D10 Scn1aRH/+ - 5.813 0.3319 16 16 D10 : Scn1aRH/+ control  vs. Chance level t(15)=6,968 < 0,0001 - - - -
3.500
D1 WT HYP 3.941 0.2496 17 17 D1 : WT HYP vs. Chance level t(16)=1,768 0.0962 - - - -
D2 WT HYP 3.176 0.2743 17 17 D2 : WT HYP vs. Chance level t(16)=1,179 0.2555 - - - -
D3 WT HYP 3.353 0.2704 17 17 D3 : WT  HYPvs. Chance level t(16)=0,5439 0.594 - - - -
D4 WT HYP 4.176 0.2606 17 17 D4 : WT  HYP vs. Chance level t(16)=2,596 0.0195 - - - -
D5 WT HYP 3.588 0.3644 17 17 D5 : WT HYP vs. Chance level t(16)=0,2421 0.8117 - - - -
D6 WT HYP 3.941 0.3685 17 17 D6 : WT HYP vs. Chance level t(16)=1,197 0.2487 - - - -
D7 WT HYP 5 0.3835 17 17 D7 : WT HYP vs. Chance level t(16)=3,912 0.0012 - - - -
D8 WT HYP 4.941 0.3262 17 17 D8 : WT HYP vs. Chance level t(16)=4,418 0.0004 - - - -
D9 WT HYP 5.882 0.2556 17 17 D9 : WT HYP vs. Chance level t(16)=9,322 < 0,0001 - - - -
D10 WT HYP 5.412 0.3328 17 17 D10 : WT HYP vs. Chance level t(16)=5,745 < 0,0001 - - - -
3.500
D1 Scn1aRH/+ SIH 3 0.2915 18 18 D1 : Scn1aRH/+ SIH vs. Chance level t(17)=1,715 0.1045 - - - -
D2 Scn1aRH/+ SIH 3.778 0.2977 18 18 D2 : Scn1aRH/+ SIH vs. Chance level t(17)=0,9332 0.3638 - - - -
D3 Scn1aRH/+ SIH 3.278 0.2532 18 18 D3 :Scn1aRH/+ SIHvs. Chance level t(17)=0,8778 0.3923 - - - -
D4 Scn1aRH/+ SIH 4.111 0.3223 18 18 D4 : Scn1aRH/+ SIHvs. Chance level t(17)=1,896 0.075 - - - -
D5 Scn1aRH/+ SIH 3.222 0.384 18 18 D5 : Scn1aRH/+ SIH vs. Chance level t(17)=0,7235 0.4792 - - - -
D6 Scn1aRH/+ SIH 3.333 0.2425 18 18 D6 : Scn1aRH/+ SIHvs. Chance level t(17)=0,6872 0.5012 - - - -
D7 Scn1aRH/+ SIH 3.889 0.3419 18 18 D7 :Scn1aRH/+ SIH vs. Chance level t(17)=1,137 0.2712 - - - -
D8 Scn1aRH/+ SIH 4.111 0.2668 18 18 D8 : Scn1aRH/+ SIH vs. Chance level t(17)=2,291 0.035 - - - -
D9 Scn1aRH/+ SIH 3.833 0.3547 18 18 D9 : Scn1aRH/+ SIH vs. Chance level t(17)=0,9397 0.3605 - - - -
D10 Scn1aRH/+ SIH 4.167 0.2712 18 18 D10 : Scn1aRH/+ SIH vs. Chance level t(17)=2,459 0.025 - - - -
3.500
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4. RESULTS – CHAPTER 4  –  SCN1ARH/+ -FLUROTHYL 
 
 
5. RESULTS – CHAPTER 5  –  SCN1A+/- -DRUG X ADMINISTRATION 
 
 
 
Mouse 
model and 
genetic 
background
Experiment Measurment
Protocol 
phase
Genotype
treatment/pro
tocol
average S.E.M
# 
values/slices
/cells
# animals Statistical test
Source of 
variation
F(DFn,DFd) / 
t (dF) 
value/U/χ²/H
p value Comparision post hoc test
t(dF) value / q(dF) 
value
p value Figure
WT HYP+Flurothyl 88.235 7.814 17 17
Scn1aRH/+ Flurothyl 61.538 13.493 13 13S
c
n
1
a
R
H
/+
 (
F
1
-
1
2
9
:B
6
)
Seizures 
Induction by 
Flurothyl
Survival curve 
comparision
Survival 
percentage 
at day 10
Log-rank (Mantel-
Cox) test
Curve 
comparision
42Aχ²(1)=3,149 0.076 - - - -
RESULTS Chapter 4- Role of flurothyl-induced seizure in cognitive/behavioral phenotypes in Scn1a RH/+ - 129:B6.
Survival during the flurothyl-induced seizures
Mouse 
model 
and 
genetic 
backgro
und
Experiment
Measur
ment
Protocol 
phase
Genotype
treatment/
protocol
average S.E.M
# 
values/slic
es/cells
# animals Statistical test
Source of 
variation
F(DFn,DFd) / t 
(dF) value/U/χ²/H
p value Comparision
post hoc 
test
t(dF) value / 
q(dF) value
p value Figure
Scn1a+/- vehicle - 14.286 7.636 21 21
Scn1a+/- SIH - 57.143 10.799 21 21
Scn1a+/- vehicle Vehicle 40.744 0.206 16 16
Scn1a+/- SIH Drug 41.207 0.143 15 15
Scn1a+/- vehicle Vehicle 39.838 0.413 13 13
Scn1a+/- SIH Drug 40.862 0.304 13 13
Scn1a+/- vehicle Vehicle 38.813 0.402 8 8
Scn1a+/- SIH Drug 38.340 0.565 10 10
Scn1a+/- vehicle Vehicle 39.960 0.181 5 5
Scn1a+/- SIH Drug 39.927 0.395 11 11
Scn1a+/- vehicle Vehicle 40.220 0.240 5 5
Scn1a+/- SIH Drug 40.410 0.311 10 10
Scn1a+/- vehicle Vehicle 0.8125 0.5261396 16 16
Scn1a+/- SIH Drug 0 0 15 15
Scn1a+/- vehicle Vehicle 0.375 0.375 16 16
Scn1a+/- SIH Drug 0.2666667 0.2666667 15 15
Scn1a+/- vehicle Vehicle 0.7333333 0.3304638 15 15
Scn1a+/- SIH Drug 0.2307692 0.1661728 13 13
Scn1a+/- vehicle Vehicle 2 0.5773503 12 12
Scn1a+/- SIH Drug 1.769231 0.7085001 13 13
Scn1a+/- vehicle Vehicle 2.625 0.4604928 8 8
Scn1a+/- SIH Drug 2.076923 0.7800521 13 13
Scn1a+/- vehicle Vehicle 2.833333 0.7031674 6 6
Scn1a+/- SIH Drug 2 0.6666667 9 9
Scn1a+/- vehicle Vehicle 2.2 0.3741657 5 5
Scn1a+/- SIH Drug 2.111111 0.5879447 9 9
Scn1a+/- vehicle Vehicle 2.4 0.5099019 5 5
Scn1a+/- SIH Drug 1.636364 0.5094155 11 11
Scn1a+/- vehicle Vehicle 2 0.7071068 5 5
Scn1a+/- SIH Drug 1.1 0.4582576 10 10
Scn1a+/- vehicle Vehicle 2.25 0.9464847 4 4
Scn1a+/- SIH Drug 1.2 0.3265986 10 10
D10
0.2693
Two-way 
ANOVA
D5: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D4: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D3:Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D1
D1: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
N1
N1: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D1
D2
D3
D4
D5
N4
D5
N5
0.9981
Two-way 
ANOVA
0.9943
 < 0.0001
0.022
N3: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D4: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
0.9854
> 0.9999
0.9937
0.9806
0.9669
0.9962
> 0.9999N2
N2: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D3
D3: Nav 1.1 KO+/- vehicle vs. 
Nav 1.1 KO+/- SIH
D2
D2: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
F (9, 190) = 0.1969
45
0.8575
> 0.9999
< 0.0001
0.3223
Sidak's
0.9992
> 0.9999
0.9062
0.1064
t(190)=0.9848
t(190)=0.7948
t(190)=0.3455
t(190)=0.731
Sidak's
t(190)=0.09551
t(190)=0.8485
t(190)=0.9848F (1, 190) = 5.337
Survival curve and spontaneous seizure activity
RESULTS Chapter 5-Collaborative work using Scn1a
+/-
B6:129 (DS) mouse model 
44A
44B
0.7691
T
e
m
p
e
ra
tu
re
 t
h
re
s
h
o
ld
 f
o
r 
s
e
iz
u
re
 
in
d
u
c
ti
o
n
D2: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D1: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
S
IH
Curve 
comparisio
n
χ²(1)=8.968 0.0027
Interaction
Day
Treatment
F (4, 96) = 1.317
S
c
n
1
a
+
/-
 -
 B
6
:1
2
9
S
IH
S
u
rv
iv
a
l 
c
u
rv
e
 
c
o
m
p
a
ri
s
io
n
Log-rank (Mantel-
Cox) test
t(96)=1.147
S
c
n
1
a
+
/-
 -
 B
6
:1
2
9
-
S
p
o
n
ta
n
e
o
u
s
 s
e
iz
u
re
 f
re
q
u
e
n
c
y
- - -
S
c
n
1
a
+
/-
 -
 B
6
:1
2
9
t(190)=0.9476
F (1, 96) = 0.9898
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N4: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
D5: Scn1a+/- vehicle vs. 
Scn1a+/- SIH
N5: Scn1a+/- vehicle vs. 
Scn1a+/-SIH
Day
Treatment
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RÉSUMÉ 
 
Les mutations du gène SCN1A, codant pour le canal sodique de type 1 potentiel-
dépendant (Nav1.1), sont impliquées dans plusieurs formes d'épilepsie du nourrisson, 
comme le Syndrome de Dravet (SD), une épilepsie rare et pharmaco-résistante ou 
l’Epilepsie généralisée avec crises fébriles plus (GEFS+), une épilepsie plus légère. 
GEFS+ et SD sont associés à des crises épileptiques fébriles dès l’âge de 6 mois. Le SD 
constitue la forme la plus grave où l’on voit apparaitre des retards mentaux mais 
également des déficits moteurs, visuels, langagiers et mnésiques au cours de l’évolution 
de la maladie. L’impact des crises épileptiques au cours de la petite enfance sur ces 
déficits cognitifs n’est pas connu. Jusqu'à présent, le SD était considéré comme étant 
une encéphalopathie épileptique où les crises étaient les principales responsables du 
phénotype à l’âge adulte.  Cependant, récemment, un rôle potentiel de la mutation dans 
les troubles cognitifs a été mis en évidence changeant a priori la définition de SD 
d’encéphalopathie épileptique à une canalopathie (Bender et al., 2013, 2016; Han et al., 
2012a). Notre projet adresse la question suivante: Quel est le rôle des crises épileptiques 
répétées présentées par les enfants SD sur les fonctions cognitives à l’âge adulte?  Pour 
cela nous avons utilisé un modèle murin de la maladie portant une mutation faux-sens 
du gène Scn1a (R1648H), et qui présente une pathologie très légère. Nous avons induit 
des crises épileptiques par hyperthermie à l’âge de 21 jours pendant 10 jours et testé les 
effets à long-terme sur ces animaux à l’âge adulte. Nos résultats révèlent que l’induction 
de crises épileptiques par hyperthermie induit une hyperactivité, des altérations dans les 
interactions sociales et des déficits en mémoire hippocampo-dépendante et cortex 
préfronto-dépendante. Ces modifications comportementales sont associées à des 
modifications de l’électrocorticogramme avec apparition de crises spontanées et à 
d’importantes modifications de l’excitabilité neuronale intrinsèque dans l’hippocampe. 
Même si le rôle possible du canal NaV1.1 dans le dysfonctionnement neuronal et l’effet 
des crises répétées ne sont probablement pas mutuellement distinctes, l’induction de 
crises répétées à un jeune âge semble donc suffisante pour convertir un modèle léger 
portant la mutation du gène Scn1a en un modèle sévère. Ainsi nous avons mis en 
évidence que les crises épileptiques répétées pendant le développement ont un fort 
impact sur la fonction cérébrale et qu’il est donc capital de les prévenir afin de 
diminuer, voir de prévenir, ces déficits.  
